

0001689548-24-00010110-Q Praxis Precision Medicines, Inc. 202411062024110675934075934075934 0 0001689548-24-000101 10-Q 64 20240930 20241106 20241106 Praxis Precision Medicines, Inc. 0001689548 2834 0000000000 DE 1231 10-Q 34 001-39620 241429280 99 HIGH STREET, 30TH FLOOR BOSTON MA 02110 617-300-8460 99 HIGH STREET, 30TH FLOOR BOSTON MA 02110 10-Q 1 prax-20240930.htm 10-Q prax-20240930false2024Q300001689548December
310.06670.06670.06670.xbri:sharesiso4217:USDiso4217:USDxbri:sharesxbri:pureprax:platformprax:candidateprax:studyprax:segmentprax:securityprax:obligation00016895482024-01-
012024-09-3000016895482024-11-0100016895482024-09-3000016895482023-12-3100016895482024-07-012024-09-3000016895482023-07-012023-09-3000016895482023-01-012023-09-
3000016895482023-11-282023-11-282001689548us-gaap:CommonStockMember2023-12-310001689548us-gaap:AdditionalPaidInCapitalMember2023-12-310001689548us-
gaap:RetainedEarningsMember2023-12-310001689548us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001689548us-gaap:AdditionalPaidInCapitalMember2024-01-
012024-03-3100016895482024-01-012024-03-310001689548prax:FollowOnOfferingMember2024-01-012024-03-310001689548us-
gaap:CommonStockMemberprax:FollowOnOfferingMember2024-01-012024-03-310001689548us-gaap:AdditionalPaidInCapitalMemberprax:FollowOnOfferingMember2024-01-012024-03-
310001689548prax:AtTheMarketOfferingMember2024-01-012024-03-310001689548us-gaap:CommonStockMemberprax:AtTheMarketOfferingMember2024-01-012024-03-310001689548us-
gaap:AdditionalPaidInCapitalMemberprax:AtTheMarketOfferingMember2024-01-012024-03-310001689548us-
gaap:CommonStockMemberprax:LicenseAndCollaborationAgreementMember2024-01-012024-03-310001689548us-
gaap:AdditionalPaidInCapitalMemberprax:LicenseAndCollaborationAgreementMember2024-01-012024-03-310001689548prax:LicenseAndCollaborationAgreementMember2024-01-012024-03-
310001689548us-gaap:CommonStockMember2024-01-012024-03-310001689548us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001689548us-
gaap:RetainedEarningsMember2024-01-012024-03-310001689548us-gaap:CommonStockMember2024-03-310001689548us-gaap:AdditionalPaidInCapitalMember2024-03-310001689548us-
gaap:RetainedEarningsMember2024-03-310001689548us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-3100016895482024-03-310001689548us-
gaap:AdditionalPaidInCapitalMember2024-04-012024-06-3000016895482024-04-012024-06-300001689548prax:FollowOnOfferingMember2024-04-012024-06-300001689548us-
gaap:CommonStockMemberprax:FollowOnOfferingMember2024-04-012024-06-300001689548us-gaap:AdditionalPaidInCapitalMemberprax:FollowOnOfferingMember2024-04-012024-06-
300001689548us-gaap:CommonStockMember2024-04-012024-06-300001689548us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300001689548us-
gaap:RetainedEarningsMember2024-04-012024-06-300001689548us-gaap:CommonStockMember2024-06-300001689548us-gaap:AdditionalPaidInCapitalMember2024-06-300001689548us-
gaap:RetainedEarningsMember2024-06-300001689548us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-3000016895482024-06-300001689548us-
gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001689548prax:AtTheMarketOfferingMember2024-07-012024-09-300001689548us-
gaap:CommonStockMemberprax:FollowOnOfferingMember2024-07-012024-09-300001689548us-gaap:AdditionalPaidInCapitalMemberprax:FollowOnOfferingMember2024-07-012024-09-
300001689548prax:FollowOnOfferingMember2024-07-012024-09-300001689548us-gaap:CommonStockMember2024-07-012024-09-300001689548us-
gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001689548us-gaap:RetainedEarningsMember2024-07-012024-09-300001689548us-
gaap:CommonStockMember2024-09-300001689548us-gaap:AdditionalPaidInCapitalMember2024-09-300001689548us-gaap:RetainedEarningsMember2024-09-300001689548us-
gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001689548us-gaap:CommonStockMember2022-12-310001689548us-gaap:AdditionalPaidInCapitalMember2022-12-
310001689548us-gaap:RetainedEarningsMember2022-12-310001689548us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-3100016895482022-12-310001689548us-
gaap:AdditionalPaidInCapitalMember2023-01-012023-03-3100016895482023-01-012023-03-310001689548prax:AtTheMarketOfferingMember2023-01-012023-03-310001689548us-
gaap:CommonStockMember2023-01-012023-03-310001689548us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001689548us-
gaap:RetainedEarningsMember2023-01-012023-03-310001689548us-gaap:CommonStockMember2023-03-310001689548us-gaap:AdditionalPaidInCapitalMember2023-03-310001689548us-
gaap:RetainedEarningsMember2023-03-310001689548us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-3100016895482023-03-310001689548us-
gaap:AdditionalPaidInCapitalMember2023-04-012023-06-3000016895482023-04-012023-06-300001689548prax:FollowOnOfferingMember2023-04-012023-06-300001689548us-
gaap:CommonStockMemberprax:FollowOnOfferingMember2023-04-012023-06-300001689548us-gaap:AdditionalPaidInCapitalMemberprax:FollowOnOfferingMember2023-04-012023-06-
300001689548us-gaap:CommonStockMemberprax:AtTheMarketOfferingMember2023-04-012023-06-300001689548us-
gaap:AdditionalPaidInCapitalMemberprax:AtTheMarketOfferingMember2023-04-012023-06-300001689548prax:AtTheMarketOfferingMember2023-04-012023-06-300001689548us-
gaap:CommonStockMember2023-04-012023-06-300001689548us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001689548us-
gaap:RetainedEarningsMember2023-04-012023-06-300001689548us-gaap:CommonStockMember2023-06-300001689548us-gaap:AdditionalPaidInCapitalMember2023-06-300001689548us-
gaap:RetainedEarningsMember2023-06-300001689548us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-3000016895482023-06-300001689548us-
gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001689548us-gaap:CommonStockMember2023-07-012023-09-300001689548us-gaap:RetainedEarningsMember2023-07-012023-
09-300001689548us-gaap:CommonStockMember2023-09-300001689548us-gaap:AdditionalPaidInCapitalMember2023-09-300001689548us-gaap:RetainedEarningsMember2023-09-
300001689548us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-3000016895482023-09-300001689548prax:FollowOnOfferingMember2024-01-012024-09-
300001689548prax:FollowOnOfferingMember2023-01-012023-09-300001689548prax:LicenseAndCollaborationAgreementMember2024-01-012024-09-
300001689548prax:LicenseAndCollaborationAgreementMember2023-01-012023-09-300001689548prax:AtTheMarketOfferingMember2024-01-012024-09-
300001689548prax:AtTheMarketOffering

emerging growth company. See the definitions “accelerated filer,” “smaller reporting company,” and “emerging growth company.” If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. A “ ” Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). A “ ” Yes A “ ” No A “ ” As of November 1, 2024, the registrant had 18,637,777 shares of common stock, \$0.0001 par value per share, outstanding.SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTSThis Quarterly Report on Form 10-Q contains express or implied forward-looking statements that are based on our management’s belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements about:the success, cost and timing of our product candidate development activities and clinical trials;our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates;the ability to license additional intellectual property relating to our product candidates from third parties and to comply with our existing license agreements and collaboration agreements;the ability and willingness of our third-party research institution collaborators to continue research and development activities relating to our product candidates;our ability to commercialize our product candidates, if approved, in light of the intellectual property rights of others;our ability to obtain funding for our operations, including funding necessary to complete further development and, if approved, commercialization of our product candidates;the commercialization of our product candidates, if approved;our plans to research, develop and, if approved, commercialize our product candidates;future agreements with third parties in connection with the commercialization of our product candidates, if approved, and any other approved product;the size and growth potential of the markets for our product candidates, and our ability to serve those markets;the rate and degree of market acceptance of our product candidates, if approved;the pricing and reimbursement of our product candidates, if approved;regulatory developments in the United States and foreign countries;our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;the success of competing therapies that are or may become available;our ability to attract and retain key scientific or management personnel; andthe accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expect,” “anticipate,” “plan,” “estimate,” “believe,” “estimate,” “predict,” “potential,” “continue” or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section titled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance. You should read this Quarterly Report on Form 10-Q and the documents that we reference in this Quarterly Report on Form 10-Q and have filed with the Securities and Exchange Commission as exhibits hereto completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements.The forward-looking statements in this Quarterly Report on Form 10-Q represent our views as of the date of this Quarterly Report on Form 10-Q. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Quarterly Report on Form 10-Q.This Quarterly Report on Form 10-Q also contains estimates, projections and other information concerning our industry, our business and the markets for our product candidates. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market, and other data from our own internal estimates and research as well as from reports, research surveys, studies, and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources. While we are not aware of any misstatements regarding any third-party information presented in this Quarterly Report on Form 10-Q, their estimates, in particular, as they relate to projections, involve numerous assumptions, are subject to risks and uncertainties and are subject to change based on various factors, including those discussed under the section titled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023.Table of ContentsA PagePART I.FINANCIAL INFORMATIONItem 1.Financial Statements (Unaudited)Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2024 and 2023Condensed Consolidated Statements of Comprehensive Loss for the Three and Nine Months Ended September 30, 2024 and 2023Condensed Consolidated Statements of Stockholders’ Equity for the Three and Nine Months Ended September 30, 2024 and 2023Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2024 and 2023Notes to Condensed Consolidated Financial StatementsItem 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations18Item 3.Quantitative and Qualitative Disclosures About Market Risk29Item 4.Controls and Procedures29PART II.OTHER INFORMATION31Item 1.Legal Proceedings31Item 1A.Risk Factors31Item 2.Unregistered Sales of Equity Securities and Use of Proceeds31Item 3.Defaults Upon Senior Securities31Item 4.Mine Safety Disclosures31Item 5.Other Information31Item 6.Exhibits32Signatures33PART I&cFINANCIAL INFORMATIONItem 1. Financial Statements.PRAXIS PRECISION MEDICINES, INC.CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)(Amounts in thousands, except share and per share data)September 30, 2024December 31, 2023AssetsCurrent assets:Cash and cash equivalents\$168,645\$81,300 Marketable securities188,387\$ — A Prepaid expenses and other current assets3,016\$ 3,580 Total current assets360,048\$ 84,880 Long-term marketable securities54,141\$ — A Property and equipment, net277\$ 588 Operating lease right-of-use assets1,374\$ 2,064 Other non-current assets416\$ 416 Total assets\$416,256\$87,948 Liabilities and stockholders’ equityCurrent liabilities:Accounts payable\$15,010\$ 5,815 Accrued expenses15,457\$ 7,416 Operating lease liabilities1,224\$ 1,126 Current portion of deferred revenue1,170\$ 1,392 Total current liabilities32,861\$ 15,749 Long-term liabilities:Non-current portion of operating lease liabilities436\$ 1,369 Non-current portion of deferred revenue293\$ 1,161 Total liabilities33,590\$ 18,279 Commitments and contingencies (Note 6)Stockholders’ equity:Preferred stock, \$0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of September 30, 2024 and December 31, 2023\$ — A Common stock, \$0.0001 par value; 150,000,000 shares authorized; 17,785,697 shares issued and outstanding as of September 30, 2024, and 8,791,877 shares issued and outstanding as of December 31, 202314\$ 13 Additional paid-in capital1,159,382\$ 723,577 Accumulated other comprehensive gain1,331\$ — A Accumulated deficit(778,061)(653,921)Total stockholders’ equity382,666\$ 69,669 Total liabilities and stockholders’ equity\$416,256\$87,948 The accompanying notes are an integral part of these condensed consolidated financial statements.1PRAXIS PRECISION MEDICINES, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(Unaudited)(Amounts in thousands, except share and per share data)Three Months EndedSeptember 30,Nine Months EndedSeptember 30,20242023Collaboration revenue\$302\$ 468\$ 1,090\$ 1,932 Operating expenses:Research and development41,881\$ 17,260\$ 96,125\$ 68,378 General and administrative15,256\$ 8,724\$ 41,174\$ 32,121 Total operating expenses57,137\$ 25,984\$ 137,299\$ 100,499 Loss from operations(\$6,835)(25,516)(136,209)(96,567)Other income:Net loss from employee stock purchase plan2,168\$ 2,168 Total other income4,925\$ 4,925 Net loss (\$1,910)(24,632)(124,140)(96,399)Net loss per share attributable to common stockholders, basic and diluted118,884,562\$ 9,039,427\$ 17,210,604\$ 5,763,121 1 Results have been retroactively adjusted to reflect the 1-for-15 reverse stock split effected on November 28, 2023. See Note 2 for details.The accompanying notes are an integral part of these condensed consolidated financial statements.2PRAXIS PRECISION MEDICINES, INC.CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS(Unaudited)(Amounts in thousands)Three Months EndedSeptember 30,Nine Months EndedSeptember 30,20242023Net loss(\$1,910)(24,632)(124,140)(96,399)Change in unrealized gain on marketable securities, net of tax1,402\$ — A 1,331\$ 173 Comprehensive loss(\$50,508)(24,632)(122,809)(96,226)The accompanying notes are an integral part of these condensed consolidated financial statements.3PRAXIS PRECISION MEDICINES, INC.CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (Unaudited)(Amounts in thousands, except share data)Common StockAdditional Paid-In CapitalAccumulated DeficitAccumulated Other Comprehensive Income (Loss)Total Stockholders’ EquitySharesAmountBalance at December 31, 20238,791,877\$ 13\$ 723,577\$ (653,921)\$ — A \$69,669 Stock-based compensation expense\$ — A \$ — A 14,475\$ — A \$ — A 14,475 Issuance of common stock from follow-on public offering and accompanying pre-funded warrants, net of underwriting discounts, commissions and offering costs of \$10,836,802,025\$ — A \$161,649\$ — A \$161,649 Issuance of common stock from at-the-market public offerings, net of issuance and commission costs of \$376,209,852\$ — A \$6,169\$ — A \$6,169 Issuance of common stock from a collaboration and license agreement443,253\$ — A \$17,265\$ — A \$17,265 Vesting of restricted stock units11,095\$ — A \$ — A \$ — A Shares withheld for taxes for vesting of restricted stock units(3,689)\$ — A (137)\$ — A (137)Issuance of common stock upon exercise of stock options3,634\$ — A \$143\$ — A \$143 Change in unrealized gain on marketable securities, net of tax\$ — A \$ — A 3A 3A Net loss\$ — A \$ — A (39,553)\$ — A (39,553)Balance at March 31, 202413,258,047\$ 13\$ 923,141\$ (693,474)\$ 3A \$229,683 Stock-based compensation expense\$ — A \$ — A 5,878\$ — A \$ — A 5,878 Issuance of common stock from follow-on public offering and accompanying pre-funded warrants, net of underwriting discounts, commissions and offering costs of \$14,013,849,558\$ 14\$ 215,987\$ — A \$215,988 Issuance of common stock from exercise of pre-funded warrants622,123\$ — A \$ — A \$ — A \$ — A Issuance of common stock under employee stock purchase plan25,146\$ — A \$311\$ — A \$311 Vesting of restricted stock units726\$ — A \$ — A \$ — A \$ — A Shares withheld for taxes for vesting of restricted stock units(242)\$ — A (13)\$ — A (13)Issuance of common stock upon exercise of stock options148\$ — A \$4\$ — A \$4 Change in unrealized loss on marketable securities, net of tax\$ — A \$ — A (74)(74)Net loss\$ — A \$ — A (32,677)\$ — A (32,677)Balance at June 30, 202417,755,506\$ 14\$ 1,145,308\$ (726,151)\$ (71)\$419,100 Stock-based compensation expense\$ — A \$12,432\$ — A \$12,432 Issuance of common stock from at-the-market public offerings, net of issuance and commission costs of \$702,5,189\$ — A \$1,442\$ — A \$1,442 Issuance of common stock from exercise of stock options4,971\$ — A \$201\$ — A \$201 Vesting of restricted stock units51\$ — A \$ — A \$ — A \$ — A Shares withheld for taxes for vesting of restricted stock units(20)\$ — A (1)\$ — A (1)Change in unrealized loss on marketable securities, net of tax\$ — A \$ — A 1,402\$ — A 1,402 Net loss\$ — A \$ — A (51,910)\$ — A (51,910)Balance at September 30, 202417,785,697\$ 14\$ 1,159,382\$ (778,061)\$1,331\$382,666 The accompanying notes are an integral part of these condensed consolidated financial statements.4PRAXIS PRECISION MEDICINES, INC.CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (continued)(Unaudited)(Amounts in thousands, except share data)Common StockAdditional Paid-In CapitalAccumulated DeficitAccumulated Other Comprehensive LossTotal Stockholders’ EquitySharesAmountBalance at December 31, 2023292,163\$ 5\$ 606,918\$ (530,644)\$ (73)\$76,106 Stock-based compensation expense\$ — A \$7,593\$ — A \$7,593 Issuance of common stock from at-the-market public offerings, net of commission costs of \$560,560,253\$ 1\$ 18,095\$ — A \$18,095 Vesting of restricted stock units11,516\$ — A \$ — A \$ — A \$ — A Shares withheld for taxes for vesting of restricted stock units(2,87

models and electrophysiology markers, to enable an efficient path to proof-of-concept in patients. Through this approach, the Company has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy. For the Company's most advanced product candidate under the Cerebrum, a platform, ulixacaltamide, our Phase 3 Essential3 clinical trials in essential tremor are ongoing. The Company is planning to conduct an interim analysis in the first quarter of 2025. Within the Company's vormaltrigine program (formerly known as PRAX-628), it announced positive results from its Photo-Paroxysmal Response ("PPR") study in the first quarter of 2024, and the Company has initiated or plans to initiate four studies to generate patient eligibility, efficacy, safety and pharmacokinetics (PK) data for the program. The Company initiated an observational study of vormaltrigine in patients with epilepsy in the third quarter of 2024, and has initiated or plans to initiate three efficacy studies. The first efficacy study will be an open label eight-week study in patients with focal onset seizures or generalized epilepsy expected to be initiated in the fourth quarter of 2024, with topline results expected in the first half of 2025. The Company also initiated a double-blind, placebo-controlled, 12-week study in focal onset seizures in the fourth quarter of 2024, with topline results expected in the second half of 2025, and plans to initiate a third efficacy study in the first half of 2025. Within the Company's relutrigine (formerly known as PRAX-562) program, it announced positive topline results from the first cohort of the EMBOLD study in the third quarter of 2024, and has initiated enrollment of the second cohort, with topline results expected in the first half of 2026. For the Company's most advanced product candidate under the Solisuda, a platform, elsunersen (formerly known as PRAX-222), it shared results from Part 1 of the EMBRAVE study in the fourth quarter of 2023, and has initiated the first arm of the global confirmatory study in Brazil. It is currently completing multiple global regulatory interactions to further expand the pivotal phase of the program later in 2024. Praxis was incorporated in 2015 and commenced operations in 2016. The Company has funded its operations primarily with proceeds from the issuance of redeemable convertible preferred stock, from the sale of common stock through an initial public offering and at-the-market offerings under its shelf registration statement, and from follow-on public offerings of common stock and pre-funded warrants to purchase common stock. From inception through September 30, 2024, the Company raised \$1.0 billion in aggregate cash proceeds from these transactions, net of issuance costs. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including but not limited to, risks associated with completing preclinical studies and clinical trials, receiving regulatory approvals for product candidates, development by competitors of new biopharmaceutical products, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Programs currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory 7 approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company's product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales. Liquidity In accordance with the Financial Accounting Standards Board (the "FASB") Accounting Standards Update (the "ASU") 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued. The Company has incurred recurring losses since its inception, including a net loss of \$124.1 million for the nine months ended September 30, 2024. In addition, as of September 30, 2024, the Company had an accumulated deficit of \$778.1 million. The Company expects to continue to generate operating losses for the foreseeable future. The Company expects that its cash, cash equivalents and marketable securities as of September 30, 2024 of \$411.2 million will be sufficient to fund its operating expenditures and capital expenditure requirements necessary to advance its research efforts and clinical trials for at least one year from the date of issuance of these condensed consolidated financial statements. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company's inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurance that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all. 2. Summary of Significant Accounting Policies Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (the "GAAP"). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (the "ASC") and ASUs of the FASB. The significant accounting policies used in preparation of these condensed consolidated financial statements for the three and nine months ended September 30, 2024 are consistent with those discussed in Note 2 to the consolidated financial statements included in the Company's 2023 Annual Report on Form 10-K, other than as noted below. Reverse Stock Split On November 28, 2023, the Company filed a Certificate of Amendment to the Company's Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The Reverse Stock Split became effective at 5:00 p.m., Eastern Time, on November 28, 2023 (the "Effective Time"). As a result of the Reverse Stock Split, every 15 shares of the Company's issued and outstanding common stock were automatically reclassified into one validly issued, fully-paid and non-assessable share of common stock. Any fractional post-split shares as a result of the Reverse Stock Split were rounded down to the nearest whole post-split share. The Reverse Stock Split did not affect the number of authorized shares of common stock or the par value of the common stock. All share amounts and per share amounts for the periods prior to the Effective Time disclosed in this Quarterly Report on Form 10-Q have been restated to reflect the Reverse Stock Split on a retroactive basis. Marketable Securities Classification The Company may invest its excess cash in money market funds and debt instruments of the U.S. Treasury, financial institutions, corporations and U.S. government agencies with strong credit ratings and an investment grade rating at or above A-1 or P-1 by two of the three nationally recognized statistical rating organizations. The Company does not believe that it is exposed to more than a nominal amount of credit risk related to any marketable securities it may invest in. The Company has established guidelines relative to diversification and maturities that maintain safety and liquidity, and periodically reviews and modifies these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity. The Company classifies its investments in debt instruments as available-for-sale. Available-for-sale investments are reported at fair value at each balance sheet date, and include any unrealized holding gains and losses in accumulated other comprehensive loss, a component of stockholders' equity. Realized gains and losses are included in the Company's condensed consolidated statements of operations. All of the Company's available-for-sale securities are available for use in its current operations. The Company classifies marketable securities as either cash equivalents, short-term, or long-term based on their stated maturity dates as it is more-likely-than-not that the Company will hold these assets through to their maturity dates. Unaudited Interim Condensed Consolidated Financial Information The accompanying condensed consolidated balance sheet as of September 30, 2024, the condensed consolidated statements of operations for the three and nine months ended September 30, 2024 and 2023, the condensed consolidated statements of comprehensive loss for the three and nine months ended September 30, 2024 and 2023, the condensed consolidated statements of cash flows for the nine months ended September 30, 2024 and 2023 and the condensed consolidated statements of stockholders' equity for the three and nine months ended September 30, 2024 and 2023 are unaudited. The unaudited interim financial statements have been prepared on the same basis as the audited annual consolidated financial statements, and in the opinion of management reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company's financial position as of September 30, 2024, the results of its operations for the three and nine months ended September 30, 2024 and 2023 and its cash flows for the nine months ended September 30, 2024 and 2023. Financial statement disclosures for the three and nine months ended September 30, 2024 and 2023 are condensed and do not include all disclosures required for an annual set of financial statements in accordance with GAAP. The results for the three and nine months ended September 30, 2024 are not necessarily indicative of results to be expected for the year ended December 31, 2024, any other interim periods, or any future year or period. Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, accrued and prepaid research and development expense, collaboration revenue, stock-based compensation expense and the recoverability of the Company's net deferred tax assets and related valuation allowance. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates. Common Stock Warrants The Company accounts for warrants to purchase shares of its common stock in accordance with the guidance in FASB ASC No. 480, Distinguishing Liabilities from Equity (ASC 480) and ASC No. 815, Derivatives and Hedging (ASC 815). The Company classifies warrants issued for the purchase of shares of its common stock as either equity or liability instruments based on an assessment of the specific terms and conditions of each respective contract. Such assessment includes determining whether the warrants are freestanding financial instruments or embedded in a host instrument, whether the warrants are liabilities within the scope of ASC 480, whether the warrants meet the definition of a derivative in ASC 815 and whether the warrants meet the requirements for equity classification pursuant to the indexation and equity classification criteria in ASC 815. The Company determines the classification for its warrants at the time of issuance and updates its assessment, as necessary. Warrants that meet all of the criteria for equity classification are recorded as a component of additional paid-in capital. Net Loss per Share Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. The calculation of weighted average number of common shares outstanding excludes shares of restricted common stock that are not vested but includes shares of common stock underlying pre-funded 9 warrants. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period, after giving consideration to the dilutive effect of potentially dilutive common shares. For purposes of this calculation, outstanding options to purchase shares of common stock, unvested shares of restricted common stock and potential shares issuable under the 2020 ESPP are considered potentially dilutive common shares. The Company has generated a net loss in all periods presented so the basic and diluted net loss per share are the same, as the inclusion of the potentially dilutive securities would be anti-dilutive. Recent Accounting Pronouncements Recently Issued Accounting Pronouncements On November 27, 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures. ASU No. 2023-07 improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The amendments included in this ASU apply to all public entities that are required to report segment information in accordance with Topic 280, including those with a single reportable segment. The amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and should be applied retrospectively to all prior periods presented in the financial statements. Upon transition, the segment expenses categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The Company only has one reportable segment and this ASU impacts disclosures only. The Company has determined that the effects of adopting the amendments in ASU 2023-07 will only impact its disclosures and not have a material impact on its consolidated financial position and the results of its operations when such amendment is adopted. On December 14, 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740) - Improvements to Income Tax Disclosures. ASU No. 2023-09 provides more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and incomes taxes paid information. For public companies, the amendments are effective for annual periods beginning after December 15, 2024 and should be applied prospectively. The Company has determined that the effects of adopting the amendments in ASU 2023-09 will only impact its disclosures and will not have a material impact on its consolidated financial position and the results of its operations when such amendment is adopted. 3. Cash Equivalents and Marketable Securities The following is a summary of the Company's investment portfolio as of September 30, 2024 (in thousands). The Company did not hold any cash equivalents or marketable securities as of December 31, 2023. As of September 30, 2024 Gross Unrealized Estimated Cost Gains/Losses Fair Value Cash equivalents: Money market funds \$81,359.4 \$ 81,359.4 Available-for-sale marketable securities: Debt securities issued by U.S. government agencies 143,283.4 900.4 \$ 144,183.4 Corporate debt securities 74,715.4 370.4 \$ 75,085.4 Commercial paper 18,543.4 45.4 \$ 18,588.4 Other debt securities 4,656.1 16.4 \$ 4,672.4 Total cash equivalents and marketable securities \$322,556.1 \$1,331.4 \$ 323,887.5 As of September 30, 2024, the Company had 3 securities with a total fair market value of \$8.0 million in an unrealized loss position. The Company believes that any unrealized losses associated with the decline in value of its securities is temporary and primarily related to the change in market interest rates since purchase, and believes that it is more likely than not that it will be able to hold its debt securities to maturity. The Company anticipates a full recovery of the amortized cost basis of its debt securities at maturity and an allowance was not recognized. Contractual maturities of the marketable securities at each balance sheet date are as follows (in thousands): 10 September 30, 2024 December 31, 2023 Within one year \$188,387.4 After one year through five years 54,141.4 Total \$242,528.8 Securities are evaluated for impairment at the end of each reporting period. The Company did not record any impairment related to its available-for-sale securities during the three and nine months ended September 30, 2024 and 2023. 4. Fair Value Measurements Fair value is defined as the price that would be received to sell an asset in an orderly transaction between market participants at the measurement date. The Company categorizes financial assets measured at fair value based on a fair value hierarchy. The following fair value hierarchy is used to classify financial assets based on observable inputs and unobservable inputs used to value the financial assets: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets; Level 2: Quoted prices for similar assets in active markets, quoted prices in markets that are not active, or inputs which are unobservable, either directly or indirectly, for substantially the full term of the asset; or Level 3: Prices or valuation techniques that require inputs that are both significant to the valuation of the asset and unobservable. The following table presents information about the Company's financial assets measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values as of September 30, 2024 (in thousands). The Company did not hold any financial assets measured at fair value on a recurring basis as of December 31, 2023. As of September 30, 2024 Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market funds \$81,359.4 \$ 81,359.4 Available-for-sale marketable securities: Debt securities issued by U.S. government agencies 144,183.4 \$ 144,183.4 Corporate debt securities \$ 75,085.4 \$ 75,085.4 Commercial paper \$ 18,588.4 \$ 18,588.4 Other debt securities \$ 4,672.4 \$ 4,672.4 \$225,542.4 \$98,345.4 \$ 323,887.5 Accrued Expenses Accrued expenses consisted of the following (in thousands): September 30, 2024 December 31, 2023 Accrued external research and development expenses \$11,756.4 \$2,957.4 Accrued personnel-related expenses 3,162.4 3,716.4 Accrued other expenses 539.4 743.4 Total accrued expenses \$15,457.4 \$7,416.4 6. Commitments and Contingencies 11 In May 2021, the Company entered into a sublease agreement for office space located in Boston, Massachusetts that expires on January 31, 2026, with no option to renew or terminate early. The base rent increases by approximately 2% annually. The Company issued a letter of credit to the landlord related to the security deposit, secured by restricted cash, which is reflected within other non-current assets on the accompanying condensed consolidated balance sheets as of September 30, 2024 and December 31, 2023. This lease qualifies as an operating lease. 7. Collaboration and License Agreements UCB Option and License Agreement In December 2022, the Company entered into an Option and License Agreement (the "Collaboration Agreement") with UCB Biopharma SRL (the "UCB") for the discovery of small molecule therapeutics as potential treatments of KCNT1-related epilepsies. Under the terms of the Collaboration Agreement, the Company has agreed to perform general biology-related research services as part of a mutually agreed upon research plan in exchange for a \$5.0 million upfront payment. In addition, the Company provided UCB an exclusive option to in-license global development and commercialization rights to any resulting KCNT1 small molecule development candidate identified as part of the research plan. If UCB exercises its option to in-license global development and commercialization rights, the Collaboration Agreement stipulates that UCB will assume research, development, manufacturing and commercialization responsibilities and costs. Under the terms of the Collaboration Agreement, the Company will be eligible to receive an option fee and future success-based development and commercialization milestone payments, totaling up to \$98.5 million, in addition to tiered royalties on net sales of any resulting products from the Collaboration Agreement. The Company concluded that UCB is a customer, and as such, the arrangement falls within the scope of Topic 606. At the commencement of the Collaboration Agreement, the Company identified one performance obligation, which was to perform the research services for UCB. The Company determined the transaction price to be \$5.0 million, comprised of the upfront payment it received. The option provided to UCB was determined not to be a material right. The Company recognizes revenue for its research services performance obligation over time using an input method over the duration of the research services. During the three and nine months ended September 30, 2024, the Company recognized \$0.3 million and \$1.1 million, respectively, in collaboration revenue related to the Collaboration Agreement in the condensed consolidated statement of operations. As of September 30, 2024, \$1.5 million was included in deferred revenue in the condensed consolidated balance sheet, of which \$1.2 million was classified as current.

Tenacia Collaboration and License Agreement

On January 4, 2024, the Company entered into an exclusive collaboration and license Agreement (the "License Agreement") with Tenacia Biotechnology (Shanghai) Co., Ltd. (the "Tenacia"), a China-based portfolio company of Bain Capital, which provides Tenacia an exclusive license to use certain intellectual property for the development and commercialization of ulixalcaltamide and products containing ulixalcaltamide in China, Hong Kong, Macau and Taiwan. Tenacia is solely responsible for the development and commercialization under the arrangement, with the exception of the associated manufacturing. The Company also entered into a Stock Purchase Agreement (the "Stock Purchase Agreement") with BCPE Tenet Holdings Cayman, Ltd. (the "BCPE"), a related party of Tenacia. Pursuant to the terms of the License Agreement, the Company was entitled to an up-front, non-refundable and non-creditable cash payment of \$5.0 million, net of certain tax withholdings. In addition, the Company is eligible to receive \$264.0 million in success-based development and commercialization milestone payments as well as tiered royalties on net sales. Pursuant to the terms of the Stock Purchase Agreement, the Company issued and sold 443,253 shares of its common stock to BCPE at a price per share of \$22.5605 for aggregate gross proceeds of \$10.0 million. The per share price was based on a 20% premium over the 30-day volume-weighted average price. Under the terms of the License Agreement, the Company granted to Tenacia an exclusive license to use certain intellectual property for the development and commercialization of ulixalcaltamide and products containing ulixalcaltamide in China, Hong Kong, Macau and Taiwan. Tenacia is solely responsible for the development and commercialization under the arrangement, with the exception of the associated manufacturing. The Company concluded that the License Agreement and the Stock Purchase Agreement is a combined arrangement since they were executed at the same time and in contemplation of each other with the same counterparty or a related party thereof and the combined arrangement falls within the scope of Topic 606. 12The Company's obligations under the arrangement comprise a single promise, or one performance obligation, related to the exclusive development and commercialization license granted to Tenacia. Total proceeds associated with the combined arrangement at inception were \$14.8 million consisting of the following: (i) \$10.0 million gross proceeds from the sale of common stock under the Stock Purchase Agreement and (ii) \$4.8 million, net of tax, related to the up-front payment under the License Agreement, both of which were received in January 2024. During the three and nine months ended September 30, 2024, the Company had not achieved any development or sales milestones or earned any royalties under the License Agreement. The Company recorded the common stock sold to BCPE at its issuance date fair value of \$38.95 per share, or \$17.3 million in the aggregate, which exceeded the proceeds received which were calculated based on the 20% premium over the prior 30-day volume-weighted average price. Accordingly, there is no transaction price allocable to the performance obligation. The Company accounted for the excess of the fair value of the equity securities issued over the total proceeds received as consideration paid to a customer for which no distinct good or service was transferred in exchange. As a result, the transaction gives rise to negative revenue on a cumulative basis in the amount of \$2.5 million, which was recorded in research and development expense in the accompanying condensed consolidated statement of operations for the three months ended March 31, 2024. For agreements where the licenses are considered separate performance obligations or represent the only performance obligation, the Company recognizes revenue at the point in time that the Company effectively grants the license, as the licenses or assignments represent functional intellectual property. As of September 30, 2024, the Company did not have any receivables or deferred revenue related to the arrangement with Tenacia. The Company did not recognize any contract assets related to costs to obtain a contract with a customer or costs to fulfill a contract with a customer through September 30, 2024 because no qualifying costs were incurred. During the three and nine months ended September 30, 2024, the Company did not recognize any revenue associated with the combined arrangement. 8. Common Stock and Preferred Stock Reverse Stock Split On November 28, 2023, the Company filed a Certificate of Amendment to the Company's Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a 1-for-15 reverse stock split of its common stock. The Reverse Stock Split became effective at 5:00 p.m., Eastern Time, on November 28, 2023. As a result of the Reverse Stock Split, every 15 shares of the Company's issued and outstanding common stock were automatically reclassified into one validly issued, fully-paid and non-assessable share of common stock. Any fractional post-split shares as a result of the Reverse Stock Split were rounded down to the nearest whole post-split share. The Reverse Stock Split did not affect the number of authorized shares of common stock or the par value of the common stock. All share amounts and per share amounts for the period prior to the Effective Time disclosed in this Quarterly Report on Form 10-Q have been restated to reflect the Reverse Stock Split on a retroactive basis. Common Stock As of September 30, 2024 and December 31, 2023, the authorized capital stock of the Company included 150,000,000 shares of common stock, \$0.0001 par value. As of September 30, 2024 and December 31, 2023, the Company did not hold any treasury shares. Follow-On Public Offerings June 2023 Public Offering On June 21, 2023, the Company completed a public offering of: (i) an aggregate of 4,296,646 shares of its common stock at a public offering price of \$14.25 per share, including the underwriters' full exercise of their option to purchase 619,979 additional shares of common stock, and (ii) pre-funded warrants to purchase 470,000 shares of common stock at a public offering price of \$14.2485 per share of common stock underlying the warrants. The purchase price per share for each pre-funded warrant represents the per share offering price for the common stock, less the \$0.0015 per share exercise price for each underlying share. Total net proceeds generated from the offering were approximately \$63.4 million, after deducting underwriting discounts, commissions and other offering expenses payable by the Company. 13 During the nine months ended September 30, 2024, all pre-funded warrants associated with this offering were exercised via a cashless exercise, resulting in 469,981 shares of common stock issued. No cash proceeds associated with the exercise were received by the Company. As of September 30, 2024, there were no pre-funded warrants associated with this offering outstanding. January 2024 Public Offering On January 16, 2024, the Company completed a public offering of: (i) an aggregate of 3,802,025 shares of its common stock at a public offering price of \$35.50 per share, including the underwriters' full exercise of their option to purchase 633,750 additional shares of common stock, and (ii) pre-funded warrants to purchase 1,056,725 shares of common stock at a public offering price of \$35.4999 per share of common stock underlying the warrants. The purchase price per share of each pre-funded warrant represents the per share offering price for the common stock, less the \$0.0001 per share exercise price of each underlying share. Total net proceeds generated from the offering were approximately \$161.6 million, after deducting underwriting discounts, commissions and other offering expenses payable by the Company. The pre-funded warrants are exercisable at any time on or after the date of issuance at the option of the holder, subject to a beneficial ownership blocker that may limit exercisability. No holder may exercise any portion of the warrants that would cause the aggregate number of shares of common stock beneficially owned by such holder, together with its affiliates, to exceed 4.99% (or 9.99%) of the issued and outstanding common stock. A holder of a pre-funded warrant may increase or decrease this percentage up to 19.99% by providing at least 61 days' prior notice to the Company. The pre-funded warrants may be settled through either physical or net share settlement. Following the occurrence of certain fundamental transactions, the holders of the pre-funded warrants have the right to receive upon exercise of the warrants the same amount and kind of securities, cash, or property as they would have been entitled to receive if they had been holders of the common shares issuable under the warrants immediately prior to such transaction. During the nine months ended September 30, 2024, 152,145 pre-funded warrants were exercised via a cashless exercise, resulting in 152,142 shares of common stock issued. No cash proceeds associated with the exercise were received by the Company. As of September 30, 2024, a total of 904,580 pre-funded warrants associated with this offering remained outstanding. April 2024 Public Offering On April 2, 2024, the Company completed a public offering of: (i) an aggregate of 3,849,558 shares of its common stock at a public offering price of \$56.50 per share, including the underwriters' full exercise of their option to purchase 530,973 additional shares of common stock, and (ii) pre-funded warrants to purchase 221,238 shares of common stock at a public offering price of \$56.4999 per share of common stock underlying the warrants. The purchase price per share for each pre-funded warrant represents the per share offering price for the common stock, less the \$0.0001 per share exercise price of each underlying share. Total net proceeds generated from the offering were approximately \$216.0 million, after deducting underwriting discounts, commissions and other offering expenses payable by the Company. The pre-funded warrants are exercisable at any time on or after the date of issuance at the option of the holder, subject to a beneficial ownership blocker that may limit exercisability. No holder may exercise any portion of the warrants that would cause the aggregate number of shares of common stock beneficially owned by such holder, together with its affiliates, to exceed 4.99% (or 9.99%) of the issued and outstanding common stock. A holder of a pre-funded warrant may increase or decrease this percentage up to 19.99% by providing at least 61 days' prior notice to the Company. The pre-funded warrants do not expire. The pre-funded warrants may be settled through either physical or net share settlement. Following the occurrence of certain fundamental transactions, the holders of the pre-funded warrants have the right to receive upon exercise of the warrants the same amount and kind of securities, cash, or property as they would have been entitled to receive if they had been holders of the common shares issuable under the warrants immediately prior to such transaction. As of September 30, 2024, none of the pre-funded warrants had been exercised and all remained outstanding. The Company determined that the pre-funded warrants related to the June 2023, January 2024, and April 2024 public offerings are freestanding financial instruments because they are both legally detachable and separately exercisable from the common stock sold in the offering. As such, the Company evaluated the pre-funded warrants to determine whether they represent instruments that require liability classification pursuant to the guidance in ASC 480. However, the Company concluded that the pre-funded warrants are not a liability within the scope of ASC 480 due to their characteristics. Further, the Company determined that the pre-funded warrants do not meet the definition of a derivative under ASC 815 because they do not meet the criteria regarding no or little initial net investment. Accordingly, the Company assessed the pre-funded warrants relative to the guidance in ASC 14N. 815-40, Contracts in Entity's Own Equity, to determine the appropriate treatment. The Company concluded that the pre-funded warrants are both indexed to its own stock and meet all other conditions for equity classification. Accordingly, the Company has classified the pre-funded warrants as permanent equity. Shares Reserved for Future Issuance The Company has reserved the following shares of common stock for future issuance: September 30, 2024 December 31, 2023 Shares reserved for exercise of outstanding stock options 1,829,324 666,163 A Shares reserved for exercise of pre-funded warrants related to the June 2023 Financing 470,000 A Shares reserved for exercise of pre-funded warrants related to the January 2024 Financing 904,580 A Shares reserved for exercise of pre-funded warrants related to the April 2024 Financing 221,238 A Shares reserved for future awards under the 2020 Stock Option and Incentive Plan 115,058 A 148,264 A Shares reserved for future awards under the 2020 Employee Stock Purchase Plan 115,883 A 53,111 A Shares reserved for future awards under the 2024 Inducement Plan 112,774 A Shares reserved for vesting of restricted stock units 222,674 A 47,145 A Total shares of authorized common stock reserved for future issuance 3,521,531 A 1,384,683 A Preferred Stock As of September 30, 2024 and December 31, 2023, the authorized capital stock of the Company included 10,000,000 shares of undesignated preferred stock, \$0.0001 par value. 9. Stock-Based Compensation 2024 Inducement Plan In January 2024, the Board of Directors (the "Board") adopted the 2024 Inducement Plan (the "Inducement Plan") without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Stock Market LLC listing rules ("Rule 5635(c)(4)"). In accordance with Rule 5635(c)(4), the Inducement Plan allows the Company to grant awards only to a newly hired employee who was not previously an employee or non-employee director or to an employee who is being rehired following a bona fide period of non-employment if such award is a material inducement to such employee entering into employment. The total shares of common stock initially authorized for issuance under the Inducement Plan was 1,000,000. In June 2024, the common stock authorized for issuance under the Inducement Plan was reduced by 870,000 shares following stockholder approval of an increase in the shares available for grant under the 2020 Stock Option and Incentive Plan (the "2020 Plan"). The total number of shares of common stock authorized for issuance under the Inducement Plan as of September 30, 2024 was 130,000 shares. 2020 Stock Option and Incentive Plan The total number of shares of common stock authorized for issuance under the 2020 Plan as of September 30, 2024 and December 31, 2023 was 1,970,833 shares and 661,240 shares, respectively. 2017 Stock Incentive Plan The total number of shares of common stock authorized for issuance under the 2017 Stock Incentive Plan (the "2017 Plan") as of September 30, 2024 and December 31, 2023 was 395,850 shares. Any authorization to issue new options under the 2017 Plan was cancelled upon the effectiveness of the 2020 Plan and no further awards will be granted under the 2017 Plan. 2020 Employee Stock Purchase Plan The total number of shares of common stock authorized for issuance under the 2020 Employee Stock Purchase Plan (the "2020 ESPP") as of September 30, 2024 and December 31, 2023 was 175,145 shares and 87,227 shares, respectively. 15 Restricted Stock Units The following table summarizes the Company's restricted stock unit activity: Shares Weighted Average Grant Date Fair Value Unvested as of December 31, 2023 1,454 \$202.27 A Issued 197,093 A 51.98 A Vested (11,856) 309.13 A Forfeited (9,712) 54.86 A Unvested as of September 30, 2024 222,674 A \$69.98 A As of September 30, 2024, total unrecognized compensation cost related to unvested restricted stock units was \$11.9 million, which is expected to be recognized over a weighted-average period of 2.84 years. Stock Options The following table summarizes the Company's stock option activity: Number of Shares Weighted Average Exercise Price per Share Weighted Average Remaining Contractual Term Aggregate Intrinsic Value (in thousands) Outstanding as of December 31, 2023 266,163 A \$160.19 A Granted 195,546 A 51.43 A Exercised (8,753) 39.75 A \$134 A Canceled or Forfeited (23,632) 127.76 A Outstanding as of September 30, 2024 1,829,324 A \$90.08 A 8.71 A \$12.80 A Exercisable as of

uncertainties. As a result of many factors, including those factors set forth in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2023, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. Overview We are a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. Normal brain function requires a delicate balance of excitation and inhibition in neuronal circuits, which, when dysregulated, can lead to abnormal function and both rare and more prevalent neurological disorders. We are applying genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms, using our understanding of shared biological targets and circuits in the brain. Each platform currently has multiple programs, with significant potential for additional program and indication expansion: “Cerebrum”, our small molecule platform, utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies “Solidus”, our antisense oligonucleotide, or ASO, platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology Our platforms utilize a deliberate, pragmatic and patient-guided approach, leveraging a suite of translational tools, including novel transgenic and predictive translational animal models and electrophysiology markers, to enable an efficient path to proof-of-concept in patients. Through this approach, we have established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy. For our most advanced product candidate under the Cerebrum, “platform, ulixalcaltamide, our Phase 3 Essential3 clinical trials in essential tremor, or ET, are ongoing. We are planning to conduct an interim analysis in the first quarter of 2025. Within our vormatrigine program (formerly known as PRAX-628), we announced positive results from our Photo-Paroxysmal Response (“PPR”) study in the first quarter of 2024, and have initiated or plan to initiate four studies to generate patient eligibility, efficacy, safety and pharmacokinetics (PK) data for the program. We initiated an observational study of vormatrigine in patients with epilepsy in the third quarter of 2024, and initiated or plan to initiate three efficacy studies. The first efficacy study will be an open label eight-week study in patients with focal onset seizures or generalized epilepsy to be initiated in the fourth quarter of 2024, with topline results expected in the first half of 2025. We have also initiated a double-blind, placebo-controlled, 12-week study in focal onset seizures in the fourth quarter of 2024, with topline results expected in the second half of 2025, and plan to initiate a third efficacy study in the first half of 2025. Within our relutrigine program (formerly known as PRAX-562), we announced positive topline results from the first cohort of our EMBOLD study in the third quarter of 2024, and have initiated enrollment of the second cohort, with topline results expected in the first half of 2026. For our most advanced product candidate under the Solidus, “platform, elsunersen (formerly known as PRAX-222), we shared results from Part 1 of the EMBRAVE study in the fourth quarter of 2023, and have initiated the first arm of our global confirmatory study in Brazil. We are currently completing multiple global regulatory interactions to further expand the pivotal phase of the program later in 2024. We were incorporated in 2015 and commenced operations in 2016. Since inception, we have devoted substantially all of our resources to developing our preclinical and clinical product candidates, building our intellectual property, or IP, portfolio, business planning, raising capital and providing general and administrative support for these operations. We employ a “virtual” research and development model, relying heavily upon external consultants, collaborators, contract development and manufacturing organizations and contract research organizations, or CROs, to conduct our preclinical and clinical activities. Since inception, we have financed our operations primarily with proceeds from the sale and issuance of equity securities. We are a development stage company and we have not generated any revenue from product sales, and do not expect to do so for several years, if at all. All of our product candidates are still in preclinical and clinical development. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our product candidates, if approved. We have incurred recurring operating losses since inception, including a net loss of \$124.1 million for the nine months ended September 30, 2024. As of September 30, 2024, we had an accumulated deficit of \$778.1 million. We expect to incur significant expenses and operating losses for the foreseeable future as we expand our research and development activities. In addition, our losses from operations may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical trials and our expenditures on other research and development activities. We anticipate that our expenses will be maintained or increased in connection with our ongoing activities, as we “advance our lead product candidate, ulixalcaltamide, through the Phase 3 Essential3 clinical trial program for ET; “advance relutrigine (formerly PRAX-562) in the EMBOLD and EMERALD clinical trials; “advance elsunersen (formerly PRAX-222) into the pivotal stage of the program; “advance vormatrigine (formerly PRAX-628) into efficacy clinical trials for focal onset seizures or generalized epilepsy; “advance our preclinical candidates to clinical trials; “further invest in our pipeline; “further invest in our manufacturing capabilities; “seek regulatory approval for our product candidates; “maintain, expand, protect and defend our IP portfolio; “acquire or in-license technology; “establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval; and “when needed, increase our headcount to support our development efforts and any future commercialization efforts. As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity, debt financings or other capital sources, including potential collaborations with other companies or other strategic transactions. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more of our product candidates or delay our pursuit of potential in-licenses or acquisitions. Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. As of September 30, 2024, we had cash, cash equivalents and marketable securities of \$411.2 million. We expect that our cash, cash equivalents and marketable securities as of September 30, 2024 will be sufficient to fund our operating expenditures and capital expenditure requirements necessary to advance our research efforts and clinical trials into 2027. The analysis included consideration of our current financial needs and ongoing research and development plans. We have based this estimate on assumptions that may provide to be wrong, and we could exhaust our available capital resources sooner than we expect. See “Liquidity and Capital Resources.” Reverse Stock Split On November 28, 2023, we filed a Certificate of Amendment to our Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a 1-for-15 reverse stock split of our common stock, or the Reverse Stock Split. The Reverse Stock Split became effective at 5:00 p.m., Eastern Time, on November 28, 2023, or the Effective Time. As a result of the Reverse Stock Split, every 15 shares of our issued and outstanding common stock were automatically reclassified into one validly issued, fully-paid and non-assessable share of common stock, subject to the treatment of fractional shares as described below, without any action on the part of the holders thereof. The Reverse Stock Split did not affect the number of authorized shares of common stock or the par value of the common stock. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who would otherwise be entitled to receive fractional shares as a result of the Reverse Stock Split were entitled to a cash payment in lieu thereof at a price equal to the fraction to which the stockholder would otherwise be entitled, multiplied by the closing price per share of the common stock (as adjusted for the Reverse Stock Split) on the Nasdaq Global Select Market on November 28, 2023, the last trading day immediately preceding the Effective Time. Financial Operations Overview Revenue We have not generated any revenue from the sale of products since inception and do not expect to generate any revenue from the sale of products for several years, if at all. As discussed in Note 7 to our condensed consolidated financial statements, we entered into an Option and License Agreement, or the Collaboration Agreement, with UCB Biopharma SRL, or UCB, in December 2022. We recognized \$0.3 million and \$1.1 million, respectively, of collaboration revenue from the Collaboration Agreement during the three and nine months ended September 30, 2024, compared to \$0.5 million and \$1.9 million, respectively, during the three and nine months ended September 30, 2023. Operating Expenses Research and Development Expenses The nature of our business and primary focus of our activities generate a significant amount of research and development costs. Research and development expenses represent costs incurred by us for the following: “discovery efforts leading to development candidates; “clinical development costs for our product candidates; and “costs to develop our manufacturing technology and infrastructure. The costs above comprise the following categories: “personnel-related expenses, including salaries, benefits and stock-based compensation expense; “expenses incurred under agreements with third parties, such as consultants, investigative sites and CROs, that conduct our preclinical and clinical studies and in-licensing arrangements; “costs incurred to maintain compliance with regulatory requirements; “costs incurred with third-party contract development and manufacturing organizations to acquire, develop and manufacture materials for preclinical and clinical studies; and “depreciation, amortization and other direct and allocated expenses, including rent and other operating costs, such as information technology, incurred as a result of our research and development activities. We expense research and development costs as incurred. We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our vendors and our clinical investigative sites. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our condensed consolidated balance sheets as prepaid expenses or accrued expenses. Non-refundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized, even when there is no alternative future use for the research and development. The capitalized amounts are expensed as the related goods are delivered or the services are performed. As a company operating in a virtual environment, a significant portion of our research and development costs have been external costs incurred by third-parties. We track direct external research and development expenses to specific platforms and product candidates upon commencement. Due to the number of ongoing studies and our ability to use resources across platforms, indirect or shared operating costs incurred for our research and development platforms, such as personnel, facility costs and certain consulting costs, are not recorded or maintained on a platform-specific basis. The following table reflects our research and development expenses, including direct expenses summarized by platform and indirect or shared operating costs recognized as research and development expenses during each period presented (in thousands):

Three Months Ended September 30, 2024	Three Months Ended September 30, 2023
\$27,474	\$5,832
\$55,226	\$23,857
\$23,857	\$1,327
\$2,806	\$4,197
\$16,330	\$2,447
\$41,881	\$17,260
\$96,125	\$68,378

Research and development expenses are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses will be maintained or increase in the foreseeable future as we advance our product candidates through the development phase, and as we continue to discover and develop additional product candidates, build manufacturing capabilities and expand into additional therapeutic areas. At this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the development of, and obtain regulatory approval for, any of our product candidates. We are also unable to predict when, if ever, material net cash inflows will commence from sales or licensing of our product candidates. This is due to the numerous risks and uncertainties associated with drug development, including the uncertainty of: “our ability to add and retain key research and development personnel; “the timing and progress of preclinical and clinical development activities; “the number and scope of preclinical and clinical programs we decide to pursue; “our ability to successfully complete clinical trials with safety, tolerability and efficacy profiles that are satisfactory to the FDA or any comparable foreign regulatory authority; “our ability to successfully develop, obtain regulatory approval for, and then successfully commercialize, our product candidates; “our successful enrollment in and completion of clinical trials; “the costs associated with the development of any additional product candidates we identify in-house or acquire through collaborations; “our ability to discover, develop and utilize biomarkers to demonstrate target engagement, pathway engagement and the impact on disease progression of our product candidates; “our ability to establish and maintain agreements with third-party manufacturers for clinical supply for our clinical trials and commercial manufacturing, if our product candidates are approved; “the terms and timing of any collaboration, license or other arrangement, including the terms and timing of any milestone payments thereunder; “our ability to obtain and maintain patent, trade secret and other IP protection and regulatory exclusivity for our product candidates, if approved; “our receipt of marketing approvals from applicable regulatory authorities; “our ability to commercialize products, if approved, whether alone or in collaboration with others; and “the continued acceptable safety profiles of our product candidates. A change in any of these variables with respect to the development of any of our product candidates would significantly change the costs, timing and viability associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to delay our planned start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect, or if we experience significant delays in enrollment in any of our planned clinical trials, we could be required to expend significant additional financial resources and time to complete our clinical development activities. We may never obtain regulatory approval for any of our product candidates. Drug commercialization will take several years and require significant development costs. General and Administrative Expense General and administrative expenses consist primarily of personnel-related costs, including salaries, benefits and stock-based compensation, for personnel in our executive, finance, legal, commercial and administrative functions. General and administrative expenses also include legal fees relating to corporate matters; professional fees for accounting, auditing, tax and administrative consulting services; commercial-related costs to support market assessments and scenario planning; insurance costs; administrative travel expenses; and facility-related expenses, which include direct depreciation costs and allocated expenses for office rent and other operating costs, such as information technology. Costs to secure and defend our IP are expensed as incurred and are classified as general and administrative expenses. These costs relate to the operation of the business and are unrelated to the research and development function or any individual platform or product candidate. We anticipate that our general and administrative expenses may increase in the future as we increase our headcount, when needed, to support the expected growth in our research and development activities and the potential commercialization of our product candidates. We also expect to incur additional IP-related expenses as we file patent applications to protect innovations arising from our research and development activities. Other Income Other Income, Net Other income, net consists of interest income from our cash, cash equivalents and marketable securities and amortization of investment premiums and discounts. Income Taxes Since our inception, we have not recorded any U.S. federal or state income tax benefits for the net losses we have incurred in each year or for our earned research and development tax credits due to our uncertainty of realizing a benefit from those items. Income taxes are determined at the applicable tax rates adjusted for non-deductible expenses, research and development tax credits and other permanent differences. Our income tax provision may be significantly affected by changes to our estimates. There was no income tax provision recognized for the three and nine months ended September 30, 2024 and 2023. Results of Operations Comparison of the Three Months Ended September 30, 2024 and 2023 The following table summarizes our condensed consolidated statements of operations for each period presented (in thousands):

Three Months Ended September 30, 2024	Three Months Ended September 30, 2023
\$302	\$468
\$(166)	\$(166)
\$41,881	\$17,260
\$24,621	\$15,256
\$8,724	\$6,532
\$24,621	\$15,256
\$1,374	\$25,984
\$31,153	\$1,534
\$(56,835)	\$(25,516)
\$(31,319)	\$(31,319)

Other income, net consists of interest income from our cash, cash equivalents and marketable securities and amortization of investment premiums and discounts. Income Taxes Since our inception, we have not recorded any U.S. federal or state income tax benefits for the net losses we have incurred in each year or for our earned research and development tax credits due to our uncertainty of realizing a benefit from those items. Income taxes are determined at the applicable tax rates adjusted for non-deductible expenses, research and development tax credits and other permanent differences. Our income tax provision may be significantly affected by changes to our estimates. There was no income tax provision recognized for the three and nine months ended September 30, 2024 and 2023. Results of Operations Comparison of the Three Months Ended September 30, 2024 and 2023 The following table summarizes our condensed consolidated statements of operations for each period presented (in thousands):

Three Months Ended September 30, 2024	Three Months Ended September 30, 2023
\$302	\$468
\$(166)	\$(166)
\$41,881	\$17,260
\$24,621	\$15,256
\$8,724	\$6,532
\$24,621	\$15,256
\$1,374	\$25,984
\$31,153	\$1,534
\$(56,835)	\$(25,516)
\$(31,319)	\$(31,319)

Other income, net consists of interest income from our cash, cash equivalents and marketable securities and amortization of investment premiums and discounts. Income Taxes Since our inception, we have not recorded any U.S. federal or state income tax benefits for the net losses we have incurred in each year or for our earned research and development tax credits due to our uncertainty of realizing a benefit from those items. Income taxes are determined at the applicable tax rates adjusted for non-deductible expenses, research and development tax credits and other permanent differences. Our income tax provision may be significantly affected by changes to our estimates. There was no income tax provision recognized for the three and nine months ended September 30, 2024 and 2023. Results of Operations Comparison of the Three Months Ended September 30, 2024 and 2023 The following table summarizes our condensed consolidated statements of operations for each period presented (in thousands):

Three Months Ended September 30, 2024	Three Months Ended September 30, 2023
\$302	\$468
\$(166)	\$(166)
\$41,881	\$17,260
\$24,621	\$15,256
\$8,724	\$6,532
\$24,621	\$15,256
\$1,374	\$25,984
\$31,153	\$1,534
\$(56,835)	\$(25,516)
\$(31,319)	\$(31,319)

Other income, net consists of interest income from our cash, cash equivalents and marketable securities and amortization of investment premiums and discounts. Income Taxes Since our inception, we have not recorded any U.S. federal or state income tax benefits for the net losses we have incurred in each year or for our earned research and development tax credits due to our uncertainty of realizing a benefit from those items. Income taxes are determined at the applicable tax rates adjusted for non-deductible expenses, research and development tax credits and other permanent differences. Our income tax provision may be significantly affected by changes to our estimates. There was no income tax provision recognized for the three and nine months ended September 30, 2024 and 2023. Results of Operations Comparison of the Three Months Ended September 30, 2024 and 2023 The following table summarizes our condensed consolidated statements of operations for each period presented (in thousands):

Three Months Ended September 30, 2024	Three Months Ended September 30, 2023
\$302	\$468
\$(166)	\$(166)
\$41,881	\$17,260
\$24,621	\$15,256
\$8,724	\$6,532
\$24,621	\$15,256
\$1,374	\$25,984
\$31,153	\$1,534
\$(56,835)	\$(25,516)
\$(31,319)	\$(31,319)

Other income, net consists of interest income from our cash, cash equivalents and marketable securities and amortization of investment premiums and discounts. Income Taxes Since our inception, we have not recorded any U.S. federal or state income tax benefits for the net losses we have incurred in each year or for our earned research and development tax credits due to our uncertainty of realizing a benefit from those items. Income taxes are determined at the applicable tax rates adjusted for non-deductible expenses, research and development tax credits and other permanent differences. Our income tax provision may be significantly affected by changes to our estimates. There was no income tax provision recognized for the three and nine months ended September 30, 2024 and 2023. Results of Operations Comparison of the Three Months Ended September 30, 2024 and 2023 The following table summarizes our condensed consolidated statements of operations for each period presented (in thousands):

Three Months Ended September 30, 2024	Three Months Ended September 30, 2023
\$302	\$468
\$(166)	\$(166)
\$41,881	\$17,260
\$24,621	\$15,256
\$8,724	\$6,532
\$24,621	\$15,256
\$1,374	\$25,984
\$31,153	\$1,534
\$(56,835)	\$(25,516)
\$(31,319)	\$(31,319)

Other income, net consists of interest income from our cash, cash equivalents and marketable securities and amortization of investment premiums and discounts. Income Taxes Since our inception, we have not recorded any U.S. federal or state income tax benefits for the net losses we have incurred in each year or for our earned research and development tax credits due to our uncertainty of realizing a benefit from those items. Income taxes are determined at the applicable tax rates adjusted for non-deductible expenses, research and development tax credits and other permanent differences. Our income tax provision may be significantly affected by changes to our estimates. There was no income tax provision recognized for the three and nine months ended September 30, 2024 and 2023. Results of Operations Comparison of the Three Months Ended September 30, 2024 and 2023 The following table summarizes our condensed consolidated statements of operations for each period presented (in thousands):

Three Months Ended September 30, 2024	Three Months Ended September 30, 2023
\$302	\$468
\$(166)	\$(166)
\$41,881	\$17,260
\$24,621	\$15,256
\$8,724	\$6,532
\$24,621	\$15,256
\$1,374	\$25,984
\$31,153	\$1,534
\$(56,835)	\$(25,516)
\$(31,319)	\$(31,319)

Other income, net consists of interest income from our cash, cash equivalents and marketable securities and amortization of investment premiums and discounts. Income Taxes Since our inception, we have not recorded any U.S. federal or state income tax benefits for the net losses we have incurred in each year or for our earned research and development tax credits due to our uncertainty of realizing a benefit from those items. Income taxes are determined at the applicable tax rates adjusted for non-deductible expenses, research and development tax credits and other permanent differences. Our income tax provision may be significantly affected by changes to our estimates. There was no income tax provision recognized for the three and nine months ended September 30, 2024 and 2023. Results of Operations Comparison of the Three Months Ended September 30, 2024 and 2023 The following table summarizes our condensed consolidated statements of operations for each period presented (in thousands):

Three Months Ended September 30, 2024	Three Months Ended September 30, 2023
\$302	\$468
\$(166)	\$(166)
\$41,881	\$17,260
\$24,621	\$15,256
\$8,724	\$6,532
\$24,621	\$15,256
\$1,374	\$25,984
\$31,153	\$1,534
\$(56,835)	\$(25,516)
\$(31,319)	\$(31,319)

Other income, net consists of interest income from our cash, cash equivalents and marketable securities and amortization of investment premiums and discounts. Income Taxes Since our inception, we have not recorded any U.S. federal or state income tax benefits for the net losses we have incurred in each year or for our earned research and development tax credits due to our uncertainty of realizing a benefit from those items. Income taxes are determined at the applicable tax rates adjusted for non-deductible expenses, research and development tax credits and other permanent differences. Our income tax provision may be significantly affected by changes to our estimates. There was no income tax provision recognized for the three and nine months ended September 30, 2024 and 2023. Results of Operations Comparison of the Three Months Ended September 30, 2024 and 2023 The following table summarizes our condensed consolidated statements of operations for each period presented (in thousands):

Three Months Ended September 30, 2024	Three Months Ended September 30, 2023
\$302	\$468
\$(166)	\$(166)
\$41,881	\$17,260
\$24,621	\$15,256
\$8,724	\$6,532
\$24,621	\$15,256
\$1,374	\$25,984
\$31,153	\$1,534
\$(56,835)	\$(25,516)
\$(31,319)	\$(31,319)

Other income, net consists of interest income from our cash, cash equivalents and marketable securities and amortization of investment premiums and discounts. Income Taxes Since our inception, we have not recorded any U.S. federal or state income tax benefits for the net losses we have incurred in each year or for our earned research and development tax credits due to our uncertainty of realizing a benefit from those items. Income taxes are determined at the applicable tax rates adjusted for non-deductible expenses, research and development tax credits and other permanent differences. Our income tax provision may be significantly affected by changes to our estimates. There was no income tax provision recognized for the three and nine months ended September 30, 2024 and 2023. Results of Operations Comparison of the Three Months Ended September 30, 2024 and 2023 The following table summarizes our condensed consolidated statements of operations for each period presented (in thousands):

Three Months Ended September 30, 2024	Three Months Ended September 30, 2023
\$302	\$468
\$(166)	\$(166)
\$41,881	\$17,260
\$24,621	\$15,256
\$8,724	\$6,532
\$24,621	\$15,256
\$1,374	\$25,984
\$31,153	\$1,534
\$(56,835)	\$(25,516)
\$(31,319)	\$(31,319)

Other income, net consists of interest income from our cash, cash equivalents and marketable securities and amortization of investment premiums and discounts. Income Taxes Since our inception, we have not recorded any U.S. federal or state income tax benefits for the net losses we have incurred in each year or for our earned research and development tax credits due to our uncertainty of realizing a benefit from those items. Income taxes are determined at the applicable tax rates adjusted for non-deductible expenses, research and development tax credits and other permanent differences. Our income tax provision may be significantly affected by changes to our estimates. There was no income tax provision recognized for the three and nine months ended September 30, 2024 and 2023. Results of Operations Comparison of the Three Months Ended September 30, 2024 and 2023 The following table summarizes our condensed consolidated statements of operations for each period presented (in thousands):

Three Months Ended September 30, 2024	Three Months Ended September 30, 2023
\$302	\$468
\$(166)	\$(166)
\$41,881	\$17,260
\$24,621	\$15,256
\$8,724	\$6,532
\$24,621	\$15,256
\$1,374	\$25,984
\$31,153	\$1,534
\$(56,835)	\$(25,516)
\$(31,319)	\$(31,319)

Other income, net consists of interest income from our cash, cash equivalents and marketable securities and amortization of investment premiums and discounts. Income Taxes Since our inception, we have not recorded any U.S. federal or state income tax benefits for the net losses we have incurred in each year or for our earned research and development tax credits due to our uncertainty of realizing a benefit from those items. Income taxes are determined at the applicable tax rates adjusted for non-deductible expenses, research and development tax credits and other permanent differences. Our income tax provision may be significantly affected by changes to our estimates. There was no income tax provision recognized for the three and nine months ended September 30, 2024 and 2023. Results of Operations Comparison of the Three Months Ended September 30, 2024 and 2023 The following table summarizes our condensed consolidated statements of operations for each period presented (in thousands):

Three Months Ended September 30, 2024	Three Months Ended September 30, 2023
\$302	\$468
\$(166)	\$(166)
\$41,881	\$17,260
\$24,621	\$15,256
\$8,724	\$6,532
\$24,621	\$15,256
\$1,374	\$25,984
\$31,153	\$1,534
\$(56,835)	\$(25,516)
\$(31,319)	\$(31,319)

Other income, net consists of interest income from our cash, cash equivalents and marketable securities and amortization of investment premiums and discounts. Income Taxes Since our inception, we have not recorded any U.S. federal or state income tax benefits for the net losses we have incurred in each year or for our earned research and development tax credits due to our uncertainty of realizing a benefit from those items. Income taxes are determined at the applicable tax rates adjusted for non-deductible expenses, research and development tax credits and other permanent differences. Our income tax provision may be significantly affected by changes to our estimates. There was no income tax provision recognized for the three and nine months ended September 30, 2024 and 2023. Results of Operations Comparison of the Three Months Ended September 30, 2024 and 2023 The following table summarizes our condensed consolidated statements of operations for each period presented (in thousands):

Three Months Ended September 30, 2024	Three Months Ended September 30, 2023
\$302	\$468
\$(166)	\$(166)
\$41,881	\$17,260
\$24,621	\$15,256
\$8,724	\$6,532
\$24,621	\$15,256
\$1,374	\$25,984
\$31,153	\$1,534
\$(56,835)	\$(25,516)
\$(31,319)	\$(31,319)

Other income, net consists of interest income from our cash, cash equivalents and marketable securities and amortization of investment premiums and discounts. Income Taxes Since our inception, we have not recorded any U.S. federal or state income tax benefits for the net losses we have incurred in each year or for our earned research and development tax credits due to our uncertainty of realizing a benefit from those items. Income taxes are determined at the applicable tax rates adjusted for non-deductible expenses, research and development tax credits and other permanent differences. Our income tax provision may be significantly affected by changes to our estimates. There was no income tax provision recognized for the three and nine months ended September 30, 2024 and 2023. Results of Operations Comparison of the Three Months Ended September 30, 2024 and 2023 The following table summarizes our condensed consolidated statements of operations for each period presented (in thousands):

Three Months Ended September 30, 2024	Three Months Ended September 30, 2023
\$302	\$468
\$(166)	\$(166)
\$41,881	\$17,260
\$24,621	\$15,256
\$8,724	\$6,532
\$24,621	\$15,256
\$1,374	\$25,984
\$31,153	\$1,534
\$(56,835)	\$(25,516)
\$(31,319)	\$(31,319)

Other income, net consists of interest income from our cash, cash equivalents and marketable securities and amortization of investment premiums and discounts. Income Taxes Since our inception, we have not recorded any U.S. federal or state income tax benefits for the net losses we have incurred in each year or for our earned research and development tax credits due to our uncertainty of realizing a benefit from those items. Income taxes are determined at the applicable tax rates adjusted for non-deductible expenses, research and development tax credits and other permanent differences. Our income tax provision may be significantly affected by changes to our estimates. There was no income tax provision recognized for the three and nine months ended September 30, 2024 and 2023. Results of Operations Comparison of the Three Months Ended September 30, 2024 and 2023 The following table summarizes our condensed consolidated statements of operations for each period presented (in thousands):

Three Months Ended September 30, 2024	Three Months Ended September 30, 2023
\$302	\$468
\$(166)	\$(166)
\$41,881	\$17,260
\$24,621	\$15,256
\$8,724	\$6,532
\$24,621	\$15,256
\$1,374	\$25,984
\$31,153	\$1,534
\$(56,835)	\$(25,516)
\$(31,319)	\$(31,319)

Other income, net consists of interest income from our cash, cash equivalents and marketable securities and amortization of investment premiums and discounts. Income Taxes Since our inception, we have not recorded any U.S. federal or state income tax benefits for the net losses we have incurred in each year or for our earned research and development tax credits due to our uncertainty of realizing a benefit from those items. Income taxes are determined at the applicable tax rates adjusted for non-deductible expenses, research and development tax credits and other permanent differences. Our income tax provision may be significantly affected by changes to our estimates. There was no income tax provision recognized for the three and nine months ended September 30, 2024 and 2023. Results of Operations Comparison of the Three Months Ended September 30, 2024 and 2023 The following table summarizes our condensed consolidated statements of operations for each period presented (in thousands):

Three Months Ended September 30, 2024	Three Months Ended September 30, 2023
\$302	\$468
\$(166)	\$(166)
\$41,881	\$17,260
\$24,621	\$15,256
\$8,724	\$6,532
\$24,621	\$15,256
\$1,374	\$25,984
\$31,153	\$1,534
\$(56,835)	\$(25,516)
\$(31,319)	\$(31,319)

Other income, net consists of interest income from our cash, cash equivalents and marketable securities and amortization of investment premiums and discounts. Income Taxes Since our inception, we have not recorded any U.S. federal or state income tax benefits for the net losses we have incurred in each year or for our earned research and development tax credits due to our uncertainty of realizing a benefit from those items. Income taxes are determined at the applicable tax rates adjusted for non-deductible expenses, research and development tax credits and other permanent differences. Our income tax provision may be significantly affected by changes to our estimates. There was no income tax provision recognized for the three and nine months ended September 30, 2024 and 2023. Results of Operations Comparison of the Three Months Ended September 30, 2024 and 2023 The following table summarizes our condensed consolidated statements of operations for each period presented (in thousands):

Three Months Ended September 30, 2024	Three Months Ended September 30, 2023
\$302	\$468
\$(166)	\$(166)
\$41,881	\$17,260
\$24,621	\$15,256
\$8,724	\$6,532
\$24,621	\$15,256
\$1,374	\$25,984
\$31,153	\$1,534
\$(56,835)	\$(25,516)
\$(31,319)	\$(31,319)

Other income, net consists of interest income from our cash, cash equivalents and marketable securities and amortization of investment premiums and discounts. Income Taxes Since our inception, we have not recorded any U.S. federal or state income tax benefits for the net losses we have incurred in each year or for our earned research and development tax credits due to our uncertainty of realizing a benefit from those items. Income taxes are determined at the applicable tax rates adjusted for non-deductible expenses, research and development tax credits and other permanent differences. Our income tax provision may be significantly affected by changes to our estimates. There was no income tax provision recognized for the three and nine months ended September 30, 2024 and 2023. Results of Operations Comparison of the Three Months Ended September 30, 2024 and 2023 The following table summarizes our condensed consolidated statements of operations for each period presented (in thousands):

Three Months Ended September 30, 2024	Three Months Ended September 30, 2023
\$302	\$468
\$(166)	\$(166)
\$41,881	\$17,260
\$24,621	\$15,256
\$8,724	\$6,532
\$24,621	\$15,256
\$1,374	\$25,984
\$31,153	\$1,534
\$(56,835)	\$(25,516)
\$(31,319)	\$(31,319)

Other income, net consists of interest income from our cash, cash equivalents and marketable securities and amortization of investment premiums and discounts. Income Taxes Since our inception, we have not recorded any U.S. federal or state income tax benefits for the net losses we have incurred in each year or for our earned research and development tax credits due to our uncertainty of realizing a benefit from those items. Income taxes are determined at the applicable tax rates adjusted for non-deductible expenses, research and development tax credits and other permanent differences. Our income tax provision may be significantly affected by changes to our estimates. There was no income tax provision recognized for the three and nine months

indirect expenses driven primarily by consulting spend; andâ€¢\$1.5 million decrease in expense related to our Solidusâ„¢ platform, driven by prior year spend associated with our elsunersen program.General and Administrative Expense23The \$6.5Â million increase in general and administrative expenses was primarily attributable to the following:â€¢\$4.6Â million increase in personnel-related costs, mainly due to increased stock-based compensation expense;â€¢\$1.4Â million increase in professional expenses mainly due to increased legal, audit and other consulting expenses; andâ€¢\$0.5Â million increase in other expenses, none of which were individually significant. Other IncomeOther income for the three months ended September 30, 2024 was comprised of interest income on our cash, cash equivalents, and marketable securities and investment premium and discount amortization. Other income for the three months ended September 30, 2023 was comprised of interest income on our cash and cash equivalents.Results of OperationsComparison of the Nine Months Ended September 30, 2024 and 2023The following table summarizes our condensed consolidated statements of operations for each period presented (in thousands):Nine Months EndedSeptember 30,Change20242023Collaboration revenues1,090Â \$1,932Â \$(842)Operating expenses:Research and development96,125Â \$68,378Â \$27,747Â A General and administrative41,174Â \$32,121Â \$9,053Â A Total operating expenses137,299Â \$100,499Â \$36,800Â A Loss from operations(136,209)(98,567)(37,642)Other income, net12,069Â \$2,168Â \$9,901Â A Total other income12,069Â \$2,168Â \$9,901Â A Net loss\$(124,140)\$(96,399)\$(27,741)Collaboration RevenueThe \$0.8Â million decrease in collaboration revenue is associated with a decrease in the revenue recorded under the Collaboration Agreement with UCB that was executed in December 2022. Changes in revenue recognized each period reflect timing of research services provided and costs incurred. Research and Development ExpenseThe following table summarizes our research and development expenses for each period presented, along with the changes in those items (in thousands):Nine Months EndedSeptember 30,Change20242023Cerebrum,â€¢\$55,226Â \$23,857Â \$31,369Â A Solidusâ„¢,â€¢4,197Â \$16,330Â \$(12,133)Personnel-related (including stock-based compensation)30,265Â \$21,744Â \$8,521Â A Other indirect research and development expenses6,437Â \$6,447Â \$(10)Total research and development expenses\$96,125Â \$68,378Â \$27,747Â A The \$27.7Â million increase in research and development expenses was primarily attributable to the following:24â€¢\$31.4Â million increase in expense related to our Cerebrum,â€¢ platform, driven primarily by:â—a \$29.5Â million increase in spend for our ulixalcaltamide program, primarily due to clinical-related activities for our Phase 3 program in ulixalcaltamide and Phase 1 trial spend, partially offset by prior year Essential1 study activity;â—a \$3.2Â million increase in clinical-related spend for our vormatrigine program, primarily driven by current quarter POWER1, RADIANT, and EMPOWER study startup activities and manufacturing spend;â—a \$0.3Â million increase in spend for our relutrigine program related to our EMBOLD study; and â—a \$1.6Â million decrease in activities for our earlier stage assets.â€¢\$12.1Â million decrease in expense related to our Solidusâ„¢ platform, driven by a prior year \$6.9Â million milestone payment due to Ionis Pharmaceuticals Inc., or Ionis, upon initiation of our elsunersen EMBRAVE study, as well as prior year study activity; andâ€¢\$8.5Â millionÂ increase in personnel-related costs, primarily stock-based compensation expense. General and Administrative ExpenseThe \$9.1Â million increase in general and administrative expenses was primarily attributable to the following:â€¢\$8.3Â million increase in personnel-related costs mainly due to increased stock-based compensation expense; â€¢\$0.3Â million increase in professional fees, primarily audit fees; andâ€¢\$0.5Â million increase in other expenses, none of which were individually significant. Other IncomeOther income for the nine months ended September 30, 2024 and 2023 was comprised of interest income on our cash, cash equivalents, and marketable securities and investment premium and discount amortization.Liquidity and Capital ResourcesSources of LiquiditySince our inception, we have incurred significant losses in each period. We have not yet commercialized any of our product candidates, which are in various phases of preclinical and clinical development, and we do not expect to generate revenue from sales of any products for several years, if at all. To date, we have financed our operations primarily with proceeds from the issuance of redeemable convertible preferred stock and from the sale of common stock through an initial public offering, common stock and pre-funded warrants through follow-on public offerings and common stock from at-the-market offerings under our shelf registration statement. From inception through SeptemberÂ 30, 2024, we have raised \$1.0 billion in aggregate cash proceeds from such transactions, net of issuance costs. As of SeptemberÂ 30, 2024, we had cash, cash equivalents and marketable securities of \$411.2Â million. In November 2021, we entered into an Open Market Sale Agreement, or the 2021 Sales Agreement, with Jefferies LLC, or Jefferies, to provide for the offering, issuance and sale of up to an aggregate amount of \$125.0 million of common stock from time to time in at-the-market offerings for which Jefferies acted as sales agent. We terminated the 2021 Sales Agreement in June 2023. On JuneÂ 21, 2023, we completed a public offering of: (i) an aggregate of 4,296,646 shares of common stock at a public offering price of \$14.25 per share, including the underwriters' full exercise of their option to purchase 619,979 additional shares of common stock, and (ii) pre-funded warrants to purchase 470,000 shares of common stock at a public offering price of \$14.2485 per share. The purchase prices per share for each pre-funded warrant represents the per share offering price for the common stock, less the \$0.0015 per share exercise price for each underlying share. Total net proceeds generated from the offering were approximately \$63.4 million, after deducting 25underwriting discounts, commissions and other offering expenses payable by us. As of June 30, 2024, all warrants associated with this offering were exercised on a cashless basis with no proceeds received by the Company.In December 2023, we entered into an Open Market Sale Agreement, or the 2023 Sales Agreement, with Jefferies, to provide for the offering, issuance and sale of up to an aggregate amount of \$75.0 million of common stock in at-the-market offerings. The 2023 Sales Agreement was terminated in January 2024. During the three months ended MarchÂ 31, 2024, we issued and sold an aggregate of 192,190 shares under the 2023 Sales Agreement for aggregate net proceeds of \$5.3 million, after deducting commissions and offering expenses payable by us.On JanuaryÂ 16, 2024, we completed a public offering of: (i) an aggregate of 3,802,025 shares of our common stock at a public offering price of \$35.50 per share, including the underwriters' full exercise of their option to purchase 633,750 additional shares of common stock, and (ii) pre-funded warrants to purchase 1,056,725 shares of common stock at a public offering price of \$35.4999 per share of common stock underlying the warrants. The purchase price per share of each pre-funded warrant represents the per share offering price for the common stock, less the \$0.0001 per share exercise price of each underlying share. Total net proceeds generated from the offering were approximately \$161.6 million, after deducting underwriting discounts, commissions and other offering expenses payable by us. As of SeptemberÂ 30, 2024, 152,145 warrants associated with this offering were exercised on a cashless basis with no cash proceeds received by the Company.In March 2024, we entered into an Open Market Sale Agreement, or the 2024 Sales Agreement, with Jefferies, to provide for the offering, issuance, and sale of up to an aggregate amount of \$150.0 million of common stock in at-the-market offerings. During the nine months ended September 30, 2024, we issued and sold an aggregate of 42,851 shares under the 2024 Sales Agreement for aggregate net proceeds of \$2.3 million, after deducting commissions and offering expenses payable by us.On AprilÂ 2, 2024, we completed a public offering of: (i) an aggregate of 3,849,558 shares of our common stock at a public offering price of \$56.50 per share, including the underwriters' full exercise of their option to purchase 530,973 additional shares of common stock, and (ii) pre-funded warrants to purchase 221,238 shares of common stock at a public offering price of \$56.4999 per share of common stock underlying the warrants. The purchase price per share for each pre-funded warrant represents the per share offering price for the common stock, less the \$0.0001 per share exercise price of each underlying share. Total net proceeds generated from the offering were approximately \$216.0 million, after deducting underwriting discounts, commissions and other offering expenses payable by us.Cash FlowsThe following table provides information regarding our cash flows for each period presented (in thousands):Nine Months EndedSeptember 30,20242023Net cash (used in) provided by:Operating activities(75,635)\$(87,275)Investing activities(237,576)39,000Â A Financing activities400,556Â \$87,745Â A Net increase in cash, cash equivalents and restricted cash\$87,345Â \$39,470Â A Operating ActivitiesOur cash flows from operating activities are greatly influenced by our use of cash for operating expenses and working capital requirements to support our business. We have historically experienced negative cash flows from operating activities as we have invested in developing our portfolio, drug discovery efforts and related infrastructure. The cash used in operating activities resulted primarily from our net losses adjusted for non-cash charges and changes in operating assets and liabilities, which are primarily the result of increased expenses and timing of vendor payments.During the nine months ended SeptemberÂ 30, 2024, net cash used in operating activities of \$75.6 million was primarily due to our \$124.1 million net loss, partially offset by \$15.8 million in changes in operating assets and 26liabilities primarily related to increases in accounts payable and accrued expenses, and \$32.7 million of non-cash charges primarily related to stock-based compensation.During the nine months ended SeptemberÂ 30, 2023, net cash used in operating activities of \$87.3 million was primarily due to our \$96.4Â million net loss and \$11.0 million in changes in operating assets and liabilities primarily related to decreases in accrued expenses and accounts payable, partially offset by \$20.1 million of non-cash charges primarily related to stock-based compensation. Investing ActivitiesDuring the nine months ended SeptemberÂ 30, 2024, net cash used in investing activities of \$237.6Â million was primarily related to purchases of marketable securities partially offset by maturities of marketable securities.During the nine months ended SeptemberÂ 30, 2023, net cash provided by investing activities of \$39.0 million was related to maturities of marketable securities.Financing ActivitiesDuring the nine months ended SeptemberÂ 30, 2024, net cash provided by financing activities of \$400.6Â million consisted primarily of net proceeds from our January 2024 and April 2024 follow-on public offerings, our at-the-market offerings and our collaboration and license agreement with Tenacia.During the nine months ended SeptemberÂ 30, 2023, net cash provided by financing activities of \$87.7 million consisted primarily of net proceeds from at-the-market offerings and our June 2023 follow-on public offering.Plan of Operation and Future Funding RequirementsWe expect our expenses to increase substantially in connection with our ongoing research and development activities, particularly as we advance the preclinical activities and clinical trials of our product candidates. As a result, we expect to incur substantial operating losses and negative operating cash flows for the foreseeable future. We anticipate that our expenses will increase substantially if and as we:â€¢advance the clinical development of our clinical-stage product candidates within our Cerebrum,â€¢ and Solidusâ„¢ platforms;â€¢advance the development of any additional product candidates;â€¢conduct research and continue preclinical development of potential product candidates;â€¢make strategic investments in manufacturing capabilities;â€¢maintain our IP portfolio and opportunistically acquire complementary IP;â€¢seek to obtain regulatory approvals for our product candidates;â€¢potentially establish a sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize any products for which we may obtain regulatory approval;â€¢when needed, add clinical, scientific, operational, financial and management information systems and personnel, including personnel to support our product development and potential future commercialization efforts and to support our operations as a public company; andâ€¢experience any delays or encounter any issues with any of the above, including but not limited to failed studies, complex results, safety issues or other regulatory challenges.We are unable to estimate the exact amount of our working capital requirements, but based on our current operating plan, we believe that our cash, cash equivalents, and marketable securities as of SeptemberÂ 30, 2024 will be sufficient to fund our operating expenses and capital expenditure requirements into 2027. However, we have based this estimate on assumptions that may prove to be wrong and we could exhaust our capital resources sooner than we expect.27Because of the numerous risks and uncertainties associated with product development and potential collaborations with third parties for the development of our product candidates, we may incorrectly estimate the timing and amounts of increased capital outlays and operating expenses associated with completing the research and development of our product candidates. Our funding requirements and timing and amount of our operating expenditures will depend on many factors, including, but not limited to:â€¢the scope, progress, results and costs of preclinical studies and clinical trials for our platforms and product candidates;â€¢the number and characteristics of product candidates and technologies that we develop or may in-license;â€¢the costs and timing of future commercialization activities, including manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval;â€¢the costs necessary to obtain regulatory approvals, if any, for products in the United States and other jurisdictions, and the costs of post-marketing studies that could be required by regulatory authorities in jurisdictions where approval is obtained;â€¢the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our IP rights and defending any IP-related claims;â€¢the continuation of our existing licensing arrangements and entry into new collaborations and licensing arrangements;â€¢the costs we incur in maintaining business operations;â€¢the costs associated with being a public company;â€¢the revenue, if any, received from commercial sales of any product candidates for which we receive marketing approval;â€¢the effect of competing technological and market developments; andâ€¢the extent to which we acquire or invest in businesses, products and technologies, including entering into licensing or collaboration arrangements for product candidates, although we currently have no commitments or agreements to complete any such acquisitions or investments in businesses.Identifying potential product candidates and conducting preclinical testing and clinical trials is a time consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if ever. Accordingly, we will need to obtain substantial additional funds to achieve our business objectives.Adequate additional funds may not be available to us on acceptable terms, or at all. We do not currently have any committed external source of funds. Market volatility could also adversely impact our ability to access capital as and when needed. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of holders of our common stock. Additional debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends and may require the issuance of warrants, which could potentially result in dilution to the holders of our common stock.If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit or terminate our product development programs or any future commercialization efforts or grant rights to develop and market product candidates to third parties that we would otherwise prefer to develop and market ourselves.28Critical Accounting Policies and Significant Judgments and EstimatesOur managementâ€™s discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.There have been no changes to our critical accounting policies from those described under the heading â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operations â€œ Critical Accounting Policies and Significant Judgments and Estimatesâ€¢ included in our Annual Report on Form 10-K filed with the SEC on March 5, 2024, other than as disclosed in Note 2 to our condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q. Recently Issued Accounting PronouncementsWe have reviewed all recently issued standards and have determined that, other than as disclosed in Note 2 to our condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q, such standards will not have a material impact on our condensed consolidated financial statements or do not otherwise apply to our current operations.ItemÂ 3. Quantitative and Qualitative Disclosures About Market RiskWe are exposed to market risk related to changes in interest rates. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because cash, cash equivalents and marketable securities we may hold at any time may be in the form of money market funds or marketable debt securities or may be invested in U.S. Treasury and U.S. government agency obligations. However, because of the low risk profile of the instruments in our portfolio at any given time, an immediate change in market interest rates of 100 basis points would not have a material impact on our financial position or results of operations.ItemÂ 4. Controls and Procedures.Managementâ€™s Evaluation of Our Disclosure Controls and ProceduresWe maintain â€œdisclosure controls and procedures,â€¢ as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act") as controls and other procedures of an issuer that are designed to ensure that information required to be disclosed by the issuer in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SECâ€™s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer's management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management

essarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our management, with the participation of our Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal financial officer, respectively), evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2024. Based on the evaluation of our disclosure controls and procedures as of September 30, 2024, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.29.Changes in Internal Control Over Financial ReportingThere were no changes in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.30.PART IIâ€œOTHER INFORMATIONItem 1. Legal Proceedings. As of the date of this Quarterly Report on Form 10-Q, we are not party to any material legal matters or claims. We may become party to legal matters and claims arising in the ordinary course of business. We cannot predict the outcome of any such legal matters or claims, and despite the potential outcomes, the existence thereof may have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.Item 1A. Risk Factors.There have been no material changes from the risk factors previously disclosed in the section entitled "Risk Factors" of our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 5, 2024.Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.Recent Sales of Unregistered Equity SecuritiesWe did not make any sales of unregistered securities during the three months ended September 30, 2024.Item 3. Defaults Upon Senior Securities.Not applicable.Item 4. Mine Safety Disclosures.Not applicable.Item 5. Other Information.(a) A A A Disclosure in lieu of reporting on a Current Report on Form 8-K.None.(b) A A A Material changes to the procedures by which security holders may recommend nominees to the board of directors.None.(c) A A A Insider Trading Arrangements and Policies.During the three months ended September 30, 2024, no director or officer of the Company adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as each term is defined in Item 408(a) of Regulation S-K.31.Item 6. Exhibits.ExhibitNumberDescription3.1Amended and Restated Certificate of Incorporation of Praxis Precision Medicines, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K (File No. 001-39620) filed on October 20, 2020).3.2Amended and Restated Bylaws of Praxis Precision Medicines, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K (File No. 001-39620) filed on January 7, 2022).4.1Form of Pre-funded Warrant (incorporated by reference to Exhibit 4.1 to the Registrant's Current Report on Form 8-K (File No. 001-39620) filed on January 12, 2024).4.2Form of Pre-funded Warrant (incorporated by reference to Exhibit 4.1 to the Registrant's Current Report on Form 8-K (File No. 001-39620) filed on March 29, 2024).10.Praxis Precision Medicines, Inc. 2020 Stock Option and Incentive Plan, as amended and restated (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K (File No. 001-39620) filed on June 6, 2024).10.2Employment Agreement Amendment Letter, dated October 11, 2024, by and between Marcio Souza and Praxis Precision Medicines, Inc. (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K (File No. 001-39620) filed on October 15, 2024).10.3Employment Agreement Amendment Letter, dated October 11, 2024, by and between Timothy Kelly and Praxis Precision Medicines, Inc. (incorporated by reference to Exhibit 10.2 to the Registrant's Current Report on Form 8-K (File No. 001-39620) filed on October 15, 2024).10.4Employment Agreement Amendment Letter, dated October 11, 2024, by and between Alex Nemiroff and Praxis Precision Medicines, Inc. (incorporated by reference to Exhibit 10.3 to the Registrant's Current Report on Form 8-K (File No. 001-39620) filed on October 15, 2024).31.1*Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.2*Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 32.1**Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 101.INS*Inline XBRL Instance Document101.SCH*Inline XBRL Taxonomy Extension Schema Document101.CAL*Inline XBRL Taxonomy Extension Calculation Linkbase Document101.DEF*Inline XBRL Taxonomy Extension Definition Linkbase Document101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document104.Cover Page Interactive Data File (embedded within the Inline XBRL document)*Filed herewith.**A A A The certifications furnished in Exhibit 32.1 hereto are deemed to accompany this Quarterly Report on Form 10-Q and will not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference.32SIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.A PRAXIS PRECISION MEDICINES, INC.Date: November 6, 2024By: /s/ Marcio Souza A Chief Executive Officer and Director (Principal Executive Officer)Date: November 6, 2024By: /s/ Timothy Kelly A Timothy Kelly A Chief Financial Officer (Principal Financial Officer)33 EX-31.1 2 exhibit31120240930.htm EX-31.1 DocumentExhibit 31.1CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002, Marcio Souza, certify that:1.I have reviewed this Quarterly Report on Form 10-Q of Praxis Precision Medicines, Inc.;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.Date: November 6, 2024By: /s/ MARCIO SOUZA A Marcio Souza A Chief Executive Officer A (Principal Executive Officer) EX-31.2 3 exhibit31220240930.htm EX-31.2 DocumentExhibit 31.2CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002, Timothy Kelly, certify that:1.I have reviewed this Quarterly Report on Form 10-Q of Praxis Precision Medicines, Inc.;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.Date: November 6, 2024By: /s/ TIMOTHY KELLY A Timothy Kelly A Chief Financial Officer A (Principal Financial Officer) EX-32.1 4 exhibit32120240930.htm EX-32.1 DocumentExhibit 32.1CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002In connection with the Quarterly Report on Form 10-Q of Praxis Precision Medicines, Inc. (the "Company") for the quarter ended September 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of their knowledge: (1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.Date: November 6, 2024By: /s/ MARCIO SOUZA A Marcio Souza A Chief Executive Officer A (Principal Executive Officer)Date: November 6, 2024By: /s/ TIMOTHY KELLY A Timothy Kelly A Chief Financial Officer A (Principal Financial Officer) EX-101.SCH 5 prax-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 9952156 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 9952157 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952158 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - Nature of the Business link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - Cash Equivalents and Marketable Securities link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - Commitments and Contingencies link:presentationLink

Transactions Disclosure [Text Block] Cover [Abstract] Cover [Abstract] Increase in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect License And Collaboration Agreement License And Collaboration Agreement [Member] License And Collaboration Agreement Trading Symbol Trading Symbol All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Non-NEOs Non-NEOs [Member] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Pay vs Performance Disclosure [Line Items] Common Stock Warrants Common Stock, Warrants [Policy Text Block] Common Stock, Warrants Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Tenacia Tenacia [Member] Tenacia Net Loss per Share Earnings Per Share, Policy [Policy Text Block] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Summary of Shares Reserved for Future Issuance Schedule Of Common Stock Reserved For Future Issuance [Table Text Block] Schedule Of Common Stock Reserved For Future Issuance Fair Value Measurements Fair Value Disclosures [Text Block] Change in unrealized gain on marketable securities, net of tax Change in unrealized gain on marketable securities, net of tax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Award Timing Disclosures [Line Items] Debt securities, available-for-sale, accumulated gross unrealized loss, current, before tax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, Current, before Tax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, Current, before Tax Other Performance Measure, Amount Other Performance Measure, Amount Common stock, outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Maturities of marketable securities Proceeds from Sale and Maturity of Marketable Securities Non-current portion of operating lease liabilities Operating Lease, Liability, Noncurrent Revenue from Contract with Customer [Abstract] Current portion of deferred revenue Contract with Customer, Liability, Current Plan Name [Domain] Plan Name [Domain] Sale of stock (in dollars per share) Sale of Stock, Price Per Share Proceeds from issuance or sale of equity Proceeds from Issuance or Sale of Equity Other non-current assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] April 2024 Follow-On Offering April 2024 Follow-On Offering [Member] April 2024 Follow-On Offering Money market funds Money market funds Money Market Funds [Member] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Plan Name [Axis] Plan Name [Axis] Equity Components [Axis] Equity Components [Axis] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Award Timing Method Award Timing Method [Text Block] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Total available-for-sale securities Debt Securities, Available-for-Sale Measurement Frequency [Axis] Measurement Frequency [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Insider Trading Policies and Procedures [Line Items] Use of Estimates Use of Estimates, Policy [Policy Text Block] Number of efficacy studies Number Of Efficacy Studies Number Of Efficacy Studies Adjustment to Compensation, Amount Adjustment to Compensation Amount Aggregate intrinsic value outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Payables and Accruals [Abstract] Payables and Accruals [Abstract] Compensation Amount Outstanding Recovery Compensation Amount Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Company Selected Measure Amount Company Selected Measure Amount Tabular List, Table Tabular List [Table Text Block] LevelA 3 Fair Value, Inputs, Level 3 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Sale of stock, volume-weighted average price, premium Sale Of Stock, Volume-Weighted Average Price, Premium Sale Of Stock, Volume-Weighted Average Price, Premium Warrants (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Issuance of common stock under employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Accrued expenses Total accrued expenses Accrued Liabilities, Current Antidilutive securities (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Securities, unrealized loss position, fair value Debt Securities, Available-for-Sale, Unrealized Loss Position Cash, cash equivalents and restricted cash, beginning of period Cash, cash equivalents and restricted cash, end of period Total cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Amortization of premiums and discounts on marketable securities, net Accretion (Amortization) of Discounts and Premiums, Investments Total unrecognized compensation cost related to unvested restricted stock units Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Current assets: Assets, Current [Abstract] Payments of tax withholdings related to vesting of restricted stock units Payment, Tax Withholding, Share-Based Payment Arrangement Issuance costs from at-the-market offering included in accrued expenses Stock Issuance Costs Incurred But Not Yet Paid Stock Issuance Costs Incurred But Not Yet Paid Treasury stock (in shares) Treasury Stock, Common, Shares Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Offering costs from follow-on offering included in accounts payable Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction Product and Service [Domain] Product and Service [Domain] Shares reserved for exercise of outstanding stock options Outstanding stock options Share-Based Payment Arrangement, Option [Member] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Depreciation expense Depreciation License License [Member] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Preferred stock, outstanding (in shares) Preferred Stock, Shares Outstanding Warrant Warrant [Member] Security Exchange Name Security Exchange Name Award Type [Axis] Award Type [Axis] Corporate debt securities Corporate Debt Securities [Member] Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Property and equipment, net Property, Plant and Equipment, Net Total liabilities Liabilities Exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Unvested Restricted Stock Units Unvested Restricted Stock Units [Member] Unvested Restricted Stock Units Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Debt Securities, Available-for-Sale Debt Securities, Available-for-Sale [Table Text Block] Research and development Research and Development Expense Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Expiration Date Trading Arrangement Expiration Date Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Operating lease liabilities Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Common stock, issued (in shares) Common Stock, Shares, Issued Accrued personnel-related expenses Accrued Personnel Related Expenses Current Accrued Personnel Related Expenses, Current, Summary of Restricted Stock Activity Nonvested Restricted Stock Shares Activity [Table Text Block] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] January 2024 Public Offering January 2024 Public Offering [Member] January 2024 Public Offering Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Issuance of common stock upon exercise of stock options (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Other-than-temporary impairment loss, debt securities, available-for-sale Other-than-temporary Impairment Loss, Debt Securities, Available-for-Sale Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Research and development Research and Development Expense [Member] Weighted Average ExerciseA Price per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Common stock, authorized (in shares) Common Stock, Shares Authorized Commercial paper Commercial Paper, Not Included with Cash and Cash Equivalents [Member] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Weighted average common shares outstanding, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Accrued external research and development expenses Accrued External Research And Development Expenses Current Accrued External Research And Development Expenses, Current, MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Total stockholdersâ€™ equity Beginning balance Ending balance Equity, Attributable to Parent Collaboration License Agreements Collaborative Arrangement Disclosure [Text Block] Within one year Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Fair Value, Recurring Fair Value, Recurring [Member] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Number of shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Sale of Stock [Domain] Sale of Stock [Domain] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Document Fiscal Period Focus Document Fiscal Period Focus January 2024 Follow-On Offering January 2024 Follow-On Offering [Member] January 2024 Follow-On Offering All Executive Categories All Executive Categories [Member] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Weighted average remaining contractual term outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Assets Assets [Abstract] Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Document Type Document Type Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Vesting of restricted stock awards (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Gross Weighted average remaining contractual term exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Maximum Maximum [Member] Follow-On Offering Follow-On Offering [Member] Follow-On Offering Upfront payment Contract with Customer, Liability Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Number of performance obligations Number Of Performance Obligations Number Of Performance Obligations Antidilutive Securities [Axis] Antidilutive Securities [Axis] Accounts payable Accounts Payable, Current Accounting Policies [Abstract] Accounting Policies [Abstract] June 2023 Follow-On Offering June 2023 Follow-On Offering [Member] June 2023 Follow-On Offering Sale of stock, value transferred Sale Of Stock, Value Transferred Sale Of Stock, Value Transferred Schedule of Fair Value of Stock Option Awards on the Grant Date Using the Black-Scholes Option Valuation Model Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Operating lease liabilities Increase (Decrease) in Operating Lease Liabilities Increase (Decrease) in Operating Lease Liabilities. Statistical Measurement [Axis] Statistical Measurement [Axis] PEO Name PEO Name Class of warrant or right, outstanding Class of Warrant or Right, Outstanding Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Award Type [Domain] Award Type [Domain] Name Outstanding Recovery, Individual Name Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Summary of Antidilutive Securities Excluded From Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Non-PEO NEO Non-PEO NEO [Member] Available-for-sale marketable securities Investments, Fair Value Disclosure Additional Paid-In Capital Additional Paid-in Capital [Member] Award Timing Predetermined Award Timing Predetermined [Flag] Debt securities, available-for-sale, amortized cost, current Debt Securities, Available-for-Sale, Amortized Cost, Current Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Net loss per share attributable to common stockholders, diluted (in dollars per share) Earnings Per Share, Diluted Issuance of common stock from exercise of pre-funded warrants (in shares) Stock Issued During Period, Shares, Exercise Of Warrants Stock Issued During Period, Shares, Exercise Of Warrants Counterparty Name [Domain] Counterparty Name [Domain] Non-cash operating lease expense Operating Lease, Right-of-Use Asset, Periodic Reduction Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Deferred revenue Increase (Decrease) in Contract with Customer, Liability Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Cash, cash equivalents, and marketable securities Cash, Cash Equivalents, and Short-Term Investments Class of warrants or rights, exercised Class Of Warrants Or Rights, Exercised Class Of Warrants Or Rights, Exercised Preferred stock, issued (in shares) Preferred Stock, Shares Issued UCB UCB [Member] UCB Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Proceeds from collaboration arrangement Proceeds From Collaboration Arrangement Proceeds From Collaboration Arrangement Other income: Nonoperating Income (Expense) [Abstract] Marketable securities Debt securities, available-for-sale, current Debt Securities, Available-for-Sale, Current Cash equivalents, accumulated gross unrealized loss, current, before tax Cash Equivalents, Accumulated Gross Unrealized Loss, Current, Before Tax Cash Equivalents, Accumulated Gross Unrealized Loss, Current, Before Tax Weighted-average period (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Total other income Nonoperating Income (Expense) Statement of Comprehensive Income [Abstract] Cash equivalents, at carrying value Cash Equivalents, at Carrying Value Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Loss from operations Operating Income (Loss) Number of reportable segments Number of Reportable Segments Total liabilities and stockholdersâ€™ equity Liabilities and Equity Subsequent Events [Text Block] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Additional paid-in capital Additional Paid in Capital Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Non-cash collaboration and license agreement expense Collaboration And License Agreement, Noncash Expense Collaboration And License Agreement, Noncash Expense Underlying Security Market Price Change Underlying Security Market Price Change, Percent Individual: Individual [Axis] Shares withheld for taxes for vesting of restricted stock units Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Name of Property [Domain] Name of Property [Domain] Cancelled or forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Restricted cash Restricted Cash Expected term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Debt securities issued by U.S. government agencies US Government Agencies Debt Securities [Member] Product and Service [Axis] Product and Service [Axis] Entity Address, State or Province Entity Address, State or Province Statement [Line Items] Statement [Line Items] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Operating expenses: Operating Expenses [Abstract] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Financial Instruments [Domain] Financial Instruments [Domain] Unvested beginning balance (in dollars per share) Unvested ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Liabilities and stockholdersâ€™ equity Liabilities and Equity [Abstract] Unaudited Interim Condensed Consolidated Financial Information Unaudited Interim Condensed Consolidated Financial Information [Policy Text Block] Unaudited interim condensed consolidated financial information Shares reserved for future awards under the 2024 Inducement Plan Inducement Plan Inducement Plan [Member] Inducement Plan Number of platforms Number Of Platforms Number Of Platforms Restatement Determination Date Restatement Determination Date Vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Issued (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Issued in Period

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Issued in Period Long-term marketable securities Debt Securities, Available-for-Sale, Noncurrent Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Adoption Date Pay vs Performance Disclosure [Table] Related Party Transactions [Abstract] Related Party Transactions [Abstract] Non-current portion of deferred revenue Contract with Customer, Liability, Noncurrent Beginning balance (in dollars per share) Ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Exercise Price Award Exercise Price Net Loss per Share Earnings Per Share [Text Block] Percentage of ownership held by sole owner and affiliates Percentage of Ownership Held by Sole Owner And Affiliates Percentage of Ownership Held by Sole Owner And Affiliates Arrangement Duration Trading Arrangement Duration Issuance of common stock under employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Issuance of common stock upon exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Stockholders' equity: Equity, Attributable to Parent [Abstract] Cash equivalents and debt securities, available-for-sale, accumulated gross unrealized loss, current, before tax Cash Equivalents And Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Loss, Current, Before Tax Cash Equivalents And Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Loss, Current, Before Tax Name of Property [Axis] Name of Property [Axis] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Other debt securities Other Debt Obligations [Member] Schedule Of Common Stock Reserved For Future Issuance [Line Items] Schedule Of Common Stock Reserved For Future Issuance [Line Items] Schedule Of Common Stock Reserved For Future Issuance Line items Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] All Individuals All Individuals [Member] Issued (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Issued in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Issued in Period, Weighted Average Grant Date Fair Value PEO PEO [Member] Cash equivalents, accumulated gross unrealized gain, current, before tax Cash Equivalents, Accumulated Gross Unrealized Gain, Current, Before Tax Cash Equivalents, Accumulated Gross Unrealized Gain, Current, Before Tax Name Trading Arrangement, Individual Name Other income, net Other Nonoperating Income (Expense) Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Proceeds from exercise of stock options and employee stock purchase plan purchases Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Milestone payments Revenue, Remaining Performance Obligation, Variable Consideration Amount Revenue, Remaining Performance Obligation, Variable Consideration Amount April 2024 Public Offering April 2024 Public Offering [Member] April 2024 Public Offering Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Percentage increase in annual base rent Percentage Increase In Annual Base Rent Percentage Increase In Annual Base Rent. Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Total shares of authorized common stock reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Local Phone Number Local Phone Number Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Total operating expenses Operating Expenses Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Number of securities Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Long-term liabilities: Liabilities, Noncurrent [Abstract] PEO Total Compensation Amount PEO Total Compensation Amount Summary of Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Vested and expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Common Stock Common Stock [Member] Measure: Measure [Axis] Asset Class [Domain] Asset Class [Domain] Cash equivalents, fair value disclosure Cash Equivalents, Fair Value Disclosure Cash Equivalents, Fair Value Disclosure Stockholders' equity note, stock split, conversion ratio Stockholders' Equity Note, Stock Split, Conversion Ratio Preferred stock, authorized (in shares) Preferred Stock, Shares Authorized Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Issuance of common stock (in shares) Stock Issued During Period, Shares, New Issues Entity Emerging Growth Company Entity Emerging Growth Company Cash equivalents, at carrying value and debt securities, available-for-sale, amortized cost Cash Equivalents, at Carrying Value And Debt Securities, Available-For-Sale, Amortized Cost Cash Equivalents, at Carrying Value And Debt Securities, Available-For-Sale, Amortized Cost Stock issuance costs Stock Issuance Costs Stock Issuance Costs Decrease in number of shares authorized to be issued (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Increase (Decrease) In Shares Authorized Share-Based Compensation Arrangement by Share-Based Payment Award, Increase (Decrease) In Shares Authorized Shares withheld for taxes for vesting of restricted stock units (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Entity Central Index Key Entity Central Index Key General and administrative General and Administrative Expense [Member] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Common Stock and Preferred Stock Equity [Text Block] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component [Domain] Equity Component [Domain] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Financial Instrument [Axis] Financial Instrument [Axis] Reconciliation of cash, cash equivalents and restricted cash: Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Pre-funded warrant Pre-Funded Warrant [Member] Pre-Funded Warrant Sale of stock, volume-weighted average price, duration Sale Of Stock, Volume-Weighted Average Price, Duration Sale Of Stock, Volume-Weighted Average Price, Duration Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Shares reserved for vesting of restricted stock units Unvested restricted stock units Restricted Stock [Member] Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward] Title Trading Arrangement, Individual Title Number of product candidates Number Of Product Candidates Number Of Product Candidates June 2023 Public Offering June 2023 Public Offering [Member] June 2023 Public Offering Statement [Table] Statement [Table] Counterparty Name [Axis] Counterparty Name [Axis] Measurement Frequency [Domain] Measurement Frequency [Domain] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] City Area Code City Area Code Current liabilities: Liabilities, Current [Abstract] Shares reserved for future awards under the 2020 Stock Option and Incentive Plan Twenty Twenty Employee Stock Incentive Plan [Member] Twenty Twenty Employee Stock Incentive Plan At-The-Market Offering At-The-Market Offering [Member] At-The-Market Offering Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Level 1 Fair Value, Inputs, Level 1 [Member] Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Office Space in Boston Massachusetts Office Space in Boston Massachusetts [Member] Office Space in Boston Massachusetts Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Debt securities, available-for-sale, accumulated gross unrealized gain, current, before tax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, Current, before Tax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, Current, before Tax Accrued expenses Increase (Decrease) in Accrued Liabilities Sale of stock, value transferred in excess of consideration received Sale Of Stock, Value Transferred In Excess Of Consideration Received Sale Of Stock, Value Transferred In Excess Of Consideration Received Number of shares exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Weighted average grant-date fair value per share (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Earnings Per Share [Abstract] Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Supplemental disclosures of non-cash activities: Supplemental Cash Flow Elements [Abstract] General and administrative General and Administrative Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Change in ownership notice, term Notice of Change, Term Notice of Change, Term Underlying Securities Award Underlying Securities Amount Sale of stock, shares, aggregate authorized amount (in shares) Sale Of Stock, Shares, Aggregate Authorized Amount Sale Of Stock, Shares, Aggregate Authorized Amount Cash Equivalents and Marketable Securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Amendment Flag Amendment Flag Entity Registrant Name Entity Registrant Name Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Schedule Of Common Stock Reserved For Future Issuance [Table] Schedule Of Common Stock Reserved For Future Issuance [Table] Schedule Of Common Stock Reserved For Future Issuance Table Fair Value as of Grant Date Award Grant Date Fair Value Subsequent Events [Abstract] Subsequent Events [Abstract] Aggregate intrinsic value vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Number of shares issued in transaction (in shares) Sale of Stock, Number of Shares Issued in Transaction Level 2 Fair Value, Inputs, Level 2 [Member] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Issuance of common stock Stock Issued During Period, Value, New Issues Entity Address, Postal Zip Code Entity Address, Postal Zip Code Summary of Stock-Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Restatement Determination Date: Restatement Determination Date [Axis] Title of 12(b) Security Title of 12(b) Security Common stock, \$0,0001 par value; 150,000,000 shares authorized; 17,785,697 shares issued and outstanding as of September 30, 2024, and 8,791,877 shares issued and outstanding as of December 31, 2023 Common Stock, Value, Issued Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Percentage change in ownership Change in Percentage of Ownership Change in Percentage of Ownership Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Forfeitures (in dollars per shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Preferred stock, \$0,0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of September 30, 2024 and December 31, 2023 Preferred Stock, Value, Issued Share-based payment arrangement Share-Based Payment Arrangement [Member] Potential shares issuable under the 2020 ESPP Employee Stock [Member] Net loss per share attributable to common stockholders, basic (in dollars per share) Earnings Per Share, Basic Accounts payable Increase (Decrease) in Accounts Payable Proceeds from stock offerings, net of issuance costs Proceeds from Issuance of Common Stock Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Purchases of property and equipment included in accounts payable Capital Expenditures Incurred but Not yet Paid Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Unrecognized compensation expense related to unvested stock based awards Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Total assets Assets Cash equivalents and debt securities, available-for-sale, accumulated gross unrealized gain, current, before tax Cash Equivalents And Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Current, Before Tax Cash Equivalents And Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Current, Before Tax Over-Allotment Option Over-Allotment Option [Member] Summary of Financial Assets Measured At Fair Value On A Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Commitments and contingencies (Note 6) Commitments and Contingencies 2020 Employee Stock Incentive Plan 2020 Employee Stock Incentive Plan [Member] 2020 Employee Stock Incentive Plan Termination Date Trading Arrangement Termination Date Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Nature of the Business Nature of Operations [Text Block] Warrants (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Collaboration revenue Revenues Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Shares reserved for future awards under the 2020 Employee Stock Purchase Plan 2020 Employee Stock Purchase Plan 2020 Employee Stock Purchase Plan [Member] Entity Address, City or Town Entity Address, City or Town After one year through five years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Summary of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Aggregate intrinsic value exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Total stock-based compensation expense Share-Based Payment Arrangement, Expense Net loss Net loss Net loss Net loss Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Investments, Debt and Equity Securities [Abstract] Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Loss Contingencies [Table] Loss Contingencies [Table] Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Entity File Number Entity File Number 2017 Stock Incentive Plan 2017 Employee Stock Incentive Plan [Member] Document Fiscal Year Focus Document Fiscal Year Focus Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Accrued other expenses Other Accrued Liabilities, Current Assets Assets, Fair Value Disclosure Name Forgone Recovery, Individual Name Aggregate intrinsic value exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Document Period End Date Document Period End Date Sale of Stock [Axis] Sale of Stock [Axis] Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Asset Class [Axis] Asset Class [Axis] Insider Trading Arrangements [Line Items] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Cash equivalents and debt securities, available-for-sale, fair value disclosure Cash Equivalents And Debt Securities, Available-for-Sale, Fair Value Disclosure Cash Equivalents And Debt Securities, Available-for-Sale, Fair Value Disclosure Adjustment to Compensation: Adjustment to Compensation [Axis] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Accumulated other comprehensive gain Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Accumulated Deficit Retained Earnings

[Member] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Weighted average common shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Executive Category: Executive Category [Axis] Name Awards Close in Time to MNPI Disclosures, Individual Name Maximum percentage of voting power Percentage of Ownership Held by Sole Owner Percentage of Ownership Held by Sole Owner Canceled or forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Entity Filer Category Entity Filer Category Transaction price Revenue, Remaining Performance Obligation, Amount Income Statement Location [Domain] Statement of Income Location, Balance [Domain] Purchases of marketable securities Payments to Acquire Debt Securities, Available-for-Sale Loss Contingencies [Line Items] Loss Contingencies [Line Items] Company Selected Measure Name Company Selected Measure Name EX-101.PRE 9 prax-20240930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v.24.3 Cover Page - shares 9 Months Ended Sep. 30, 2024 Nov. 01, 2024 Cover [Abstract] A A Document Type 10-Q A Document Quarterly Report true A Document Period End Date Sep. 30, 2024 A Document Transition Report false A Entity File Number 001-39620 A Entity Registrant Name PRAXIS PRECISION MEDICINES, INC. A Entity Incorporation, State or Country Code DE A Entity Tax Identification Number 47-195942 A Entity Address, Address Line One 99 High Street A Entity Address, Address Line Two 30th Floor A Entity Address, City or Town Boston A Entity Address, State or Province MA A Entity Address, Postal Zip Code 02110 A City Area Code 617 A Local Phone Number 300-8460 A Title of 12(b) Security Common Stock, par value \$0.0001 per share A Trading Symbol PRAX A Security Exchange Name NASDAQ A Entity Current Reporting Status Yes A Entity Interactive Data Current Yes A Entity Filer Category Non-accelerated Filer A Entity Small Business true A Entity Emerging Growth Company false A Entity Shell Company false A Entity Common Stock, Shares Outstanding A 18,637,777 Amendment Flag false A Document Fiscal Year Focus 2024 A Document Fiscal Period Focus Q3 A Entity Central Index Key 0001689548 A Current Fiscal Year End Date -12-31 A X - Definition Boolean flag that is true when the XBRL content amends previously-filed or accepted submission. + References No definition available. + Details Name: dei:AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - Definition Area code of city + References No definition available. + Details Name: dei:CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItem Type Balance Type: na Period Type: duration X - Definition Cover page. + References No definition available. + Details Name: dei:CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition End date of current fiscal year in the format -MM-DD. + References No definition available. + Details Name: dei:CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - Definition Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + References No definition available. + Details Name: dei:DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - Definition This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + References No definition available. + Details Name: dei:DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - Definition For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + References No definition available. + Details Name: dei:DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateTimeItemType Balance Type: na Period Type: duration X - Definition Boolean flag that is true only for a form used as an quarterly report. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a> + Details Name: dei:DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - Definition Boolean flag that is true only for a form used as a transition report. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1> + Details Name: dei:DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - Definition The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + References No definition available. + Details Name: dei:DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItem Type Balance Type: na Period Type: duration X - Definition Address Line 1 such as Attn, Building Name, Street Name + References No definition available. + Details Name: dei:EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItem Type Balance Type: na Period Type: duration X - Definition Address Line 2 such as Street or Suite number + References No definition available. + Details Name: dei:EntityAddressAddressLine2 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItem Type Balance Type: na Period Type: duration X - Definition Name of the City or Town + References No definition available. + Details Name: dei:EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItem Type Balance Type: na Period Type: duration X - Definition Code for the postal or zip code + References No definition available. + Details Name: dei:EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItem Type Balance Type: na Period Type: duration X - Definition Name of the state or province. + References No definition available. + Details Name: dei:EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItem Type Balance Type: na Period Type: duration X - Definition A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei:EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItem Type Balance Type: na Period Type: duration X - Definition Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + References No definition available. + Details Name: dei:EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - Definition Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + References No definition available. + Details Name: dei:EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItem Type Balance Type: na Period Type: duration X - Definition Indicate if registrant meets the emerging growth company criteria. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei:EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - Definition Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + References No definition available. + Details Name: dei:EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItem Type Balance Type: na Period Type: duration X - Definition Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei:EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItem Type Balance Type: na Period Type: duration X - Definition Two-character EDGAR code representing the state or country of incorporation. + References No definition available. + Details Name: dei:EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItem Type Balance Type: na Period Type: duration X - Definition Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Regulation S-T -Number 232 -Section 405> + Details Name: dei:EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItem Type Balance Type: na Period Type: duration X - Definition The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei:EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItem Type Balance Type: na Period Type: duration X - Definition Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei:EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - Definition Indicates that the company is a Smaller Reporting Company (SRC). + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei:EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - Definition The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2> + Details Name: dei:EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItem Type Balance Type: na Period Type: duration X - Definition Local phone number for entity. + References No definition available. + Details Name: dei:LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItem Type Balance Type: na Period Type: duration X - Definition Title of a 12(b) registered security. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b> + Details Name: dei:Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItem Type Balance Type: na Period Type: duration X - Definition Name of the Exchange on which a security is registered. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1> + Details Name: dei:SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItem Type Balance Type: na Period Type: duration X - Definition Trading symbol of an instrument as listed on an exchange. + References No definition available. + Details Name: dei:TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItem Type Balance Type: na Period Type: duration XML 12 R2.htm IDEA: XBRL DOCUMENT v.24.3 Condensed Consolidated Balance Sheets (Unaudited) - USD (\$) \$ in Thousands Sep. 30, 2024 Dec. 31, 2023 Current assets: A A Cash and cash equivalents \$ 168,645 \$ 81,300 Marketable securities 188,387 0 Prepaid expenses and other current assets 3,016 3,580 Total current assets 360,048 84,880 Long-term marketable securities 54,141 0 Property and equipment, net 277 588 Operating lease right-of-use assets 1,374 2,064 Other non-current assets 416 416 Total assets 416,256 87,948 Current liabilities: A A Accounts payable 15,010 5,815 Accrued expenses 15,457 7,416 Operating lease liabilities 1,224 1,126 Current portion of deferred revenue 1,170 1,392 Total current liabilities 32,861 15,749 Long-term liabilities: A A Non-current portion of operating lease liabilities 436 1,369 Non-current portion of deferred revenue 293 1,161 Total liabilities 33,590 18,279 Commitments and contingencies (Note 6) 3 Stockholders' equity: A A Preferred stock, \$0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of September A 30, 2024 and December A 31, 2023 0 0 Common stock, \$0.0001 par value; 150,000,000 shares authorized; 17,785,697 shares issued and outstanding as of September A 30, 2024, and 8,791,877 shares issued and outstanding as of December A 31, 2023 14 13 Additional paid-in capital 1,159,382 723,577 Accumulated other comprehensive gain 1,331 0 Accumulated deficit (778,061) (653,921) Total stockholders' equity 382,666 69,669 Total liabilities and stockholders' equity \$ 416,256 \$ 87,948 X - Definition Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(19\)\(a\)\)](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10> + Details Name: us-gaap Accounts Payable Current Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - Definition Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(20\)\)](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap Accrued Liabilities Current Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - Definition Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A> Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11> Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2) Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(h\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2) Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(30\)\(a\)\(4\)\)](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(23\)\(a\)\(3\)\)](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1> Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14> + Details Name: us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - Definition Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + References Reference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10> Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(18\)\)](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1> Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(30\)\(a\)\(1\)\)](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap Additional Paid In Capital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - Definition Amount of asset recognized for present right to economic benefit. + References Reference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48> Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49> Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1) Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32) Reference 5: [http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32) Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32) Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32) Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32) Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32) Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32) Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32) Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32) Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32) Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32) Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32) Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32) Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32) Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32) Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32) Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32) Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32) Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32) Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 1](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)

[Page 22 - Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-3Reference 5:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(bb\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 9:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12:](#) [http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13:](#) [http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(12\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(8\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 18:](#) [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 19:](#) [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 20:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 21:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 22:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 23:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 24:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 25:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 26:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 27:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 28:](#) [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-3Reference 30:](#) [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(11\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap Assets Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(bb\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6:](#) [http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 10:](#) [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 11:](#) [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 12:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 13:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://](#)

1Reference 6:

7:

10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6:

Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\) \(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4) (i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 11: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 21: <http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42>Reference 22: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)Reference 23: <http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40>Reference 24: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-05\(b\)\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2) + Details Name: us-gaap Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16> + Details Name: us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10> + Details Name: us-gaap_ IncomeStatementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionRatio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph \(SAB Topic 4.C\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4) + Details Name: us-gaap StockholdersEquityNoteStockSplitConversionRatio Namespace Prefix: us-gaap_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration XML 16 R6.htm IDEA: XBRL DOCUMENT 3.24.3 Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD (\$) in Thousands 3 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Statement of Comprehensive Income [Abstract] A A A Net loss (\$51,910) (\$124,632) (\$124,140) (\$96,399) Change in unrealized gain on marketable securities, net of tax 1,402 0 1,331 173 Comprehensive loss (\$50,508) (\$24,632) (\$122,809) (\$96,226) X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(24\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(26\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(22\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 23: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 28: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 29:

[illegible]

Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-60B>Reference 33: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 34: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28B>Reference 35: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1A>Reference 36: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1B>Reference 37: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478524/942-220-S99-1> + Details Name: us-gaap NetIncomeLoss Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481800/320-10-50-9>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-10A>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-11> + Details Name: us-gaap OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap SharesPaidForTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478448/946-505-2>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479886/946-10-S99-3>Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionTotal number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap StockIssuedDuringPeriodSharesRestrictedStockAwardGross Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(i)(iv)(02) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAggregate change in value for stock issued during the period as a result of employee stock purchase plan. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-11>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478009/946-205-4>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478448/946-505-50-2>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 8: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 5: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-2>Reference 8: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 11: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 12: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 13: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28B>Reference 14: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480418/310-10-S99-2> + Details Name: us-gaap StockholdersEquity Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 18 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical) - USD (\$) \$ in Thousands 3 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2023 Mar. 31, 2023 Follow-On Offering A A A Stock issuance costs A \$ 14,013 \$ 10,836 \$ 4,484 A At-The-Market Offering A A A A Stock issuance costs \$ 70 A \$ 376 A \$ 560 X - DefinitionStock Issuance Costs + ReferencesNo definition available. + Details Name: prax StockIssuanceCosts Namespace Prefix: prax Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap SubsidiarySaleOfStockAxis=prax FollowOnOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap SubsidiarySaleOfStockAxis=prax AtTheMarketOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: XML 19 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Cash Flows (Unaudited) - USD (\$) \$ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Cash flows from operating activities: A A Net loss \$ (124,140) \$ (96,399) Adjustments to reconcile net loss to net cash used in operating activities: A A Depreciation expense 311 321 Stock-based compensation expense 32,785 19,131 Non-cash operating lease expense 690 619 Amortization of premiums and discounts on marketable securities, net (3,620) 47 Non-cash collaboration and license agreement expense 2,500 0 Changes in operating assets and liabilities: A A Prepaid expenses and other current assets 564 8,109 Accounts payable 9,195 (7,556) Accrued expenses 8,005 (8,871) Operating lease liabilities (835) (744) Deferred revenue (1,090) (1,932) Net cash used in operating activities (75,635) (87,275) Cash flows from investing activities: A A Purchases of marketable securities (302,101) 0 Maturities of marketable securities 64,525 39,000 Net cash (used in) provided by investing activities (237,576) 39,000 Cash flows from financing activities: A A Payments of tax withholdings related to vesting of restricted stock units (151) (132) Proceeds from exercise of stock options and employee stock purchase plan purchases 659 310 Net cash provided by financing activities 400,556 87,745 Increase in cash, cash equivalents and restricted cash 87,345 39,470 Cash, cash equivalents and restricted cash, beginning of period 81,716 62,031 Cash, cash equivalents and restricted cash, end of period 169,061 101,501 Reconciliation of cash, cash equivalents and restricted cash: A A Cash and cash equivalents 168,645 101,085 Restricted cash 416 416 Total cash, cash equivalents and restricted cash 169,061 101,501 Supplemental disclosures of non-cash activities: A A Issuance costs from at-the-market offering included in accrued expenses 36 0 Offering costs from follow-on offering included in accounts payable 0 184 Purchases of property and equipment included in accounts payable 0 50 Follow-On Offering A A Cash flows from financing activities: A A Proceeds from stock offerings, net of issuance costs 377,636 63,439 License And Collaboration Agreement A A Cash flows from financing activities: A A Proceeds from stock offerings, net of issuance costs 14,765 0 At-The-Market Offering A A Cash flows from financing activities: A A Proceeds from stock offerings, net of issuance costs \$ 7,647 \$ 24,128 X - DefinitionCollaboration And License Agreement, Noncash Expense + ReferencesNo definition available. + Details Name: prax CollaborationAndLicenseAgreementNoncashExpense Namespace Prefix: prax Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIncrease (Decrease) in Operating Lease Liabilities. + ReferencesNo definition available. + Details Name: prax IncreaseDecreaseInOperatingLeaseLiabilities Namespace Prefix: prax Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionStock Issuance Costs Incurred But Not Yet Paid + ReferencesNo definition available. + Details Name: prax StockIssuanceCostsIncurredButNotYetPaid Namespace Prefix: prax Data Type:

xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 - SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem

ItemType Balance Type: na Period Type: duration X - DefinitionFuture cash outflow to pay for purchases of fixed assets that have occurred. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482913/230-10-50-4>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482913/230-10-50-3>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482913/230-10-50-5> + Details Name: us-gaap_CapitalExpendituresIncurredButNotYetPaid Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483467/210-10-45-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-4> + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482913/230-10-50-8>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477401/830-230-45-1> + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of debt issuance costs that were incurred during a noncash or partial noncash transaction. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482913/230-10-50-4>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482913/230-10-50-3>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482913/230-10-50-5> + Details Name: us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-1> + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 912 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478345/912-310-45-11>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_IncreaseDecreaseInContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem

ItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem

ItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem

ItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-25> + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem

ItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147476176/805-60-65-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478666/740-323-65-2>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-1>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 17: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-10>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1>Reference 20: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-1>Reference 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/21474780097/470-10-S99-1A>Reference 23: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 24: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 25: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 26: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 27: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 28: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 29: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher

ASB - URL: <https://asc.fasb.org/1943274/2147482097/470-10-S99-1BReference> 30: <http://www.xbrl.org/2003/role/disclosureRef-Topic> 700 - Name Accounting Standards Codification - Section S99 - Paragraph 1B - Subparagraph (SX 210.13-02(a)(4)(iv)) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference> 31: <http://www.xbrl.org/2003/role/disclosureRef-Topic> 470 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1B - Subparagraph (SX 210.13-02(a)(5)) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference> 32: <http://www.xbrl.org/2003/role/disclosureRef-Topic> 260 - SubTopic 10 - Name Accounting Standards Codification - Section 45 - Paragraph 60B - Subparagraph (a) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference> 33: <http://www.xbrl.org/2003/role/disclosureRef-Topic> 205 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 7 - Publisher FASB - URI <https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference> 34: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic> 230 - SubTopic 10 - Name Accounting Standards Codification - Section 45 - Paragraph 28 - Publisher FASB - URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference> 35: <http://www.xbrl.org/2003/role/disclosureRef-Topic> 220 - SubTopic 10 - Name Accounting Standards Codification - Section 45 - Paragraph 1A - Subparagraph (a) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference> 36: <http://www.xbrl.org/2003/role/disclosureRef-Topic> 220 - SubTopic 10 - Name Accounting Standards Codification - Section 45 - Paragraph 1B - Subparagraph (a) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference> 37: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic> 942 - SubTopic 220 - Name Accounting Standards Codification - Section S99 - Paragraph 1 - Subparagraph (SX 210.9-04(22)) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147478524/942-220-S99-1> + Details Name: us-gaap NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic> 230 - SubTopic 10 - Name Accounting Standards Codification - Section 45 - Paragraph 28 - Subparagraph (b) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap OperatingLeaseRightOfUseAssetAmortizationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic> 230 - SubTopic 10 - Name Accounting Standards Codification - Section 45 - Paragraph 15 - Subparagraph (a) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147482740/230-10-45-15> + Details Name: us-gaap PaymentsRelatedToTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic> 320 - SubTopic 10 - Name Accounting Standards Codification - Section 45 - Paragraph 11 - Publisher FASB - URI <https://asc.fasb.org/1943274/2147481830/320-10-45-11Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic> 230 - SubTopic 10 - Name Accounting Standards Codification - Section 45 - Paragraph 13 - Subparagraph (a) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147482740/230-10-45-13Reference> 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic> 230 - SubTopic 10 - Name Accounting Standards Codification - Section 45 - Paragraph 11 - Publisher FASB - URI <https://asc.fasb.org/1943274/2147482740/230-10-45-11> + Details Name: us-gaap PaymentsToAcquireAvailableForSaleSecuritiesDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic> 942 - SubTopic 11 - Subparagraph (a) - SubTopic 230 - Publisher FASB - URI <https://asc.fasb.org/1943274/2147482740/230-10-45-14> + Details Name: us-gaap ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic> 942 - SubTopic 11 - Subparagraph (a) - SubTopic 230 - Publisher FASB - URI <https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic> 942 - SubTopic 11 - Subparagraph (a) - SubTopic 230 - Publisher FASB - URI <https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic> 942 - SubTopic 11 - Subparagraph (a) - SubTopic 230 - Publisher FASB - URI <https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic> 942 - SubTopic 11 - Subparagraph (a) - SubTopic 230 - Publisher FASB - URI <https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic> 942 - SubTopic 11 - Subparagraph (a) - SubTopic 230 - Publisher FASB - URI <https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic> 942 - SubTopic 11 - Subparagraph (a) - SubTopic 230 - Publisher FASB - URI <https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic> 942 - SubTopic 11 - Subparagraph (a) - SubTopic 230 - Publisher FASB - URI <https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic> 942 - SubTopic 11 - Subparagraph (

SeptemberÂ 30, 2024 and 2023. Financial statement disclosures for the three and nine months ended SeptemberÂ 30, 2024 and 2023 are condensed and do not include all disclosures required for an annual set of financial statements in accordance with GAAP.The results for the three and nine months ended SeptemberÂ 30, 2024 are not necessarily indicative of results to be expected for the year ended DecemberÂ 31, 2024, any other interim periods, or any future year or period.Use of EstimatesThe preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, accrued and prepaid research and development expense, collaboration revenue, stock-based compensation expense and the recoverability of the Companyâ€™s net deferred tax assets and related valuation allowance. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.Common Stock WarrantsThe Company accounts for warrants to purchase shares of its common stock in accordance with the guidance in FASB ASC No. 480, Distinguishing Liabilities from Equity (ASC 480) and ASC No. 815, Derivatives and Hedging (ASC 815). The Company classifies warrants issued for the purchase of shares of its common stock as either equity or liability instruments based on an assessment of the specific terms and conditions of each respective contract. Such assessment includes determining whether the warrants are freestanding financial instruments or embedded in a host instrument, whether the warrants are liabilities within the scope of ASC 480, whether the warrants meet the definition of a derivative in ASC 815 and whether the warrants meet the requirements for equity classification pursuant to the indexation and equity classification criteria in ASC 815. The Company determines the classification for its warrants at the time of issuance and updates its assessment, as necessary. Warrants that meet all of the criteria for equity classification are recorded as a component of additional paid-in capital.Net Loss per ShareBasic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. The calculation of weighted average number of common shares outstanding excludes shares of restricted common stock that are not vested but includes shares of common stock underlying pre-funded warrants. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period, after giving consideration to the dilutive effect of potentially dilutive common shares. For purposes of this calculation, outstanding options to purchase shares of common stock, unvested shares of restricted common stock and potential shares issuable under the 2020 ESPP are considered potentially dilutive common shares. The Company has generated a net loss in all periods presented so the basic and diluted net loss per share are the same, as the inclusion of the potentially dilutive securities would be anti-dilutive.Recent Accounting PronouncementsRecently Issued Accounting PronouncementsOn November 27, 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures. ASU No. 2023-07 improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The amendments included in this ASU apply to all public entities that are required to report segment information in accordance with Topic 280, including those with a single reportable segment. The amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and should be applied retrospectively to all prior periods presented in the financial statements. Upon transition, the segment expenses categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The Company only has one reportable segment and this ASU impacts disclosures only. The Company has determined that the effects of adopting the amendments in ASU 2023-07 will only impact its disclosures and not have a material impact on its consolidated financial position and the results of its operations when such amendment is adopted.On December 14, 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740) - Improvements to Income Tax Disclosures. ASU No. 2023-09 provides more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and incomes taxes paid information. For public companies, the amendments are effective for annual periods beginning after December 15, 2024 and should be applied prospectively. The Company has determined that the effects of adopting the amendments in ASU 2023-09 will only impact its disclosures and will not have a material impact on its consolidated financial position and the results of its operations when such amendment is adopted. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1>Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 940 -SubTopic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/940-320/tableOfContent](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Cash Equivalents and Marketable Securities 9 Months Ended Sep. 30, 2024 Investments, Debt and Equity Securities [Abstract] A Cash Equivalents and Marketable Securities Cash Equivalents and Marketable SecuritiesThe following is a summary of the Company's investment portfolio as of SeptemberÂ 30, 2024 (in thousands). The Company did not hold any cash equivalents or marketable securities as of DecemberÂ 31, 2023. As of September 30, 2024Gross UnrealizedEstimatedCostGainsLossesFair ValueCash equivalents:Money market funds$81,359A $â€”A $â€”A $81,359A Available-for-sale marketable securities:Debt securities issued by U.S. government agencies143,283A 900A $â€”A 144,183A Corporate debt securities74,715A 370A $â€”A 75,085A Commercial paper18,543A 45A $â€”A 18,588A Other debt securities4,656A 16A $â€”A 4,672A Total cash equivalents and marketable securities$322,556A $1,331A $â€”A $323,887A As of SeptemberÂ 30, 2024, the Company had 3 securities with a total fair market value of $8.0 million in an unrealized loss position. The Company believes that any unrealized losses associated with the decline in value of its securities is temporary and primarily related to the change in market interest rates since purchase, and believes that it is more likely than not that it will be able to hold its debt securities to maturity. The Company anticipates a full recovery of the amortized cost basis of its debt securities at maturity and an allowance was not recognized.Contractual maturities of the marketable securities at each balance sheet date are as follows (in thousands):September 30, 2024December 31, 2023Within one year$188,387A $â€”A After one year through five years54,141A $â€”A Total$242,528A $â€”A Securities are evaluated for impairment at the end of each reporting period. The Company did not record any impairment related to its available-for-sale securities during the three and nine months ended SeptemberÂ 30, 2024 and 2023. X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for investments in certain debt and equity securities. + ReferencesReference 1: <a href=)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/320/tableOfContent](http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1403 -Paragraph b -Publisher SECReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/320/tableOfContent)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10](http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6)Reference 7: [http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/942-320/tableOfContent + Details Name: us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R13.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] A Fair Value Measurements Fair Value MeasurementsFair value is defined as the price that would be received to sell an asset in an orderly transaction between market participants at the measurement date. The Company categorizes financial assets measured at fair value based on a fair value hierarchy. The following fair value hierarchy is used to classify financial assets based on observable inputs and unobservable inputs used to value the financial assets:â€¢Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets;â€¢Level 2: Quoted prices for similar assets in active markets, quoted prices in markets that are not active, or inputs which are unobservable, either directly or indirectly, for substantially the full term of the asset; orâ€¢Level 3: Prices or valuation techniques that require inputs that are both significant to the valuation of the asset and unobservable.The following table presents information about the Companyâ€™s financial assets measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values as of SeptemberÂ 30, 2024 (in thousands). The Company did not hold any financial assets measured at fair value on a recurring basis as of DecemberÂ 31, 2023.As of September 30, 2024Level1Level4Level3TotalAssets:Cash equivalents:Money market funds$81,359A $â€”A $â€”A $81,359A Available-for-sale marketable securities:Debt securities issued by U.S. government agencies144,183A $â€”A $â€”A 144,183A Corporate debt securitiesâ€”A 75,085A $â€”A 75,085A Commercial paperâ€”A 18,588A $â€”A 18,588A Other debt securitiesâ€”A 4,672A $â€”A 4,672A $225,542A $98,345A $â€”A $323,887A X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); and (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: <a href=)Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 12: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details Name: us-gaap_FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses 9 Months Ended Sep. 30, 2024 Payables and Accruals [Abstract] A Accrued Expenses Accrued ExpensesAccrued expenses consisted of the following (in thousands):September 30, 2024December 31, 2023Accrued external research and development expenses$11,756A $2,957A Accrued personnel-related expenses3,162A 3,716A Accrued other expenses539A 743A Total accrued expenses$15,457A $7,416A X - DefinitionThe entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. + ReferencesReference 1: <a href=)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(24\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1>Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContent](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 25 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies 9 Months Ended Sep. 30, 2024 Commitments and Contingencies Disclosure [Abstract] A Commitments and Contingencies Commitments and ContingenciesIn May 2021, the Company entered into a sublease agreement for office space located in Boston, Massachusetts that expires on January 31, 2026, with no option to renew or terminate early. The base rent increases by approximately 2% annually. The Company issued a letter of credit to the landlord related to the security deposit, secured by restricted cash, which is reflected within other non-current assets on the accompanying condensed consolidated balance sheets as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023. This lease qualifies as an operating lease. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: <a href=)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4](http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4)Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContent>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4](http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4)Reference 6:

COLLABORATION AND LICENSE AGREEMENTS

The Company entered into a Collaboration Agreement with UCB Biopharma SRL (the "Collaboration Agreement") for the discovery of small molecule therapeutics as potential treatments of KCNT1-related epilepsies. Under the terms of the Collaboration Agreement, the Company has agreed to perform general biology-related research services as part of a mutually agreed upon research plan in exchange for a \$5.0 million upfront payment. In addition, the Company provided UCB an exclusive option to in-license global development and commercialization rights to any resulting KCNT1 small molecule development candidate identified as part of the research plan. If UCB exercises its option to in-license global development and commercialization rights, the Collaboration Agreement stipulates that UCB will assume research, development, manufacturing and commercialization responsibilities and costs. Under the terms of the Collaboration Agreement, the Company will be eligible to receive an option fee and future success-based development and commercialization milestone payments, totaling up to \$98.5 million, in addition to tiered royalties on net sales of any resulting products from the Collaboration Agreement. The Company concluded that UCB is a customer, and as such, the arrangement falls within the scope of Topic 606. At the commencement of the Collaboration Agreement, the Company identified one performance obligation, which was to perform the research services for UCB. The Company determined the transaction price to be \$5.0 million, comprised of the upfront payment it received. The option provided to UCB was determined not to be a material right. The Company recognizes revenue for its research services performance obligation over time using an input method over the duration of the research services. During the three and nine months ended September 30, 2024, the Company recognized \$0.3 million and \$1.1 million, respectively, in collaboration revenue related to the Collaboration Agreement in the condensed consolidated statement of operations. As of September 30, 2024, \$1.5 million was included in deferred revenue in the condensed consolidated balance sheet, of which \$1.2 million was classified as current. Tenacia Collaboration and License Agreement On January 4, 2024, the Company entered into an exclusive collaboration and license agreement (the "License Agreement") with Tenacia Biotechnology (Shanghai) Co., Ltd. (the "Tenacia"), a China-based portfolio company of Bain Capital, which provides Tenacia an exclusive license to use certain intellectual property for the development and commercialization of ulixacaltamide and products containing ulixacaltamide in China, Hong Kong, Macau and Taiwan. Tenacia is solely responsible for the development and commercialization under the arrangement, with the exception of the associated manufacturing. The Company also entered into a Stock Purchase Agreement (the "Stock Purchase Agreement") with BCPE Tenet Holdings Cayman, Ltd. (the "BCPE"), a related party of Tenacia. Pursuant to the terms of the License Agreement, the Company was entitled to an up-front, non-refundable and non-creditable cash payment of \$5.0 million, net of certain tax withholdings. In addition, the Company is eligible to receive \$264.0 million in success-based development and commercialization milestone payments as well as tiered royalties on net sales. Pursuant to the terms of the Stock Purchase Agreement, the Company issued and sold 443,253 shares of its common stock to BCPE at a price per share of \$22.5605 for aggregate gross proceeds of \$10.0 million. The per share price was based on a 20% premium over the 30-day volume-weighted average price. Under the terms of the License Agreement, the Company granted to Tenacia an exclusive license to use certain intellectual property for the development and commercialization of ulixacaltamide and products containing ulixacaltamide in China, Hong Kong, Macau and Taiwan. Tenacia is solely responsible for the development and commercialization under the arrangement, with the exception of the associated manufacturing. The Company concluded that the License Agreement and the Stock Purchase Agreement is a combined arrangement since they were executed at the same time and in contemplation of each other with the same counterparty or a related party thereof and the combined arrangement falls within the scope of Topic 606. The Company's obligations under the arrangement comprise a single promise, or one performance obligation, related to the exclusive development and commercialization license granted to Tenacia. Total proceeds associated with the combined arrangement at inception were \$14.8 million consisting of the following: (i) \$10.0 million gross proceeds from the sale of common stock under the Stock Purchase Agreement and (ii) \$4.8 million, net of tax, related to the up-front payment under the License Agreement, both of which were received in January 2024. During the three and nine months ended September 30, 2024, the Company had not achieved any development or sales milestones or earned any royalties under the License Agreement. The Company recorded the common stock sold to BCPE at its issuance date fair value of \$38.95 per share, or \$17.3 million in the aggregate, which exceeded the proceeds received which were calculated based on the 20% premium over the prior 30-day volume-weighted average price. Accordingly, there is no transaction price allocable to the performance obligation. The Company accounted for the excess of the fair value of the equity securities issued over the total proceeds received as consideration paid to a customer for which no distinct good or service was transferred in exchange. As a result, the transaction gives rise to negative revenue on a cumulative basis in the amount of \$2.5 million, which was recorded in research and development expense in the accompanying condensed consolidated statement of operations for the three months ended March 31, 2024. For agreements where the licenses are considered separate performance obligations or represent the only performance obligation, the Company recognizes revenue at the point in time that the Company effectively grants the license, as the licenses or assignments represent functional intellectual property. As of September 30, 2024, the Company did not have any receivables or deferred revenue related to the arrangement with Tenacia. The Company did not recognize any contract assets related to costs to obtain a contract with a customer or costs to fulfill a contract with a customer through September 30, 2024 because no qualifying costs were incurred. During the three and nine months ended September 30, 2024, the Company did not recognize any revenue associated with the combined arrangement.

X - Definition The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants. + References Reference 1:

[illegible]

Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap NetIncomeLoss Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 33 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Sep. 30, 2024 Trading Arrangements, by Individual A Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd Rule10b51ArrAdoptedFlag Namespace Prefix: ecd Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd Rule10b51ArrTrmtdFlag Namespace Prefix: ecd Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd TradingArrByIndTable Namespace Prefix: ecd Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 34 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies (Policies) 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Á Basis of Presentation Basis of PresentationThe accompanying condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (â€œGAAPâ€œ). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (â€œASCâ€œ) and ASUs of the FASB.The significant accounting policies used in preparation of these condensed consolidated financial statements for the three and nine months ended SeptemberÂ 30, 2024 are consistent with those discussed in Note 2 to the consolidated financial statements included in the Company's 2023 Annual Report on Form 10-K, other than as noted below.Reverse Stock SplitOn NovemberÂ 28, 2023, the Company filed a Certificate of Amendment to the Company's Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The Reverse Stock Split became effective at 5:00 p.m., Eastern Time, on NovemberÂ 28, 2023 (the "Effective Time").As a result of the Reverse Stock Split, every 15 shares of the Company's issued and outstanding common stock were automatically reclassified into one validly issued, fully-paid and non-assessable share of common stock. Any fractional post-split shares as a result of the Reverse Stock Split were rounded down to the nearest whole post-split share. The Reverse Stock Split did not affect the number of authorized shares of common stock or the par value of the common stock. All share amounts and per share amounts for the periods prior to the Effective Time disclosed in this Quarterly Report on Form 10-Q have been restated to reflect the Reverse Stock Split on a retroactive basis.Marketable Securities ClassificationThe Company may invest its excess cash in money market funds and debt instruments of the U.S. Treasury, financial institutions, corporations and U.S. government agencies with strong credit ratings and an investment grade rating at or above A-1 or P-1 by two of the three nationally recognized statistical rating organizations. The Company does not believe that it is exposed to more than a nominal amount of credit risk related to any marketable securities it may invest in. The Company has established guidelines relative to diversification and maturities that maintain safety and liquidity, and periodically reviews and modifies these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity.The Company classifies its investments in debt instruments as available-for-sale. Available-for-sale investments are reported at fair value at each balance sheet date, and include any unrealized holding gains and losses in accumulated other comprehensive loss, a component of stockholdersâ€™ equity. Realized gains and losses are included in the Company's condensed consolidated statements of operations. All of the Company's available-for-sale securities are available for use in its current operations. The Company classifies marketable securities as either cash equivalents, short-term, or long-term based on their stated maturity dates as it is more-likely-than-not that the Company will hold these assets through to their maturity dates. Unaudited Interim Condensed Consolidated Financial Information Unaudited Interim Condensed Consolidated Financial InformationThe accompanying condensed consolidated balance sheet as of SeptemberÂ 30, 2024, the condensed consolidated statements of operations for the three and nine months ended SeptemberÂ 30, 2024 and 2023, the condensed consolidated statements of comprehensive loss for the three and nine months ended SeptemberÂ 30, 2024 and 2023, the condensed consolidated statements of cash flows for the nine months ended SeptemberÂ 30, 2024 and 2023 and the condensed consolidated statements of stockholdersâ€™ equity for the three and nine months ended SeptemberÂ 30, 2024 and 2023 are unaudited. The unaudited interim financial statements have been prepared on the same basis as the audited annual consolidated financial statements, and in the opinion of management reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Companyâ€™s financial position as of SeptemberÂ 30, 2024, the results of its operations for the three and nine months ended SeptemberÂ 30, 2024 and 2023 and its cash flows for the nine months ended SeptemberÂ 30, 2024 and 2023. Financial statement disclosures for the three and nine months ended SeptemberÂ 30, 2024 and 2023 are condensed and do not include all disclosures required for an annual set of financial statements in accordance with GAAP.The results for the three and nine months ended SeptemberÂ 30, 2024 are not necessarily indicative of results to be expected for the year ended DecemberÂ 31, 2024, any other interim periods, or any future year or period. Use of Estimates Use of EstimatesThe preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, accrued and prepaid research and development expense, collaboration revenue, stock-based compensation expense and the recoverability of the Companyâ€™s net deferred tax assets and related valuation allowance. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates. Common Stock Warrants Common Stock WarrantsThe Company accounts for warrants to purchase shares of its common stock in accordance with the guidance in FASB ASC No. 480, Distinguishing Liabilities from Equity (ASC 480) and ASC No. 815, Derivatives and Hedging (ASC 815). The Company classifies warrants issued for the purchase of shares of its common stock as either equity or liability instruments based on an assessment of the specific terms and conditions of each respective contract. Such assessment includes determining whether the warrants are freestanding financial instruments or embedded in a host instrument, whether the warrants are liabilities within the scope of ASC 480, whether the warrants meet the definition of a derivative in ASC 815 and whether the warrants meet the requirements for equity classification pursuant to the indexation and equity classification criteria in ASC 815. The Company determines the classification for its warrants at the time of issuance and updates its assessment, as necessary. Warrants that meet all of the criteria for equity classification are recorded as a component of additional paid-in capital. Net Loss per Share Net Loss per ShareBasic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. The calculation of weighted average number of common shares outstanding excludes shares of restricted common stock that are not vested but includes shares of common stock underlying pre-funded warrants. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period, after giving consideration to the dilutive effect of potentially dilutive common shares. For purposes of this calculation, outstanding options to purchase shares of common stock, unvested shares of restricted common stock and potential shares issuable under the 2020 ESPP are considered potentially dilutive common shares. The Company has generated a net loss in all periods presented so the basic and diluted net loss per share are the same, as the inclusion of the potentially dilutive securities would be anti-dilutive. Recent Accounting Pronouncements Recent Accounting PronouncementsRecently Issued Accounting PronouncementsOn November 27, 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures. ASU No. 2023-07 improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The amendments included in this ASU apply to all public entities that are required to report segment information in accordance with Topic 280, including those with a single reportable segment. The amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and should be applied retrospectively to all prior periods presented in the financial statements. Upon transition, the segment expenses categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The Company only has one reportable segment and this ASU impacts disclosures only. The Company has determined that the effects of adopting the amendments in ASU 2023-07 will only impact its disclosures and not have a material impact on its consolidated financial position and the results of its operations when such amendment is adopted.On December 14, 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740) - Improvements to Income Tax Disclosures. ASU No. 2023-09 provides more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and incomes taxes paid information. For public companies, the amendments are effective for annual periods beginning after December 15, 2024 and should be applied prospectively. The Company has determined that the effects of adopting the amendments in ASU 2023-09 will only impact its disclosures and will not have a material impact on its consolidated financial position and the results of its operations when such amendment is adopted. X - DefinitionCommon Stock, Warrants + ReferencesNo definition available. + Details Name: prax CommonStockWarrantsPolicyTextBlock Namespace Prefix: prax Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionUnaudited interim condensed consolidated financial information + ReferencesNo definition available. + Details Name: prax UnauditedInterimCondensedConsolidatedFinancialInformationPolicyTextBlock Namespace Prefix: prax Data Type: dtr-types1:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap AccountingPoliciesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 + Details Name: us-gaap EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic

10 - Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2009/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap UseOfEstimates Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 35 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Cash Equivalents and Marketable Securities (Tables) 9 Months Ended Sep. 30, 2024 Investments, Debt and Equity Securities [Abstract] A Debt Securities, Available-for-Sale The following is a summary of the Company's investment portfolio as of SeptemberA 30, 2024 (in thousands). The Company did not hold any cash equivalents or marketable securities as of DecemberA 31, 2023. As of September 30, 2024Gross UnrealizedEstimatedCostGainsLossesFair ValueCash equivalents:Money market funds\$81,359A \$â€”A \$â€”A \$81,359A Available-for-sale marketable securities:Debt securities issued by U.S. government agencies143,283A 900A â€”A 144,183A Corporate debt securities74,715A 370A â€”A 75,085A Commercial paper18,543A 45A â€”A 18,588A Other debt securities4,656A 16A â€”A 4,672A Total cash equivalents and marketable securities\$22,556A 11,331A \$â€”A \$323,887A Contractual maturities of the marketable securities at each balance sheet date are as follows (in thousands):September 30, 2024December 31, 2023Within one year\$188,387A \$â€”A After one year through five years54,141A â€”A Total\$242,528A \$â€”A X - DefinitionTabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3 + Details Name: us-gaap DebtSecuritiesAvailableForSaleTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 36 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements (Tables) 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] A Summary of Financial Assets Measured At Fair Value On A Recurring Basis The following table presents information about the Companyâ€™s financial assets measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values as of SeptemberA 30, 2024 (in thousands). The Company did not hold any financial assets measured at fair value on a recurring basis as of DecemberA 31, 2023.As of September 30, 2024LevelA 1LevelA 2LevelA 3TotalAssets:Cash equivalents:Money market funds\$81,359A \$â€”A \$â€”A \$81,359A Available-for-sale marketable securities:Debt securities issued by U.S. government agencies144,183A â€”A â€”A 144,183A Corporate debt securitiesâ€”A 75,085A â€”A 75,085A Commercial paperâ€”A 18,588A â€”A 18,588A Other debt securitiesâ€”A 4,672A â€”A 4,672A \$225,542A \$98,345A \$â€”A \$323,887A X - DefinitionTabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap FairValueAssetsMeasuredOnRecurringBasisTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap FairValueDisclosuresAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 37 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses (Tables) 9 Months Ended Sep. 30, 2024 Payables and Accruals [Abstract] A Summary of Accrued Expenses Accrued expenses consisted of the following (in thousands):September 30, 2024December 31, 2023Accrued external research and development expenses\$11,756A \$2,957A Accrued personnel-related expenses\$3,162A 3,716A Accrued other expenses\$39A 743A Total accrued expenses\$15,457A \$7,416A X - ReferencesNo definition available. + Details Name: us-gaap PayablesAndAccrualsAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accrued liabilities. + ReferencesNo definition available. + Details Name: us-gaap ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 38 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Common Stock and Preferred Stock (Tables) 9 Months Ended Sep. 30, 2024 Stockholders' Equity Note [Abstract] A Summary of Shares Reserved for Future Issuance The Company has reserved the following shares of common stock for future issuance:September 30, 2024December 31, 2023Shares reserved for exercise of outstanding stock options1,829,324A 666,163A Shares reserved for exercise of pre-funded warrants related to the June 2023 Financingâ€”A 470,000A Shares reserved for exercise of pre-funded warrants related to the January 2024 Financing904,580A â€”A Shares reserved for exercise of pre-funded warrants related to the April 2024 Financing221,238A â€”A Shares reserved for future awards under the 2020 Stock Option and Incentive Plan15,058A 148,264A Shares reserved for future awards under the 2020 Employee Stock Purchase Plan15,883A 53,111A Shares reserved for future awards under the 2024 Inducement Plan112,774A â€”A Shares reserved for vesting of restricted stock units222,674A 47,145A Total shares of authorized common stock reserved for future issuance\$3,521,531A 1,384,683A X - DefinitionSchedule Of Common Stock Reserved For Future Issuance + ReferencesNo definition available. + Details Name: prax ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock Namespace Prefix: prax Data Type: dtr-types:1textBlockItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap StockholdersEquityNoteAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 39 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation (Tables) 9 Months Ended Sep. 30, 2024 Share-Based Payment Arrangement [Abstract] A Summary of Restricted Stock Activity The following table summarizes the Companyâ€™s restricted stock unit activity:SharesWeightedAverageGrantA DateFair ValueUnvested as of December 31, 202347,145A \$202.27A Issued197,097A 51.98A Vested(11,856)309.13A Forfeited(9,712)54.86A Unvested as of September 30, 2024222,674A \$69.98A Summary of Stock Option Activity The following table summarizes the Companyâ€™s stock option activity:Number ofSharesWeightedAverageExerciseA Priceper ShareWeightedAverageRemainingContractualTermAggregateIntrinsicA Value(In years)(InA thousands)Outstanding as of December 31, 2023366,163A \$160.19A Granted1,195,546A 51.43A Exercised(8,753)39.75A Cancelled or Forfeited(23,632)127.76A Outstanding as of September 30, 20241,829,324A 90.08A 8.71\$12,800A Exercisable as of September 30, 2024878,111A 102.13A 7.93\$6,963A Vested and expected to vest as of September 30, 20241,829,324A \$90.08A 8.71\$12,800A Schedule of Fair Value of Stock Option Awards on the Grant Date Using the Black-Scholes Option Valuation Model The weighted-average assumptions that the Company used in the Black-Scholes option pricing model to determine the grant-date fair value of stock options granted to employees and non-employees on the date of grant were as follows for the three and nine months ended SeptemberA 30, 2024:Three Months EndedSeptember 30,Nine Months EndedSeptember 30,20242024Risk-free interest rate4.06A %4.01A %Expected term (in years)6.006.00Expected volatility101.00A %96.48A %Expected dividend yieldâ€”A %â€”A %Weighted average grant-date fair value per share\$45.95A \$40.73A Summary of Stock-Based Compensation Expense Stock-based compensation expense was allocated as follows (in thousands):Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2024202320242023Research and development\$4,640A \$2,035A \$12,298A \$6,176A General and administrative7,792A 3,728A 20,487A 12,955A Total stock-based compensation expense\$12,432A \$3,763A \$32,785A \$19,131A X - ReferencesNo definition available. + Details Name: us-gaap DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the changes in outstanding nonvested restricted stock shares. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Subparagraph (c) -Paragraph 2 -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap NonvestedRestrictedStockSharesActivityTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 40 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Net Loss per Share (Tables) 9 Months Ended Sep. 30, 2024 Earnings Per Share [Abstract] A Summary of Antidilutive Securities Excluded From Computation of Earnings Per Share The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have been anti-dilutive:Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2024202320242023Outstanding stock options1,829,324A 658,417A 1,829,324A 658,417A Unvested restricted stock units222,674A 42,241A 222,674A 42,241A Potential shares issuable under the 2020 ESPP7,391A 10,780A 7,391A 10,780A 2,059,389A 711,438A 2,059,389A 711,438A X - ReferencesNo definition available. + Details Name: us-gaap EarningsPerShareAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 41 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Nature of the Business -Additional Information (Details) \$ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 USD (\$) candidate platform Jun. 30, 2024 USD (\$) Mar. 31, 2024 USD (\$) Sep. 30, 2023 USD (\$) Jun. 30, 2023 USD (\$) Mar. 31, 2023 USD (\$) Sep. 30, 2024 USD (\$) study candidate platform Sep. 30, 2023 USD (\$) Dec. 31, 2023 USD (\$) Organization, Consolidation and Presentation of Financial Statements [Abstract] A A A A A A A A Number of platforms | platform 2 A A A A A A 2 A A A Number of product candidates | candidate 4 A A A A A 4 A A Number of efficacy studies | study A A A A A A 4 A A Proceeds from issuance or sale of equity A A A A A \$ 1,000,000 A A Net loss \$ 51,910 \$ 32,677 \$ 39,553 \$ 24,632 \$ 34,312 \$ 37,455 124,140 \$ 96,399 A Accumulated deficit 778,061 A A A A 778,061 A \$ 653,921 Cash, cash equivalents, and marketable securities \$ 411,200 A \$ A \$ 411,200 A A X - DefinitionNumber Of Efficacy Studies + ReferencesNo definition available. + Details Name: prax NumberOfEfficacyStudies Namespace Prefix: prax Data Type: xbrli:integerItem Type Balance Type: na Period Type: duration X - DefinitionNumber Of Platforms + ReferencesNo definition available. + Details Name: prax NumberOfPlatforms Namespace Prefix: prax Data Type: xbrli:integerItem Type Balance Type: na Period Type: instant X - DefinitionNumber Of Product Candidates + ReferencesNo definition available. + Details Name: prax NumberOfProductCandidates Namespace Prefix: prax Data Type: xbrli:integerItem Type Balance Type: na Period Type: instant X - DefinitionCash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (S21.0-5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap CashCashEquivalentsAndShortTermInvestments Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionThe portion of

profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 13: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 16: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 17: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(1\)\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 23: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 28: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 29: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 30: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 31: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 32: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 33: <http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 34: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 35: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A)Reference 36: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B)Reference 37: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(22\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1) + Details Name: us-gaap NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-03\(i\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3) + Details Name: us-gaap ProceedsFromIssuanceOrSaleOfEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(30\)\(a\)\(3\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(h\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(23\)\(a\)\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(17\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 8: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1) + Details Name: us-gaap RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 42 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies (Details) 9 Months Ended Nov. 28, 2023 Sep. 30, 2024 segment Accounting Policies [Abstract] A Stockholders' equity note, stock split, conversion ratio 0.0667 A Number of reportable segments A 1 X - ReferencesNo definition available. + Details Name: us-gaap AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47](http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47)Reference 2: [http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54](http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54)Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18> + Details Name: us-gaap NumberOfReportableSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionRatio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph \(SAB Topic 4.C\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4) + Details Name: us-gaap StockholdersEquityNoteStockSplitConversionRatio1 Namespace Prefix: us-gaap_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration XML 43 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Cash Equivalents and Marketable Securities - Investment Profile (Details) - USD (\$) \$ in Thousands Sep. 30, 2024 Dec. 31, 2023 Debt Securities, Available-for-sale [Line Items] A Debt securities, available-for-sale, current \$ 188,387 \$ 0 Cash equivalents, at carrying value and debt securities, available-for-sale, amortized cost 322,556 A Cash equivalents and debt securities, available-for-sale, accumulated gross unrealized gain, current, before tax 1,331 A Cash equivalents and debt securities, available-for-sale, accumulated gross unrealized loss, current, before tax 0 A Cash equivalents and debt securities, available-for-sale, fair value disclosure 323,887 A Money market funds A Debt Securities, Available-for-sale [Line Items] A Cash equivalents, at carrying value 81,359 A Cash equivalents, accumulated gross unrealized gain, current, before tax 0 A Cash equivalents, accumulated gross unrealized loss, current, before tax 0 A Cash equivalents, fair value disclosure 81,359 A Debt securities issued by U.S. government agencies A Debt Securities, Available-for-sale [Line Items] A Debt securities, available-for-sale, amortized cost, current 143,283 A Debt securities, available-for-sale, accumulated gross unrealized gain, current, before tax 900 A Debt securities, available-for-sale, accumulated gross unrealized loss, current, before tax 0 A Debt securities, available-for-sale, current 144,183 A Corporate debt securities A Debt Securities, Available-for-sale [Line Items] A Debt securities, available-for-sale, amortized cost, current 74,715 A Debt securities, available-for-sale, accumulated gross unrealized gain, current, before tax 370 A Debt securities, available-for-sale, accumulated gross unrealized loss, current, before tax 0 A Debt securities, available-for-sale, current 75,085 A Commercial paper A Debt Securities, Available-for-sale [Line Items] A Debt securities, available-for-sale, amortized cost, current 18,543 A Debt securities, available-for-sale, accumulated gross unrealized gain, current, before tax 45 A Debt securities, available-for-sale, accumulated gross unrealized loss, current, before tax 0 A Debt securities, available-for-sale, current 18,588 A Other debt securities A Debt Securities, Available-for-sale [Line Items] A Debt securities, available-for-sale, amortized cost, current 4,656 A Debt securities, available-for-sale, accumulated gross unrealized gain, current, before tax 16 A Debt securities, available-for-sale, accumulated gross unrealized loss, current, before tax 0 A Debt securities, available-for-sale, current \$ 4,672 A X - DefinitionCash Equivalents, Accumulated Gross Unrealized Gain, Current, Before Tax + ReferencesNo definition available. + Details Name: prax CashEquivalentsAccumulatedGrossUnrealizedGainCurrentBeforeTax Namespace Prefix: prax_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCash Equivalents, Accumulated Gross Unrealized Loss, Current, Before Tax + ReferencesNo definition available. + Details Name: prax CashEquivalentsAccumulatedGrossUnrealizedLossCurrentBeforeTax Namespace Prefix: prax_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCash Equivalents And Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Current, Before Tax + ReferencesNo definition available. + Details Name: prax CashEquivalentsAndDebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax Namespace Prefix: prax_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCash Equivalents And Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Loss, Current, Before Tax + ReferencesNo definition available. + Details Name: prax CashEquivalentsAndDebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax Namespace Prefix:

Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-599-1>Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1) + Details Name: us-gaap_CashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1> + Details Name: us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(aa\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(aaa\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 8: <http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3>Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3) + Details Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_OtherDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 44 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Cash Equivalents and Marketable Securities - Narrative (Details) 3 Months Ended 9 Months Ended Sep. 30, 2024 USD (\$) security Sep. 30, 2023 USD (\$) Sep. 30, 2024 USD (\$) security Sep. 30, 2023 USD (\$) Investments, Debt and Equity Securities [Abstract] Á Á Á Number of securities | security 3 Á 3 Á Securities, unrealized loss position, fair value \$ 8,000,000.0 Á \$ 8,000,000.0 Á Other-than-temporary impairment loss, debt securities, available-for-sale \$ 0 \$ 0 \$ 0 \$ 0 X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8>Reference 2: [http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6](http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6)Reference 3: <http://www.xbrl.org/1943274/2147479106/326-30-50-4> + Details Name: us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6](http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(b\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4](http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4) + Details Name: us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 8A -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-8A> + Details Name: us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 45 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Cash Equivalents and Marketable Securities - Contractual Maturity of Marketable Securities (Details) - USD (\$) Sep. 30, 2024 Dec. 31, 2023 Investments, Debt and Equity Securities [Abstract] Á Á Within one year \$ 188,387,000 \$ 0 After one year through five years 54,141,000 0 Total available-for-sale securities \$ 242,528,000 \$ 0 X - DefinitionFair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 320 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A](http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 320 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A) + Details Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 320 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A](http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 320 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A) + Details Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103>Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100>Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(aa\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 7: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(6\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-599-1)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1> + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 46 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on a Recurring Basis (Details) - Fair Value, Recurring - USD (\$) Sep. 30, 2024 Dec. 31, 2023 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Á Á Assets \$ 323,887,000 \$ 0 Level 1 Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Á Á Assets 225,542,000 Á Level 2 Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Á Á Assets 98,345,000 Á Level 3 Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Á Á Assets 0 Á Money market funds Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Á Á Cash equivalents 81,359,000 Á Money market funds | Level 1 Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Á Á Cash equivalents 81,359,000 Á Money market funds | Level 2 Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Á Á Cash equivalents 0 Á Money market funds | Level 3 Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Á Á Cash equivalents 0 Á Debt securities issued by U.S. government agencies Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Á Á Available-for-sale marketable securities 144,183,000 Á Debt securities issued by U.S. government agencies | Level 1 Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Á Á Available-for-sale marketable securities 144,183,000 Á Debt securities issued by U.S. government agencies | Level 2 Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Á Á Available-for-sale marketable securities 0 Á Debt securities issued by U.S. government agencies | Level 3 Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Á Á Available-for-sale marketable securities 0 Á Corporate debt securities Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Á Á Available-for-sale marketable securities 75,085,000 Á Corporate debt securities | Level 1 Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Á Á Available-for-sale marketable securities 0 Á Corporate debt securities | Level 2 Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Á Á Available-for-sale marketable securities 75,085,000 Á Corporate debt securities | Level 3 Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Á Á Available-for-sale marketable securities 0 Á Commercial paper Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Á Á Available-for-sale marketable securities 18,588,000 Á Commercial paper | Level 1 Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Á Á Available-for-sale marketable securities 0 Á Commercial paper | Level 2 Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Á Á Available-for-sale marketable securities 18,588,000 Á Commercial paper | Level 3 Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Á Á Available-for-sale marketable securities 0 Á Other debt securities Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Á Á Available-for-sale marketable securities 4,672,000 Á Other debt securities | Level 1 Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Á Á Available-for-sale marketable securities 0 Á Other debt securities | Level 2 Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Á Á Available-for-sale marketable securities 4,672,000 Á Other debt securities | Level 3 Á Á Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Á Á Available-for-sale marketable securities \$ 0 Á X - DefinitionFair value portion of asset recognized for present right to economic benefit. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2) + Details Name: us-gaap_AssetsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2) + Details Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 9:

[Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4:](#)

[http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(a\) -Publisher FASB -URI](#)

[https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-](#)

[gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value portion of investment securities, including, but not limited to, marketable securities,](#)

[derivative financial instruments, and investments accounted for under the equity method. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -](#)

[Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2:](#)

[http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(b\) -Publisher FASB -URI](#)

[https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -](#)

[Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap InvestmentsFairValueDisclosure Namespace](#)

[Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap FairValueByMeasurementFrequencyAxis=us-](#)

[gaap FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap FairValueByFairValueHierarchyLevelAxis=us-](#)

[gaap FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap FairValueByFairValueHierarchyLevelAxis=us-](#)

[gaap FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap FairValueByFairValueHierarchyLevelAxis=us-](#)

[gaap FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap FairValueByAssetClassAxis=us-gaap MoneyMarketFundsMember](#)

[Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap FairValueByAssetClassAxis=us-gaap USGovernmentAgenciesDebtSecuritiesMember Namespace Prefix:](#)

[Data Type: na Balance Type: Period Type: X - Details Name: us-gaap FairValueByAssetClassAxis=us-gaap CorporateDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type:](#)

[Period Type: X - Details Name: us-gaap FairValueByAssetClassAxis=us-gaap CommercialPaperNotIncludedWithCashAndCashEquivalentsMember Namespace Prefix: Data Type: na Balance](#)

[Type: Period Type: X - Details Name: us-gaap FairValueByAssetClassAxis=us-gaap OtherDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R37.htm](#)

[IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses - Summary of Accrued Expenses \(Details\) - USD \(\\$\) in Thousands Sep. 30, 2024 Dec. 31, 2023 Payables and Accruals \[Abstract\] A](#)

[Accrued external research and development expenses \\$ 11,756 \\$ 2,957 Accrued personnel-related expenses 3,162 3,716 Accrued other expenses 539 743 Total accrued expenses \\$ 15,457 \\$](#)

[7,416 X - DefinitionAccrued External Research And Development Expenses, Current. + ReferencesNo definition available. + Details Name:](#)

[prax AccruedExternalResearchAndDevelopmentExpensesCurrent Namespace Prefix: prax Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAccrued](#)

[Personnel Related Expenses, Current. + ReferencesNo definition available. + Details Name: prax AccruedPersonnelRelatedExpensesCurrent Namespace Prefix: prax Data Type:](#)

[xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are](#)

[statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest,](#)

[rent and utilities. Used to reflect the current portion of the liabilities \(due within one year or within the normal operating cycle if longer\). + ReferencesReference 1: http://fasb.org/us-](#)

[gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(20\)\) -Publisher FASB -URI](#)

[https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap AccruedLiabilitiesCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type:](#)

[credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1:](#)

[http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(20\)\) -Publisher FASB -URI](#)

[https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type:](#)

[credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap PayablesAndAccrualsAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance](#)

[Type: na Period Type: duration XML 48 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Additional Information \(Details\) May 31, 2021 Office Space in Boston](#)

[Massachusetts A Loss Contingencies \[Line Items\] A Percentage increase in annual base rent 2.00% X - DefinitionPercentage Increase In Annual Base Rent. + ReferencesNo definition available.](#)

[+ Details Name: prax PercentageIncreaseInAnnualBaseRent Namespace Prefix: prax Data Type: dt-tyres:percentItem Type Balance Type: na Period Type: instant X - DefinitionLine items](#)

[represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. +](#)

[ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(a\)](#)

[- Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting](#)

[Standards Codification -Section 50 -Paragraph 9 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 3:](#)

[http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI](#)

[https://asc.fasb.org/1943274/2147483359/720-20-50-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -](#)

[Paragraph 27 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting](#)

[Standards Codification -Section 50 -Paragraph 9 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 6:](#)

[http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(b\) -Publisher FASB -URI](#)

[https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -](#)

[Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting](#)

[Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details Name: us-gaap LossContingenciesLineItems Namespace](#)

[Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Details Name:](#)

[srt RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=prax OfficeSpaceInBostonMassachusettsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49](#)

[R39.htm IDEA: XBRL DOCUMENT v3.24.3 Collaboration License Agreements - Narrative \(Details\) \\$ / shares in Units, \\$ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended Jan. 04,](#)

[2024 USD \(\\$ \) obligation \\$ / shares Shares Jan. 31, 2024 USD \(\\$ \) Sep. 30, 2024 USD \(\\$ \) \\$ / shares Sep. 30, 2023 USD \(\\$ \) Sep. 30, 2023 USD \(\\$ \) Dec. 31, 2023](#)

[USD \(\\$ \) Dec. 31, 2022 USD \(\\$ \) obligation Disaggregation of Revenue \[Line Items\] A A A A A A Number of performance obligations | obligation 1 A A A A A 1 Collaboration](#)

[revenue A A A A A 302 468 \\$ 1,090 \\$ 1,932 A A Current portion of deferred revenue A A 1,170 A 1,170 A 1,392 A UCB | License A A A A A A Disaggregation of Revenue \[Line](#)

[Items\] A A A A A A Upfront payment A A 1,500 A 1,500 A A \\$ 5,000 Milestone payments A A A A A A 98,500 Transaction price A A A A A A \\$ 5,000 Current portion of](#)

[deferred revenue A A A 1,200 A 1,200 A A Tenacia A A A A A A Disaggregation of Revenue \[Line Items\] A A A A A A Number of shares issued in transaction \(in shares\) |](#)

[shares 443,253 A A A A A Sale of stock \(in dollars per share\) | \\$ / shares \\$ 22.5605 A \\$ 38.95 A \\$ 38.95 A A Proceeds from stock offerings, net of issuance costs \\$ 10,000 \\$ 10,000](#)

[A A A A A Sale of stock, volume-weighted average price, premium 20.00% A A 20.00% A A Sale of stock, volume-weighted average price, duration 30 days A A 30 days A A A](#)

[Proceeds from collaboration arrangement A 14,800 A A A A A Sale of stock, value transferred A A A \\$ 17,300 A A Sale of stock, value transferred in excess of consideration](#)

[received A A A \\$ 2,500 A A A Tenacia | License A A A A A A Disaggregation of Revenue \[Line Items\] A A A A A A Upfront payment \\$ 5,000 \\$ 4,800 A A A A A](#)

[Milestone payments \\$ 264,000 A A A A A X - DefinitionNumber Of Performance Obligations + ReferencesNo definition available. + Details Name:](#)

[prax NumberOfPerformanceObligations Namespace Prefix: prax Data Type: xbrli:integerItem Type Balance Type: na Period Type: instant X - DefinitionProceeds From Collaboration](#)

[Arrangement + ReferencesNo definition available. + Details Name: prax ProceedsFromCollaborationArrangement Namespace Prefix: prax Data Type: xbrli:monetaryItemType Balance Type:](#)

[credit Period Type: duration X - DefinitionRevenue, Remaining Performance Obligation, Variable Consideration Amount + ReferencesNo definition available. + Details Name:](#)

[prax RevenueRemainingPerformanceObligationVariableConsiderationAmount Namespace Prefix: prax Data Type: xbrli:monetaryItemType Balance Type:](#)

-URI https://asc.fasb.org/1943274/2147480097/4/70-10-S99-1ARefrence 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap Revenues Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + ReferencesNo definition available. + Details Name: us-gaap SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + ReferencesNo definition available. + Details Name: us-gaap SaleOfStockPricePerShare Namespace Prefix: us-gaap Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - Details Name: srt CounterpartyNameAxis=prax UCMBMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt ProductOrServiceAxis=us-gaap LicenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt CounterpartyNameAxis=prax TenaciaMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Common Stock and Preferred Stock - Additional Information (Details) \$ / shares in Units, \$ in Millions 3 Months Ended Apr. 02, 2024 USD (\$) \$ / shares shares Jan. 16, 2024 USD (\$) \$ / shares shares Nov. 28, 2023 Jan. 21, 2023 USD (\$) \$ / shares shares Jun. 30, 2024 shares Sep. 30, 2024 \$ / shares shares Dec. 31, 2023 \$ / shares shares Schedule Of Common Stock Reserved For Future Issuance [Line Items] Á Á Á Á Á Stockholders' equity note, stock split, conversion ratio Á Á 0.0667 Á Á Á Á Common stock, authorized (in shares) Á Á Á Á Á 150,000,000 150,000,000 Common stock, par value (in dollars per share) | \$ / shares Á Á Á Á Á \$ 0.0001 \$ 0.0001 Treasury stock (in shares) Á Á Á Á Á 0 Issuance of common stock from exercise of pre-funded warrants (in shares) Á Á Á Á Á 622,123 Á Á Preferred stock, authorized (in shares) Á Á Á Á Á 10,000,000 10,000,000 Preferred stock, par value (in dollars per share) | \$ / shares Á Á Á Á Á \$ 0.0001 \$ 0.0001 Pre-funded warrant | Maximum Á Á Á Á Á Á Á Schedule Of Common Stock Reserved For Future Issuance [Line Items] Á Á Á Á Á Á Á Maximum percentage of voting power Á Á Á Á Á 4.99% Á Percentage of ownership held by sole owner and affiliates Á Á Á Á Á 9.99% Á Percentage change in ownership Á Á Á Á Á 19.99% Á Warrant Á Á Á Á Á Á Á Schedule Of Common Stock Reserved For Future Issuance [Line Items] Á Á Á Á Á Á Change in ownership notice, term Á Á Á Á Á 61 days Á June 2023 Public Offering Á Á Á Á Á Á Á Schedule Of Common Stock Reserved For Future Issuance [Line Items] Á Á Á Á Á Á Common stock, authorized (in shares) Á Á Á 4,296,646 Á Á Sale of stock (in dollars per share) | \$ / shares Á Á Á 14.25 Á Á Á Proceeds from stock offerings, net of issuance costs | \$ Á Á Á 63.4 Á Á Á June 2023 Public Offering | Pre-funded warrant Á Á Á Á Á Á Á Schedule Of Common Stock Reserved For Future Issuance [Line Items] Á Á Á Á Á Á Sale of stock (in dollars per share) | \$ / shares Á Á Á 14.2485 Á Á Á Warrants (in shares) Á Á Á 470,000 Á Á Issuance of common stock from exercise of pre-funded warrants (in shares) Á Á Á 469,981 Á Á June 2023 Public Offering | Warrant Á Á Á Á Á Á Á Schedule Of Common Stock Reserved For Future Issuance [Line Items] Á Á Á Á Á Warrants (in dollars per share) | \$ / shares Á Á Á 0.0015 Á Á Á Over-Allotment Option Á Á Á Á Á Á Á Schedule Of Common Stock Reserved For Future Issuance [Line Items] Á Á Á Á Á Á Number of shares issued in transaction (in shares) 530,973 633,750 Á 619,979 Á Á Á January 2024 Public Offering Á Á Á Á Á Á Á Schedule Of Common Stock Reserved For Future Issuance [Line Items] Á Á Á Á Á Á Sale of stock (in dollars per share) | \$ / shares Á Á Á 35.50 Á Á Á Á Proceeds from stock offerings, net of issuance costs | \$ Á 161.6 Á Á Á Á Sale of stock, shares, aggregate authorized amount (in shares) Á 3,802,025 Á Á Á Á January 2024 Public Offering | Pre-funded warrant Á Á Á Á Á Á Á Schedule Of Common Stock Reserved For Future Issuance [Line Items] Á Á Á Á Á Á Sale of stock (in dollars per share) | \$ / shares Á \$ 35.4999 Á Á Á Á Warrants (in shares) Á 1,056,725 Á Á Á Á Issuance of common stock from exercise of pre-funded warrants (in shares) Á Á Á Á Á 152,142 Á Class of warrants or rights, exercised Á Á Á Á Á 152,145 Á Class of warrant or right, outstanding Á Á Á 904,580 Á January 2024 Public Offering | Warrant Á Á Á Á Á Á Á Schedule Of Common Stock Reserved For Future Issuance [Line Items] Á Á Á Á Á Warrants (in dollars per share) | \$ / shares Á \$ 0.0001 Á Á Á Á April 2024 Public Offering Á Á Á Á Á Á Á Schedule Of Common Stock Reserved For Future Issuance [Line Items] Á Á Á Á Á Á Sale of stock (in dollars per share) | \$ / shares Á 56.50 Á Á Á Á Proceeds from stock offerings, net of issuance costs | \$ 216.0 Á Á Á Á Sale of stock, shares, aggregate authorized amount (in shares) 3,849,558 Á Á Á Á April 2024 Public Offering | Pre-funded warrant Á Á Á Á Á Á Á Schedule Of Common Stock Reserved For Future Issuance [Line Items] Á Á Á Á Á Á Sale of stock (in dollars per share) | \$ / shares Á 56.4999 Á Á Á Á Warrants (in shares) 221,238 Á Á Á Á April 2024 Public Offering | Warrant Á Á Á Á Á Á Á Schedule Of Common Stock Reserved For Future Issuance [Line Items] Á Á Á Á Á Á Warrants (in dollars per share) | \$ / shares \$ 0.0001 Á Á Á Á X - DefinitionChange in Percentage of Ownership + ReferencesNo definition available. + Details Name: prax ChangeInPercentageOfOwnership Namespace Prefix: prax Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionClass Of Warrants Or Rights, Exercised + ReferencesNo definition available. + Details Name: prax ClassOfWarrantsOrRightsExercised Namespace Prefix: prax Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNotice of Change, Term + ReferencesNo definition available. + Details Name: prax NoticeOfChangeTerm Namespace Prefix: prax Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPercentage of Ownership Held by Sole Owner + ReferencesNo definition available. + Details Name: prax PercentageOfOwnershipHeldBySoleOwner Namespace Prefix: prax Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of Ownership Held by Sole Owner And Affiliates + ReferencesNo definition available. + Details Name: prax PercentageOfOwnershipHeldBySoleOwnerAndAffiliates Namespace Prefix: prax Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionSale Of Stock, Shares, Aggregate Authorized Amount + ReferencesNo definition available. + Details Name: prax SaleOfStockSharesAggregateAuthorizedAmount Namespace Prefix: prax Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionSchedule Of Common Stock Reserved For Future Issuance Line items + ReferencesNo definition available. + Details Name: prax ScheduleOfCommonStockReservedForFutureIssuanceLineItems Namespace Prefix: prax Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionStock Issued During Period, Shares, Exercise Of Warrants + ReferencesNo definition available. + Details Name: prax StockIssuedDuringPeriodSharesExerciseOfWarrants Namespace Prefix: prax Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights Namespace Prefix: us-gaap Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap PreferredStockSharesAuthorized Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + ReferencesNo definition available. + Details Name: us-gaap SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + ReferencesNo definition available. + Details Name: us-gaap SaleOfStockPricePerShare Namespace Prefix: us-gaap Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionRatio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4 + Details Name: us-gaap StockholdersEquityNoteStockSplitConversionRatio1 Namespace Prefix: us-gaap Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - DefinitionNumber of previously issued common shares repurchased by the issuing entity and held in treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap TreasuryStockCommonShares Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap ClassOfWarrantOrRightAxis=prax PreFundedWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt RangeAxis=srt MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap ClassOfWarrantOrRightAxis=us-gaap WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap SubsidiarySaleOfStockAxis=us-gaap OverAllotmentOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap SubsidiarySaleOfStockAxis=prax January2024PublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap SubsidiarySaleOfStockAxis=prax April2024PublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Common Stock and Preferred Stock - Summary of Common Stock Reserved For Future Issuance (Details) - shares Sep. 30, 2024 Dec. 31, 2023 Schedule Of Common Stock Reserved For Future Issuance [Line Items] Á Á Total shares of authorized common stock reserved for future issuance (in shares) 3,521,531 1,384,683 Shares reserved for exercise of outstanding stock options Á Á Schedule Of Common Stock Reserved For Future Issuance [Line Items] Á Á Total shares of authorized common stock reserved for future issuance (in shares) 1,829,324 666,163 Pre-funded warrant | June 2023 Follow-On Offering Á Á Schedule Of Common Stock Reserved For Future Issuance [Line Items] Á Á Total shares of authorized common stock reserved for future issuance (in shares) 0 470,000 Pre-funded warrant | January 2024 Follow-On Offering Á Á Schedule Of Common Stock Reserved For Future Issuance [Line Items] Á Á Total shares of authorized common stock reserved for future issuance (in shares) 904,580 0 Pre-funded warrant | April 2024 Follow-On Offering Á Á Schedule Of Common Stock Reserved For Future Issuance [Line Items] Á Á Total shares of authorized common stock reserved for future issuance (in shares) 221,238 0 Share-based payment arrangement | Shares reserved for future awards under the 2020 Stock Option and Incentive Plan Á Á Schedule Of Common Stock Reserved For Future Issuance [Line Items] Á Á Total shares of authorized common stock reserved for future issuance (in shares) 115,058 148,264 Share-based payment arrangement | Shares reserved for future awards under the 2020 Employee Stock Purchase Plan Á Á Schedule Of Common Stock Reserved For Future Issuance [Line Items] Á Á Total shares of authorized common stock reserved for future issuance (in shares) 115,883 53,111 Share-based payment arrangement | Shares reserved for future awards under the 2024 Inducement Plan Á Á Schedule Of Common Stock Reserved For Future Issuance [Line Items] Á Á Total shares of authorized common stock reserved for future issuance (in shares) 112,774 0 Shares reserved for vesting of restricted stock units Á Á Schedule Of Common Stock Reserved For Future Issuance [Line Items] Á Á Total shares of authorized common stock reserved for future issuance (in shares) 222,674 47,145 X - DefinitionSchedule Of Common Stock Reserved For Future Issuance Line items + ReferencesNo definition available. + Details Name: prax ScheduleOfCommonStockReservedForFutureIssuanceLineItems Namespace Prefix: prax Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-

gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=prax_PreFundedWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=prax_June2023FollowOnOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=prax_January2024FollowOnOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=prax_April2024FollowOnOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=prax_TwentyTwentyEmployeeStockIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=prax_TwentyTwentyEmployeeStockPurchasePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=prax_InducementPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML S2 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Additional Information (Details) - USD (\$) in Millions 1 Months Ended 9 Months Ended Jun. 30, 2024 Sep. 30, 2024 Jan. 31, 2023 Unvested Restricted Stock Units \$ \$ \$ Share-based Compensation Arrangement by Share-based Payment Award [Line Items] \$ \$ \$ Total unrecognized compensation cost related to unvested restricted stock units \$ \$ 11.9 \$ \$ Weighted-average period (in years) \$ 2 years 10 months 2 days \$ \$ Shares reserved for exercise of outstanding stock options \$ \$ \$ Share-based Compensation Arrangement by Share-based Payment Award [Line Items] \$ \$ \$ Weighted-average period (in years) \$ 2 years 6 months 18 days \$ \$ Unrecognized compensation expense related to unvested stock based awards \$ \$ 43.6 \$ \$ Inducement Plan \$ \$ \$ Share-based Compensation Arrangement by Share-based Payment Award [Line Items] \$ \$ \$ Number of shares authorized (in shares) \$ 130,000 1,000,000 \$ Decrease in number of shares authorized to be issued (in shares) 870,000 \$ \$ \$ 2020 Employee Stock Incentive Plan \$ \$ \$ Share-based Compensation Arrangement by Share-based Payment Award [Line Items] \$ \$ \$ \$ Number of shares authorized (in shares) \$ 1,970,833 \$ 661,240 2017 Stock Incentive Plan \$ \$ \$ Share-based Compensation Arrangement by Share-based Payment Award [Line Items] \$ \$ \$ Number of shares authorized (in shares) \$ 395,850 \$ 395,850 2020 Employee Stock Purchase Plan \$ \$ \$ Share-based Compensation Arrangement by Share-based Payment Award [Line Items] \$ \$ \$ \$ Number of shares authorized (in shares) \$ 175,145 \$ 87,227 X - DefinitionShare-Based Compensation Arrangement By Share-Based Payment Award, Increase (Decrease) In Shares Authorized + ReferencesNo definition available. + Details Name: prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInSharesAuthorized Namespace Prefix: prax_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix: us-gaap_Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost to be recognized for option under share-based payment arrangement. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480483/718-10-35-1D>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480483/718-10-35-3>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(v) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 20: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 23: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 24: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 25: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 26: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 27: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 28: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=prax_InducementPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=prax_A2020EmployeeStockIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=prax_A2017EmployeeStockIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=prax_TwentyTwentyEmployeeStockPurchasePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML S3 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Summary of Restricted Stock Activity (Details) - Unvested restricted stock units 9 Months Ended Sep. 30, 2024 \$ / shares Shares \$ Beginning balance (in shares) | shares 47,145 Issued (in shares) | shares 197,097 Vested (in shares) | shares (1,856) Forfeited (in shares) | shares (9,712) Ending balance (in shares) | shares 222,674 Weighted Average Grant Date Fair Value \$ Unvested beginning balance (in dollars per share) | \$ / shares \$ 202.27 Issued (in dollars per share) | \$ / shares 51.98 Vested (in dollars per share) | \$ / shares 309.13 Forfeitures (in dollars per share) | \$ / shares 54.86 Unvested ending balance (in dollars per share) | \$ / shares \$ 69.98 X - DefinitionShare-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Issued in Period + ReferencesNo definition available. + Details Name: prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod Namespace Prefix: prax_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionShare-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Issued in Period, Weighted Average Grant Date Fair Value + ReferencesNo definition available. + Details Name: prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: prax_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with

the terms of the arrangement. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(02\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Summary of Stock Option Activity (Details) - USD (\$) \$ / shares in Units, \$ in Thousands 9 Months Ended Sep. 30, 2024 Number of Shares Â Beginning balance (in shares) 666,163 Granted (in shares) 1,195,546 Exercised (in shares) (8,753) Canceled or forfeited (in shares) (23,632) Ending balance (in shares) 1,829,324 Number of shares exercisable (in shares) 878,111 Vested and expected to vest (in shares) 1,829,324 Weighted Average ExerciseÂ Price per Share Â Beginning balance (in dollars per share) \$ 160.19 Granted (in dollars per share) 51.43 Exercised (in dollars per share) 39.75 Canceled or forfeited (in dollars per share) 127.76 Ending balance (in dollars per share) 90.08 Exercisable (in dollars per share) 121.03 Vested and expected to vest (in dollars per share) \$ 90.08 Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Â Weighted average remaining contractual term outstanding 8 years 8 months 15 days Weighted average remaining contractual term exercisable 7 years 11 months 4 days Weighted average remaining contractual term vested and expected to vest 8 years 8 months 15 days Aggregate intrinsic value exercised \$ 134 Aggregate intrinsic value outstanding 12,800 Aggregate intrinsic value exercisable 6,963 Aggregate intrinsic value vested and expected to vest \$ 12,800 X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionAmount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(03\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details> Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionNumber of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionWeighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(02\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(03\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details> Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDtnHnMns' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 718 -SubTopic 10 -Subparagraph \(e\)\(1\) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDtnHnMns' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/214748112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(02\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/214748112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details) Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration XML 55 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Schedule of Fair Value of Stock Option Awards on the Grant Date Using the Black-Scholes Option Valuation Model (Details) - \$ / shares 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2024 Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â A Risk-free interest rate 4.06% 4.01% Expected term (in years) 6 years 6 years Expected volatility 101.00% 96.48% Expected dividend yield 0.00% 0.00% Shares reserved for exercise of outstanding stock options Â A Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â A Weighted average grant-date fair value per share (in dollars per share) \$ 45.95 \$ 40.73 X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(iv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details)

[illegible]

[The following text contains extremely dense, non-readable characters and symbols, likely representing corrupted or encrypted data. It appears to be a single continuous block of text.]

[illegible]

```

normal 8pt Helvetica, Arial, sans-serif; margin-bottom: 2em; }
report hr { border: 1px solid #ac6; }
% Top labels %
report th { background-color: #ac6; color: black; font-weight: bold; text-align: center; }
report th void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, sans-serif; text-align: left; }
report pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; }
% word wrap: break word; %
report td.pl.a { cursor: pointer; display: block; width: 200px; overflow: hidden; }
report td.pl.div.a { width: 200px; }
report td.pl.a:hover { background-color: #ffc; }
% Header rows %
report tr.th { background-color: #ac6; color: black; font-weight: bold; }
% Calendars %
report ro { background-color: #f0f0f0; }
% Even rows %
report reu { background-color: #def; }
report reu td { border-bottom: 1px solid black; }
% Odd rows %
report ro { background-color: white; }
report ro td { border-bottom: 1px solid black; }
report row table td { border-bottom: 0px solid black; }
% styles for footnote marker %
report fn { white-space: nowrap; }
% styles for numeric types %
report nump { text-align: right; white-space: nowrap; }
report nump { padding-left: 2em; }
report nump { padding: 0 4em 0px 2em; }
% styles for text types %
report text { text-align: left; white-space: normal; }
report text.big { margin-bottom: 1em; width: 17em; }
report text.more { display: none; }
report text.note { font-style: italic; font-weight: bold; }
report text.small { width: 10em; }
report sup { font-style: italic; }
report outerFootnotes { font-size: 1em; }
% XML 62 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3.1.htm 213 235 1 true 50 0 false false R1.htm 0000001 Document Cover Page Sheet http://praxismedicines.com/role/CoverPageSheet Cover Page Cover 1 false false R2.htm 9952151 Statement Condensed Consolidated Balance Sheets (Unaudited) Sheet http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 9952152 Statement Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 9952153 Statement Condensed Consolidated Statements of Operations (Unaudited) Sheet http://praxismedicines.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) Sheet http://praxismedicines.com/role/CondensedConsolidatedStatementsOfOperationsUnauditedParenthetical Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) Statements 5 false false R6.htm 9952155 Statement Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Sheet http://praxismedicines.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Statements 6 false false R7.htm 9952156 Statement Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Statements 7 false false R8.htm 9952157 Statement Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical) Sheet http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical) Statements 8 false false R9.htm 9952158 Statement Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 9 false false R10.htm 9952159 Disclosure Nature of the Business Sheet http://praxismedicines.com/role/NatureOfTheBusiness Nature of the Business Notes 10 false false R11.htm 9952160 Disclosure Summary of Significant Accounting Policies Sheet http://praxismedicines.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 11 false false R12.htm 9952161 Disclosure Cash Equivalents and Marketable Securities Sheet http://praxismedicines.com/role/CashEquivalentsAndMarketableSecurities Cash Equivalents and Marketable Securities Notes 12 false false R13.htm 9952162 Disclosure Fair Value Measurements Sheet http://praxismedicines.com/role/FairValueMeasurements Fair Value Measurements Notes 13 false false R14.htm 9952163 Disclosure Accrued Expenses Sheet http://praxismedicines.com/role/AccruedExpenses Accrued Expenses Notes 14 false false R15.htm 9952164 Disclosure Commitments and Contingencies Sheet http://praxismedicines.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 9952165 Disclosure Collaboration License Agreements Sheet http://praxismedicines.com/role/CollaborationLicenseAgreements Collaboration License Agreements Notes 16 false false R17.htm 9952166 Disclosure Common Stock and Preferred Stock Sheet http://praxismedicines.com/role/CommonStockAndPreferredStock Common Stock and Preferred Stock Notes 17 false false R18.htm 9952167 Disclosure Stock-Based Compensation Sheet http://praxismedicines.com/role/StockBasedCompensation Stock-Based Compensation Notes 18 false false R19.htm 9952168 Disclosure Net Loss per Share Sheet http://praxismedicines.com/role/NetLossPerShare Net Loss per Share Notes 19 false false R20.htm 9952169 Disclosure Related Party Transactions Sheet http://praxismedicines.com/role/RelatedPartyTransactions Related Party Transactions Notes 20 false false R21.htm 9952170 Disclosure Subsequent Events Sheet http://praxismedicines.com/role/SubsequentEvents Subsequent Events Notes 21 false false R22.htm 995410 Disclosure Pay vs Performance Disclosure Sheet http://praxismedicines.com/role/PayVsPerformance Pay vs Performance Disclosure Notes 22 false false R23.htm 995445 Disclosure Insider Trading Arrangements Sheet http://praxismedicines.com/role/InsiderTradingArrangements Insider Trading Arrangements Notes 23 false false R24.htm 995447 Disclosure Summary of Significant Accounting Policies (Policies) Sheet http://praxismedicines.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://praxismedicines.com/role/SummaryOfSignificantAccountingPolicies 24 false false R25.htm 9954472 Disclosure Cash Equivalents and Marketable Securities (Tables) Sheet http://praxismedicines.com/role/CashEquivalentsAndMarketableSecuritiesTables Cash Equivalents and Marketable Securities (Tables) Tables http://praxismedicines.com/role/CashEquivalentsAndMarketableSecurities 25 false false R26.htm 9954473 Disclosure Fair Value Measurements (Tables) Sheet http://praxismedicines.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://praxismedicines.com/role/FairValueMeasurements 26 false false R27.htm 9954474 Disclosure Accrued Expenses (Tables) Sheet http://praxismedicines.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://praxismedicines.com/role/AccruedExpenses 27 false false R28.htm 9954475 Disclosure Common Stock and Preferred Stock (Tables) Sheet http://praxismedicines.com/role/CommonStockAndPreferredStockTables Common Stock and Preferred Stock (Tables) Tables http://praxismedicines.com/role/CommonStockAndPreferredStock 28 false false R29.htm 9954476 Disclosure Stock-Based Compensation (Tables) Sheet http://praxismedicines.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://praxismedicines.com/role/StockBasedCompensation 29 false false R30.htm 9954477 Disclosure Net Loss per Share (Tables) Sheet http://praxismedicines.com/role/NetLossPerShareTables Net Loss per Share (Tables) Tables http://praxismedicines.com/role/NetLossPerShare 30 false false R31.htm 9954478 Disclosure Nature of the Business - Additional Information (Details) Sheet http://praxismedicines.com/role/NatureOfTheBusinessAdditionalInformationDetails Nature of the Business - Additional Information (Details) Details 31 false false R32.htm 9954479 Disclosure Summary of Significant Accounting Policies (Details) Sheet http://praxismedicines.com/role/SummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://praxismedicines.com/role/SummaryOfSignificantAccountingPolicies 32 false false R33.htm 9954480 Disclosure Cash Equivalents and Marketable Securities - Investment Profile (Details) Sheet http://praxismedicines.com/role/CashEquivalentsAndMarketableSecuritiesInvestmentProfileDetails Cash Equivalents and Marketable Securities - Investment Profile (Details) Details 33 false false R34.htm 9954481 Disclosure Cash Equivalents and Marketable Securities - Narrative (Details) Sheet http://praxismedicines.com/role/CashEquivalentsAndMarketableSecuritiesNarrativeDetails Cash Equivalents and Marketable Securities - Narrative (Details) Details 34 false false R35.htm 9954482 Disclosure Cash Equivalents and Marketable Securities - Contractual Maturity of Marketable Securities (Details) Sheet http://praxismedicines.com/role/CashEquivalentsAndMarketableSecuritiesContractualMaturityOfMarketableSecuritiesDetails Cash Equivalents and Marketable Securities - Contractual Maturity of Marketable Securities (Details) Details 35 false false R36.htm 9954483 Disclosure Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on a Recurring Basis (Details) Sheet http://praxismedicines.com/role/FairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on a Recurring Basis (Details) Details 36 false false R37.htm 9954484 Disclosure Accrued Expenses - Summary of Accrued Expenses (Details) Sheet http://praxismedicines.com/role/AccruedExpensesSummaryOfAccruedExpensesDetails Accrued Expenses - Summary of Accrued Expenses (Details) Details 37 false false R38.htm 9954485 Disclosure Commitments and Contingencies - Additional Information (Details) Sheet http://praxismedicines.com/role/CommitmentsAndContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information (Details) Details 38 false false R39.htm 9954486 Disclosure Collaboration License Agreements - Narrative (Details) Sheet http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails Collaboration License Agreements - Narrative (Details) Details 39 false false R40.htm 9954487 Disclosure Common Stock and Preferred Stock - Additional Information (Details) Sheet http://praxismedicines.com/role/CommonStockAndPreferredStockAdditionalInformationDetails Common Stock and Preferred Stock - Additional Information (Details) Details 40 false false R41.htm 9954488 Disclosure Common Stock and Preferred Stock - Summary of Common Stock Reserved For Future Issuance (Details) Sheet http://praxismedicines.com/role/CommonStockAndPreferredStockSummaryOfCommonStockReservedForFutureIssuanceDetails Common Stock and Preferred Stock - Summary of Common Stock Reserved For Future Issuance (Details) Details 41 false false R42.htm 9954489 Disclosure Stock-Based Compensation - Additional Information (Details) Sheet http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails Stock-Based Compensation - Additional Information (Details) Details 42 false false R43.htm 9954490 Disclosure Stock-Based Compensation - Summary of Restricted Stock Activity (Details) Sheet http://praxismedicines.com/role/StockBasedCompensationSummaryOfRestrictedStockActivityDetails Stock-Based Compensation - Summary of Restricted Stock Activity (Details) Details 43 false false R44.htm 9954491 Disclosure Stock-Based Compensation - Summary of Stock Option Activity (Details) Sheet http://praxismedicines.com/role/StockBasedCompensationSummaryOfStockOptionActivityDetails Stock-Based Compensation - Summary of Stock Option Activity (Details) Details 44 false false R45.htm 9954492 Disclosure Stock-Based Compensation - Schedule of Fair Value of Stock Option Awards on the Grant Date Using the Black-Scholes Option Valuation Model (Details) Sheet http://praxismedicines.com/role/StockBasedCompensationScheduleOfFairValueOfStockOptionAwardsOntheGrantDateUsingtheBlackScholesOptionValuationModelDetails Stock-Based Compensation - Schedule of Fair Value of Stock Option Awards on the Grant Date Using the Black-Scholes Option Valuation Model (Details) Details 45 false false R46.htm 9954493 Disclosure Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) Sheet http://praxismedicines.com/role/StockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) Details 46 false false R47.htm 9954494 Disclosure Net Loss per Share - Summary of antidilutive securities excluded from computation of earnings per share (Details) Sheet http://praxismedicines.com/role/NetLossPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails Net Loss per Share - Summary of antidilutive securities excluded from computation of earnings per share (Details) Details 47 false false All Reports Book All Reports prax 20240930.htm prax 20240930.xsd prax 20240930-cal.xml prax 20240930-def.xml prax 20240930-lab.xml prax 20240930-pre.xml prax 20240930-prs.xml http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ed/2024 true true ISON 65 MetaLinks.json IDEA: XBRL DOCUMENT ("version": "2.2", "instance": ("prax 20240930.htm": ("nsprefix": "prax", "nsuri": "http://praxismedicines.com/20240930", "dts": ("inline": ("local": ("prax 20240930.htm" |), "schema": ("local": ("prax 20240930.xsd" |), "remote": ("http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ed-2006-02-27.xsd", "http://www.xbrl.org/ltr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/ltr/role/net-2009-12-16.xsd", "http://www.xbrl.org/ltr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extendible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/s
```

[illegible]

```

30, "firstAnchor": f "contextRef": "c-1", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f "ix.continuation": "body", "html": "1", "reportCount": "1", "baseRef": "prax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": f "contextRef": "c-1", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f "ix.continuation": "body", "html": "1", "reportCount": "1", "baseRef": "prax-20240930.htm", "first": true, "unique": true }, "R31": f "role": "http://praxismedicines.com/role/NatureOfTheBusinessAdditionalInformationDetails", "longName": "9954478 - Disclosure - Nature of the Business - Additional Information (Details)", "shortName": "Nature of the Business - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": f "contextRef": "c-3", "name": "prax:NumberOfPlatforms", "unitRef": "platform", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": f "span": "div", "div": "ix.continuation": "body", "html": "1", "reportCount": "1", "baseRef": "prax-20240930.htm", "first": true, "unique": true }, "R32": f "role": "http://praxismedicines.com/role/SummaryOfSignificantAccountingPoliciesDetails", "longName": "9954479 - Disclosure - Summary of Significant Accounting Policies (Details)", "shortName": "Summary of Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": f "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": f "span": "div", "div": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "ix.continuation": "body", "html": "1", "reportCount": "1", "baseRef": "prax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": f "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": f "span": "div", "div": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "ix.continuation": "body", "html": "1", "reportCount": "1", "baseRef": "prax-20240930.htm", "first": true, "unique": true }, "R33": f "role": "http://praxismedicines.com/role/CashEquivalentsAndMarketableSecuritiesInvestmentProfileDetails", "longName": "9954480 - Disclosure - Cash Equivalents and Marketable Securities Investment Profile (Details)", "shortName": "Cash Equivalents and Marketable Securities - Investment Profile (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": f "contextRef": "c-3", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": f "span": "td", "tr": "table", "div": "body", "html": "1", "reportCount": "1", "baseRef": "prax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": f "contextRef": "c-3", "name": "prax:CashEquivalentsAtCarryingValueAndDebtSecuritiesAvailableForSaleAmortizedCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": f "span": "td", "tr": "table", "div": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix.continuation": "body", "html": "1", "reportCount": "1", "baseRef": "prax-20240930.htm", "unique": true }, "R34": f "role": "http://praxismedicines.com/role/CashEquivalentsAndMarketableSecuritiesNarrativeDetails", "longName": "9954481 - Disclosure - Cash Equivalents and Marketable Securities Narrative (Details)", "shortName": "Cash Equivalents and Marketable Securities - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": f "contextRef": "c-3", "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOFPositions", "unitRef": "security", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": f "span": "div", "div": "ix.continuation": "body", "html": "1", "reportCount": "1", "baseRef": "prax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": f "contextRef": "c-5", "name": "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": f "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale", "span": "div", "ix.continuation": "body", "html": "1", "reportCount": "1", "baseRef": "prax-20240930.htm", "unique": true }, "R35": f "role": "http://praxismedicines.com/role/CashEquivalentsAndMarketableSecuritiesContractualMaturityOfMarketableSecuritiesDetails", "longName": "9954482 - Disclosure - Cash Equivalents and Marketable Securities - Contractual Maturity of Marketable Securities (Details)", "shortName": "Cash Equivalents and Marketable Securities - Contractual Maturity of Marketable Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": f "contextRef": "c-3", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": f "span": "td", "tr": "table", "div": "ix.continuation": "body", "html": "1", "reportCount": "1", "baseRef": "prax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": f "contextRef": "c-3", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": f "span": "td", "tr": "table", "div": "ix.continuation": "body", "html": "1", "reportCount": "1", "baseRef": "prax-20240930.htm", "first": true, "unique": true }, "R36": f "role": "http://praxismedicines.com/role/FairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails", "longName": "9954483 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on a Recurring Basis (Details)", "shortName": "Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on a Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": f "contextRef": "c-132", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": f "span": "td", "tr": "table", "div": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTableTextBlock", "ix.continuation": "body", "html": "1", "reportCount": "1", "baseRef": "prax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": f "contextRef": "c-132", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": f "span": "td", "tr": "table", "div": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTableTextBlock", "ix.continuation": "body", "html": "1", "reportCount": "1", "baseRef": "prax-20240930.htm", "first": true, "unique": true }, "R37": f "role": "http://praxismedicines.com/role/AccruedExpensesSummaryOfAccruedExpensesDetails", "longName": "9954484 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details)", "shortName": "Accrued Expenses - Summary of Accrued Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": f "contextRef": "c-3", "name": "prax:AccruedExternalResearchAndDevelopmentExpensesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": f "span": "td", "tr": "table", "div": "ix.continuation": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "body", "html": "1", "reportCount": "1", "baseRef": "prax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": f "contextRef": "c-3", "name": "prax:AccruedExternalResearchAndDevelopmentExpensesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": f "span": "td", "tr": "table", "div": "ix.continuation": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "body", "html": "1", "reportCount": "1", "baseRef": "prax-20240930.htm", "first": true, "unique": true }, "R38": f "role": "http://praxismedicines.com/role/CommitmentsAndContingenciesAdditionalInformationDetails", "longName": "9954485 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "shortName": "Commitments and Contingencies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": f "contextRef": "c-133", "name": "prax:PercentageIncreaseInAnnualBaseRent", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": f "span": "div", "div": "ix.continuation": "body", "html": "1", "reportCount": "1", "baseRef": "prax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": f "contextRef": "c-133", "name": "prax:PercentageIncreaseInAnnualBaseRent", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": f "span": "div", "div": "ix.continuation": "body", "html": "1", "reportCount": "1", "baseRef": "prax-20240930.htm", "first": true, "unique": true }, "R39": f "role": "http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails", "longName": "9954486 - Disclosure - Collaboration License Agreements - Narrative (Details)", "shortName": "Collaboration License Agreements - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": f "contextRef": "c-139", "name": "prax:NumberOfPerformanceObligations", "unitRef": "obligation", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": f "span": "div", "div": "ix.continuation": "body", "html": "1", "reportCount": "1", "baseRef": "prax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": f "contextRef": "c-139", "name": "prax:NumberOfPerformanceObligations", "unitRef": "obligation", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": f "span": "div", "div": "ix.continuation": "body", "html": "1", "reportCount": "1", "baseRef": "prax-20240930.htm", "first": true, "unique": true }, "R40": f "role": "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails", "longName": "9954487 - Disclosure - Common Stock and Preferred Stock - Additional Information (Details)", "shortName": "Common Stock and Preferred Stock - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": f "contextRef": "c-3", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": f "span": "div", "div": "ix.continuation": "body", "html": "1", "reportCount": "1", "baseRef": "prax-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": f "contextRef": "c-3", "name": "us-gaap:TreasuryStockCommonShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": f "us-gaap:TreasuryStockCommonShares", "span": "div", "div": "ix.continuation": "body", "html": "1", "reportCount": "1", "baseRef": "prax-20240930.htm", "unique": true }, "R41": f "role": "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryOfCommonStockReservedForFutureIssuanceDetails", "longName": "9954488 - Disclosure - Common Stock and Preferred Stock - Summary of Common Stock Reserved For Future Issuance (Details)", "shortName": "Common Stock and Preferred Stock - Summary of Common Stock
```

```
202930.htm": "first": true, "unique": true } } }, "tag": { "prax A2017EmployeeStockIncentivePlanMember": { "xbrlType": "domainItemType", "nsuri": "http://praxismedicines.com/20240930/"}}, {"labelname": "A2017EmployeeStockIncentivePlanMember", "presentation": { "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails"}, {"lang": { "en-us": { "role": { "terseLabel": "2017 Stock Incentive Plan", "label": "2017 Employee Stock Incentive Plan [Member]" } } } }, "auth ref": { "prax A2020EmployeeStockIncentivePlanMember": { "xbrlType": "domainItemType", "nsuri": "http://praxismedicines.com/20240930/"}}, {"labelname": "A2020EmployeeStockIncentivePlanMember", "presentation": { "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails"}, {"lang": { "en-us": { "role": { "terseLabel": "2020 Employee Stock Incentive Plan", "label": "2020 Employee Stock Incentive Plan [Member]" } } } }, "documentation": { "2020 Employee Stock Incentive Plan" } }, "auth ref": { "us-gaap AccountingPoliciesAbstract": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024/"}}, {"labelname": "Accounting Policies Abstract", "presentation": { "http://praxismedicines.com/role/AccruedExpenses"}, {"lang": { "en-us": { "role": { "terseLabel": "Accrued Expenses [Abstract]", "label": "Accounting Policies [Abstract]" } } } }, "auth ref": { "us-gaap AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024/"}}, {"labelname": "Accounts Payable And Accrued Liabilities Disclosure Text Block", "presentation": { "http://praxismedicines.com/role/AccruedExpenses"}, {"lang": { "en-us": { "role": { "terseLabel": "Accrued Expenses", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } } }, "auth ref": { "r33", "r35", "r38", "r755" } }, "us-gaap AccountsPayableCurrent": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024/"}}, {"labelname": "Accounts Payable Current", "order": "credit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } } }, "auth ref": { "r33", "r565" } } }, "us-gaap AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024/"}}, {"labelname": "Accretion Amortization Of Discounts And Premiums Investments", "order": "credit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Amortization of premiums and discounts on marketable securities, net", "label": "Accretion (Amortization) of Discounts and Premiums Investments", "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method." } } } } }, "auth ref": { "r55" } } }, "prax AccruedExternalResearchAndDevelopmentExpensesCurrent": { "xbrlType": "monetaryItemType", "nsuri": "http://praxismedicines.com/20240930/"}}, {"labelname": "Accrued External Research And Development Expenses Current", "order": "debit", "calculation": { "http://praxismedicines.com/role/AccruedExpensesSummaryOfAccruedExpensesDetails": { "parentTag": "us-gaap AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://praxismedicines.com/role/AccruedExpensesSummaryOfAccruedExpensesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Accrued external research and development expenses", "label": "Accrued External Research And Development Expenses Current", "documentation": "Accrued External Research And Development Expenses Current." } } } } }, "auth ref": { "us-gaap AccruedLiabilitiesCurrent": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024/"}}, {"labelname": "Accrued Liabilities Current", "order": "credit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "http://praxismedicines.com/role/AccruedExpensesSummaryOfAccruedExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://praxismedicines.com/role/AccruedExpensesSummaryOfAccruedExpensesDetails": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "totalLabel": "Total accrued expenses", "label": "Accrued Liabilities Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } } } }, "auth ref": { "r35" } } }, "prax AccruedPersonnelRelatedExpensesCurrent": { "xbrlType": "monetaryItemType", "nsuri": "http://praxismedicines.com/20240930/"}}, {"labelname": "Accrued Personnel Related Expenses Current", "order": "credit", "calculation": { "http://praxismedicines.com/role/AccruedExpensesSummaryOfAccruedExpensesDetails": { "parentTag": "us-gaap AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://praxismedicines.com/role/AccruedExpensesSummaryOfAccruedExpensesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Accrued personnel related expenses", "label": "Accrued Personnel Related Expenses Current", "documentation": "Accrued Personnel Related Expenses Current." } } } } }, "auth ref": { "us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024/"}}, {"labelname": "Accumulated Other Comprehensive Income Loss Net Of Tax", "order": "credit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive gain", "label": "Accumulated Other Comprehensive Income (Loss) Net of Tax", "documentation": "Amount after tax of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } } } }, "auth ref": { "r13", "r14", "r48", "r96", "r417", "r442", "r443" } } }, "us-gaap AccumulatedOtherComprehensiveIncomeMember": { "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024/"}}, {"labelname": "Accumulated Other Comprehensive Income Member", "presentation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "label": "AOI Attributable To Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } } } }, "auth ref": { "r1", "r6", "r14", "r313", "r316", "r360", "r438", "r439", "r679", "r680", "r681", "r686", "r687", "r688", "r689" } } }, "ecd Additional402vDisclosureTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024/"}}, {"labelname": "Additional 402(v) Disclosure Text Block", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } } } }, "auth ref": { "r620" } } }, "us-gaap AdditionalPaidInCapital": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024/"}}, {"labelname": "Additional Paid In Capital", "order": "credit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Additional paid in capital", "label": "Additional Paid In Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } } } }, "auth ref": { "r43", "r565", "r611" } } }, "us-gaap AdditionalPaidInCapitalMember": { "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024/"}}, {"labelname": "Additional Paid In Capital Member", "presentation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Additional Paid In Capital", "label": "Additional Paid In Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } } } }, "auth ref": { "r451", "r696", "r697", "r698", "r699", "r756", "r812" } } }, "ecd AdjToCompAmt": { "xbrlType": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024/"}}, {"labelname": "Adj To Comp Amt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation Amount", "label": "Adjustment to Compensation Amount" } } } } }, "auth ref": { "r633" } } }, "ecd AdjToCompAxis": { "xbrlType": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024/"}}, {"labelname": "Adj To Comp Axis", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation", "label": "Adjustment to Compensation [Axis]" } } } } }, "auth ref": { "r633" } } }, "ecd AdjToNonPeeNeoCompFnTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024/"}}, {"labelname": "Adj To Non Pee Neo Comp Fn Text Block", "presentation": { "http://xbrl.sec.gov/ecd/2024/"}}, {"labelname": "Adj To Non Pee Neo Comp Fn Text Block", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } } } }, "auth ref": { "r633" } } }, "ecd AdjToPeeCompFnTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024/"}}, {"labelname": "Adj To Pee Comp Fn Text Block", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Adjustment to PEO Compensation Footnote", "label": "Adjustment to PEO Compensation Footnote [Text Block]" } } } } }, "auth ref": { "r633" } } }, "us-gaap AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024/"}}, {"labelname": "Adjustments Related To Tax Withholding For Share Based Compensation", "order": "debit", "presentation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Shares withheld for taxes for vesting of restricted stock units", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement." } } } } }, "auth ref": { "us-gaap AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-g
```

table." } } },"auth_ref":[""],"us-gaap_AntidilutiveSecuritiesNameDomain":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AntidilutiveSecuritiesNameDomain"},"presentation":{"http://praxismedicines.com/role/NetLossperShareSummaryofAntidilutiveSecuritiesExcludedfromComputationofEarningsperShareDetails"},"lang":{"en-us":{"role":{"terseLabel":"Antidilutive Securities Name [Domain]","label":"Antidilutive Securities Name [Domain]","documentation":"Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."}}},"auth_ref":["r21"],"prax_April2024FollowOnOfferingMember":{"xbrltype":"domainItemType","nsuri":"http://praxismedicines.com/20240930","localname":"April2024FollowOnOfferingMember"},"presentation":{"http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails"},"lang":{"en-us":{"role":{"terseLabel":"April 2024 Follow-On Offering","label":"April 2024 Follow-On Offering [Member]","documentation":"April 2024 Follow-On Offering"}}},"auth_ref":[""],"prax_April2024PublicOfferingMember":{"xbrltype":"domainItemType","nsuri":"http://praxismedicines.com/20240930","localname":"April2024PublicOfferingMember"},"presentation":{"http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails"},"lang":{"en-us":{"role":{"terseLabel":"April 2024 Public Offering","label":"April 2024 Public Offering [Member]","documentation":"April 2024 Public Offering"}}},"auth_ref":[""],"us-gaap_Assets":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"Assets","crdr":"debit","calculation":{"http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited":{"parentTag":null,"weight":null,"order":null,"root":true},"presentation":{"http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited"},"lang":{"en-us":{"role":{"totalLabel":"Total assets","label":"Assets","documentation":"Amount of asset recognized for present right to economic benefit."}}},"auth_ref":["r65","r73","r95","r116","r146","r148","r152","r153","r193","r219","r220","r221","r222","r223","r224","r225","r226","r227","r308","r310","r348","r413","r475","r533","r534","r565","r583","r722","r723","r766"]},"us-gaap_AssetsAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AssetsAbstract"},"presentation":{"http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited"},"lang":{"en-us":{"role":{"terseLabel":"Assets","label":"Assets [Abstract]"}}}},"auth_ref":[""],"us-gaap_AssetsCurrent":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AssetsCurrent","crdr":"debit","calculation":{"http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited":{"parentTag":null,"weight":1.0,"order":3.0},"presentation":{"http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited"},"lang":{"en-us":{"role":{"totalLabel":"Total current assets","label":"Assets Current","documentation":"Amount of asset recognized for present right to economic benefit, classified as current."}}},"auth_ref":["r90","r97","r116","r193","r219","r220","r221","r222","r223","r224","r225","r226","r227","r308","r310","r348","r565","r722","r723","r766"]},"us-gaap_AssetsCurrentAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AssetsCurrentAbstract"},"presentation":{"http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited"},"lang":{"en-us":{"role":{"terseLabel":"Current assets","label":"Assets Current [Abstract]"}}}},"auth_ref":[""],"us-gaap_AssetsFairValueDisclosure":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AssetsFairValueDisclosure","crdr":"debit","calculation":{"http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails":{"parentTag":null,"weight":null,"order":null,"root":true},"presentation":{"http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"},"lang":{"en-us":{"role":{"totalLabel":"Assets","label":"Assets Fair Value Disclosure","documentation":"Fair value portion of asset recognized for present right to economic benefit."}}},"auth_ref":["r324","r325","r555"]},"prax_AtTheMarketOfferingMember":{"xbrltype":"domainItemType","nsuri":"http://praxismedicines.com/20240930","localname":"AtTheMarketOfferingMember"},"presentation":{"http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"},"lang":{"en-us":{"role":{"terseLabel":"At The Market Offering","label":"At The Market Offering [Member]","documentation":"At The Market Offering"}}},"auth_ref":[""],"us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue","crdr":"debit","calculation":{"http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesContractualMaturityofMarketableSecuritiesDetails":{"parentTag":"us-gaap_AvailableForSaleSecuritiesDebtSecurities","weight":1.0,"order":2.0},"presentation":{"http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesContractualMaturityofMarketableSecuritiesDetails"},"lang":{"en-us":{"role":{"terseLabel":"After one year through five years","label":"Debt Securities Available for Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five","documentation":"Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."}}},"auth_ref":["r171","r410"]},"us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue","crdr":"debit","calculation":{"http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesContractualMaturityofMarketableSecuritiesDetails":{"parentTag":"us-gaap_AvailableForSaleSecuritiesDebtSecurities","weight":1.0,"order":1.0},"presentation":{"http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesContractualMaturityofMarketableSecuritiesDetails"},"lang":{"en-us":{"role":{"terseLabel":"Within one year","label":"Debt Securities Available for Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One","documentation":"Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."}}},"auth_ref":["r170","r409"]},"us-gaap_AvailableForSaleSecuritiesDebtSecurities":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AvailableForSaleSecuritiesDebtSecurities","crdr":"debit","calculation":{"http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesContractualMaturityofMarketableSecuritiesDetails":{"parentTag":null,"weight":null,"order":null,"root":true},"presentation":{"http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesContractualMaturityofMarketableSecuritiesDetails"},"lang":{"en-us":{"role":{"totalLabel":"Total available for sale securities","label":"Debt Securities Available for Sale","documentation":"Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)."}}},"auth_ref":["r164","r201","r324","r405","r555","r558","r697","r760","r761","r762"]},"us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AvailableForSaleSecuritiesDebtSecuritiesCurrent","crdr":"debit","calculation":{"http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesInvestmentProfileDetails":{"parentTag":"prax_CashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure","weight":1.0,"order":1.0},"presentation":{"http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited"},"lang":{"en-us":{"role":{"terseLabel":"Debt securities, available for sale, current","label":"Debt Securities Available for Sale, Current","documentation":"Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale), classified as current."}}},"auth_ref":["r160","r201"]},"us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AvailableForSaleSecuritiesDebtSecuritiesNoncurrent","crdr":"debit","calculation":{"http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited"},"lang":{"en-us":{"role":{"terseLabel":"Long-term marketable securities","label":"Debt Securities Available for Sale, Noncurrent","documentation":"Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale), classified as noncurrent."}}},"auth_ref":["r93","r160","r201"]},"ecd_AwardExrcPrce":{"xbrltype":"perShareItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AwardExrcPrce"},"presentation":{"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"Exercise Price","label":"Award Exercise Price"}}},"auth_ref":["r655"]},"ecd_AwardGrantDateFairValue":{"xbrltype":"monetaryItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AwardGrantDateFairValue"},"presentation":{"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"Fair Value as of Grant Date","label":"Award Grant Date Fair Value"}}},"auth_ref":["r656"]},"ecd_AwardTmgDiscInclnItems":{"xbrltype":"stringItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AwardTmgDiscInclnItems"},"lang":{"en-us":{"role":{"label":"Award Timing Disclosures [Line Items]"},"auth_ref":["r651"]}}},"ecd_AwardTmgHwMnpiCnsdrdTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AwardTmgHwMnpiCnsdrdTextBlock"},"presentation":{"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"Award Timing How MNPI Considered","label":"Award Timing How MNPI Considered [Text Block]}}},"auth_ref":["r651"]},"ecd_AwardTmgMethodTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AwardTmgMethodTextBlock"},"presentation":{"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"Award Timing Method","label":"Award Timing Method [Text Block]}}},"auth_ref":["r651"]},"ecd_AwardTmgMnpiCnsdrdFlag":{"xbrltype":"booleanItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AwardTmgMnpiCnsdrdFlag"},"presentation":{"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"Award Timing MNPI Considered","label":"Award Timing MNPI Considered [Flag]}}},"auth_ref":["r651"]},"ecd_AwardTmgMnpiDiscTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AwardTmgMnpiDiscTextBlock"},"presentation":{"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"Award Timing MNPI Disclosure","label":"Award Timing MNPI Disclosure [Text Block]}}},"auth_ref":["r651"]},"ecd_AwardTmgPredtrmndFlag":{"xbrltype":"booleanItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AwardTmgPredtrmndFlag"},"presentation":{"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"Award Timing Predetermined","label":"Award Timing Predetermined [Flag]}}},"auth_ref":["r651"]},"us-gaap_AwardTypeAxis":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AwardTypeAxis"},"presentation":{"http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails"},"lang":{"en-us":{"role":{"terseLabel":"Award Type [Axis]","label":"Award Type [Axis]","documentation":"Information by type of award under share-based payment arrangement."}}},"auth_ref":["r265","r266","r267","r268","r269","r270","r271","r272","r273","r274","r275","r276","r277","r278","r279","r280","r281","r282","r283","r284","r285","r286","r287","r288","r289","r290"]},"ecd_AwardUndrlygSecuritiesAmt":{"xbrltype":"decimalItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AwardUndrlygSecuritiesAmt"},"presentation":{"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"Underlying Securities","label":"Award Underlying Securities Amount"}}},"auth_ref":["r654"]},"ecd_AwardsCloseToMnpiDiscInclnName":{"xbrltype":"stringItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AwardsCloseToMnpiDiscInclnName"},"presentation":{"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"Name","label":"Awards Close in Time to MNPI Disclosures, Individual Name"}}},"auth_ref":["r653"]},"ecd_AwardsCloseToMnpiDiscTable":{"xbrltype":"stringItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AwardsCloseToMnpiDiscTable"},"presentation":{"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"Awards Close in Time to MNPI Disclosures","label":"Awards Close in Time to MNPI Disclosures [Table]}}},"auth_ref":["r652"]},"ecd_AwardsCloseToMnpiDiscTableTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AwardsCloseToMnpiDiscTableTextBlock"},"presentation":{"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"Awards Close in Time to MNPI Disclosures, Table","label":"Awards Close in Time to MNPI Disclosures [Table Text Block]}}},"auth_ref":["r652"]},"us-gaap_BasisOfAccountingPolicyPolicyTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"BasisOfAccountingPolicyPolicyTextBlock"},"presentation":{"http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPolicies"},"lang":{"en-us":{"role":{"terseLabel":"Basis of Presentation","label":"Basis of Accounting, Policy [Policy Text Block]","documentation":"Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."}}},"auth_ref":[""],"us-gaap_CapitalExpendituresIncurredButNotYetPaid":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"CapitalExpendituresIncurredButNotYetPaid","crdr":"credit","presentation":{"http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"},"lang":{"en-us":{"role":{"terseLabel":"Purchases of property and equipment included in accounts payable","label":"Capital Expenditures Incurred but Not yet Paid","documentation":"Future cash outflow to pay for purchases of fixed assets that have occurred."}}},"auth_ref":["r18","r19","r20"]},"us-gaap_CashAndCashEquivalentsAtCarryingValue":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"CashAndCashEquivalentsAtCarryingValue","crdr":"debit","calculation":{"http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited":{"parentTag":"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents","weight":1.0,"order":1.0},"presentation":{"http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited":{"parentTag":"us-gaap_AssetsCurrent","weight":1.0,"order":2.0},"presentation":{"http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited"},"lang":{"en-us":{"role":{"terseLabel":"Cash and cash equivalents","label":"Cash and Cash Equivalents, At Carrying Value","documentation":"Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."}}},"auth_ref":["r17","r22","r524"]},"us-gaap_CashAndCashEquivalentsFairValueDisclosure":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"CashAndCashEquivalentsFairValueDisclosure","crdr":"debit","calculation":{"http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails":{"parentTag":"us-gaap_AssetsFairValueDisclosure","weight":1.0,"order":2.0},"presentation":{"http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails"},"lang":{"en-us":{"role":{"terseLabel":"Cash equivalents","label":"Cash and Cash Equivalents, Fair Value Disclosure","documentation":"Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."}}},"auth_ref":["r758","r759"]},"us-gaap_CashCashEquivalentsAndShortTermInvestments":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"CashCashEquivalentsAndShortTermInvestments","crdr":"debit","presentation":{"http://praxismedicines.com/role/NatureoftheBusinessAdditionalInformationDetails"},"lang":{"en-us":{"

role: "roleLabel": "Cash, cash equivalents, and marketable securities", "label": "Cash, Cash Equivalents, and Short-Term Investments", "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable." } } } , "auth_ref": "r678" } } , "us-gaap": CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents { "xbrlytype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } } , "presentation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period", "totalLabel": "Total cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } } , "auth_ref": "r17", "r53", "r113" } } , "us-gaap": CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract { "xbrlytype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "presentation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents (Abstract)" } } } , "auth_ref": { } } } , "us-gaap": CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect { "xbrlytype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } } , "presentation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "totalLabel": "Increase in cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } } , "auth_ref": "r0", "r53" } } , "prax": CashEquivalentsAccumulatedGrossUnrealizedGainCurrentBeforeTax { "xbrlytype": "monetaryItemType", "nsuri": "http://praxismedicines.com/20240930", "localname": "CashEquivalentsAccumulatedGrossUnrealizedGainCurrentBeforeTax", "crdr": "credit", "calculation": { "http://praxismedicines.com/role/CashEquivalentsAndMarketableSecuritiesInvestmentProfileDetails": { "parentTag": "us-gaap: CashEquivalentsAtCarryingValue", "weight": 1.0, "order": 3.0 } } , "presentation": { "http://praxismedicines.com/role/CashEquivalentsAndMarketableSecuritiesInvestmentProfileDetails": { "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents, accumulated gross unrealized gain, current, before tax", "label": "Cash Equivalents, Accumulated Gross Unrealized Gain, Current, Before Tax", "documentation": "Cash Equivalents, Accumulated Gross Unrealized Gain, Current, Before Tax" } } } , "auth_ref": { } } , "prax": CashEquivalentsAndDebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax { "xbrlytype": "monetaryItemType", "nsuri": "http://praxismedicines.com/20240930", "localname": "CashEquivalentsAndDebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax", "crdr": "credit", "calculation": { "http://praxismedicines.com/role/CashEquivalentsAndMarketableSecuritiesInvestmentProfileDetails": { "parentTag": "us-gaap: CashEquivalentsAtCarryingValueAndDebtSecuritiesAvailableForSaleAmortizedCost", "weight": 1.0, "order": 2.0 } } , "presentation": { "http://praxismedicines.com/role/CashEquivalentsAndMarketableSecuritiesInvestmentProfileDetails": { "lang": { "en-us": { "role": { "negatedLabel": "Cash equivalents, accumulated gross unrealized loss, current, before tax", "label": "Cash Equivalents, Accumulated Gross Unrealized Loss, Current, Before Tax", "documentation": "Cash Equivalents, Accumulated Gross Unrealized Loss, Current, Before Tax" } } } , "auth_ref": { } } , "prax": CashEquivalentsAndDebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax { "xbrlytype": "monetaryItemType", "nsuri": "http://praxismedicines.com/20240930", "localname": "CashEquivalentsAndDebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CashEquivalentsAndMarketableSecuritiesInvestmentProfileDetails": { "parentTag": "us-gaap: CashEquivalentsAtCarryingValueAndDebtSecuritiesAvailableForSaleAmortizedCost", "weight": 1.0, "order": 2.0 } } , "presentation": { "http://praxismedicines.com/role/CashEquivalentsAndMarketableSecuritiesInvestmentProfileDetails": { "lang": { "en-us": { "role": { "totalLabel": "Cash equivalents and debt securities, available for sale, accumulated gross unrealized gain, current, before tax", "label": "Cash Equivalents And Debt Securities, Available For Sale, Accumulated Gross Unrealized Gain, Current, Before Tax", "documentation": "Cash Equivalents And Debt Securities, Available For Sale, Accumulated Gross Unrealized Gain, Current, Before Tax" } } } , "auth_ref": { } } , "prax": CashEquivalentsAndDebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax { "xbrlytype": "monetaryItemType", "nsuri": "http://praxismedicines.com/20240930", "localname": "CashEquivalentsAndDebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CashEquivalentsAndMarketableSecuritiesInvestmentProfileDetails": { "parentTag": "us-gaap: CashEquivalentsAtCarryingValueAndDebtSecuritiesAvailableForSaleAmortizedCost", "weight": 1.0, "order": 2.0 } } , "presentation": { "http://praxismedicines.com/role/CashEquivalentsAndMarketableSecuritiesInvestmentProfileDetails": { "lang": { "en-us": { "role": { "negatedTotalLabel": "Cash equivalents and debt securities, available for sale, accumulated gross unrealized loss, current, before tax", "label": "Cash Equivalents And Debt Securities, Available For Sale, Accumulated Gross Unrealized Loss, Current, Before Tax", "documentation": "Cash Equivalents And Debt Securities, Available For Sale, Accumulated Gross Unrealized Loss, Current, Before Tax" } } } , "auth_ref": { } } , "prax": CashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure { "xbrlytype": "monetaryItemType", "nsuri": "http://praxismedicines.com/20240930", "localname": "CashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CashEquivalentsAndMarketableSecuritiesInvestmentProfileDetails": { "parentTag": "us-gaap: CashEquivalentsAtCarryingValueAndDebtSecuritiesAvailableForSaleAmortizedCost", "weight": 1.0, "order": 3.0 } } , "presentation": { "http://praxismedicines.com/role/CashEquivalentsAndMarketableSecuritiesInvestmentProfileDetails": { "lang": { "en-us": { "role": { "totalLabel": "Cash equivalents and debt securities, available for sale, fair value disclosure", "label": "Cash Equivalents And Debt Securities, Available For Sale, Fair Value Disclosure", "documentation": "Cash Equivalents And Debt Securities, Available For Sale, Fair Value Disclosure" } } } , "auth_ref": { } } , "us-gaap": CashEquivalentsAtCarryingValue { "xbrlytype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CashEquivalentsAndMarketableSecuritiesInvestmentProfileDetails": { "parentTag": "prax: CashEquivalentsAtCarryingValueAndDebtSecuritiesAvailableForSaleAmortizedCost", "weight": 1.0, "order": 1.0 } } , "presentation": { "http://praxismedicines.com/role/CashEquivalentsAndMarketableSecuritiesInvestmentProfileDetails": { "parentTag": null, "weight": null, "order": null, "root": true } } , "presentation": { "http://praxismedicines.com/role/CashEquivalentsAndMarketableSecuritiesInvestmentProfileDetails": { "lang": { "en-us": { "role": { "totalLabel": "Cash equivalents at carrying value", "label": "Cash Equivalents, at Carrying Value", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } } , "auth_ref": "r677", "r778" } } , "prax": CashEquivalentsAtCarryingValueAndDebtSecuritiesAvailableForSaleAmortizedCost { "xbrlytype": "monetaryItemType", "nsuri": "http://praxismedicines.com/20240930", "localname": "CashEquivalentsAtCarryingValueAndDebtSecuritiesAvailableForSaleAmortizedCost", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CashEquivalentsAndMarketableSecuritiesInvestmentProfileDetails": { "parentTag": null, "weight": null, "order": null, "root": true } } , "presentation": { "http://praxismedicines.com/role/CashEquivalentsAndMarketableSecuritiesInvestmentProfileDetails": { "lang": { "en-us": { "role": { "totalLabel": "Cash equivalents at carrying value and debt securities, available for sale, amortized cost", "label": "Cash Equivalents, at Carrying Value And Debt Securities, Available For Sale, Amortized Cost", "documentation": "Cash Equivalents, at Carrying Value And Debt Securities, Available For Sale, Amortized Cost" } } } , "auth_ref": { } } , "prax": CashEquivalentsFairValueDisclosure { "xbrlytype": "monetaryItemType", "nsuri": "http://praxismedicines.com/20240930", "localname": "CashEquivalentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CashEquivalentsAndMarketableSecuritiesInvestmentProfileDetails": { "parentTag": "prax: CashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure", "weight": 1.0, "order": 2.0 } } , "presentation": { "http://praxismedicines.com/role/CashEquivalentsAndMarketableSecuritiesInvestmentProfileDetails": { "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents, fair value disclosure", "label": "Cash Equivalents, Fair Value Disclosure", "documentation": "Cash Equivalents, Fair Value Disclosure" } } } , "auth_ref": { } } , "prax": ChangeInPercentageOfOwnership { "xbrlytype": "percentItemType", "nsuri": "http://praxismedicines.com/20240930", "localname": "ChangeInPercentageOfOwnership", "presentation": { "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Percentage change in ownership", "label": "Change in Percentage of Ownership", "documentation": "Change in Percentage of Ownership" } } } , "auth_ref": { } } , "ecd": ChangedPeerGroupFnTextBlock { "xbrlytype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } } , "auth_ref": "r631" } } , "ecd": ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdsVstdInCvrdYrMember { "xbrlytype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } } , "auth_ref": "r628" } } , "ecd": ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrY

"/http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap-NetCashProvidedUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": { "/http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Non-cash collaboration and license agreement expense", "label": "Collaboration And License Agreement, Noncash Expense", "documentation": "Collaboration And License Agreement, Noncash Expense" } } }, "auth-ref": { "us-gaap-CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": { "/http://praxismedicines.com/role/CollaborationLicenseAgreements": { "lang": { "en-us": { "role": { "terseLabel": "Collaboration License Agreements", "label": "Collaborative Arrangement Disclosure [Text Block]", "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants." } } }, "auth-ref": { "r78", "r80", "r66" } }, "us-gaap-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember", "presentation": { "/http://praxismedicines.com/role/CashEquivalentsAndMarketableSecuritiesInvestmentProfileDetails": { "lang": { "en-us": { "role": { "terseLabel": "Commercial paper", "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents." } } }, "auth-ref": { "r272", "r11" }, "us-gaap-CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "/http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap-LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": { "/http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 6)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth-ref": { "r39", "r66", "r44", "r462" } }, "us-gaap-CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]", "documentation": "Commitments and Contingencies Disclosure TextBlock", "presentation": { "/http://praxismedicines.com/role/CommitmentsAndContingencies": { "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth-ref": { "r58", "r211", "r212", "r517", "r715", "r717" } }, "us-gaap-CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": { "/http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Total shares of authorized common stock reserved for future issuance (in shares)", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth-ref": { "r42" } }, "us-gaap-CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": { "/http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth-ref": { "r573", "r574", "r575", "r577", "r578", "r579", "r580", "r686", "r687", "r689", "r756", "r810", "r812" } }, "us-gaap-CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": { "/http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth-ref": { "r42" } }, "us-gaap-CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": { "/http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Common stock, authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth-ref": { "r42", "r463" } }, "us-gaap-CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": { "/http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnauditedParentetical": { "lang": { "en-us": { "role": { "terseLabel": "Common stock, issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth-ref": { "r42" } }, "us-gaap-CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": { "/http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnauditedParentetical": { "lang": { "en-us": { "role": { "terseLabel": "Common stock, outstanding (in shares)", "label": "Common Stock, Shares Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth-ref": { "r7", "r42", "r463", "r481", "r812", "r813" } }, "us-gaap-CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "/http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap-StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": { "/http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Common stock, 0.0001 par value, 150,000,000 shares authorized, 17,785,697 shares issued and outstanding as of Septemberu00a030, 2024, and 9,791,877 shares issued and outstanding as of Decemberu00a031, 2023", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth-ref": { "r42", "r416", "r565" } }, "prax-CommonStockWarrantsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://praxismedicines.com/20240930", "localname": "CommonStockWarrantsPolicyTextBlock", "presentation": { "/http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "terseLabel": "Common Stock Warrants", "label": "Common Stock, Warrants [Policy Text Block]", "documentation": "Common Stock, Warrants" } } }, "auth-ref": { "1" } }, "ced-CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": { "/http://xbrl.sec.gov/ced/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "documentation": "Compensation Actually Paid vs. Net Income [Text Block]", "presentation": { "/http://xbrl.sec.gov/ced/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]", "documentation": "Compensation Actually Paid vs. Other Measure [Text Block]", "presentation": { "/http://xbrl.sec.gov/ced/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "documentation": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "presentation": { "/http://praxismedicines.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "/http://praxismedicines.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited": { "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth-ref": { "r15", "r101", "r103", "r108", "r406", "r424", "r425" } }, "us-gaap-ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": { "/http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Upfront payment", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth-ref": { "r248", "r249", "r251" } }, "us-gaap-ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "/http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap-LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": { "/http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Current portion of deferred revenue", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth-ref": { "r248", "r249", "r251" } }, "us-gaap-ContractWithCustomerLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "calculation": { "/http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap-Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": { "/http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Non-current portion of deferred revenue", "label": "Contract with Customer, Liability, Noncurrent", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth-ref": { "r248", "r249", "r251" } }, "us-gaap-CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateDebtSecuritiesMember", "presentation": { "/http://praxismedicines.com/role/CashEquivalentsAndMarketableSecuritiesInvestmentProfileDetails": { "lang": { "en-us": { "role": { "terseLabel": "Corporate debt securities", "label": "Corporate Debt Securities [Member]", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth-ref": { "r549", "r551", "r555", "r556", "r571", "r807" } }, "srt-CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": { "/http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]", "documentation": "Amount of debt issuance costs that were incurred during a noncash or partial noncash transaction." } } }, "auth-ref": { "r18", "r19", "r20" } }, "prax-DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://praxismedicines.com/20240930", "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax", "crdr": "credit", "calculation": { "/http://praxismedicines.com/role/CashEquivalentsAndMarketableSecuritiesInvestmentProfileDetails": { "parentTag": "prax-CashEquivalentsAndDebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax", "weight": 1.0, "order": 2.0 } }, "presentation": { "/http://praxismedicines.com/role/CashEquivalentsAndMarketableSecuritiesInvestmentProfileDetails": { "lang": { "en-us": { "role": { "terseLabel": "Debt securities, available for sale, accumulated gross unrealized gain, current, before tax", "label": "Debt Securities, Available for Sale, Accumulated Gross Unrealized Gain, Current, before Tax", "documentation": "Debt Securities, Available for Sale, Accumulated Gross Unrealized Loss, Current, before Tax", "presentation": { "/http://praxismedicines.com/role/CashEquivalentsAndMarketableSecuritiesInvestmentProfileDetails": { "parentTag": "us-gaap-DebtSecuritiesAvailableForSaleAmortizedCostCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": { "/http://praxismedicines.com/role/CashEquivalentsAndMarketableSecuritiesInvestmentProfileDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Debt securities, available for sale, accumulated gross unrealized loss, current, before tax", "label": "Debt Securities, Available for Sale, Accumulated Gross Unrealized Loss, Current, before Tax", "documentation": "Debt Securities, Available for Sale, Accumulated Gross Unrealized Loss, Current, before Tax" } } }, "auth-ref": { "1" }, "us-gaap-DebtSecuritiesAvailableForSaleAmortizedCostCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent", "crdr": "debit", "calculation": { "/http://praxismedicines.com/role/CashEquivalentsAndMarketableSecuritiesInvestmentProfileDetails": { "parentTag": "prax-CashEquivalentsAtCarryingValueAndDebtSecuritiesAvailableForSaleAmortizedCost", "weight": 1.0, "order": 2.0 } }, "presentation": { "/http://praxismedicines.com/role/CashEquivalentsAndMarketableSecuritiesInvestmentProfileDetails": { "lang": { "en-us": { "role": { "totalLabel": "Debt securities, available for sale, amortized cost, current", "label": "Debt Securities, Available for Sale, Amortized Cost, Current", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair

value recognized in other comprehensive income (available for sale), classified as current." } } } , "auth_ref": { "r201": "r698" } } } , "us-gaap-DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": { "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesInvestmentProfileDetails": { "lang": { "en-us": { "role": { "terseLabel": "Debt Securities. Available for sale [Table]", "label": "Debt Securities. Available for Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } } } , "auth_ref": { "r162": "r163", "r164": "r165", "r166": "r167", "r168": "r169", "r170": "r171", "r172": "r173" } } } , "us-gaap-DebtSecuritiesAvailableForSaleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "presentation": { "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesTables": { "lang": { "en-us": { "role": { "terseLabel": "Debt Securities. Available for Sale [Table Text Block]", "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } } } , "auth_ref": { "r698": "r699", "r700": "r701", "r702": "r703", "r704": "r705", "r706": "r707", "r708": "r709" } } } , "us-gaap-DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "crdr": "debit", "presentation": { "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Securities. unrealized loss position, fair value", "label": "Debt Securities. Available for Sale, Unrealized Loss Position", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale), in unrealized loss position without allowance for credit loss." } } } } , "auth_ref": { "r75": "r203", "r537" } } } , "us-gaap-DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "presentation": { "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Number of securities", "label": "Debt Securities. Available for Sale, Unrealized Loss Position, Number of Positions", "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available for sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } } } , "auth_ref": { "r76": "r204" } } } , "us-gaap-Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } } } , "presentation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "lang": { "en-us": { "role": { "verboseLabel": "Depreciation expense", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } } } , "auth_ref": { "r4": "r26" } } } , "us-gaap-DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": { "http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } } , "auth_ref": { "r250": "r542", "r543", "r544": "r545", "r546": "r547", "r548" } } } , "us-gaap-DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": { "http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } } } , "auth_ref": { "r250": "r542", "r543", "r544": "r545", "r546": "r547", "r548" } } } , "us-gaap-DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": { "http://praxismedicines.com/role/StockBasedCompensation": { "lang": { "en-us": { "role": { "terseLabel": "Stock-Based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } } } , "auth_ref": { "r260": "r264", "r202": "r203", "r205": "r553" } } } , "us-gaap-DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } } } , "auth_ref": { } } , "dei-DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": { "http://praxismedicines.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } } } , "auth_ref": { } } } , "dei-DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": { "http://praxismedicines.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } } } , "auth_ref": { } } } , "dei-DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": { "http://praxismedicines.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K, the date of the report, the date of the earliest event reported, for the EDGAR submission types of Form N-1A, the filing date, for all other submission types, the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } } } , "auth_ref": { } } } , "dei-DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": { "http://praxismedicines.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } } } , "auth_ref": { "r587" } } } , "dei-DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": { "http://praxismedicines.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } } } , "auth_ref": { "r619" } } } , "dei-DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": { "http://praxismedicines.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } } } , "auth_ref": { } } } , "ced-DvdsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInThCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "DvdsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInThCompForCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ced/ro/PyPDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } } } , "auth_ref": { "r630" } } } , "us-gaap-EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } } } , "auth_ref": { } } , "us-gaap-EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Net loss per share attributable to common stockholders, basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } } } , "auth_ref": { "r109": "r124", "r125": "r126", "r127": "r128", "r129": "r134", "r136": "r138", "r139": "r140", "r145": "r304", "r307": "r321", "r322": "r407", "r426": "r529" } } } , "us-gaap-EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Net loss per share attributable to common stockholders, diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } } } , "auth_ref": { "r109": "r124", "r125": "r126", "r127": "r128", "r129": "r136", "r138", "r139": "r140", "r145": "r304", "r307": "r321", "r322": "r407", "r426": "r529" } } } , "us-gaap-EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": { "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "terseLabel": "Net Loss per Share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } } } , "auth_ref": { "r21": "r22", "r142" } } } , "us-gaap-EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": { "http://praxismedicines.com/role/NetLossperShare": { "lang": { "en-us": { "role": { "terseLabel": "Net Loss per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } } } , "auth_ref": { "r133": "r143", "r144" } } } , "us-gaap-EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": { "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails": { "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } } , "auth_ref": { } } } , "us-gaap-EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": { "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Total unrecognized compensation cost related to unvested restricted stock units", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } } } , "auth_ref": { "r204" } } } , "us-gaap-EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": { "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Weighted average period (in years)", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in PnYnMnDnHnMnS format, for example, P1Y5M13D represents reported fact of one year, five months, and thirteen days." } } } } , "auth_ref": { "r294" } } } , "us-gaap-EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": { "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation expense related to unvested stock based awards", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } } } , "auth_ref": { "r754" } } } , "us-gaap-EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockMember", "presentation": { "http://praxismedicines.com/role/NetLossperShareSummaryofantidilutivesecuritiesexcludedfromcomputationofearningspershareDetails": { "lang": { "en-us": { "role": { "terseLabel": "Potential shares issuable under the 2020 ESPP", "label": "Employee Stock [Member]", "documentation": "An Employee Stock Purchase Plan is a tax efficient means by which employees of a corporation can purchase the corporation's stock." } } } } , "auth_ref": { } } } , "us-gaap-EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": { "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails": { "http://praxismedicines.com/role/NetLossperShareSummaryofantidilutivesecuritiesexcludedfromcomputationofearningspershareDetails", "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails", "http://praxismedicines.com/role/StockBasedCompensationScheduleofFairValueofStockOptionAwardsOntheGrantDateUsingtheBlackScholesOptionValuationModelDetails": { "lang": { "en-us": { "role": { "terseLabel": "Shares reserved for exercise of outstanding stock options", "verboseLabel": "Outstanding stock options", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } } } , "auth_ref": { } } } , "dei-EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": { "http://praxismedicines.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } } } , "auth_ref": { } } } , "dei-EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": { "http://praxismedicines.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } } } , "auth_ref": { } } } , "dei-EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": { "http://praxismedicines.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } } } , "auth_ref": { } } } , "dei-EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": { "http://praxismedicines.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } } } , "auth_ref": { } } } , "dei-EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": { "http://praxismedicines.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } } } , "auth_ref": { } } } , "dei-EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": { "http://praxismedicines.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } } } , "auth_ref": { "r585" } } } , "dei-EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": {

```

http://praxismedicines.com/role/CoverPage" | "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings. Instrument. } } }, "auth ref": { "1" }, "dei": "EntityCurrentReportingStatus", { "xbrlytype": "yesNoItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": { "http://praxismedicines.com/role/CoverPage" | "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports) and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. } } }, "auth ref": { "1" }, "dei": "EntityEmergingGrowthCompany", { "xbrlytype": "booleanItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": { "http://praxismedicines.com/role/CoverPage" | "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria. } } }, "auth ref": { "r585" } }, "dei": "EntityFileNumber", { "xbrlytype": "fileNumberItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": { "http://praxismedicines.com/role/CoverPage" | "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. } } }, "auth ref": { "1" }, "dei": "EntityFilerCategory", { "xbrlytype": "filerCategoryItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": { "http://praxismedicines.com/role/CoverPage" | "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. } } }, "auth ref": { "r585" } }, "dei": "EntityIncorporationStateCountryCode", { "presentation": { "http://praxismedicines.com/role/CoverPage" | "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation. } } }, "auth ref": { "1" }, "dei": "EntityInteractiveDataCurrent", { "xbrlytype": "yesNoItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": { "http://praxismedicines.com/role/CoverPage" | "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). } } }, "auth ref": { "r669" } }, "dei": "EntityRegistrantName", { "xbrlytype": "normalizedStringItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": { "http://praxismedicines.com/role/CoverPage" | "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. } } }, "auth ref": { "r585" } }, "dei": "EntityShellCompany", { "xbrlytype": "booleanItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": { "http://praxismedicines.com/role/CoverPage" | "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. } } }, "auth ref": { "r585" } }, "dei": "EntitySmallBusiness", { "xbrlytype": "booleanItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": { "http://praxismedicines.com/role/CoverPage" | "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC). } } }, "auth ref": { "r585" } }, "dei": "EntityTaxIdentificationNumber", { "xbrlytype": "employerIdItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": { "http://praxismedicines.com/role/CoverPage" | "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9 digit value assigned by the IRS. } } }, "auth ref": { "r585" } }, "dei": "EqtyAwrdsAdjFnTextBlock", { "xbrlytype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PrpDisclosure" | "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth ref": { "r624" } }, "dei": "EqtyAwrdsAdjIsExclValRprtInSummryCompstnTblMember", { "xbrlytype": "domainItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjIsExclValRprtInSummryCompstnTblMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PrpDisclosure" | "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth ref": { "r665" } }, "dei": "EqtyAwrdsAdjIsMember", { "xbrlytype": "domainItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjIsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PrpDisclosure" | "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments [Member]" } } }, "auth ref": { "r665" } }, "dei": "EqtyAwrdsInSummryCompstnTblForApblYrMember", { "xbrlytype": "domainItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForApblYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PrpDisclosure" | "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } } }, "auth ref": { "r665" } }, "dei": "us-gaap-EquityComponentDomain", { "xbrlytype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" | "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc. } } }, "auth ref": { "r73", "r88", "r104", "r105", "r106", "r119", "r120", "r121", "r123", "r128", "r130", "r132", "r147", "r194", "r195", "r207", "r247", "r299", "r300", "r301", "r302", "r303", "r305", "r306", "r307", "r312", "r314", "r315", "r316", "r317", "r320", "r340", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r360", "r422", "r438", "r439", "r440", "r451", "r502" } }, "dei": "EqtyValuationAssumptionDifferenceFnTextBlock", { "xbrlytype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyValuationAssumptionDifferenceFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PrpDisclosure" | "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth ref": { "r634" } }, "dei": "ErrCompAnalysisTextBlock", { "xbrlytype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" | "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth ref": { "r592", "r602", "r612", "r644" } }, "dei": "ErrCompRecoveryTable", { "xbrlytype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" | "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth ref": { "r590", "r590", "r600", "r641" } }, "dei": "ExecutiveCategoryAxis", { "xbrlytype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/PrpDisclosure" | "lang": { "en-us": { "role": { "terseLabel": "Executive Category", "label": "Executive Category [Axis]" } } }, "auth ref": { "r640" } }, "dei": "us-gaap-FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", { "xbrlytype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": { "http://praxismedicines.com/role/FairValueMeasurementsSummaryOfFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" | "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. } } }, "auth ref": { "r324", "r325", "r338", "r555" } }, "dei": "us-gaap-FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", { "xbrlytype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": { "http://praxismedicines.com/role/FairValueMeasurementsSummaryOfFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" | "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis. } } }, "auth ref": { "r324", "r325", "r338", "r555" } }, "dei": "us-gaap-FairValueAssetsMeasuredOnRecurringBasisTextBlock", { "xbrlytype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": { "http://praxismedicines.com/role/FairValueMeasurementsTables" | "lang": { "en-us": { "role": { "terseLabel": "Summary of Financial Assets Measured at Fair Value On A Recurring Basis", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets, including financial instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). } } }, "auth ref": { "
```

"us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": {
"http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": { "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth-ref": { "r220", "r253", "r254", "r255", "r256", "r257", "r258", "r323", "r325", "r326", "r327", "r328", "r337", "r338", "r340", "r372", "r373", "r374", "r539", "r540", "r549", "r550", "r551", "r555", "r558" } }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": {
"http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": { "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth-ref": { "r555", "r758", "r759", "r760", "r761", "r762", "r764" } }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": {
"http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesInvestmentProfileDetails": { "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth-ref": { "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r196", "r197", "r198", "r199", "r200", "r202", "r205", "r206", "r230", "r244", "r318", "r345", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r423", "r537", "r555", "r556", "r558", "r560", "r561", "r562", "r563", "r564", "r566", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r679", "r710", "r711", "r712", "r757", "r760", "r761", "r762", "r763", "r764" } }, "prax_FollowOnOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://praxismedicines.com/20240930", "localname": "FollowOnOfferingMember", "presentation": {
"http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
"http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited": {
"http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnauditedParentetical": { "lang": { "en-us": { "role": { "terseLabel": "Follow-On Offering", "label": "Follow-On Offering [Member]", "documentation": "Follow-On Offering" } } }, "auth-ref": { } }, "ced_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": {
"http://xbrl.sec.gov/ced/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth-ref": { "r596", "r606", "r616", "r648" } }, "ced_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": {
"http://xbrl.sec.gov/ced/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth-ref": { "r596", "r606", "r616", "r648" } }, "ced_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": { "http://xbrl.sec.gov/ced/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth-ref": { "r596", "r606", "r616", "r648" } }, "ced_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": { "http://xbrl.sec.gov/ced/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth-ref": { "r50", "r485" } }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": {
"http://praxismedicines.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails": { "lang": { "en-us": { "role": { "verboseLabel": "General and administrative", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth-ref": { "r50" } }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth-ref": { } }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": {
"http://praxismedicines.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails": { "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth-ref": { "r208", "r209", "r210", "r330", "r334", "r339", "r435", "r437", "r488", "r522", "r557", "r780" } }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": {
"http://praxismedicines.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails": { "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth-ref": { "r209", "r210", "r330", "r334", "r339", "r435", "r437", "r488", "r522", "r557", "r780" } }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "presentation": {
"http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth-ref": { "r3" } }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "presentation": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Increase (Decrease) in Contract with Customer Liability", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth-ref": { "r402", "r682" } }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "verboseLabel": "Changes in operating assets and liabilities", "label": "Increase (Decrease) in Operating Capital [Abstract]", "documentation": "Changes in operating assets and liabilities." } } }, "auth-ref": { } }, "prax_IncreaseDecreaseInOperatingLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://praxismedicines.com/20240930", "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "presentation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "verboseLabel": "Operating lease liabilities", "label": "Increase (Decrease) in Operating Lease Liabilities", "documentation": "Increase (Decrease) in Operating Lease Liabilities." } } }, "auth-ref": { } }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "presentation": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth-ref": { "r3" } }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth-ref": { } }, "ced_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "IndividualAxis", "presentation": { "http://xbrl.sec.gov/ced/role/AwardTimingDisclosure": { "http://xbrl.sec.gov/ced/role/ErrCompDisclosure": { "http://xbrl.sec.gov/ced/role/InsiderTradingArrangements": { "http://xbrl.sec.gov/ced/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Individual", "label": "Individual [Axis]", "documentation": "Individual" } } }, "auth-ref": { "r596", "r606", "r616", "r640", "r648", "r652", "r660" } }, "prax_InducementPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://praxismedicines.com/20240930", "localname": "InducementPlanMember", "presentation": { "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails": { "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Shares reserved for future awards under the 2024 Inducement Plan", "label": "Inducement Plan [Member]", "documentation": "Inducement Plan" } } }, "auth-ref": { } }, "ced_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "InsiderTradingArrLineItems", "presentation": { "http://xbrl.sec.gov/ced/role/InsiderTradingArrLineItems": { "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "documentation": "Insider Trading Arrangements" } } }, "auth-ref": { "r588", "r664" } }, "ced_InsiderTradingPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "InsiderTradingPoliciesProcAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ced/role/InsiderTradingPoliciesProc": { "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]", "documentation": "Insider Trading Policies and Procedures Adopted" } } }, "auth-ref": { "r588", "r664" } }, "ced_InsiderTradingPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "InsiderTradingPoliciesProcNotAdoptedTextBlock", "presentation": { "http://xbrl.sec.gov/ced/role/InsiderTradingPoliciesProc": { "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "documentation": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth-ref": { "r588", "r664" } }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "presentation": { "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Investments", "label": "Investments", "documentation": "Investments" } } }, "auth-ref": { } }, "us-gaap_InvestmentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsFairValueDisclosure", "presentation": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://praxismedicines.com/role/FairValueMeasurementsSummaryofFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": { "lang": { "en-us": { "role": { "terseLabel": "Available for sale marketable securities", "label": "Investments, Fair Value Disclosure", "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method." } } }, "auth-ref": { "r758", "r759", "r763" } }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": { "http://praxismedicines.com/role/CashEquivalentsandMarketableSecurities": { "lang": { "en-us": { "role": { "terseLabel": "Cash Equivalents and Marketable Securities", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth-ref": { "r69", "r87", "r158", "r161", "r346", "r347", "r775" } }, "prax_January2024FollowOnOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://praxismedicines.com/20240930", "localname": "January2024FollowOnOfferingMember", "presentation": { "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails": { "lang": { "en-us": { "role": { "terseLabel": "January 2024 Follow-On Offering", "label": "January 2024 Follow-On Offering [Member]", "documentation": "January 2024 Follow-On Offering" } } }, "auth-ref": { } }, "prax_January2024PublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://praxismedicines.com/20240930", "localname": "January2024PublicOfferingMember", "presentation": { "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "January 2024 Public Offering", "label": "January 2024 Public Offering [Member]", "documentation": "January 2024 Public Offering" } } }, "auth-ref": { } }, "prax_June2023FollowOnOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://praxismedicines.com/20240930", "localname": "June2023FollowOnOfferingMember", "presentation": {

"http://praxismedicines.com/role/CommonStockAndPreferredStockSummaryOfCommonStockReservedForFutureIssuanceDetails"/>,"lang": {"en-us": {"role": {"terseLabel": "June 2023 Follow On Offering"}, "label": "June 2023 Follow On Offering [Member]"}, "documentation": "June 2023 Follow On Offering"}}, {"auth_ref": [], "prax_June2023PublicOfferingMember": {"xbrltype": {"domainItemType": "nsuri": "http://praxismedicines.com/20240930", "localname": "June2023PublicOfferingMember"}, "presentation": {"http://praxismedicines.com/role/CommonStockAndPreferredStockAdditionalInformationDetails"/>,"lang": {"en-us": {"role": {"terseLabel": "June 2023 Public Offering"}, "label": "June 2023 Public Offering [Member]"}, "documentation": "June 2023 Public Offering"}}, {"auth_ref": [], "us-gaap_Liabilities": {"xbrltype": {"monetaryItemType": "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities"}, "credit": {"calculation": {"http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited"/>,"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity"}, "weight": 1.0, "order": 1.0}}, {"presentation": {"http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited"/>,"lang": {"en-us": {"role": {"totalLabel": "Total liabilities"}, "label": "Liabilities"}, "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."}}, {"auth_ref": ["r12", "r34", "r35", "r36", "r37", "r38", "r39", "r40", "r116", "r193", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r309", "r310", "r311", "r348", "r461", "r530", "r583", "r722", "r766", "r767"}], "us-gaap_LiabilitiesAndStockholdersEquity": {"xbrltype": {"monetaryItemType": "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity"}, "credit": {"calculation": {"http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited"/>,"parentTag": null, "weight": null, "order": null, "root": true}}, {"presentation": {"http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited"/>,"lang": {"en-us": {"role": {"totalLabel": "Total liabilities and stockholders' equity"}, "label": "Liabilities and Equity"}, "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."}}, {"auth_ref": ["r47", "r67", "r410", "r565", "r685", "r713", "r765"}], "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {"xbrltype": {"stringItemType": "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract"}, "presentation": {"http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited"/>,"lang": {"en-us": {"role": {"verboseLabel": "Liabilities and stockholders' equity"}, "label": "Liabilities and Equity [Abstract]"}}, {"auth_ref": [], "us-gaap_LiabilitiesCurrent": {"xbrltype": {"monetaryItemType": "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent"}, "credit": {"calculation": {"http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited"/>,"parentTag": "us-gaap_Liabilities"}, "weight": 1.0, "order": 3.0}}, {"presentation": {"http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited"/>,"lang": {"en-us": {"role": {"totalLabel": "Total current liabilities"}, "label": "Liabilities Current"}, "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."}}, {"auth_ref": ["r36", "r91", "r116", "r193", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r309", "r310", "r311", "r348", "r565", "r722", "r766", "r767"}], "us-gaap_LiabilitiesCurrentAbstract": {"xbrltype": {"stringItemType": "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract"}, "presentation": {"http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited"/>,"lang": {"en-us": {"role": {"verboseLabel": "Current liabilities"}, "label": "Liabilities Current [Abstract]"}}, {"auth_ref": [], "us-gaap_LiabilitiesNoncurrentAbstract": {"xbrltype": {"stringItemType": "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract"}, "presentation": {"http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited"/>,"lang": {"en-us": {"role": {"terseLabel": "Long-term liabilities"}, "label": "Liabilities Noncurrent [Abstract]"}}, {"auth_ref": [], "prax_LicenseAndCollaborationAgreementMember": {"xbrltype": {"domainItemType": "nsuri": "http://praxismedicines.com/20240930", "localname": "LicenseAndCollaborationAgreementMember"}, "presentation": {"http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"/>,"http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited"/>,"lang": {"en-us": {"role": {"terseLabel": "License And Collaboration Agreement"}, "label": "License And Collaboration Agreement [Member]"}, "documentation": "License And Collaboration Agreement"}}, {"auth_ref": [], "us-gaap_LicenseMember": {"xbrltype": {"domainItemType": "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LicenseMember"}, "presentation": {"http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails"/>,"lang": {"en-us": {"role": {"terseLabel": "License"}, "label": "License [Member]"}, "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."}}, {"auth_ref": ["r726"], "dei_LocalPhoneNumber": {"xbrltype": {"normalizedStringItemType": "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber"}, "presentation": {"http://praxismedicines.com/role/CoverPage"/>,"lang": {"en-us": {"role": {"terseLabel": "Local Phone Number"}, "label": "Local Phone Number"}, "documentation": "Local phone number for entity."}}, {"auth_ref": [], "us-gaap_LossContingenciesLineItems": {"xbrltype": {"stringItemType": "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems"}, "presentation": {"http://praxismedicines.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"/>,"lang": {"en-us": {"role": {"terseLabel": "Loss Contingencies [Line Items]"}, "label": "Loss Contingencies [Line Items]"}, "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."}}, {"auth_ref": ["r213", "r214", "r215", "r216", "r217", "r259", "r297", "r328", "r401", "r434", "r436", "r444", "r453", "r454", "r510", "r511", "r512", "r513", "r514", "r520", "r521", "r536", "r541", "r552", "r558", "r559", "r563", "r564", "r568", "r724", "r768", "r769", "r770", "r771", "r772", "r773"}], "ced_MeasureAxis": {"xbrltype": {"stringItemType": "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "MeasureAxis"}, "presentation": {"http://xbrl.sec.gov/ced/role/PvpDisclosure"/>,"lang": {"en-us": {"role": {"terseLabel": "Measure"}, "label": "Measure [Axis]"}}, {"auth_ref": ["r632"], "ced_MeasureName": {"xbrltype": {"normalizedStringItemType": "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "MeasureName"}, "presentation": {"http://xbrl.sec.gov/ced/role/PvpDisclosure"/>,"lang": {"en-us": {"role": {"terseLabel": "Name"}, "label": "Measure Name"}}, {"auth_ref": ["r632"]}, {"ced_MnpiDiscTimedForCompValFlag": {"xbrltype": {"booleanItemType": "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "MnpiDiscTimedForCompValFlag"}, "presentation": {"http://xbrl.sec.gov/ced/role/AwardTimingDisclosure"/>,"lang": {"en-us": {"role": {"terseLabel": "MNPI Disclosure Timed for Compensation Value [Flag]"}}, {"auth_ref": ["r651"]}, {"us-gaap_MoneyMarketFundsMember": {"xbrltype": {"domainItemType": "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember"}, "presentation": {"http://praxismedicines.com/role/CashEquivalentsAndMarketableSecuritiesInvestmentProfileDetails"/>,"http://praxismedicines.com/role/FairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"/>,"lang": {"en-us": {"role": {"terseLabel": "Money market funds"}, "label": "Money market funds"}, "documentation": "Fund that invests in short-term money market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."}}, {"auth_ref": ["r727"]}, {"ced_MtrlTermsOfTrdArrTextBlock": {"xbrltype": {"textBlockItemType": "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "MtrlTermsOfTrdArrTextBlock"}, "presentation": {"http://xbrl.sec.gov/ced/role/InsiderTradingArrangements"/>,"lang": {"en-us": {"role": {"terseLabel": "Material Terms of Trading Arrangement"}, "label": "Material Terms of Trading Arrangement [Text Block]"}}, {"auth_ref": ["r659"]}, {"ced_NamedExecutiveOfficersFnTextBlock": {"xbrltype": {"textBlockItemType": "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "NamedExecutiveOfficersFnTextBlock"}, "presentation": {"http://xbrl.sec.gov/ced/role/PvpDisclosure"/>,"lang": {"en-us": {"role": {"terseLabel": "Named Executive Officers, Footnote"}, "label": "Named Executive Officers, Footnote [Text Block]"}}, {"auth_ref": ["r632"]}, {"us-gaap_NatureOfOperations": {"xbrltype": {"textBlockItemType": "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NatureOfOperations"}, "presentation": {"http://praxismedicines.com/role/NatureOfTheBusiness"/>,"lang": {"en-us": {"role": {"verboseLabel": "Nature of the Business"}, "label": "Nature of Operations [Text Block]"}, "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."}}, {"auth_ref": ["r77", "r85"}], "us-gaap_NetCashProvidedByUsedInFinancingActivities": {"xbrltype": {"monetaryItemType": "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities"}, "credit": {"debit": {"calculation": {"http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"/>,"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"}, "weight": 1.0, "order": 2.0}}, {"presentation": {"http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"/>,"lang": {"en-us": {"role": {"totalLabel": "Net cash provided by financing activities"}, "label": "Net Cash Provided by (Used in) Financing Activities"}, "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed; or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."}}, {"auth_ref": ["r112"]}, {"us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {"xbrltype": {"stringItemType": "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract"}, "presentation": {"http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"/>,"lang": {"en-us": {"role": {"verboseLabel": "Cash flows from financing activities"}, "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"}}, {"auth_ref": [], "us-gaap_NetCashProvidedByUsedInInvestingActivities": {"xbrltype": {"monetaryItemType": "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities"}, "credit": {"debit": {"calculation": {"http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"/>,"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"}, "weight": 1.0, "order": 1.0}}, {"presentation": {"http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"/>,"lang": {"en-us": {"role": {"totalLabel": "Net cash (used in) provided by investing activities"}, "label": "Net Cash Provided by (Used in) Investing Activities"}, "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."}}, {"auth_ref": ["r112"]}, {"us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {"xbrltype": {"stringItemType": "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract"}, "presentation": {"http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"/>,"lang": {"en-us": {"role": {"verboseLabel": "Cash flows from investing activities"}, "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"}}, {"auth_ref": [], "us-gaap_NetCashProvidedByUsedInOperatingActivities": {"xbrltype": {"monetaryItemType": "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities"}, "calculation": {"http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"/>,"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"}, "weight": 1.0, "order": 3.0}}, {"presentation": {"http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"/>,"lang": {"en-us": {"role": {"totalLabel": "Net cash used in operating activities"}, "label": "Net Cash Provided by (Used in) Operating Activities"}, "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."}}, {"auth_ref": ["r53", "r54", "r55"]}, {"us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {"xbrltype": {"stringItemType": "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract"}, "presentation": {"http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"/>,"lang": {"en-us": {"role": {"verboseLabel": "Cash flows from operating activities"}, "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"}}, {"auth_ref": [], "us-gaap_NetIncomeLoss": {"xbrltype": {"monetaryItemType": "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss"}, "credit": {"calculation": {"http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"/>,"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities"}, "weight": 1.0, "order": 1.0}}, {"http://praxismedicines.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited"/>,"parentTag": "us-gaap_ComprehensiveIncomeNetOfTax"}, {"weight": 1.0, "order": 2.0}}, {"http://praxismedicines.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"/>,"parentTag": null, "weight": null, "order": null, "root": true}}, {"presentation": {"http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"/>,"http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited"/>,"http://praxismedicines.com/role/NatureOfTheBusinessAdditionalInformationDetails"/>,"http://xbrl.sec.gov/ced/role/PvpDisclosure"/>,"lang": {"en-us": {"role": {"totalLabel": "Net loss"}, "label": "Net loss"}, "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."}}, {"auth_ref": ["r49", "r55", "r68", "r89", "r100", "r102", "r106", "r116", "r122", "r124", "r125", "r126", "r127", "r128", "r131", "r132", "r137", "r193", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r304", "r307", "r322", "r348", "r421", "r493", "r501", "r502", "r581", "r722"}], "us-gaap_NewAccountingPronouncementsPolicyTextBlock": {"xbrltype": {"textBlockItemType": "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyTextBlock"}, "presentation": {"http://praxismedicines.com/role/SummaryOfSignificantAccountingPoliciesPolicies"/>,"lang": {"en-us": {"role": {"terseLabel": "Recent Accounting Pronouncements"}, "label": "New Accounting Pronouncements [Policy Text Block]"}, "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."}}, {"auth_ref": [], "ced_NonGaapMeasureDescriptionTextBlock": {"xbrltype": {"textBlockItemType": "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "NonGaapMeasureDescriptionTextBlock"}, "presentation": {"http://xbrl.sec.gov/ced/role/PvpDisclosure"/>,"lang": {"en-us": {"role": {"terseLabel": "Non-GAAP Measure Description"}, "label": "Non-GAAP Measure Description [Text Block]"}}, {"auth_ref": ["r632"], "ced_NonNeosMember": {"xbrltype": {"domainItemType": "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "NonNeosMember"}, "presentation": {"http://xbrl.sec.gov/ced/role/ErrCompDisclosure"/>,"lang": {"en-us": {"role": {"terseLabel": "Non-NEOs"}, "label": "Non-NEOs [Member]"}}, {"auth_ref": ["r596", "r606", "r616", "r640", "r648"}], "ced_NonPeeNeoAvgCompActuallyPaidAmt": {"xbrltype": {"monetaryItemType": "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "NonPeeNeoAvgCompActuallyPaidAmt"}, "presentation": {"http://xbrl.sec.gov/ced/role/PvpDisclosure"/>,"lang": {"en-us": {"role": {"terseLabel": "Non-PEO-NEO Average Compensation Actually Paid Amount"}, "label": "Non-PEO-NEO Average Compensation Actually Paid Amount"}}, {"auth_ref": ["r623"]}, {"ced_NonPeeNeoAvgTotalCompAmt": {"xbrltype": {"monetaryItemType": "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "NonPeeNeoAvgTotalCompAmt"}, "presentation": {"http://xbrl.sec.gov/ced/role/PvpDisclosure"/>,"lang": {"en-us": {"role": {"terseLabel": "Non-PEO-NEO Average Total Compensation Amount"}, "label": "Non-PEO-NEO Average Total Compensation Amount"}}, {"auth_ref": ["r623"], "ced_NonPeeNeoMember": {"xbrltype": {"domainItemType": "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "NonPeeNeoMember"}, "presentation": {"http://xbrl.sec.gov/ced/role/PvpDisclosure"/>,"lang": {"en-us": {"role": {"terseLabel": "Non-PEO NEO"}, "label": "Non-PEO NEO [Member]"}}, {"auth_ref": ["r640"]}, {"ced_NonRule10b51ArrAdoptedFlag": {"xbrltype": {"booleanItemType": "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "NonRule10b51ArrAdoptedFlag"}, "presentation": {"http://xbrl.sec.gov/ced/role/InsiderTradingArrangements"/>,"lang": {"en-us": {"role": {"terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"}, "label": "Non-Rule 10b5-1 Arrangement Adopted"}}

Adopted [Flag]] } } , "auth_ref": { "r659" } } , "ecd NonRule10b51ArrTrmtdFlag": { "xbrlytype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmtdFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "terseLabel": "Non Rule 10b51 Arrangement Terminated", "label": "Non Rule 10b51 Arrangement Terminated [Flag]] } } , "auth_ref": { "r659" } } , "us-gaap NonoperatingIncomeExpense": { "xbrlytype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "parentTag": "us-gaap NetIncomeLoss", "weight": 1.0, "order": 2.0 } } , "presentation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "lang": { "en-us": { "role": { "totalLabel": "Total other income", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "auth_ref": { "r51" } } , "us-gaap NonoperatingIncomeExpenseAbstract": { "xbrlytype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Other income", "label": "Nonoperating Income (Expense) [Abstract]] } } , "auth_ref": { } } , "us-gaap NonvestedRestrictedStockSharesActivityTableTextBlock": { "xbrlytype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "presentation": { "http://praxismedicines.com/role/StockBasedCompensationTables": { "lang": { "en-us": { "role": { "terseLabel": "Summary of Restricted Stock Activity", "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares." } } } , "auth_ref": { "r11" } } } , "prax_NoticeOfChangeTerm": { "xbrlytype": "durationItemType", "nsuri": "http://praxismedicines.com/20240930", "localname": "NoticeOfChangeTerm", "presentation": { "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Change in ownership notice, term", "label": "Notice of Change, Term", "documentation": "Notice of Change, Term" } } } , "auth_ref": { } } } , "prax_NumberOfEfficacyStudies": { "xbrlytype": "integerItemType", "nsuri": "http://praxismedicines.com/20240930", "localname": "NumberOfEfficacyStudies", "presentation": { "http://praxismedicines.com/role/NatureoftheBusinessAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Number of efficacy studies", "label": "Number Of Efficacy Studies", "documentation": "Number Of Efficacy Studies" } } } , "auth_ref": { } } } , "prax_NumberOfPerformanceObligations": { "xbrlytype": "integerItemType", "nsuri": "http://praxismedicines.com/20240930", "localname": "NumberOfPerformanceObligations", "presentation": { "http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Number of performance obligations", "label": "Number Of Performance Obligations", "documentation": "Number Of Performance Obligations" } } } , "auth_ref": { } } } , "prax_NumberOfPlatforms": { "xbrlytype": "integerItemType", "nsuri": "http://praxismedicines.com/20240930", "localname": "NumberOfPlatforms", "presentation": { "http://praxismedicines.com/role/NatureoftheBusinessAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Number of platforms", "label": "Number Of Platforms", "documentation": "Number Of Platforms" } } } , "auth_ref": { } } } , "prax_NumberOfProductCandidates": { "xbrlytype": "integerItemType", "nsuri": "http://praxismedicines.com/20240930", "localname": "NumberOfProductCandidates", "presentation": { "http://praxismedicines.com/role/NatureoftheBusinessAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Number of product candidates", "label": "Number Of Product Candidates", "documentation": "Number Of Product Candidates" } } } , "auth_ref": { } } } , "us-gaap NumberOfReportableSegments": { "xbrlytype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": { "http://praxismedicines.com/role/SummaryofSignificantAccountingPoliciesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } } , "auth_ref": { "r532", "r535", "r692" } } } , "prax_OfficeSpaceInBostonMassachusettsMember": { "xbrlytype": "domainItemType", "nsuri": "http://praxismedicines.com/20240930", "localname": "OfficeSpaceInBostonMassachusettsMember", "presentation": { "http://praxismedicines.com/role/CommitmentsandContingenciesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Office Space in Boston Massachusetts", "label": "Office Space in Boston Massachusetts [Member]", "documentation": "Office Space in Boston Massachusetts" } } } , "auth_ref": { } } } , "us-gaap OperatingExpenses": { "xbrlytype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "parentTag": "us-gaap OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } } , "presentation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } } , "auth_ref": { } } } , "us-gaap OperatingExpensesAbstract": { "xbrlytype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Operating Expenses [Abstract]] } } , "auth_ref": { } } } , "us-gaap OperatingIncomeLoss": { "xbrlytype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "parentTag": "us-gaap NetIncomeLoss", "weight": 1.0, "order": 1.0 } } , "presentation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } } , "auth_ref": { "r72", "r531", "r691", "r693", "r694", "r695", "r696" } } } , "us-gaap OperatingLeaseLiabilityCurrent": { "xbrlytype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } } , "presentation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } } , "auth_ref": { "r359" } } } , "us-gaap OperatingLeaseLiabilityNoncurrent": { "xbrlytype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap Liabilities", "weight": 1.0, "order": 1.0 } } , "presentation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Non-current portion of operating lease liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } } , "auth_ref": { "r358" } } } , "us-gaap OperatingLeaseRightOfUseAsset": { "xbrlytype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap Assets", "weight": 1.0, "order": 4.0 } } , "presentation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Operating lease right of use assets", "label": "Operating Lease, Right of Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } } , "auth_ref": { "r357" } } } , "us-gaap OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrlytype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } } , "presentation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Non-cash operating lease expense", "label": "Operating Lease, Right of Use Asset, Periodic Reduction", "documentation": "Amount of periodic reduction over lease term of carrying amount of right of use asset from operating lease." } } } , "auth_ref": { "r692" } } } , "us-gaap OrganizationConsolidationAndPresentationOffinancialStatementsAbstract": { "xbrlytype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOffinancialStatementsAbstract", "presentation": { "http://praxismedicines.com/role/ConsolidationAndPresentationOffinancialStatementsAbstract": { "lang": { "en-us": { "role": { "terseLabel": "Organization Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization Consolidation and Presentation of Financial Statements [Abstract]] } } , "auth_ref": { } } } , "us-gaap OtherAccruedLiabilitiesCurrent": { "xbrlytype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://praxismedicines.com/role/AccruedExpensesSummaryofAccruedExpensesDetails": { "parentTag": "us-gaap AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } } , "presentation": { "http://praxismedicines.com/role/AccruedExpensesSummaryofAccruedExpensesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Accrued other expenses", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } } , "auth_ref": { "r35" } } } , "us-gaap OtherAssetsNoncurrent": { "xbrlytype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap Assets", "weight": 1.0, "order": 1.0 } } , "presentation": { "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Other non-current assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } } , "auth_ref": { "r94" } } } , "us-gaap OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "xbrlytype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited": { "parentTag": "us-gaap ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } } , "presentation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Change in unrealized gain on marketable securities, net of tax", "label": "Change in unrealized gain on marketable securities, net of tax", "documentation": "Change in unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available for sale." } } } , "auth_ref": { "r98", "r99", "r192" } } } , "us-gaap OtherDebtSecuritiesMember": { "xbrlytype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherDebtSecuritiesMember", "presentation": { "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesInvestmentProfileDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other debt securities", "label": "Other Debt Obligations [Member]", "documentation": "Investments in debt securities classified as other." } } } , "auth_ref": { "r714", "r727" } } } , "us-gaap OtherNonoperatingIncomeExpense": { "xbrlytype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "parentTag": "us-gaap NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } } , "presentation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Other income, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } } , "auth_ref": { "r52" } } } , "ecd OtherPerfMeasureAmt": { "xbrlytype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } } , "auth_ref": { "r632" } } } , "us-gaap OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale": { "xbrlytype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale", "crdr": "debit", "presentation": { "http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other than temporary impairment loss, debt securities, available for sale", "label": "Other than temporary impairment loss, Debt Securities, Available for Sale", "documentation": "Amount of other than temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale), recognized in earnings and other comprehensive loss (OCI)." } } } , "auth_ref": { "r74" } } } , "ecd OutstandingAggtErrCompAmt": { "xbrlytype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } } , "auth_ref": { "r594", "r604", "r614", "r646" } } } , "ecd OutstandingRecoveryCompAmt": { "xbrlytype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } } , "auth_ref": { "r597", "r607", "r617", "r649" } } } , "us-gaap OverAllotmentOptionMember": { "xbrlytype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OverAllotmentOptionMember", "presentation": { "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Over Allotment Option", "label": "Over Allotment Option [Member]", "documentation": "Right given to the underwriter to sell additional shares over the initial allotment." } } } , "auth_ref": { } } } , "ecd PayVsPerformanceDisclosureLineItems": { "xbrlytype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]] } } , "auth_ref": { "r621" } } } , "us-gaap PayablesAndAccrualsAbstract": { "xbrlytype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Payables and Accruals [Abstract]", "label": "Payables and Accruals [Abstract]] } } , "auth_ref": { } } } , "us-gaap PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrlytype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } } , "presentation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments of tax withholdings related to vesting of restricted stock units", "label": "Payment, Tax Withholding, Share Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } } , "auth_ref": { "r11" } } } , "us-gaap PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "xbrlytype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "crdr": "credit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } } , "presentation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "negatedLabel": "Purchases of marketable securities", "label": "Payments to Acquire Debt Securities, Available for Sale", "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } } , "auth_ref": { "r16", "r110", "r159" } } } , "ecd PeerGroupIssuersFnTextBlock": { "xbrlytype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]] } } , "auth_ref": { "r631" } } } , "ecd PeerGroupTotalShareholderRtnAmt": { "xbrlytype":

"monetaryItemType": "nsuri", "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount", "auth ref": "r631", "ecd PeoActuallyPaidCompAmt", "xbrltype": "monetaryItemType", "nsuri", "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount", "auth ref": "r623", "ecd PeoMember", "xbrltype": "domainItemType", "nsuri", "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "PEO", "label": "PEO {Member}", "auth ref": "r640", "ecd PeoName", "xbrltype": "normalizedStringItemType", "nsuri", "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "PEO Name", "label": "PEO Name", "auth ref": "r633", "ecd PeoTotalCompAmt", "xbrltype": "monetaryItemType", "nsuri", "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount", "auth ref": "r622", "prax PercentageIncreaseInAnnualBaseRent", "xbrltype": "percentItemType", "nsuri", "http://praxismedicines.com/20240930", "localname": "PercentageIncreaseInAnnualBaseRent", "presentation": "http://praxismedicines.com/role/CommitmentsandContingenciesAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "Percentage increase in annual base rent", "label": "Percentage Increase In Annual Base Rent", "documentation": "Percentage Increase In Annual Base Rent", "auth ref": "prax PercentageOfOwnershipHeldBySoleOwner", "xbrltype": "percentItemType", "nsuri", "http://praxismedicines.com/20240930", "localname": "PercentageOfOwnershipHeldBySoleOwner", "presentation": "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "Maximum percentage of voting power", "label": "Percentage of Ownership Held by Sole Owner", "documentation": "Percentage of Ownership Held by Sole Owner", "auth ref": "prax PercentageOfOwnershipHeldBySoleOwnerAndAffiliates", "xbrltype": "percentItemType", "nsuri", "http://praxismedicines.com/20240930", "localname": "PercentageOfOwnershipHeldBySoleOwnerAndAffiliates", "presentation": "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "Percentage of ownership held by sole owner and affiliates", "label": "Percentage of Ownership Held by Sole Owner And Affiliates", "documentation": "Percentage of Ownership Held by Sole Owner And Affiliates", "auth ref": "PlanNameAxis", "xbrltype": "stringItemType", "nsuri", "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails", "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "Plan Name {Axis}", "label": "Plan Name {Axis}", "documentation": "Information by plan name for share based payment arrangement", "auth ref": "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "us-gaap PlanNameDomain", "xbrltype": "domainItemType", "nsuri", "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails", "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "Plan Name {Domain}", "label": "Plan Name {Domain}", "documentation": "Plan name for share based payment arrangement", "auth ref": "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "ecd PnsnAdjsPrtSvcCstMember", "xbrltype": "domainItemType", "nsuri", "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrtSvcCstMember", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost {Member}", "auth ref": "r624", "ecd PnsnAdjsSvcCstMember", "xbrltype": "domainItemType", "nsuri", "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost {Member}", "auth ref": "r668", "ecd PnsnBnftsAdjFnTextBlock", "xbrltype": "textBlockItemType", "nsuri", "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "Pension Benefits Adjustments Footnote", "label": "Pension Benefits Adjustments Footnote {Text Block}", "auth ref": "r623", "prax PreFundedWarrantMember", "xbrltype": "domainItemType", "nsuri", "http://praxismedicines.com/20240930", "localname": "PreFundedWarrantMember", "presentation": "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails", "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": "en-us", "role": "terseLabel", "Pre-funded warrant", "label": "Pre-Funded Warrant {Member}", "documentation": "Pre-Funded Warrant", "auth ref": "us-gaap PreferredStockParOrStatedValuePerShare", "xbrltype": "porShareItemType", "nsuri", "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails", "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnauditedParentetical", "lang": "en-us", "role": "terseLabel", "Preferred stock par value (in dollars per share)", "label": "Preferred Stock Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer", "auth ref": "r41", "r232", "us-gaap PreferredStockSharesAuthorized", "xbrltype": "sharesItem", "nsuri", "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails", "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnauditedParentetical", "lang": "en-us", "role": "terseLabel", "Preferred stock authorized (in shares)", "label": "Preferred Stock Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws", "auth ref": "r41", "r463", "us-gaap PreferredStockSharesIssued", "xbrltype": "sharesItem", "nsuri", "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnauditedParentetical", "lang": "en-us", "role": "terseLabel", "Preferred stock issued (in shares)", "label": "Preferred Stock Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt", "auth ref": "r41", "r232", "us-gaap PreferredStockSharesOutstanding", "xbrltype": "sharesItem", "nsuri", "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnauditedParentetical", "lang": "en-us", "role": "terseLabel", "Preferred stock outstanding (in shares)", "label": "Preferred Stock Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased", "auth ref": "r41", "r463", "r481", "r812", "us-gaap PreferredStockValue", "xbrltype": "monetaryItem", "nsuri", "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation", "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "parentTag": "us-gaap StockholdersEquity", "weight": 1.0, "order": 3.0, "presentation": "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "lang": "en-us", "role": "terseLabel", "Preferred stock, \$0.0001 par value, 10,000,000 shares authorized and no shares issued or outstanding as of September 30, 2024 and December 31, 2023", "label": "Preferred Stock Value Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity", "auth ref": "r41", "r415", "r565", "us-gaap PrepaidExpenseAndOtherAssetsCurrent", "xbrltype": "monetaryItem", "nsuri", "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation", "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "parentTag": "us-gaap AssetsCurrent", "weight": 1.0, "order": 1.0, "presentation": "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "lang": "en-us", "role": "terseLabel", "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer", "auth ref": "r678", "prax ProceedsFromCollaborationArrangement", "xbrltype": "monetaryItem", "nsuri", "http://praxismedicines.com/20240930", "localname": "ProceedsFromCollaborationArrangement", "crdr": "credit", "presentation": "http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Proceeds from collaboration arrangement", "label": "Proceeds From Collaboration Arrangement", "documentation": "Proceeds From Collaboration Arrangement", "auth ref": "us-gaap ProceedsFromIssuanceOfCommonStock", "xbrltype": "monetaryItem", "nsuri", "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation", "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "parentTag": "us-gaap NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0, "presentation": "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails", "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": "en-us", "role": "terseLabel", "Proceeds from stock offerings, net of issuance costs", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity", "auth ref": "r2", "r21", "us-gaap ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "xbrltype": "monetaryItem", "nsuri", "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "crdr": "debit", "calculation", "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "parentTag": "us-gaap NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0, "presentation": "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": "en-us", "role": "terseLabel", "Proceeds from exercise of stock options and employee stock purchase plan purchases", "label": "Proceeds Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised", "documentation": "Amount of cash inflow from issuance of shares under share based payment arrangement. Includes, but is not limited to, option exercised", "auth ref": "r2", "r10", "us-gaap ProceedsFromIssuanceOfSaleOfEquity", "xbrltype": "monetaryItem", "nsuri", "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfSaleOfEquity", "crdr": "debit", "presentation": "http://praxismedicines.com/role/NatureOfTheBusinessAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "Proceeds from issuance or sale of equity", "label": "Proceeds from Issuance or Sale of Equity", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity", "auth ref": "r2", "r446", "us-gaap ProceedsFromSaleAndMaturityOfMarketableSecurities", "xbrltype": "monetaryItem", "nsuri", "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "calculation", "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "parentTag": "us-gaap NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0, "presentation": "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "lang": "en-us", "role": "terseLabel", "Maturities of marketable securities", "label": "Proceeds from Sale and Maturity of Marketable Securities", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held to maturity or available for sale) during the period", "auth ref": "srt ProductOrServiceAxis", "xbrltype": "stringItemType", "nsuri", "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": "http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Product and Service {Axis}", "label": "Product and Service {Axis}", "auth ref": "r154", "r403", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r523", "r542", "r567", "r568", "r569", "r570", "r572", "r720", "r721", "r725", "r726", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r808", "r809", "srt ProductsAndServicesDomain", "xbrltype": "domainItemType", "nsuri", "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": "http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Product and Service {Domain}", "label": "Product and Service {Domain}", "auth ref": "r154", "r403", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r523", "r542", "r567", "r568", "r569", "r570", "r572", "r720", "r721", "r725", "r726", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r808", "r809", "us-gaap PropertyPlantAndEquipmentNet", "xbrltype": "monetaryItem", "nsuri", "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation", "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "parentTag": "us-gaap Assets", "weight": 1.0, "order": 2.0, "presentation": "http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "lang": "en-us", "role": "terseLabel", "Property and equipment, net", "label": "Property Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures", "auth ref": "r15", "r359", "r411", "r420", "r565", "ecd PvpTable", "xbrltype": "stringItem", "nsuri", "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure {Table}", "auth ref": "r621", "ecd PvpTableTextBlock", "xbrltype": "textBlockItem", "nsuri", "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "Pay vs Performance Disclosure Table", "label": "Pay vs Performance {Table Text Block}", "auth ref": "r621", "srt RangeAxis", "xbrltype": "stringItem", "nsuri", "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "Statistical Measurement {Axis}", "label": "Statistical Measurement {Domain}", "auth ref": "r214", "r215", "r216", "r217", "r252", "r259", "r287", "r288", "r289", "r297", "r328", "r375", "r384", "r401", "r434", "r436", "r444", "r453", "r454", "r510", "r511", "r512", "r513", "r514", "r520", "r521", "r536", "r541", "r552", "r558", "r559", "r563", "r564", "r568", "r575", "r716", "r724", "r761", "r769", "r770", "r771", "r772", "r773", "srt RangeMember", "xbrltype": "domainItem", "nsuri", "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "Statistical Measurement {Domain}", "label": "Statistical Measurement {Domain}", "auth ref": "r214", "r215", "r216", "r217", "r252", "r259", "r287", "r288", "r289", "r297", "r328", "r375", "r384", "r401", "r434", "r436", "r444", "r453", "r454", "r510", "r511", "r512", "r513", "r514", "r520", "r521", "r536", "r541", "r552", "r558", "r559", "r563", "r564", "r568", "r575", "r716", "r724", "r761", "r769", "r770", "r771", "r772", "r773", "srt RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis", "xbrltype": "stringItem", "nsuri", "http://fasb.org/srt/2024", "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis", "presentation": "http://praxismedicines.com/role/CommitmentsandContingenciesAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "Name of Property {Axis}", "label": "Name of Property {Axis}", "auth ref": "r518", "r519", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "srt RealEstateAndAccumulatedDepreciationNameOfPropertyDomain", "xbrltype": "domainItem", "nsuri", "http://fasb.org/srt/2024", "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain", "presentation": "http://praxismedicines.com/role/CommitmentsandContingenciesAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "Name of Property {Domain}", "label": "Name of Property {Domain}", "auth ref": "r518", "r519", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r820"

"#821" } },"ecd_RecoveryOfErrCompDisclosureLineItems":{"xbrltype":"stringItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"RecoveryOfErrCompDisclosureLineItems"}, {"lang":"en-us","role":{"label":"Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"} } },"auth ref":{"#589","#590","#609","#641" } },"us-gaap_RelatedPartyTransactionsAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"RelatedPartyTransactionsAbstract"}, {"lang":"en-us","role":{"terseLabel":"Related Party Transactions [Abstract]"} } },"auth ref":{"#17","#228","#234","#365","#385","#412","#526","#527" } },"us-gaap_RelatedPartyTransactionsDisclosureTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"RelatedPartyTransactionsDisclosureTextBlock"}, {"presentation":{"http://praxismedicines.com/role/RelatedPartyTransactions"} } },"lang":{"en-us":{"role":{"terseLabel":"Related Party Transactions [Text Block]"},"documentation":"The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } },"auth ref":{"#361","#362","#363","#364","#366","#448","#449","#450","#466","#487","#488","#507","#509" } },"ert_RepurchaseAgreementCounterpartyNameDomain":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/ert/2024","localname":"RepurchaseAgreementCounterpartyNameDomain"}, {"presentation":{"http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails"} } },"lang":{"en-us":{"role":{"terseLabel":"Counterparty Name [Domain]"},"documentation":"Counterparty Name [Domain]"} } },"auth ref":{"#17","#118","#228","#234","#365","#385","#412","#526","#527" } },"us-gaap_ResearchAndDevelopmentExpense":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"ResearchAndDevelopmentExpense"}, {"ordr":{"debit","calculation":{"http://praxismedicines.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited":{"parentTag":"us-gaap_OperatingExpenses","weight":1.0,"order":1.0},"presentation":{"http://praxismedicines.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"} } } },"lang":{"en-us":{"role":{"terseLabel":"Research and development"},"documentation":"Research and Development Expense"}, {"documentation":"Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } },"auth ref":{"#298","#522","#533","#774" } },"us-gaap_ResearchAndDevelopmentExpenseMember":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"ResearchAndDevelopmentExpenseMember"}, {"presentation":{"http://praxismedicines.com/role/StockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"} } },"lang":{"en-us":{"role":{"verboseLabel":"Research and development"},"label":"Research and Development Expense [Member]"}, {"documentation":"Primary financial statement caption in which the reported facts about research and development expense have been included." } } },"auth ref":{"#17","ecd_RestatementDateAxis":{"xbrltype":"stringItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"RestatementDateAxis"}, {"presentation":{"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"} } },"lang":{"en-us":{"role":{"terseLabel":"Restatement Determination Date"},"label":"Restatement Determination Date [Axis]"} } },"auth ref":{"#590","#600","#610","#642" } },"ecd_RestatementDeterminationDate":{"xbrltype":"dateItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"RestatementDeterminationDate"}, {"presentation":{"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"} } },"lang":{"en-us":{"role":{"terseLabel":"Restatement Determination Date"},"label":"Restatement Determination Date"} } },"auth ref":{"#591","#601","#611","#643" } },"ecd_RestatementDoesNotRequireRecoveryTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"RestatementDoesNotRequireRecoveryTextBlock"}, {"presentation":{"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"} } },"lang":{"en-us":{"role":{"terseLabel":"Restatement does not require Recovery"},"label":"Restatement Does Not Require Recovery [Text Block]"} } },"auth ref":{"#598","#608","#618","#650" } },"us-gaap_RestrictedCash":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"RestrictedCash"}, {"ordr":{"debit","calculation":{"http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited":{"parentTag":"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"},"weight":1.0,"order":2.0},"presentation":{"http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"} } } },"lang":{"en-us":{"role":{"terseLabel":"Restricted cash"},"label":"Restricted Cash"}, {"documentation":"Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } },"auth ref":{"#677","#684","#776","#778" } },"us-gaap_RestrictedStockMember":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"RestrictedStockMember"}, {"presentation":{"http://praxismedicines.com/role/CommonStockandPreferredStockSummaryOfCommonStockReservedForFutureIssuanceDetails"}, {"http://praxismedicines.com/role/NetLossPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"}, {"http://praxismedicines.com/role/StockBasedCompensationSummaryOfRestrictedStockActivityDetails"}, {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"} } },"lang":{"en-us":{"role":{"verboseLabel":"Shares reserved for vesting of restricted stock units"},"terseLabel":"Unvested restricted stock units"},"label":"Restricted Stock [Member]"},"documentation":"Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } },"auth ref":{"#21" } },"us-gaap_RetainedEarningsAccumulatedDeficit":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"RetainedEarningsAccumulatedDeficit"}, {"ordr":{"credit","calculation":{"http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited":{"parentTag":"us-gaap_StockholdersEquity"},"weight":1.0,"order":2.0},"presentation":{"http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited"}, {"http://praxismedicines.com/role/CondensedConsolidatedBalanceSheetsUnaudited":{"http://praxismedicines.com/role/NatureOfTheBusinessAdditionalInformationDetails"} } } },"lang":{"en-us":{"role":{"terseLabel":"Accumulated deficit"},"negatedLabel":"Accumulated deficit"},"label":"Retained Earnings (Accumulated Deficit)"}, {"documentation":"Amount of accumulated undistributed earnings (deficit)."} } },"auth ref":{"#44","#60","#418","#441","#443","#447","#464","#565" } },"us-gaap_RetainedEarningsMember":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"RetainedEarningsMember"}, {"presentation":{"http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited"} } },"lang":{"en-us":{"role":{"terseLabel":"Accumulated Deficit"},"label":"Retained Earnings [Member]"},"documentation":"Accumulated undistributed earnings (deficit)."} } },"auth ref":{"#88","#119","#120","#121","#123","#128","#130","#132","#104","#195","#207","#299","#300","#301","#302","#303","#305","#306","#307","#312","#314","#315","#317","#320","#355","#356","#438","#440","#451","#812" } },"us-gaap_RevenueFromContractWithCustomerAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"RevenueFromContractWithCustomerAbstract"}, {"lang":{"en-us":{"role":{"label":"Revenue from Contract with Customer [Abstract]"} } } },"auth ref":{"#17","us-gaap_RevenueRemainingPerformanceObligation":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"RevenueRemainingPerformanceObligation"}, {"ordr":{"credit","presentation":{"http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails"} } },"lang":{"en-us":{"role":{"terseLabel":"Transaction price"},"label":"Revenue Remaining Performance Obligation, Amount"}, {"documentation":"Amount of transaction price allocated to performance obligation that has not been recognized as revenue." } } },"auth ref":{"#84" } },"prax_RevenueRemainingPerformanceObligationVariableConsiderationAmount":{"xbrltype":"monetaryItemType","nsuri":"http://praxismedicines.com/20240930","localname":"RevenueRemainingPerformanceObligationVariableConsiderationAmount"}, {"ordr":{"credit","presentation":{"http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails"} } },"lang":{"en-us":{"role":{"terseLabel":"Milestone payments"},"label":"Revenue Remaining Performance Obligation, Variable Consideration Amount"}, {"documentation":"Revenue Remaining Performance Obligation, Variable Consideration Amount"} } },"auth ref":{"#17","us-gaap_Revenues":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"Revenues"}, {"ordr":{"credit","calculation":{"http://praxismedicines.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited":{"parentTag":"us-gaap_OperatingIncomeLoss"},"weight":1.0,"order":2.0},"presentation":{"http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails"}, {"http://praxismedicines.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"} } } },"lang":{"en-us":{"role":{"terseLabel":"Collaboration revenue"},"label":"Revenues"}, {"documentation":"Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."} } } },"auth ref":{"#70","#71","#107","#116","#146","#149","#150","#151","#153","#154","#155","#156","#193","#219","#220","#221","#222","#223","#224","#225","#226","#227","#348","#408","#533","#722" } },"ecd_Rule10b51ArrAdoptedFlag":{"xbrltype":"booleanItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"Rule10b51ArrAdoptedFlag"}, {"presentation":{"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"} } },"lang":{"en-us":{"role":{"terseLabel":"Rule 10b5-1 Arrangement Adopted"},"label":"Rule 10b5-1 Arrangement Adopted [Flag]"} } } },"auth ref":{"#659" } },"ecd_Rule10b51ArrTrmndFlag":{"xbrltype":"booleanItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"Rule10b51ArrTrmndFlag"}, {"presentation":{"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"} } },"lang":{"en-us":{"role":{"terseLabel":"Rule 10b5-1 Arrangement Terminated"},"label":"Rule 10b5-1 Arrangement Terminated [Flag]"} } } },"auth ref":{"#659" } },"us-gaap_SaleOfStockNameOfTransactionDomain":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"SaleOfStockNameOfTransactionDomain"}, {"presentation":{"http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails"}, {"http://praxismedicines.com/role/CommonStockandPreferredStockSummaryOfCommonStockReservedForFutureIssuanceDetails"}, {"http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"}, {"http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited"}, {"http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical"} } },"lang":{"en-us":{"role":{"terseLabel":"Sale of Stock [Domain]"},"label":"Sale of Stock [Domain]"},"documentation":"Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } },"auth ref":{"#17","us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction":{"xbrltype":"sharesItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"SaleOfStockNumberOfSharesIssuedInTransaction"}, {"presentation":{"http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails"}, {"http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails"} } },"lang":{"en-us":{"role":{"terseLabel":"Number of shares issued in transaction (in shares)"},"label":"Sale of Stock, Number of Shares Issued in Transaction"}, {"documentation":"The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } },"auth ref":{"#17","us-gaap_SaleOfStockPricePerShare":{"xbrltype":"perShareItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"SaleOfStockPricePerShare"}, {"presentation":{"http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails"}, {"http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails"} } },"lang":{"en-us":{"role":{"terseLabel":"Sale of stock (in dollars per share)"},"label":"Sale of Stock, Price Per Share"}, {"documentation":"Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } },"auth ref":{"#17","prax_SaleOfStockSharesAggregateAuthorizedAmount":{"xbrltype":"sharesItemType","nsuri":"http://praxismedicines.com/20240930","localname":"SaleOfStockSharesAggregateAuthorizedAmount"}, {"presentation":{"http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails"} } },"lang":{"en-us":{"role":{"terseLabel":"Sale of stock, shares, aggregate authorized amount (in shares)"},"label":"Sale Of Stock, Shares, Aggregate Authorized Amount"}, {"documentation":"Sale Of Stock, Shares, Aggregate Authorized Amount"} } },"auth ref":{"#17","prax_SaleOfStockValueTransferred":{"xbrltype":"monetaryItemType","nsuri":"http://praxismedicines.com/20240930","localname":"SaleOfStockValueTransferred"}, {"ordr":{"debit","presentation":{"http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails"} } },"lang":{"en-us":{"role":{"terseLabel":"Sale of stock, value transferred"},"label":"Sale Of Stock, Value Transferred"}, {"documentation":"Sale Of Stock, Value Transferred"} } },"auth ref":{"#17","prax_SaleOfStockValueTransferredInExcessOfConsiderationReceived":{"xbrltype":"monetaryItemType","nsuri":"http://praxismedicines.com/20240930","localname":"SaleOfStockValueTransferredInExcessOfConsiderationReceived"}, {"ordr":{"credit","presentation":{"http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails"} } },"lang":{"en-us":{"role":{"terseLabel":"Sale of stock, value transferred in excess of consideration received"},"label":"Sale Of Stock, Value Transferred In Excess Of Consideration Received"}, {"documentation":"Sale Of Stock, Value Transferred In Excess Of Consideration Received"} } },"auth ref":{"#17","prax_SaleOfStockVolumeWeightedAveragePriceDuration":{"xbrltype":"durationItemType","nsuri":"http://praxismedicines.com/20240930","localname":"SaleOfStockVolumeWeightedAveragePriceDuration"}, {"presentation":{"http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails"} } },"lang":{"en-us":{"role":{"terseLabel":"Sale of stock, volume weighted average price, duration"},"label":"Sale Of Stock, Volume Weighted Average Price, Duration"}, {"documentation":"Sale Of Stock, Volume Weighted Average Price, Duration"} } },"auth ref":{"#17","prax_SaleOfStockVolumeWeightedAveragePricePremium":{"xbrltype":"percentItemType","nsuri":"http://praxismedicines.com/20240930","localname":"SaleOfStockVolumeWeightedAveragePricePremium"}, {"presentation":{"http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails"} } },"lang":{"en-us":{"role":{"terseLabel":"Sale of stock, volume weighted average price, premium"},"label":"Sale Of Stock, Volume Weighted Average Price, Premium"}, {"documentation":"Sale Of Stock, Volume Weighted Average Price, Premium"} } },"auth ref":{"#17","us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"ScheduleOfAccruedLiabilitiesTableTextBlock"}, {"presentation":{"http://praxismedicines.com/role/AccruedExpensesTables"} } },"lang":{"en-us":{"role":{"terseLabel":"Summary of Accrued Expenses"},"label":"Schedule of Accrued Liabilities [Table Text Block]"}, {"documentation":"Tabular disclosure of the components of accrued liabilities." } } },"auth ref":{"#17","us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"}, {"presentation":{"http://praxismedicines.com/role/NetLossPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"} } },"lang":{"en-us":{"role":{"terseLabel":"Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"},"label":"Antidilutive Security, Excluded EPS Calculation [Table]"},"documentation":"Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } },"auth ref":{"#21" } },"us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"}, {"presentation":{"http://praxismedicines.com/role/NetLossPerShareTables"} } },"lang":{"en-us":{"role":{"terseLabel":"Summary of Antidilutive Securities Excluded From Computation of Earnings Per Share [Table Text Block]"},"documentation":"Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } },"auth ref":{"#21" } },"us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"ScheduleOfAvailableForSaleSecuritiesLineItems"}, {"presentation":{"http://praxismedicines.com/role/CashEquivalentsandMarketableSecuritiesInvestmentProfileDetails"} } },"lang":{"en-us":{"role":{"terseLabel":"Debt Securities, Available for sale [Line Items]"},"label":"Debt Securities, Available for Sale [Line Items]"}, {"documentation":"Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } },"auth ref":{"#162","#163","#164","#165","#166","#167","#168","#169","#170","#171","#172","#173" } },"prax_ScheduleOfCommonStockReservedForFutureIssuanceLineItems":{"xbrltype":"stringItemType","nsuri":"http://praxismedicines.com/20240930","localname":"ScheduleOfCommonStockReservedForFutureIssuanceLineItems"}, {"presentation":{"http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails"}, {"http://praxismedicines.com/role/CommonStockandPreferredStockSummaryOfCommonStockReservedForFutureIssuanceDetails"} } },"lang":{"en-us":{"role":{"terseLabel":"Schedule Of Common Stock Reserved For Future Issuance [Line Items]"},"label":"Schedule Of Common Stock Reserved For Future Issuance [Line Items]"},"documentation":"Schedule Of Common Stock Reserved For Future Issuance [Line Items]"} } },"auth ref":{"#17","prax_ScheduleOfCommonStockReservedForFutureIssuanceTable":{"xbrltype":"stringItemType","nsuri":"http://praxismedicines.com/20240930","localname":"ScheduleOfCommonStockReservedForFutureIssuanceTable"}, {"presentation":{"

["http://praxismedicines.com/role/CommonStockAndPreferredStockAdditionalInformationDetails"](http://praxismedicines.com/role/CommonStockAndPreferredStockAdditionalInformationDetails),
"http://praxismedicines.com/role/CommonStockAndPreferredStockSummaryOfCommonStockReservedForFutureIssuanceDetails" }, {"lang": { "en-us": { "role": { "terseLabel": "Schedule Of Common Stock Reserved For Future Issuance [Table]", "label": "Schedule Of Common Stock Reserved For Future Issuance [Table]", "documentation": "Schedule Of Common Stock Reserved For Future Issuance Table" } } }, {"auth_ref": [] }, {"prax_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": { "xbrltype": "stringItem", "textBlockItemType": "nsuri": "http://praxismedicines.com/20240930", "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "presentation": { "http://praxismedicines.com/role/CommonStockAndPreferredStockTables" }, {"lang": { "en-us": { "role": { "terseLabel": "Summary of Shares Reserved for Future Issuance", "label": "Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]", "documentation": "Schedule Of Common Stock Reserved For Future Issuance" } } }, {"auth_ref": [] }, {"us_gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": { "http://praxismedicines.com/role/StockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" }, {"lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "label": "Share Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements" } } }, {"auth_ref": { "r30" } } }, {"us_gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": { "http://praxismedicines.com/role/StockBasedCompensationTables" }, {"lang": { "en-us": { "role": { "terseLabel": "Summary of Stock-Based Compensation Expense", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement" } } }, {"auth_ref": { "r30" } } }, {"us_gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": { "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails" }, {"http://praxismedicines.com/role/StockBasedCompensationScheduleOffFairValueOfStockOptionAwardsOntheGrantDateUsingtheBlackScholesOptionValuationModelDetails" }, {"http://praxismedicines.com/role/StockBasedCompensationSummaryOfRestrictedStockActivityDetails" }, {"lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement" } } }, {"auth_ref": { "r261", "r263", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290" } } }, {"us_gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": { "http://praxismedicines.com/role/StockBasedCompensationTables" }, {"lang": { "en-us": { "role": { "terseLabel": "Summary of Stock Option Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted average grant date fair value" } } }, {"auth_ref": { "r6", "r9", "r62" } } }, {"us_gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": { "http://praxismedicines.com/role/StockBasedCompensationTables" }, {"lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value of Stock Option Awards on the Grant Date Using the Black-Scholes Option Valuation Model", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions" } } }, {"auth_ref": { "r64" } } }, {"dei_Security12bTitle": { "xbrltype": "securityTitleItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": { "http://praxismedicines.com/role/CoverPage" }, {"lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security" } } }, {"auth_ref": { "r584" } } }, {"dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": { "http://praxismedicines.com/role/CoverPage" }, {"lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered" } } }, {"auth_ref": { "r586" } } }, {"us_gaap_ShareBasedCompensation": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crd": "debit", "calculation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us_gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, {"presentation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" }, {"lang": { "en-us": { "role": { "verboseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement" } } }, {"auth_ref": { "r3" } } }, {"us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": { "http://praxismedicines.com/role/StockBasedCompensationSummaryOfRestrictedStockActivityDetails" }, {"lang": { "en-us": { "role": { "negatedTerseLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period" } } }, {"auth_ref": { "r281" } } }, {"us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": { "http://praxismedicines.com/role/StockBasedCompensationSummaryOfRestrictedStockActivityDetails" }, {"lang": { "en-us": { "role": { "terseLabel": "Forfeitures (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event" } } }, {"auth_ref": { "r281" } } }, {"prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod": { "xbrltype": "sharesItem", "nsuri": "http://praxismedicines.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod", "presentation": { "http://praxismedicines.com/role/StockBasedCompensationSummaryOfRestrictedStockActivityDetails" }, {"lang": { "en-us": { "role": { "terseLabel": "Issued (in shares)", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Issued in Period", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Issued in Period" } } }, {"auth_ref": [] }, {"prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItem", "nsuri": "http://praxismedicines.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue", "presentation": { "http://praxismedicines.com/role/StockBasedCompensationSummaryOfRestrictedStockActivityDetails" }, {"lang": { "en-us": { "role": { "terseLabel": "Unvested (in shares)", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period" } } }, {"auth_ref": [] }, {"us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": { "http://praxismedicines.com/role/StockBasedCompensationSummaryOfRestrictedStockActivityDetails" }, {"lang": { "en-us": { "role": { "periodStartLabel": "Unvested beginning balance (in dollars per share)", "periodEndLabel": "Unvested ending balance (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options" } } }, {"auth_ref": { "r276", "r277" } } }, {"us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": { "http://praxismedicines.com/role/StockBasedCompensationSummaryOfRestrictedStockActivityDetails" }, {"lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant Date Fair Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term" } } }, {"auth_ref": { "r288" } } }, {"us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": { "http://praxismedicines.com/role/StockBasedCompensationScheduleOffFairValueOfStockOptionAwardsOntheGrantDateUsingtheBlackScholesOptionValuationModelDetails" }, {"lang": { "en-us": { "role": { "terseLabel": "Expected dividend yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period" } } }, {"auth_ref": { "r287" } } }, {"us_gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": { "http://praxismedicines.com/role/StockBasedCompensationScheduleOffFairValueOfStockOptionAwardsOntheGrantDateUsingtheBlackScholesOptionValuationModelDetails" }, {"lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk-Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares" } } }, {"auth_ref": { "r289" } } },

"prax_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInSharesAuthorized": { "xbrltype": "sharesItem", "nsuri": "http://praxismedicines.com/2024/09/30", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInSharesAuthorized", "presentation": ["http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails"] }, "lang": ["en-us"], "role": ["negatedLabel"], "Decrease in number of shares authorized to be issued (in shares)": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Increase (Decrease) In Shares Authorized", "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Increase (Decrease) In Shares Authorized" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails"] }, "http://praxismedicines.com/role/StockBasedCompensationScheduleOffFairValueOfStockOptionAwardsOnTheGrantDateUsingTheBlackScholesOptionValuationModelDetails": { "http://praxismedicines.com/role/StockBasedCompensationSummaryOfRestrictedStockActivityDetails" } }, "lang": ["en-us"], "role": ["terseLabel"], "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]": { "label": "Share Based Compensation Arrangement by Share-based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r261", "r263", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": ["http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails"] }, "lang": ["en-us"], "role": ["terseLabel"], "Number of shares authorized (in shares)": { "label": "Share Based Compensation Arrangement by Share Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": ["r554"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": ["http://praxismedicines.com/role/StockBasedCompensationSummaryOfStockOptionActivityDetails"] }, "lang": ["en-us"], "role": ["terseLabel"], "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]": { "label": "Share Based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": ["http://praxismedicines.com/role/StockBasedCompensationSummaryOfStockOptionActivityDetails"] }, "lang": ["en-us"], "role": ["terseLabel"], "Number of shares exercisable (in shares)": { "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": ["r270"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": ["http://praxismedicines.com/role/StockBasedCompensationSummaryOfStockOptionActivityDetails"] }, "lang": ["en-us"], "role": ["terseLabel"], "Exercisable (in dollars per share)": { "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": ["r270"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": ["http://praxismedicines.com/role/StockBasedCompensationSummaryOfStockOptionActivityDetails"] }, "lang": ["en-us"], "role": ["terseLabel"], "Aggregate intrinsic value exercised": { "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Exercises in Period, Intrinsic Value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": ["r283"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": ["http://praxismedicines.com/role/StockBasedCompensationSummaryOfStockOptionActivityDetails"] }, "lang": ["en-us"], "role": ["negatedLabel"], "Cancelled or forfeited (in shares)": { "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": ["r274"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://praxismedicines.com/role/StockBasedCompensationSummaryOfStockOptionActivityDetails"] }, "lang": ["en-us"], "role": ["verboseLabel"], "Granted (in shares)": { "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r272"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://praxismedicines.com/role/StockBasedCompensationScheduleOffFairValueOfStockOptionAwardsOnTheGrantDateUsingTheBlackScholesOptionValuationModelDetails"] }, "lang": ["en-us"], "role": ["terseLabel"], "Weighted average grant date fair value per share (in dollars per share)": { "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": ["r282"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://praxismedicines.com/role/StockBasedCompensationSummaryOfStockOptionActivityDetails"] }, "lang": ["en-us"], "role": ["terseLabel"], "Aggregate intrinsic value outstanding": { "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r29"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://praxismedicines.com/role/StockBasedCompensationSummaryOfStockOptionActivityDetails"] }, "lang": ["en-us"], "role": ["periodStartLabel"], "Beginning balance (in shares)": { "periodEndLabel": "Ending balance (in shares)", "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r268", "r269"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://praxismedicines.com/role/StockBasedCompensationSummaryOfStockOptionActivityDetails"] }, "lang": ["en-us"], "role": ["periodStartLabel"], "Beginning balance (in dollars per share)": { "periodEndLabel": "Ending balance (in dollars per share)", "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r266", "r269"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": ["http://praxismedicines.com/role/StockBasedCompensationSummaryOfStockOptionActivityDetails"] }, "lang": ["en-us"], "role": ["terseLabel"], "Weighted Average Exercise Price Rollforward": { "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": ["http://praxismedicines.com/role/StockBasedCompensationSummaryOfStockOptionActivityDetails"] }, "lang": ["en-us"], "role": ["terseLabel"], "Aggregate intrinsic value vested and expected to vest": { "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r284"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": ["http://praxismedicines.com/role/StockBasedCompensationSummaryOfStockOptionActivityDetails"] }, "lang": ["en-us"], "role": ["terseLabel"], "Vested and expected to vest (in shares)": { "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r284"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://praxismedicines.com/role/CommonStockandPreferredStockSummaryOfCommonStockReservedForFutureIssuanceDetails"] }, "http://praxismedicines.com/role/StockBasedCompensationAdditionalInformationDetails": { "http://praxismedicines.com/role/StockBasedCompensationScheduleOffFairValueOfStockOptionAwardsOnTheGrantDateUsingTheBlackScholesOptionValuationModelDetails" } }, "http://praxismedicines.com/role/StockBasedCompensationSummaryOfRestrictedStockActivityDetails": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" } }, "lang": ["en-us"], "role": ["terseLabel"], "Award Type [Domain]": { "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": ["http://praxismedicines.com/role/StockBasedCompensationSummaryOfStockOptionActivityDetails"] }, "lang": ["en-us"], "role": ["terseLabel"], "Exercised (in dollars per share)": { "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": ["r273"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": ["http://praxismedicines.com/role/StockBasedCompensationSummaryOfStockOptionActivityDetails"] }, "lang": ["en-us"], "role": ["terseLabel"], "Granted (in dollars per share)": { "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r272"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": ["http://praxismedicines.com/role/StockBasedCompensationScheduleOffFairValueOfStockOptionAwardsOnTheGrantDateUsingTheBlackScholesOptionValuationModelDetails"] }, "lang": ["en-us"], "role": ["terseLabel"], "Expected term (in years)": { "label": "Share Based Compensation Arrangement by Share Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDnInHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r286"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr":

```

"presentation": { "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" | "lang": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic value exercisable." | "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Exercisable, Intrinsic Value." | "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } | "auth ref": { "r29" } } | "us-gaap:ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": { "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" | "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining contractual term exercisable." | "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term." | "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } | "auth ref": { "r29" } } | "us-gaap:ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward", "presentation": { "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" | "lang": { "en-us": { "role": { "terseLabel": "Number of Shares." | "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Nonvested, Number of Shares (Roll Forward)." | "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } | "auth ref": { } } | "us-gaap:ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": { "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" | "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining contractual term outstanding." | "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term." | "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } | "auth ref": { "r63" } } | "us-gaap:ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": { "http://praxismedicines.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" | "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining contractual term vested and expected to vest." | "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term." | "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } | "auth ref": { "r284" } } | "us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "presentation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" | "lang": { "en-us": { "role": { "negatedTerseLabel": "Shares withheld for taxes for vesting of restricted stock units (in shares)." | "label": "Share Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation." | "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share based payment arrangement." } } | "auth ref": { } } | "us-gaap:SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": { "http://praxismedicines.com/role/SummaryofSignificantAccountingPolicies" | "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies." | "label": "Significant Accounting Policies (Text Block)." | "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } | "auth ref": { "r56" | "r14" } } | "us-gaap:StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" | "lang": { "en-us": { "role": { "terseLabel": "Equity Components (Axis)." | "label": "Equity Components (Axis)." | "documentation": "Information by component of equity." } } | "auth ref": { "r7" | "r42" | "r45" | "r46" | "r88" | "r104" | "r105" | "r106" | "r119" | "r120" | "r121" | "r123" | "r128" | "r130" | "r132" | "r147" | "r194" | "r195" | "r207" | "r247" | "r290" | "r300" | "r301" | "r302" | "r303" | "r305" | "r306" | "r307" | "r312" | "r313" | "r314" | "r315" | "r316" | "r317" | "r320" | "r349" | "r350" | "r351" | "r352" | "r353" | "r354" | "r355" | "r356" | "r360" | "r422" | "r438" | "r439" | "r440" | "r451" | "r503" } } | "us-gaap:StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" | "lang": { "en-us": { "role": { "terseLabel": "Statement (Line Items)." | "label": "Statement (Line Items)." | "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } | "auth ref": { "r119" | "r120" | "r121" | "r147" | "r356" | "r403" | "r445" | "r452" | "r455" | "r456" | "r457" | "r458" | "r459" | "r460" | "r463" | "r466" | "r467" | "r468" | "r469" | "r470" | "r471" | "r472" | "r473" | "r474" | "r476" | "r477" | "r478" | "r479" | "r480" | "r482" | "r484" | "r485" | "r489" | "r490" | "r491" | "r492" | "r493" | "r494" | "r495" | "r496" | "r497" | "r498" | "r499" | "r500" | "r503" | "r576" } } | "us-gaap:StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows (Abstract)." | "label": "Statement of Cash Flows (Abstract)." } } | "auth ref": { } } | "us-gaap:StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position (Abstract)." | "label": "Statement of Financial Position (Abstract)." } } | "auth ref": { } } | "us-gaap:StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income (Abstract)." } } | "auth ref": { } } | "us-gaap:StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity (Abstract)." | "label": "Statement of Stockholders' Equity (Abstract)." } } | "auth ref": { } } | "us-gaap:StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" | "lang": { "en-us": { "role": { "terseLabel": "Statement (Table)." | "label": "Statement (Table)." | "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } | "auth ref": { "r119" | "r120" | "r121" | "r147" | "r157" | "r356" | "r403" | "r445" | "r452" | "r455" | "r456" | "r457" | "r458" | "r459" | "r460" | "r463" | "r466" | "r467" | "r468" | "r469" | "r470" | "r471" | "r472" | "r473" | "r474" | "r476" | "r477" | "r478" | "r479" | "r480" | "r482" | "r484" | "r485" | "r489" | "r490" | "r491" | "r492" | "r493" | "r494" | "r495" | "r496" | "r497" | "r498" | "r499" | "r500" | "r503" | "r576" } } | "us-gaap:StockPriceOrTSREstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/eed/role/AwardTimingDisclosure", "localname": "StockPriceOrTSREstimationMethodTextBlock", "presentation": { "http://xbrl.sec.gov/eed/role/ErrCompDisclosure" | "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method." | "label": "Stock Price or TSR Estimation Method (Text Block)." | "auth ref": { "r593" | "r603" | "r613" | "r645" } } | "us-gaap:StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": { "http://xbrl.sec.gov/eed/role/AwardTimingDisclosure" | "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)." | "label": "Stock Appreciation Rights (SARs) (Member)." | "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } | "auth ref": { } } | "us-gaap:StockCompensationPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockCompensationPlanMember", "presentation": { "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryofCommonStockReservedForFutureIssuanceDetails": { "http://xbrl.sec.gov/eed/role/AwardTimingDisclosure" | "lang": { "en-us": { "role": { "terseLabel": "Share-based payment arrangement." | "label": "Share Based Payment Arrangement (Member)." | "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares." } } | "auth ref": { "r690" } } | "prax:StockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://praxismedicines.com/20240930", "localname": "StockIssuanceCosts", "credit": "debit", "presentation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnauditedParent": { "lang": { "en-us": { "role": { "terseLabel": "Stock issuance costs." | "label": "Stock Issuance Costs." | "documentation": "Stock Issuance Costs." } } | "auth ref": { } } | "prax:StockIssuanceCostsInc
```

```

StockholdersEquityNoteDisclosureTextBlock : { "xbrlytype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": { "http://praxismedicines.com/role/CommonStockandPreferredStock": { "lang": "en-us", "role": "terseLabel", "Common Stock and Preferred Stock", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } }, "auth_ref": { "r59": "r115", "r231": "r233", "r235": "r236", "r237": "r238", "r239": "r240", "r241": "r242", "r243": "r245", "r247": "r319", "r506": "r508", "r516": "1" }, "us-gaap StockholdersEquityNoteStockSplitConversionRatio": { "xbrlytype": "pureItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteStockSplitConversionRatio", "presentation": { "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails": "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfOperationsUnauditedParenthetical", "http://praxismedicines.com/role/SummaryOfSignificantAccountingPoliciesDetails": { "lang": "en-us", "role": "terseLabel", "Stockholders' equity note, stock split, conversion ratio", "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one." } }, "auth_ref": { "r61": "1" }, "us-gaap SubsequentEventsAbstract": { "xbrlytype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": "en-us", "role": "terseLabel", "Subsequent Events [Abstract]", "label": "Subsequent Events [Abstract]" } }, "auth_ref": { "1" }, "us-gaap SubsequentEventsTextBlock": { "xbrlytype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": { "http://praxismedicines.com/role/SubsequentEvents": { "lang": "en-us", "role": "terseLabel", "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } }, "auth_ref": { "r367": "r368", "1" }, "us-gaap SubsidiarySaleOfStockAxis": { "xbrlytype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": { "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails": "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryOfCommonStockReservedForFutureIssuanceDetails", "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited": "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical", "lang": "en-us", "role": "terseLabel", "Sale of Stock [Axis]", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } }, "auth_ref": { "1" }, "us-gaap SupplementalCashFlowElementsAbstract": { "xbrlytype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowElementsAbstract", "presentation": { "http://praxismedicines.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "lang": "en-us", "role": "terseLabel", "Supplemental disclosures of non-cash activities", "label": "Supplemental Cash Flow Elements [Abstract]" } }, "auth_ref": { "1" }, "ecsd TabularListTableTextBlock": { "xbrlytype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": "en-us", "role": "terseLabel", "Tabular List Table", "label": "Tabular List [Table Text Block]" } }, "auth_ref": { "r630": "1" }, "prax TenaciaMember": { "xbrlytype": "domainItem", "nsuri": "http://praxismedicines.com/20240930", "localname": "TenaciaMember", "presentation": { "http://praxismedicines.com/role/CollaborationLicenseAgreementsNarrativeDetails": { "lang": "en-us", "role": "terseLabel", "Tenacia", "label": "Tenacia [Member]", "documentation": "Tenacia" } }, "auth_ref": { "1" }, "ecsd TotalShareholderRtnAmt": { "xbrlytype": "monetaryItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": "en-us", "role": "terseLabel", "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount", "documentation": "Total Shareholder Return Amount" } }, "auth_ref": { "r631": "1" }, "ecsd TotalShareholderRtnVsPeerGroupTextBlock": { "xbrlytype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": "en-us", "role": "terseLabel", "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } }, "auth_ref": { "r638": "1" }, "ecsd TradingArrAxis": { "xbrlytype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": "en-us", "role": "terseLabel", "Trading Arrangement", "label": "Trading Arrangement [Axis]" } }, "auth_ref": { "r658": "1" }, "ecsd TradingArrByIndTable": { "xbrlytype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": "en-us", "role": "terseLabel", "Trading Arrangements by Individual", "label": "Trading Arrangements by Individual [Table]" } }, "auth_ref": { "r660": "1" }, "doi TradingSymbol": { "xbrlytype": "stringItem", "nsuri": "http://xbrl.sec.gov/doi/2024", "localname": "TradingSymbol", "presentation": { "http://praxismedicines.com/role/CoverPage": { "lang": "en-us", "role": "terseLabel", "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } }, "auth_ref": { "1" }, "us-gaap TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrlytype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": { "http://praxismedicines.com/role/CashEquivalentsAndMarketableSecuritiesInvestmentProfileDetails": { "lang": "en-us", "role": "terseLabel", "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } }, "auth_ref": { "r162": "r163", "r164": "r165", "r166": "r167", "r168": "r169", "r170": "r171", "r172": "r173", "r174": "r175", "r176": "r177", "r178": "r179", "r180": "r181", "r182": "r183", "r184": "r185", "r186": "r187", "r188": "r189", "r190": "r191", "r230": "r244", "r318": "r345", "r360": "r370", "r371": "r372", "r373": "r374", "r375": "r376", "r377": "r378", "r379": "r380", "r381": "r382", "r383": "r386", "r387": "r388", "r389", "r390", "r391": "r392", "r393": "r394", "r395": "r396", "r397": "r398", "r399", "r400", "r423": "r555", "r556": "r558", "r559", "r560", "r561", "r562": "r563", "r564", "r566": "r670", "r671", "r672", "r673", "r674": "r675", "r676": "r709", "r710", "r711": "r712", "r757": "r760", "r761", "r762": "r763", "r764": "1" }, "ecsd TrdArrAdoptionDate": { "xbrlytype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": "en-us", "role": "terseLabel", "Adoption Date", "label": "Trading Arrangement Adoption Date" } }, "auth_ref": { "r661": "1" }, "ecsd TrdArrDuration": { "xbrlytype": "durationItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": "en-us", "role": "terseLabel", "Arrangement Duration", "label": "Trading Arrangement Duration" } }, "auth_ref": { "r662": "1" }, "ecsd TrdArrExpirationDate": { "xbrlytype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": "en-us", "role": "terseLabel", "Expiration Date", "label": "Trading Arrangement Expiration Date" } }, "auth_ref": { "r662": "1" }, "ecsd TrdArrIndName": { "xbrlytype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": "en-us", "role": "terseLabel", "Name", "label": "Trading Arrangement Individual Name" } }, "auth_ref": { "r660": "1" }, "ecsd TrdArrIndTitle": { "xbrlytype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": "en-us", "role": "terseLabel", "Title", "label": "Trading Arrangement Individual Title" } }, "auth_ref": { "r660": "1" }, "ecsd TrdArrSecuritiesAggAvailAmt": { "xbrlytype": "sharesItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": "en-us", "role": "terseLabel", "Aggregate Available", "label": "Trading Arrangement Securities Aggregate Available Amount" } }, "auth_ref": { "r663": "1" }, "ecsd TrdArrTerminationDate": { "xbrlytype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": "en-us", "role": "terseLabel", "Termination Date", "label": "Trading Arrangement Termination Date" } }, "auth_ref": { "r661": "1" }, "us-gaap TreasuryStockCommonShares": { "xbrlytype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonShares", "presentation": { "http://praxismedicines.com/role/CommonStockandPreferredStockAdditionalInformationDetails": { "lang": "en-us", "role": "terseLabel", "Treasury stock (in shares)", "label": "Treasury Stock, Common Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } }, "auth_ref": { "r27": "1" }, "prax TwentyTwentyEmployeeStockIncentivePlanMember": { "xbrlytype": "domainItem", "nsuri": "http://praxismedicines.com/20240930", "localname": "TwentyTwentyEmployeeStockIncentivePlanMember", "presentation": { "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryOfCommonStockReservedForFutureIssuanceDetails": { "lang": "en-us", "role": "terseLabel", "Shares reserved for future awards under the 2020 Stock Option and Incentive Plan", "label": "Twenty Twenty Employee Stock Incentive Plan [Member]", "documentation": "Twenty Twenty Employee Stock Incentive Plan" } }, "auth_ref": { "1" }, "prax TwentyTwentyEmployeeStockPurchasePlanMember": { "xbrlytype": "domainItem", "nsuri": "http://praxismedicines.com/20240930", "localname": "TwentyTwentyEmployeeStockPurchasePlanMember", "presentation": { "http://praxismedicines.com/role/CommonStockandPreferredStockSummaryOfCommonStockReservedForFutureIssuanceDetails": { "lang": "en-us", "role": "terseLabel",
```

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[https://asc.fash.org/1943274/2147480081/944-40-50-7A">https://asc.fash.org/1943274/2147480081/944-40-50-7A](#), "r803"; { "role": "[http://www.xbrl.org/2009/role/commonPracticeRef](#)", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "74", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "[https://asc.fash.org/1943274/2147480081/944-40-50-7A](#)", "r804"; { "role": "[http://www.xbrl.org/2009/role/commonPracticeRef](#)", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "75", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "[https://asc.fash.org/1943274/2147480081/944-40-50-7B](#)", "r805"; { "role": "[http://www.xbrl.org/2009/role/commonPracticeRef](#)", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "76", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "[https://asc.fash.org/1943274/2147480081/944-40-50-7C](#)", "r806"; { "role": "[http://www.xbrl.org/2009/role/commonPracticeRef](#)", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "77", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "[https://asc.fash.org/1943274/2147480081/944-40-50-7D](#)", "r807"; { "role": "[http://www.xbrl.org/2009/role/commonPracticeRef](#)", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "78", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "[https://asc.fash.org/1943274/2147480081/944-40-50-7E](#)", "r808"; { "role": "[http://www.xbrl.org/2009/role/commonPracticeRef](#)", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "79", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "[https://asc.fash.org/1943274/2147480081/944-40-50-7F](#)", "r809"; { "role": "[http://www.xbrl.org/2009/role/commonPracticeRef](#)", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "80", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "[https://asc.fash.org/1943274/2147480081/944-40-50-7G](#)", "r810"; { "role": "[http://www.xbrl.org/2009/role/commonPracticeRef](#)", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "[https://asc.fash.org/1943274/214748009/946-205-45-4-1](#)", "r811"; { "role": "[http://www.xbrl.org/2009/role/commonPracticeRef](#)", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "[https://asc.fash.org/1943274/2147479134/946-220-S99-1-1](#)", "r812"; { "role": "[http://www.xbrl.org/2009/role/commonPracticeRef](#)", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "[https://asc.fash.org/1943274/2147479134/946-220-S99-3-1](#)", "r813"; { "role": "[http://www.xbrl.org/2009/role/commonPracticeRef](#)", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "[https://asc.fash.org/1943274/2147479134/946-220-S99-3-1](#)", "r814"; { "role": "[http://www.xbrl.org/2009/role/commonPracticeRef](#)", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "[https://asc.fash.org/1943274/2147478979/970-360-S99-1-1](#)", "r815"; { "role": "[http://www.xbrl.org/2009/role/commonPracticeRef](#)", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "[https://asc.fash.org/1943274/2147478979/970-360-S99-1-1](#)", "r816"; { "role": "[http://www.xbrl.org/2009/role/commonPracticeRef](#)", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "[https://asc.fash.org/1943274/2147478979/970-360-S99-1-1](#)", "r817"; { "role": "[http://www.xbrl.org/2009/role/commonPracticeRef](#)", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "[https://asc.fash.org/1943274/2147478979/970-360-S99-1-1](#)", "r818"; { "role": "[http://www.xbrl.org/2009/role/commonPracticeRef](#)", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "[https://asc.fash.org/1943274/2147478979/970-360-S99-1-1](#)", "r819"; { "role": "[http://www.xbrl.org/2009/role/commonPracticeRef](#)", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "[https://asc.fash.org/1943274/2147478979/970-360-S99-1-1](#)", "r820"; { "role": "[http://www.xbrl.org/2009/role/commonPracticeRef](#)", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "[https://asc.fash.org/1943274/2147478979/970-360-S99-1-1](#)", "r821"; { "role": "[http://www.xbrl.org/2009/role/commonPracticeRef](#)", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "[https://asc.fash.org/1943274/2147478979/970-360-S99-1-1](#)" } ZIP 66 0001689548 24 000101 xbrl.zip IDEA XBRL DOCUMENT begin 644 0001689548 24 000101 xbrl.zip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ihs y 6.SI+IGWE 0V4BJ I@>4T&19>0 XCBBE.B> NV M5&42@<

[The following text contains extremely noisy and illegible characters, likely representing corrupted data or a heavily distorted document. It appears to be a mix of random letters, numbers, and symbols.]

1-G67%6.8%~QZ-PTG@XBN\$Z\$R13\$&\$BYM\$2%2N:~\$7010.-=K-1"RC.P%G0%9-8D2L8Y1Q8F\$KDK(\$~G"BV-M414W4+X"R-CRUBW6<42F)*CWC<1K1U0(N)0?;E6A4J5
6FSYH3+740?44C)/@HE17\$&@&6HW\$W\$PR%NP0CJ0M#@7M1.S:~A4M%1BXP=OZ+K90J50*(BT-ARL\$0.-C*=HWN2:86HS"5+U\$R
M1M1.=ZAGQ0THC)6(O9H+L+LWQ9K90(U.=@A+O#&BH+D509J+D8BLU+>MNOL(A)N0%3?1HW?T1:1Y/DL+/HZ+15KNC"MTFC=@OPHQM;PU7Y:18VY+1
M8BD@MTFL"6"WOYR1K#U#H<VOGPRU109YCU1B03YRT+1"R-ABJA7P@M+WG+V+E)EC\$3#1#@>9(7%.-WG2=DI>7W)M12ZET"HE23Q0VM#@Q(F)E7"MQ-F-N?T
D6P6R=1L9Y-M61AE1=1S&#E#."O1M6E"7Q1R9"DD@CH8R1.N15\$RDEKDI7AVCUOMD7%0"MSOLZ9Y9R- (W7&B-JC)G6P'DZ90.~2GKM\$103YM#@=183?JH(BENZ6-&
MYM&T6N-9YV?T\$1<@>16>5K#1\$#<~1JXE'<3?1EXXNG4B1#AD"=C".0#MF2"~\$A4G16R-2CF/KH"\$\$\$5\$14P9Z7+1+C(A.L60.~\$X&C)=F\$K~1VDT+V0~^YZTK-OC29)4W4
M\$&Z#F#@>1R-MR3RNB2N.Y+1~NXYK7\$70%APC:(1C3-#1=N@>QH<1M1?7%NH~29BL0JODLART#BJP.8>K-N34FO7@NL@R3(%0#M?3)Z~Q~Q~Z<INK
MP#@>KLD(G1"2US>YXFCUD\$H3>1L\$5B1V?76T+ZHL13B3A-M89B87@:501>85U0?0"OKIYZ7O1G\$~>@>WT~?1(3~>D2J@:HO3(1~HJ)N1\$X
~17+IG<1&AF8DPQK\$Z.8"8FYUJ26XAJMJD\$HX42491T"NH"6%~"IKUL3*G1X4QX8.G.PZ10T@1E2PHU?/XMK11MO0&QSR)=~20Y<7>J1:Y1\$9~#G-37UCF-
64(s)OEZW?~<UJOA@M"PM%4D21>BQX98"4XHI44515\$FZE+U4RG4"~<@>710%10AK121-MB-~9%4F7?~>9K13D2JVDV?~%YEMLE1\$1DY&76~9YWRWVO?<
<~8%1EV=41M~"M.XIGTK&5\$NRI"MT@WE1>YH'H-L5-1(2%1)=T#.-MO-BX1Z3QW"8H'D-2(4)HD:TY\$~\$A21SFU?~>9IQ@D01@<(X2~604TAQ61W-M2OD/QN:0(E)H.N.
L0/@0J>"ARAL12AHN"V."92F"RN9(K#W+0+1X)1MY.N=78QZ4WTZ+0-93LH73=>2-4FR%01.Y1SN+ZW1C-21(17DSM2+0A1019)E.E~0A-XMRK2OVS..JF14+0XMEU1+
L1~6\$4+M7HP9X70H+GDS.P.MFF+JMHX80A1X+1)@PLEGOD~<7\$S&107~<JG-#="MKN191=B~<91%1E-WT\$#>#>0TPH7MHID:&#>YX01NH=1Q~&91966%
M/FC>#SR901F+1"=1Z+13~1%#@>L1N1RE13UB"LEVI22AB>749AKTQGS&Q89:HS19A0Q.OB"AT+A.DW~.EE?Y>19H)M&#>Z33C<@&KJX181070MZ=SC2QY(M)X~>8G-
\$80-R+1\$H/M,0A4+~5\$01MFF4#K<1618HRU1>99BDBB4.M~FWX1\$5?P2RT1DOZG\$7%1@Q0-H27F-GK34BI9FB2E440SHR68EX%MX&
~%5"VTEJH11~9-1B1J-1M.VW2Z@1GEL"PN8-U-YK~&H+R15-L-5H~1EJ~UUEEDZ4.H~G&SYYO2.M.PD44>A1U?60H67?CUV.G6>9.8~D16~J+ZT~\$~#1.CPHID>1%
MO1Q9-1WS/B=<HP=>727H.GIT+~8.4G:3PNSP~Y3@OS70>~1\$~1#2-MT@HAB82J?FA2M3?~>D\$2.8N7GCV9P?FOX.SBVGPM.#JX1A+JC19~M7~#1.X2=<T2688X~
=01J1H6<R158)~\$20X#KOYH1.CYH7=4>@1@3-?M+P+I@<1HU:7\$8U'B+8DT@YV71A/R+OR?UG07+TOH=VURG.OIAB?0MP./M1.\$9FGGET=FY1.*4(7C~/B601D1F0F0S0Q:
G.S~>1>8TLDH.#F-M1J0XQ\$OQ+HDD?~.ME3)NELPBN>LY#K%+1H1?H21-LWUB1(C.X"~(M6E)D2B1APV.1-P.H.KZC:2LY>4-BV.H@:R3\$Y?76S34B==31FLR8=
M27@QOQHP.S133FV102@>S156%~>5J)DEQ5D1\$18BCR7Z>Y9+9#M..MDDP.~>YV.JOKY&N0-W.1-L?Y1\$YSC9D)3C1~1\$Y2@>6D~#RZAMXE(5.24AP
M27R>FV'PRXV/RU41BM#D>3U4(1HBDH<8N6-3%O4\$~1ORT.1"DS.MF-INVH.Z1\$1"AVEV~M~>0H0DY~>D0G1T.4IN<V3A4&7M18.O1X&F1FM8W.X1EORZ6MRU.XLH/
MPETH1=NU(C)E\$26P.W1MZL1A.W=ASVTFMSH?~3M1S8B0M90D.PRG.C.OGH#1YFDB8.M0KJ&TFEE.MY.UBUDZ>26.62\$45JFK26WE1416FBYH-JBLP\$~>5&Z1A-
)MV:1G?~1L.Y/L'ZW~J1A:@1A*~LO1~XF6:4L@X.M@0-1P\$)@-MOUC.PV3C<~>1=JW?~R\$<(EHS09V0023U)ZKLF.ITXHS16~)MN~>1)YC%D/PI#GTF.SM<~&=2~@W10/@~YI
10X)1A\$1G.M71671@QD091T\$=X1W&R3#JZEDV3UBVNI RJ&=G8RW\$S.BVX.SVDV01>1>S&M'FKPA.C~"A/A&@H)~A@>6TLG:5D1~IUF1<@&9K;(#F~LW19D.03HRZ-MI
(1FA>C~3PPT.FV1&40>@<XG+1>?N?..VHGAC&V7KK44N1?R4-M21A=(M1~T~>D?30Y?~>VTZXCV=AVHNUA\$~\$>7~>740"MC~>Q1T%J1Q45Q\$~R+~>1L0N1
514/Q~W.CW~#A1V+1F7EZU5.Y.H#~.C.M09J.KP~&=2WT&8L7D>P1IG61E10>~82C~N6W9171PWH<~MC.MH1-
7%~09~7SN?1Q9J:ENE2.B4R2@BW0.MHX&K(KL64%HLCTO=FER6.MG-MB-8WOED68Y1/DH1@4DY1M1+1+KR.YE5Y1?TGU1(OF092)~"M1RM@~%~>M27ROH19.96MXP
RINEHU.CK1?Q@VS0VOD2Q&#JF-L1S2-IH<P%(26).MLY1K/G7JISG=95C.@5W>>N1H@C1F162FA&R#&WM.EY7(0\$W\$S<~+1L2
Q.GK4).>5S.119%J.RX%4P6WMH?0X>U9WXGH>UJUNOHSNKM.GCEM(HJ96A71E)W\$K6\$1HW+K~#..MU>E780M(DYELM\$)Q<~0 MNV~TRU>>~J81Q11~<1COP+>?&
~1G12ZALTE~(JHP~LXM>ZAAW2XHQ6Z7Z.ME#>KCVD2GX1L@JMUU~1JFF7-1M1E1C1QW1H1LFF9#X~>HNBTE.G017/7C<1-KHAI15-R.OK(DWF~)9MH&MCH5N-
F@Q(0D.2A1Z.KL.F<1A4C1SPS~1TFK1N163&5.COPDW&14U7%N+133.M87LFXH10>=06M?B1Y61U0+1&@G7V?1C~>ZV%1H7128HRE1)101~>J38Y?~
MDSC1GH#H1Z0FHYBT19U#Y=UX-1Z2E/QGHH<~><<~.RB1.7%ZM1GZ1FE.TIP:U9N.S5D08.H0.Q3Z1U1W&AW58YRD8U3+R.(CBZ~K%A0)MT&N9~3WJUDI~610
V4~5\$R~#R1R2>Z.4~<LH16B6X~A12M2.W2HV%NA/HUGE+Z.6~+MS101#ZH>7Z(4@YK/M14&AF1#~>#Z.OXV-1#)E18Z21O4Z0SA4YK1O~C.M3T?1T+U=WO.2VF1~1K21-
1TXR~N1P+260-2K+~1L<C82?QLND5Y12V4M\$H@~&9-0~>@&S1C(M3=GR1=G.S73JE~RN5/9Z:4W~U91E&G9~N(M1T+1~9\$Z@>E9YHW78M10*~&QCO7F2Z-HZ?
C%#YQ#1+1C.Y+1+~?~5.MXXV.U\$~<Q.0234M@>Q(=2)4YOY6JG~9N0J3L~762Z.W.F?><1~M2.W4L1OP(N)~>7>1>2.U.1Q1K~1U.DP5Y.Y8H9.EGAT3POE&XFE210~>
MZ1~1L.R5X#V1ZP~1E1LUR095M761#AV1~1ZP1A1Q50P\$1(C0%WMWA+Y(YZBH~1#OPKY~3E41~1%DU/1X&S.M1Y~1HP1(KN87\$152315FK~4123T7WE1U.9Y8W.UKPW?2
WRX+X1OAO1~MP2141>C@.81MZ6G+V.P~537~EOMH1Y7Z~<~<~10\$PLT~1~5(F+1~1S~1H~5KVL/TX1E)MH1~>R+G2K41EGCWWIT14C~013?1Z

[illegible]

8-8U715LM5CE2@AEV6H3551:/VA%:781P43V5:BD=IYOG=Q1UZR*~M.Z1T1263ICQI%A19%F6KAU2+Y.MJH9-1L=Y2T5ZX-G:BD6^5L+6^6#^1&ZQI
M~JFWA.F#5#7PB/XQI=(:C;C1HB0DZ%0ETMCMJH04\$1\$P1Z2.R1~M~A=M-R4+B+6:RHX;Z%6.(L1B-WE)*E.B#(1J5WBW200~G:1-U:ZUSJ#5.6AO.-1V)8X#=>B.16KAS
MM6M33L6A1MBGTZ04HEPECZS.C#>Z&LFI0R#4EFTWUBX>(H<4Y;1B7~M~X\$5#1=J=JROWQ7D1GT1Z).G.#5-Z1HY^1>4N0<10U1H10~1>CV30S0J1ZV.Y6f=5?
X72P4YGE.THHI.M#KUE*4KNRHO5=1.6CS76P2CO6GZ%+0+&A.WBET2.W.NXK%W2N%3IO6P.M7.3(15M8KE1(HU<XK14B)(89=H6RZL#2S07TZGBABIP)#7R1>3R.SXF.M~M~
(BAJ+DPR22)41C1#>1K5(EJH8OZ16W*FK&AJA+5<0)231(EZBBT+MSGJ3M.WN0V21M7J1M1T(NZB+5)-63TD=>NPT+VW9DN%ZYZBZ1J1T.F.M1>#BJA'+A/ZCY:
Z3O=PI9.M#6AC/L1/I(C%>VHN:8(1H1MKNKTU#N#~VY(R\$1DH^5-USE+KOC3#5\$1M=6&51#LSYZ>N4%)5.613-5R+3X6&V=74=H%-3ABR.(1=3^s8?2&K&#/
MKX<Z*AY1=9:55?ZEF1J>2VYV1K&SXZ.GM(P&1EY>WNX7F:RYE55^0\$0\$10L#L7VUB1CKCEK7D?7D\$8H05JHBMV:NG.@@#4.MO:GRBOX(1#FV1Z5-?
83C&HXNM2G1R1E>=>Y(O+1LTD9.KT.19K0XB/MC8MOD+18(=1K7W5U1>B#0#7V0B1E1>E9P8RY4)URG7Q4#JYB=M:No2CI.MHMTFY.<1G=>NF.TQJSC.V5B9LA#HUT+1P
T02OW~.Y+WP.MY4HE.FE1Z121:1U1L1.7R0W8C8G1:51G19N21/2%P1U/V.R#A9Q9C.MSWD.WUD1#>JANCIH#B#W3HM/U1/L~%09S&M&37RA4Y40I).F^VY6XL#
(1ATYQI).1WGS7=2.7.VN.2=16JMS#K#F8.M=D@C.A+VW.H3&2DVNH9H8JEF&C>A3&1ES&EV15#7P:1E59C1#>N42PZP%&M3#641D31\$5:5R~E5NC9A41.6V\$.(GZ4FM5?
N93G3~.M#U&C.(W3P2D6DVC1.FC\$G%G%1+SY=RM.MKCN3?E&K1AN2I5QO1J434AWG2G13Q)XDUJEC27.M08AE&M0#F#=#H<A(M=)K<C>JP2#0&0AT12R2.1H2NBX\$5.52
M45G/061H.UUB&1E6N-KVC.L~M069%1C6V&K+076B3.X%A=(SGY+1770+YPM:9F.NG<04P54SD22.7)QZ1=77ZV8F1F<C>B417L0.B2RYZ1D0F1MR2Q?
P.2.N18Y8#BRN1E4V7.PHS~.s=3V1W/M8J1=>A.A.NSV=7+.M+1BLL1A9A1#M#P#>JAMSKO6Q.O1d&#%+7*NZK2BCX17FRE#JY/KD(1#M.Z0615VJR1OL6W.M
H0DR312IFDRPARN(65S.H1.WSDHGO="040+16417"MLB1W1F+B#1*UR=SRU.HL2AY1A1B2)=(>1XU%2DK06HM06I/HX.L&ZN+6.3"MZ.%Q0T<1TUM7W+8.Z\$D4#1
HHJA.6+3.2/2A16P1+17P53DM7~1%>M=1.DA
00M.Z162.61TR<0Y2W7.O1EGGCC121JHDS?JVH0?D60N<51#19&ZGYO(C.M9X<0B55P1#5U1GTY3?WSA2V1YUUK19K2U6M..FJ).FJ<A&8&^TT#E159MR-
1W>)DS0SH<..4SL#1!0<19ED6101PT#R.#(E.DS.#IC86PN<0&ULY510#>3<YT#.C>W1JG1/X.#Z+Y+L<@BWH<CGYAU<M1H?~1>40=L.NCK1
(5D.NX10DH>=>K&150.2>BHT0=1I.P#58J7.0DSH.M1#XE10#1P.(BMSZ21.2775H#C<ZKZ2)889AHX1GBUY<1>.WG)SI<GIZ.M1G1SWZ3<GXR-7
H&#>1>1.TDNVLV1H>+OUZ2=39<1DZ61FJ.MSH1204M>1Q(=1P5C518R&P16+J#1#122U1UN1(NZ57#21>104EX.M1.JS+Y#>N&S-O3?9B&8YQ1GR.#A.41
MAHFXSC6G28389#7512A1JES=X0XG1ETAL1V1#>1J4SXE11#M.CWK30#O#E.TK4WC.HR11.0R#B#%JX/3/67XDG63.PCJ20U.HG6V1.M.AW.O6Y04B105XT95.GY.D
(WH.A4A83=>117=D97&Z7X4.L1F1P.HC#M.N#N).UGZ&LA1X0E.UAG.FW<1Z2.38Z1>@/X1X0U&WB<=<R1>5P@RQ0?7Z.3XZ9ZG1F1.BOM.83IMDI.B~RR0.&J9C
MA2S1XFO14OYN=8.G:R1R1RCYU1P(AE)<X&5\$#1L16G1H7.B8J6M1XG1JHKE4WHN<3K0?26S(O1.D1\$5200WAF1F1(6B0K7ERZOMC8PD9
MX1JDXP.019M1.FLFC50MA18.HOOLV.RG10&K427C3AOFB*J#M#D#.C.L.#5&P1VDK(13A1T5+X19P#P1UZH1A12HL9(1#(1#<1>2CF.M1=5D.
Q01YVZ<1GDS8C65(9F5E1&4ZA2+P1L1.O169:(V01E1=CGZD.MR.E06?T0.9M1U/ILE.S5<#YX.S1T70)(A&K1#3P.MDR>T2G.12%SE7C%2YU5#1+1N1+>B53?2.1%?
(0\$>BDB6.P1WFOY1P.M#<K>1+147A3232~.P.R1RZK-ZTC<=&\$9SR1\$51#J.31O3Y67EIE.HCUPGR.MXOE6H\$00.K&C.(KABC=L1#1Y1A21MP+>Y1TLYCPY1>N&+R70=T74.
MT<F4P<0LT1?2XWRX1#5<9S.G&URK8L2.Y18H1.M192ZU1X.S+T.AC<=>+>@%#MS#~D562X(ZBR10D1)Z1D60.G1+7+1=MR.M1OH1Z3@18=7&69X1<?%7.B.TX50JH&
H1X.AA#4#1L1C1X.A95MB.LS?M<T3UR=5NBH6.P&K7B9N2C<3T..V.X.VY1M3R#M=1HPOCNH.O1N#M=76
M451>F0V01342NF2148MT72~1HJ6&E1EZUT81TOK+2.3H1F1(1#>+M2)=M=20Z1(XRAM1.IV&W=B3PZ5%1VE47<1<=<D>I@0J10+Z15%04=>EF)9\$&E+2U&55)0)O\$
H02.H1#M>=>EL@N1CX141>16C1L1.078.Z5H1@031Y21.CLR1SL4A1P1.M25=B2JZBRH1A1DHR1TN1S659XH171.2N>1X3+1.F3T1M.TP1R02W1W7?O
M=D+JZ5+FU858VEYU1C41EWS1#2H1E.>Q.72G<2DA%041821V4W+HP.M=AL12P5H1#5#03/0>21%F70.1E(NBTRH1A&21N.3XFC.YWFKV1H1LMNB.MYU1JWERX5?
1Z@1FM1KM=7D.PP51H13H1B2.LK9<@5JH1F1G1H1G@HB.P#M<6Y=5>3#3R01?N4.TYB~28P&S0U#M<P5T.M%8U=>LEA1T1#1E.H1%2+<#<1>A3.M91.HH1.GTMI-
H2>NB#X1Y1G01R.H4/01H186CXV.KAV1Z10H1H7?1<M>G*FPD44%KS#>+Y1WQ2IC6&4\$U1HYT1L16.SL(1#%#ZH0WEW5O1A1.6#1PCTY7A
M1VD=>2P#PJQ=8J1U.XD1D<A.C1E0M11#F1(PM.O.CGM21EB<@UKR5E2FQ4886>3CE1&C#P+6(05)18MGRF1M1S10)M.M1\$N0:0&RE0>.N#C10\$FH#1#21>1>41LU7
+U4FF1T1>=>W1XAU.M160%0ZV11(1=6271V&K&1#>@70Y1HG25#H960+21I2+5V+4A.K9Z1#>M1X#7.7&X1JY1YNA>=>B#5W1X.7L8.
V6LLM1@0HVA4PU)O.M18N26.001.E.M1@=<C17O1.P#EKK0?70Y1VGGN24GZ1.91=1A+U&X1O1U1LF=1#<\$9>DZ.CC1P1>EPDK1B.(KX5B#C11+>1B65P7(6A1
M@K(R1#N1V41O3)1#Y1M(41#X#CE11R1.91OP26H1.O114R04*RK1810X\$<5\$M1MU(S&K1UXN=6H1J1#&516MO1>SV6F=4PZFO1M14R0.T1GE4#H058M54
MEW1)~1T.UUAT@811SVCMXU1U1=OY2?8.X6P20&1K141TG3+P%W2M.O18LBC11=O1Z1C.IX&5#0VYX11100F1J1U1KUNX6P1ICM
M01M1X9EOGDY.HB5<0VA2N1&3W500K.MBEC.XS.HY1&9H&J1O.C.U.EKM1K.MC#Q.SH=301MGV1YEDRC60M1X#*40~R59B9C.QWRRW7HD1FK1KB.8
MW1

MM=MG1:0>C3T6 [A*P6L9T]V JH<+>MXY+7F>+>4<4X3+1BY6V5S(2'4AXF7"=7*IDB:G8IR(G/B0V38C+I+Z+M)=ITP#0#...19I>2
0.6K>0%CR0EX5%.PKOTWY7>B.FE7HHPXJZO.S@*#4N@-MX:GK-W<=2KUBTS.MMMNBX*MF@*A=*(P@E@KQOEC.F#P@D5>@C6(F@M.P67HXL-D+=ID7FZ.M@GT*Y%G<+>
14>>0.0A-00V1%.7803<000 914.MW7B@8IV74+24RRS1D-M*PUP.<IPO005.5+1WE<#NTRK9*DJ@7M8W.U.RWJ6Y5965?>F>+>Q C< M&UEN&S#>7.1338 LL=Z6H& F78
=41QI3JY MW%G@QON+Q7 ZFD?F2%M.9UY61YJD100 M+FE L+>P1Q18C@P3 MD3\$S\$A7P>S.STABE-SM5@+>1UD4X08105Q1 (I=7P1GJBX.&K&A8*+>M62*X8H
@QNTQ@PM.0(JE&S2+>1S<69R.D).%>F<+>C 6.9<#GH.P5HFGD+S MJH 08>+>1BQ H+>U.02MB PVY4@PN@74YV7+O&D+>F I2@H1G1ACIO M*PK>UD5Z Tl.CJG<+>
Z7&M5L>1J255ZL6WG3Z+L>+>2CW\$B(H-8D).D.>B1 LMQ+X7)YI*+>Q8E5GB+>L.TUWH9.366>9Q.00 M*W*Q@U15B>QE+518<N.T*MP2&X0.Y1.S5YI
W5L>V.U>+>RLW>7.21S<K6MZG-6E.M+>BMH.51> W9=5L 6U7.S2C6.0%NTR&+>1<S@Q%G+>(SR3=QZP@F5852MPSD4> MC-A*MB.DXGWEH74JUR=015D9NWH?
*F2F.F73R&T.RRL>?JN9Y?P D0<H M+Y+>G5?YFN1+>U=CX&B8%1JG.>.(U#T8BIK<M1P6D-MHEZ.J0>=>#P7M/JZ?>A473>3Q76G?FLB:WS9-B1+>H&SBN0.<C
M.-9U+>H+>H1B>?F.0T53(M<+>RPNJ1%WWI/L OH15+>U+>L<+>QPE(HN* M.648+>F1132"> SR+>E31J?#7%&K<+>3 S1+>=R1J0 Wl>+>L1+>O=BF.
MVNYINW\K1>2G0F8%N1N<+>I09Y 3U6+>HYW+>M@Y5X.R5?27X6J9Y*E.WH+>7+>U0?>XG1N<+>K-ED1?UEFCHJ/6S.H1+>U.00Y 7&+>81>G1<@C1FHPHSGHE13 "22960+>L
M+>3<=>98&61E 710.9.L+>FTEFW7P10>*>LWE.U+>GYM1<MRHJ.8>Y M-31?>Q-G&+>(4DP@3>2F>2C5?1.01H+>2PDLGWYUJZK.I6G31N+>BBDIEJ
M1+>9C+>F7L>BH+>J5+>ESS9S<+>1G6.8SJVLUX+>WY6W10.9M+>ANOS10>#21MZ>+>W&WZ1?>4- WB9J9G3S<=>+>Z3FE04>SFL4GUN1661V...A*JOIR9>
MU2>5T6G?F/H/MA4\$5+>FF83<K<+>16G8.15P1R*X\$3(H1X+>Y H.SUK+>M0S JJS2DZ>D+>B1ORYN<+>E>G<+>I.DJDC81EPBS:RFD@LH85L.0Q**MCS?>
81Y(F44W?>V10J.M.LN2+>U+>+>17*+>+>7.0 NFARIOVN8AGS2>GF.M2.F15X.ZM7H12?G* N.6151L5P>2>Z(CVSVYV Y3#1 3Q>9L1Z>P81?ML11X
PNF=2R1R9WQ1M1T1TAX5EN.6#SB75H<+>(21Q07)F9>X05+>82&6Y+>U9E9+>U0521H2X YM+>7+>3/NVJ1P.D1*1(BYCRM155&A1+>TF+>S+>T1+>N3E*96SBN54>D\$C=5
"N.<+>P+>VA>+>UATUGUKUY MSV&K8YFSC90Z0%<S1>H360.(Q08H1X<S.K.(HB)<+>0.BU9SPIEGZ+>MCSFI.#2>QY+>L&G8F&+>HRJ\$K+>#J13PW1+>W.Y2>=OF*(2N6VZ
MOD RES+>B@>0AD1<+>0VPD>9D505%WM&... "Q08?N1N9SKSW*FX+>5JR* M+>GRS0+>A+>7%ICU>+>(2M.J0.GKU9+>IZX70/K.0YJC+>VHM."HEBDB8RDN+>MB
+>8882121.224F4H2S>+>8C9N95L8K7<+>7.1 U0N19PE14>1YR/R(AA80XOG*Y M)(4D8>BF0>3C+>+>TV851<CO>8+>IY>?H1U1FO X<+>I+>D1P"6S#Y V K+S
MDX(X1ZHN32%2KS.8<=>SHDY1A+>ZQ<8?>T1S)G02%G1CF 20T13+>4 XE1D M.105&T 1#16S;>D LMO@O7)I8E0H1X&XSTT+>N.PE-P+>L+>9P20R1Q5@+>+>E
MBW(2120AY&OD>NL5>+>CSE51U1F3T1MP9S?>DBDDP2D0<OPS N.CFB.742 M4ACU+>+>U>=>08&01+>3&VU+>=3&6NAS213?UO1+>1PIS01YK4.3%J1U MB1X>0C<
>BU1FQ03SMF1ZP1+>#>DQ0Q1P755\$S\$C0210Y90.<Q>291?U.O. M1AOUN7Z.T144W.U1M49G91&+>XOEYB1#>WWO1+>V9MDM1<+>Y.M.Y7ZV.MC@OF7FOX6D
@I.Z\$N&1B2V71L-D>Q MEFF1(81+>U@>2W1GRJRO>N0*#R1B>+>IDE8M51&E+>Z+>36D+>16L.X#2 MO*W3OD4+>+>RG+>KMEEP0+>E7YD4B09.VU.MW662\$<XJ5\$>
(TEHJ+>HJ.O MW&+>QOY24KF1ZC-6J0) HO+>F7.ZWPX>+>21ADP1T1C1X\$>H@6G M5B+>HB86G>0F<C+>JHT1L6ZWM.Q4=UW46U&L1+>LIP+>XW.(X\$X&C&C1M>>
M5>+>B052FY29?81C+>+>1KJ3+>OF1.O/Al X(HK\$S+>HACQ6110XD1LPRQ MAT+>+>41#5N1+>XA213>96F+>HPD443V.HG1LSZYP1.LKORU1M.N.4D&+>AWE
MK8UJR1.L.KD<K.HU9>XG5Z-7F29RDZ+>E>+>R>Y>4B92F+>4.91S21#HB0K1MCF+>+>3#1+>H1G1.9T&H.X6Z7MF3F M+>J+>2>1JW>VO1#LEUD&ONJ.7>1A%<(K
E+>VQNT=7K>01WV3XOP0A.(S.Z\$F-WBR.V4.S.NK+>+>M.F.D.R2>S.G+>+>5 MPC5)<S1YZB&+>+>MH&G.CAVS.LU7H6Z.8EURJ+>L2Q1(H1Q0<+>(H1H80..M181H1+>19I70.GW@L
fBWV3P.11L5WLJHJ91JYMG+>VOVZ4AD@>JLS.MH1P1M*ZS)OY562-TG=2F4+>K.S)>@YFOW&+>0JLCL7T1JOG&Z F+>U6JMYN1&S2 71G2 29*Q0+>4B00B.G.
(4>112JHR<+>1&G+>7C>Y871#NFZ& MPSNZH.N/C1@/33QW X1R7E#10+>4=&L@WN<+>#0 A.71<B\$SDI-FC+>80+>M+>O3A>+>G&+>5J.CDRWK191&P+>F+>
(1QZ.M.0+>3&D01Z6F+>X)333031+>M+>FM/G+>63#1LNB9U@3L10.133D01530HX8V14 YP1P38K305&<+>12(=>M% M+>7S15H1+>2OEPQ0+>4# 8L.FLQ7R1U>O+>H1=Z(MJH@2F.
6.S&S&G1BM0#>8\$>010C+>00C.FH1U+>Z\$2PSWX @.79G9V9.9W&K9+>P26&E+>A.C.W1Q77R1U+>V.MNME5S1R1V9R#P2>3.P00KZTN@E\$>9
K&PSD3&+>14851AHT1+>14QO71ZL MN.1+>+>+>3S2PZD1Z JMGCG.S180M16 AZ.M&+>0T.7N8.9VPTUHO78G=U7R.M41RHLD+>B.U8 JWGCVZAW1F+>M.
6E5P+>J4A=3IMM+>+>JUZ727A24+>A (M&KW)S82+>T&HJ1R781Z7F7H(4T1AZW&+>+>V1L617

UWV909.F@IV>25RB4) DEQTL@U58.V^DL^HU1.90K3I^M7#>.&1%TO+ND:4A>ELQ^F8L^YLBGI.EK70#5IYEYAJPM3^2V>^MW_IWSD0
MYS+XWQ_YDY376UXAN."921%UDD5^H8DA83%&^IX5@>...I9>JFZIS=6^L5^MY>@.(SVOIUR5H0?P7%?&&.(CTTP1502IQ^9>XBY@<JH6>^O)8-BG.KZK-M^?2ES6V15.J9N^/^^>
=>5NEKDP.OKZ>OJNB4N/HTS0(XP0.CP<4-W2.M@FR&Z<@U.617E10^+X^6^F2U>HL2HPHO?U4ZRB0#R#>@>BFG&XBR<9>.<1%I2L^AX
MG:ECGRU5HC^4HUH0IBPKK^2GHC&OPI^4H(FQF)1LYE-R^>51%L^NBM/L^M4FWR^U8U(BH^+>=6UPV>1-8UNFO?W5X^3MYK^MVFDM^M9F
1#>KCSCEPU@>50FRIK3G39BU@>4@219J50@>X7OUE.L87YK1^2N.MX7^<=1L^NBM^HDS01^G(C&O&H#>LH#>S8.(RCR^<J>JDT9T9X^V.J@G5^M18OVD5^KE@U?>
>F.6^M%YV.I.C)Z1#>IKERCQ.CDI6U.T&N@>#90(X)O.M+3L7.\$22.N%590#>+E.%MRQCX45K+N.YZP61+L7.C7%2N6SW=MOQ3Z7.Y1.MW122U.MOQU=V.
J4TFSXB&5YG8DKB72N<=2J%>=J+L.W>56J7IN<+M^+F2.SC.##4FSG5?>JDXFY^M%9G3^+SW>?+B<=O)PYSU+L7.PI9QO<M^H(PNC^7I.KY(Z89EO8(W^*YF12*
J0F9P=V5729IB^IGE7W^GU06C#W#^X/M 02^E4.C.AFK%>P.M2S&C&C^N9W^LD=3OSE.N338IK5F%FYM<@4>8>J8XLNFDFV^OJD7^HU
MG(GA4U08^P1)=1L.CP6:5FQZL@>#=&#&H5FGY^W2Y^CDE.3X1=DF=1.MJ98+6>9.S15A1D^1.CT.L7.MW2.7M1^24NSYU1<D>P.C6:324Y^O1^O3I.M.(TO15M&(&BZ8^T1=1
(##.P.W%31S^K2QOG<=6^GJT4LD^L.M801^>3^CQ5DL^>9AF.G6RQ.9ZED?>69FSJ2.BJ<C^R^FID>J^VNYGH8<C^M+1^U.O.Y>U>8UQ107I2>515A^7325KK^K9>#>1
FW7M^Y1665<+W.M.ORG(H94R.2D4..X35L56.B0P.R^P=^GIMW.81<1M8&PHC=F.O7^8X)W@M<3>1.K6<=NV6HEOVA.3ZLP16M+04BM9YU.S.BP=OH3I^>M1D.C:Q#2U/OOMI
MWV^W4XP^GEOK6^J6F1G5ROB^V^Y6WG54E@N7IFE.MVIR9N6^T^CV8430W^M6&VY16BV&SZI>E^W5V#<=VNM>YI@NAAG^OVP+O^U(XKBE.MS?O1D<C
MG(9AF^Z9B8N7^M>H9Y>=1.M@G77JYQ1Q1ZV?^Y.20>W05+1^+D1J>^3>C^H.@HSA1^SW0F7D^P2^MKHJ^+4TV4Y@P^P20(AFR,6)^%O1E01.S^\$>O>@IPBX.A^="2;5/6
M^JQDZ>OJ0>I469N&(&H+N)H.DN>#>>2PDIIT^G50R2D^YF.%5S.9JPE.M.KVYZN^9H@15108ZC.SU<8.CG>2GNY^K659D4@>8@9PBN1^U\$.68^8.M3001^1=1
<5#P(BQ9BR>=1G20Y^T&IK^M(3^M.55.S5PD31^>4022DRV.M^R^M+Q^/ZC<IV.HI^SEXR<GLU.4^7)5FU2>W^=F1<YJUTO2E6U1>5R.M71^L\$HSHV1L^SLH<^&V1
<260BU9^U1^A1^352>B=6040AHL>M.EY=7KW%&^TBQ2I(BBR3^YZO(O1ZI.D>G+L\$D90F&^1G^3JFV5W.BPV.MDV^SIB8^I0^X^+1^0G1X.F\$^#4.S^MV&T
%HLWA<7R6IM.MXE1MO#E7U/4V^C^H276M05>FX.E%7NM>+FT<1YK.MWE>O6E<=U6@<=L778^J@FIH>89D<5=>W14@.M2)DD1^E=TK<=PLI082.MG^8HJ5Y\$>
%HB^BRT.3^C^MPPR9QCI4E/4H^O^NG.TWMU.W4G.GCE^6.M381^9C>9>.>O6K.OV1V\$6\$1.C.X085%>#<C&ESFLI7V1&E^4G1.XE07FH83+AA^5Y3M3%
M2I<KDFE7^2017M5Y^YL&GMQX."64<4^Y\$1HQC+HW.N6(1E19J0@O.0^2I).MNE2I0R1Z26H1ZL^>#O#PZZ547\$1L>?>+@MFJ<N^D197^BCL^OZR^M^@1<=0&S
O)QI5E58R15DQO4YEEER=1^@H(KY61^5.UZIUO^+^OQOET^MR^R.MUYA5(AGD.Y2=10TIOEA^4^R)1492G1.8A@K&W.5=>QMBV.7L>6.MMV74ZWJH6.
%6UXI^U+O69F689.Y.IF^1^>W+T^G^H2^PZ^XP^P>D^P>4^Y^M&R.FGDW.6PL^P>L<5V.N8.%@>4.MKD10960S@D>MJV74QFZX^+4W.M15^S9B?>
(-t.KH8F.HK.X0A4D.Y\$XPBFBB^NID<9^+>A37P0\$12P^UPF4.M+4BE.\$14KZ(OJ56H3Z<^IP4GMKI6PLS..^4YIM^144PT^2^O)46P1A^M^GTD^f(O8P6B1<H#<
=<HOQVE>^AYDK^B0.C@V65^REFXH)6OD^YLOM<4^M+>1672JPVJ.C1&PA61(EL%>#>2+TSGX(GWG7@&P.P.I.MC71^R^6RK^7^M)^SD^4I00+GTNN&7^IWK^+>D1^+7#46
^HK.M01^27^085^EFTMT7WHL520^XB(DI3P51%J8ES&K^>+YK.OIPE.NIYW^M^M^C^7H.HI7Z^U^PD^P^R\$W@&KZ5Q4^1P^P.S^GJ^VMNC^R^Z^J1.IAV^08MU
^30@>#K5TJ^?>#<0>#J)TO.MGW6B1H\$J2^245MSQW1=>1BWQ01^1M2^ZIDBPW^1(MWZAA5K&S(S\$#612B)2^G155D1^5EAE61^1^J4N.D188<=Q^M6C<+S8M^
MFR8#55UJQ.V9E51M6&ZUD^G^Z7Z^7^AO/PWK^E4^L^C^B&A1^E\$>+E1J1=>=S^QO^H5P^<=M10\$O<=CQ^>+40EUL4^+>O.P6P25^TPUBEU7H(C^>30T9Z%
%BMH^741@C^>2TGC^C42SR8)8P1V?>KE@L^N\$A.AHNS@IGT8764IG^CDV^M5E1H^QI(A.M81^%L<+1^+TH>CWP^O^YCP715.ZEK^YCG^B.W^YKK^7.M30^3JK3Z<
^98EFO^X^>#4.MPP3P6^V.^B3IT^=W1(VPZ5P^I^P62R1^>O.MI^Y7?>0TFUXF37NP1^U^MWIHH^8L^?>VZB#V.YX1S1&@08)BIMHH(6HJ5A^ME%\$6:0&P^NDP0>=7JYV.T8^>UV=
F13(5ZVT^>BH>N^ZB\$X^Y1^6NNH.M1D^XAKX^L^C^=U1P2..#>PLRV88U029YEV0EL^BVM2^0^1^O=5P.L5Z4^>KBJ^MF(XC21^C^J1G9>5^%C0@<
%TG6>=+4144?>UE6S9H167A^>K^>+D^N5>=I7E.M0.W12K15P^%55&AL&FK.UWHL^Y^+AOS^>N1N25Y&E^JDK@.HBD^>GWI^M2?D1^O1@TTA^Y\$S1^0W^>J8B0CHBWT@MOI
(M=>X17X^W0<=>MAR.3.C9RHJ^>T^K4H1UDF4>72H15^@>I^P^FRGD01^7XCK.M+0^05>Z+7V05K8RL9D7.AIX&S&BT.IPRAS6489HF&^A^Z2.6Z517R^MFN^GR@fK>*&
>Y6B.G186LM.\$4.I1M6G52MN.OE1^>+>ANZ5H66C\$G.M.MX@fQ1D^5V.O1Q6N^>CTIDED2&Z7&LE25.0UL^P1K&W&C.WG0.6M^>Z2^C^>V^#>
^JRPKX^Q@ZEPL/L4EMNNX^>(2\$O.9FP^>#411).BG.B5<+1^MYJH1<E1<=>Y^A&^FJ\$>T0033^XU@NP.D1L41@X^D78.L^Q.RX?S=RG&M.)ZH(^>2G
8Y.M.DXU31@>9H/RT8M^9.N95^Y.5HJ0YF.GPOG<C^SPJ1J^+1WZK5^73HJ^JBF.MWZ0>Z>K0^L3>^U^S..^F1>+1^YFZK4.QW>+1^YK62M\$1^f@Y^YK6I>M5^6/
100.571^Y1^M^TWK<=>=OBBVYJ.KJF^>+KY^>J9..1RJ5CF^U=+>A4^Y1LZHLSPM>9D^0TUE3>^U^O^F2>3UW1FZK4.QW>+1^YK62M\$1^f@Y^YK6I>M5^6/
HXP+JCK1Y^P70D1A5^M^JBA.M^W.HI\$1^>L94>63N^N

[illegible]

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|X|>7WOJZ>0K-YV7MOSLY?>71?07%>OGI>R'OHS(6M511&8&1'H3Q%>2IG32TJ/QON1>|X%>=>P#P&X_70+OLNMJ+ V0=N@4E(C&SVT M9J9>PVS7)FS@DGO=>M7>TJ2=P@>Y/.F.OJ3J0L.TIBWU2JCE58.WAKW-M%+X)<2">DUURH.GI @4N4RK'H&(-LMV2.5"9R<=>V+>+>XHU?HREZJ) M-0/5R3WU7Z2.QIYHXH.8Q_XZ&0C2"1.N.6+>1"RU4TWI/L5L/1/M.OB&6GKJ0.0.1J>+>16f=EN6F%SN.MMA13NGI3ZDZINC8WN+1Y=QIY+50V?Y.N.LF6I&YEFWF?AM- Y9J2FM?O.>HERNJ2?_452SC#H.#1&1.L93712"V+>FEUKA.W-2?>6IP9LSES&WS.MH6XJG.ONCH=H%>P&CK&8#<(X)J5@DBB%>0.8I<=>C&H<=>C@>D@PG?HEK MWEOQ@>|>JGMDM+12YN<|0>=>NAO?>C.M7E.EQOVS+G9ENIUYF77D(GR- Y)M(HYKXSG.06K2.0EFQO).VELL.AQP?>EXMKI.X3KSWFA.90U9+BS5&2&M P.M.SA90A1YBDDMQM<KKQOQMAXG6?>C.M5E.HKZJF.DS8UTMYFV.BGM.DG)ACF.MN3>927TJ.A-RIGX%(@N.8.N)3?>SXHR<MRTT2.7?>2A0(BA'DG<+1-10CKI&S%OGIM?> I34.X#>K0>=>MO<=>ZS/QS.7068.W=4JBUIY0>C.0.4.GOR?>=H3W>X&H04JZGH@A2JM.HHMA(C&KJA.ZS.2A#>M?>TWW%A4=2M%>@DRJ(3&S)0Q_Y?R0%E=(PDUOKVZ7%>QETM =/WEW@)H= MIMQ@L+4YL(B7-8JIC_U>BHG<2D1LD)>#>NK8WIKL2_V-5A-2072WSI@>+>K&N&D45?1.<=>6-15"IG&8M6X+|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

1 8*+ZIK>3N9DVAZ1*217+2+1F97 M6G+6*5*5*KLJ*KOBERACAG&I&1 D:BTAFS-##5CBH08#2-ZX-1-Q*J32&K7AP M&F&CIOPH:UJ- &+SGG51+0 M.B=9X*U*GGAGQ+M(MD)Q&F&2.F&7+1AH9V*U*U*HNA2*V7H7-APWB9ECFJ.M*#C&B08+U+1-G2-M*Q&*&I&@XP.0*4.P+V0.C.2Jf@MQC.FEJ3-DHWOY(JYX MZ+6Wf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

0001689548 us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30
0001689548 us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30
0001689548 us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001689548 us-
gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001689548 us-
gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001689548 us-
gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001689548 us-
gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001689548 us-
gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30
0001689548 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Memberus-
gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001689548 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-
gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001689548 us-
gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001689548 us-
gaap:OtherDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001689548 us-
gaap:OtherDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001689548 us-
gaap:OtherDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001689548 us-
gaap:OtherDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001689548 us-gaap:FairValueInputsLevel1Memberus-
gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001689548 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30
0001689548 us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001689548 us-
gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001689548 prax:OfficeSpaceInBostonMassachusettsMember 2021-05-31 0001689548 prax:UCBMemberus-
gaap:LicenseMember 2022-12-31 0001689548 prax:UCBMemberus-gaap:LicenseMember 2024-09-30 0001689548 prax:TenaciaMemberus-gaap:LicenseMember 2024-01-01
0001689548 prax:TenaciaMember 2024-01-04 2024-01-04 0001689548 prax:TenaciaMember 2024-01-04 0001689548 prax:TenaciaMember 2024-01-01 2024-01-31 0001689548 prax:TenaciaMember 2024-09-30 0001689548 prax:TenaciaMember 2024-01-01 2024-09-30 0001689548 prax:June2023PublicOfferingMember 2023-06-21 0001689548 us-gaap:OverAllotmentOptionMember 2023-06-21 2023-06-21 0001689548
prax:PreFundedWarrantMemberprax:June2023PublicOfferingMember 2023-06-21 0001689548 us-gaap:WarrantMemberprax:June2023PublicOfferingMember 2023-06-21
0001689548 prax:June2023PublicOfferingMember 2023-06-21 2023-06-21 0001689548 prax:PreFundedWarrantMemberprax:June2023PublicOfferingMember 2024-01-01 2024-09-30 0001689548 prax:January2024PublicOfferingMember 2024-01-16 2024-01-16 0001689548 prax:January2024PublicOfferingMember 2024-01-16 0001689548 us-
gaap:OverAllotmentOptionMember 2024-01-16 2024-01-16 0001689548 prax:PreFundedWarrantMemberprax:January2024PublicOfferingMember 2024-01-16 0001689548 us-
gaap:WarrantMemberprax:January2024PublicOfferingMember 2024-01-16 0001689548 srt:MaximumMemberprax:PreFundedWarrantMember 2024-01-01 2024-09-30
0001689548 us-gaap:WarrantMember 2024-01-01 2024-09-30 0001689548 prax:PreFundedWarrantMemberprax:January2024PublicOfferingMember 2024-01-01 2024-09-30
0001689548 prax:PreFundedWarrantMemberprax:January2024PublicOfferingMember 2024-09-30 0001689548 prax:April2024PublicOfferingMember 2024-04-02 2024-04-02
0001689548 prax:April2024PublicOfferingMember 2024-04-02 0001689548 us-gaap:OverAllotmentOptionMember 2024-04-02 2024-04-02 0001689548
prax:PreFundedWarrantMemberprax:April2024PublicOfferingMember 2024-04-02 0001689548 us-gaap:WarrantMemberprax:April2024PublicOfferingMember 2024-04-02
0001689548 us-gaap:EmployeeStockOptionMember 2024-09-30 0001689548 us-gaap:EmployeeStockOptionMember 2023-12-31 0001689548
prax:PreFundedWarrantMemberprax:June2023FollowOnOfferingMember 2024-09-30 0001689548 prax:PreFundedWarrantMemberprax:June2023FollowOnOfferingMember 2023-12-31 0001689548 prax:PreFundedWarrantMemberprax:January2024FollowOnOfferingMember 2024-09-30 0001689548
prax:PreFundedWarrantMemberprax:January2024FollowOnOfferingMember 2023-12-31 0001689548 prax:PreFundedWarrantMemberprax:April2024FollowOnOfferingMember 2024-09-30 0001689548 prax:PreFundedWarrantMemberprax:April2024FollowOnOfferingMember 2023-12-31 0001689548 us-
gaap:StockCompensationPlanMemberprax:TwentyTwentyEmployeeStockIncentivePlanMember 2024-09-30 0001689548 us-
gaap:StockCompensationPlanMemberprax:TwentyTwentyEmployeeStockIncentivePlanMember 2023-12-31 0001689548 us-
gaap:StockCompensationPlanMemberprax:TwentyTwentyEmployeeStockPurchasePlanMember 2024-09-30 0001689548 us-
gaap:StockCompensationPlanMemberprax:TwentyTwentyEmployeeStockPurchasePlanMember 2023-12-31 0001689548 us-
gaap:StockCompensationPlanMemberprax:InducementPlanMember 2024-09-30 0001689548 us-gaap:StockCompensationPlanMemberprax:InducementPlanMember 2023-12-31 0001689548 us-gaap:RestrictedStockMember 2024-09-30 0001689548 us-gaap:RestrictedStockMember 2023-12-31 0001689548 prax:InducementPlanMember 2024-01-31
0001689548 prax:InducementPlanMember 2024-06-01 2024-06-01 0001689548 prax:InducementPlanMember 2024-09-30 0001689548
prax:A2020EmployeeStockIncentivePlanMember 2024-09-30 0001689548 prax:A2020EmployeeStockIncentivePlanMember 2023-12-31 0001689548
prax:A2017EmployeeStockIncentivePlanMember 2024-09-30 0001689548 prax:A2017EmployeeStockIncentivePlanMember 2023-12-31 0001689548
prax:TwentyTwentyEmployeeStockPurchasePlanMember 2024-09-30 0001689548 prax:TwentyTwentyEmployeeStockPurchasePlanMember 2023-12-31 0001689548 us-
gaap:RestrictedStockMember 2024-01-01 2024-09-30 0001689548 prax:UnvestedRestrictedStockUnitsMember 2024-09-30 0001689548
prax:UnvestedRestrictedStockUnitsMember 2024-01-01 2024-09-30 0001689548 us-gaap:EmployeeStockOptionMember 2024-07-01 2024-09-30 0001689548 us-
gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001689548 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-09-30 0001689548 us-
gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001689548 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-09-30 0001689548
us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001689548 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-01 2024-09-30
0001689548 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-01 2023-09-30 0001689548 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-09-30
0001689548 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-09-30 0001689548 us-gaap:EmployeeStockOptionMember 2024-07-01 2024-09-30
0001689548 us-gaap:EmployeeStockOptionMember 2023-07-01 2023-09-30 0001689548 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001689548 us-
gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001689548 us-gaap:RestrictedStockMember 2024-07-01 2024-09-30 0001689548 us-gaap:RestrictedStockMember 2023-07-01 2023-09-30 0001689548
us-gaap:EmployeeStockMember 2024-07-01 2024-09-30

Company raised \$1.0 billion in aggregate cash proceeds from these transactions, net of issuance costs.

The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including but not limited to, risks associated with completing preclinical studies and clinical trials, receiving regulatory approvals for product candidates, development by competitors of new biopharmaceutical products, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Programs currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance reporting capabilities. Even if the Company's product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales.

Liquidity

The Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued.

The Company has incurred recurring losses since its inception, including a net loss of \$124.1 million for the nine months ended September 30, 2024. In addition, as of September 30, 2024, the Company had an accumulated deficit of \$778.1 million. The Company expects to continue to generate operating losses for the foreseeable future.

The Company expects that its cash, cash equivalents and marketable securities as of September 30, 2024 of \$411.2 million will be sufficient to fund its operating expenditures and capital expenditure requirements necessary to advance its research efforts and clinical trials for at least one year from the date of issuance of these condensed consolidated financial statements. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company's inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurance that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all.

Summary of Significant Accounting Policies

Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America ("GAAP"). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification ("ASC") and ASUs of the FASB.

The significant accounting policies used in preparation of these condensed consolidated financial statements for the three and nine months ended September 30, 2024 are consistent with those discussed in Note 2 to the consolidated financial statements included in the Company's 2023 Annual Report on Form 10-K, other than as noted below.

Reverse Stock Split

On November 28, 2023, the Company filed a Certificate of Amendment to the Company's Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The Reverse Stock Split became effective at 5:00 p.m., Eastern Time, on November 28, 2023 (the "Effective Time").

The Reverse Stock Split was applied to all shares of common stock outstanding as of the Effective Time. As a result of the Reverse Stock Split, every 15 shares of the Company's issued and outstanding common stock were automatically reclassified into one validly issued, fully-paid and non-assessable share of common stock. Any fractional post-split shares as a result of the Reverse Stock Split were rounded down to the nearest whole post-split share. The Reverse Stock Split did not affect the number of authorized shares of common stock or the par value of the common stock. All share amounts and per share amounts for the periods prior to the Effective Time disclosed in this Quarterly Report on Form 10-Q have been restated to reflect the Reverse Stock Split on a retroactive basis.

Marketable Securities Classification

The Company may invest its excess cash in money market funds and debt instruments of the U.S. Treasury, financial institutions, corporations and U.S. government agencies with strong credit ratings and an investment grade rating at or above A-1 or P-1 by two of the three nationally recognized statistical rating organizations. The Company does not believe that it is exposed to more than a nominal amount of credit risk related to any marketable securities.

it may invest in. The Company has established guidelines relative to diversification and maturities that maintain safety and liquidity, and periodically reviews and modifies these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity.

The Company classifies its investments in debt instruments as available-for-sale. Available-for-sale investments are reported at fair value at each balance sheet date, and include any unrealized holding gains and losses in accumulated other comprehensive loss, a component of stockholders' equity. Realized gains and losses are included in the Company's condensed consolidated statements of operations. All of the Company's available-for-sale securities are available for use in its current operations. The Company classifies marketable securities as either cash equivalents, short-term, or long-term based on their stated maturity dates as it is more likely than not that the Company will hold these assets through to their maturity dates.

Unaudited Interim Condensed Consolidated Financial Information

The accompanying condensed consolidated balance sheet as of September 30, 2024, the condensed consolidated statements of operations for the three and nine months ended September 30, 2024 and 2023, the condensed consolidated statements of comprehensive loss for the three and nine months ended September 30, 2024 and 2023, the condensed consolidated statements of cash flows for the nine months ended September 30, 2024 and 2023 and the condensed consolidated statements of stockholders' equity for the three and nine months ended September 30, 2024 and 2023 are unaudited. The unaudited interim financial statements have been prepared on the same basis as the audited annual consolidated financial statements, and in the opinion of management reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company's financial position as of September 30, 2024, the results of its operations for the three and nine months ended September 30, 2024 and 2023 and its cash flows for the nine months ended September 30, 2024 and 2023. Financial statement disclosures for the three and nine months ended September 30, 2024 and 2023 are condensed and do not include all disclosures required for an annual set of financial statements in accordance with GAAP.

The results for the three and nine months ended September 30, 2024 are not necessarily indicative of results to be expected for the year ended December 31, 2024, any other interim periods, or any future year or period.

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, accrued and prepaid research and development expense, collaboration revenue, stock-based compensation expense and the recoverability of the Company's net deferred tax assets and related valuation allowance. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.

Common Stock Warrants

The Company accounts for warrants to purchase shares of its common stock in accordance with the guidance in FASB ASC No. 480.

Distinguishing Liabilities from Equity

Derivatives and Hedging

The Company classifies warrants issued for the purchase of shares of its common stock as either equity or liability instruments based on an assessment of the specific terms and conditions of each respective contract. Such assessment includes determining whether the warrants are freestanding financial instruments or embedded in a host instrument, whether the warrants are liabilities within the scope of ASC 480, whether the warrants meet the definition of a derivative in ASC 815 and whether the warrants meet the requirements for equity classification pursuant to the indexation and equity classification criteria in ASC 815. The Company determines the classification for its warrants at the time of issuance and updates its assessment, as necessary. Warrants that meet all of the criteria for equity classification are recorded as a component of additional paid-in capital.

Net Loss per Share

Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. The calculation of weighted average number of common shares outstanding excludes shares of restricted common stock that are not vested but includes shares of common stock underlying pre-funded warrants.

Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period, after giving consideration to the dilutive effect of potentially dilutive common shares. For purposes of this calculation, outstanding options to purchase shares of common stock, unvested shares of restricted common stock and potential shares issuable under the 2020 ESPP are considered potentially dilutive common shares. The Company has generated a net loss in all periods presented so the basic and diluted net loss per share are the same, as the inclusion of the potentially dilutive securities would be anti-dilutive.

Recent Accounting Pronouncements

Recently Issued Accounting Pronouncements

On November 27, 2023, the FASB issued ASU No. 2023-07, "Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures". ASU No. 2023-07 improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The amendments included in this ASU apply to all public entities that are required to report segment information in accordance with Topic 280, including those with a single reportable segment. The amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and should be applied retrospectively to all prior periods presented in the financial statements. Upon transition, the segment expenses categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The Company only has one reportable segment and this ASU impacts disclosures only. The Company has determined that the effects of adopting the amendments in ASU 2023-07 will only impact its disclosures and not have a material impact on its consolidated financial position and the results of its operations when such amendment is adopted.

Income Taxes (Topic 740) - Improvements to Income Tax Disclosures

ASU No. 2023-09 provides more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and incomes taxes paid information. For public companies, the amendments are effective for annual periods beginning after December 15, 2024 and should be applied prospectively. The Company has determined that the effects of adopting the amendments in ASU 2023-09 will only impact its disclosures and will not have a material impact on its consolidated

financial position and the results of its operations when such amendment is adopted. </div><div style="margin-top:6pt">Basis of Presentation</div><div style="margin-top:6pt;text-indent:24.75pt">The accompanying condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America ("GAAP"). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification ("ASC") and ASUs of the FASB.</div><div style="margin-top:12pt;text-indent:24.75pt">The significant accounting policies used in preparation of these condensed consolidated financial statements for the three and nine months ended September 30, 2024 are consistent with those discussed in Note 2 to the consolidated financial statements included in the Company's 2023 Annual Report on Form 10-K, other than as noted below.</div><div style="margin-top:12pt">Reverse Stock Split</div><div style="margin-top:6pt;text-indent:24.75pt">On November 28, 2023, the Company filed a Certificate of Amendment to the Company's Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The Reverse Stock Split became effective at 5:00 p.m. Eastern Time, on November 28, 2023 (the "Effective Time").</div><div style="margin-top:12pt;text-indent:24.75pt">As a result of the Reverse Stock Split, every 15 shares of the Company's issued and outstanding common stock were automatically reclassified into one validly issued, fully-paid and non-assessable share of common stock. Any fractional post-split shares as a result of the Reverse Stock Split were rounded down to the nearest whole post-split share. The Reverse Stock Split did not affect the number of authorized shares of common stock or the par value of the common stock. All share amounts and per share amounts for the periods prior to the Effective Time disclosed in this Quarterly Report on Form 10-Q have been restated to reflect the Reverse Stock Split on a retroactive basis.</div><div style="margin-top:12pt">Marketable Securities Classification</div><div style="margin-top:6pt;text-indent:24.75pt">The Company may invest its excess cash in money market funds and debt instruments of the U.S. Treasury, financial institutions, corporations and U.S. government agencies with strong credit ratings and an investment grade rating at or above A-1 or P-1 by two of the three nationally recognized statistical rating organizations. The Company does not believe that it is exposed to more than a nominal amount of credit risk related to any marketable securities.</div><div style="margin-top:6pt">it may invest in. The Company has established guidelines relative to diversification and maturities that maintain safety and liquidity, and periodically reviews and modifies these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity.</div><div style="margin-top:6pt;text-indent:24.75pt">The Company classifies its investments in debt instruments as available-for-sale. Available-for-sale investments are reported at fair value at each balance sheet date, and include any unrealized holding gains and losses in accumulated other comprehensive loss, a component of stockholders' equity. Realized gains and losses are included in the Company's condensed consolidated statements of operations. All of the Company's available-for-sale securities are available for use in its current operations. The Company classifies marketable securities as either cash equivalents, short-term, or long-term based on their stated maturity dates as it is more likely than not that the Company will hold these assets through to their maturity dates.</div><div style="margin-top:12pt">Unaudited Interim Condensed Consolidated Financial Information</div><div style="margin-top:6pt;text-indent:24.75pt">The accompanying condensed consolidated balance sheet as of September 30, 2024, the condensed consolidated statements of operations for the three and nine months ended September 30, 2024 and 2023, the condensed consolidated statements of comprehensive loss for the three and nine months ended September 30, 2024 and 2023, the condensed consolidated statements of cash flows for the nine months ended September 30, 2024 and 2023 and the condensed consolidated statements of stockholders' equity for the three and nine months ended September 30, 2024 and 2023 are unaudited. The unaudited interim financial statements have been prepared on the same basis as the audited annual consolidated financial statements, and in the opinion of management reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company's financial position as of September 30, 2024, the results of its operations for the three and nine months ended September 30, 2024 and 2023 and its cash flows for the nine months ended September 30, 2024 and 2023. Financial statement disclosures for the three and nine months ended September 30, 2024 and 2023 are condensed and do not include all disclosures required for an annual set of financial statements in accordance with GAAP.</div><div style="margin-top:12pt;text-indent:24.75pt">The results for the three and nine months ended September 30, 2024 are not necessarily indicative of results to be expected for the year ended December 31, 2024, any other interim periods, or any future year or period.</div><div style="margin-top:12pt">Use of Estimates</div><div style="margin-top:6pt;text-indent:24.75pt">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, accrued and prepaid research and development expense, collaboration revenue, stock-based compensation expense and the recoverability of the Company's net deferred tax assets and related valuation allowance. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.</div><div style="margin-top:12pt">Common Stock Warrants</div><div style="margin-top:6pt;text-indent:24.75pt">The Company accounts for warrants to purchase shares of its common stock in accordance with the guidance in FASB ASC No. 480.</div><div style="margin-top:6pt;text-indent:24.75pt">Distinguishing Liabilities from Equity</div><div style="margin-top:6pt;text-indent:24.75pt">(ASC 480) and ASC No. 815.</div><div style="margin-top:6pt;text-indent:24.75pt">The Company classifies warrants issued for the purchase of shares of its common stock as either equity or liability instruments based on an assessment of the specific terms and conditions of each respective contract. Such assessment includes determining whether the warrants are freestanding financial instruments or embedded in a host instrument, whether the warrants are liabilities within the scope of ASC 480, whether the warrants meet the definition of a derivative in ASC 815 and whether the warrants meet the requirements for equity classification pursuant to the indexation and equity classification criteria in ASC 815. The Company determines the classification for its warrants at the time of issuance and updates its assessment, as necessary. Warrants that meet all of the criteria for equity classification are recorded as a component of additional paid-in capital.</div><div style="margin-top:12pt;text-align:justify">Net Loss per Share</div><div style="margin-top:6pt;text-indent:24.75pt">Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. The calculation of weighted average number of common shares outstanding excludes shares of restricted common stock that are not vested but includes shares of common stock underlying pre-funded</div><div style="margin-top:6pt">warrants. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period, after giving consideration to the dilutive effect of potentially dilutive common shares. For purposes of this calculation, outstanding options to purchase shares of common stock, unvested shares of restricted common stock and potential shares issuable under the 2020 ESPP are considered potentially dilutive common shares. The Company has generated a net loss in all periods presented so the basic and diluted net loss per share are the same, as the inclusion of the potentially dilutive securities would be anti-dilutive.</div><div style="margin-top:12pt">Recent Accounting Pronouncements</div><div style="margin-top:12pt">Recently Issued Accounting Pronouncements</div><div style="margin-top:6pt;text-indent:24.75pt">On November 27, 2023, the FASB issued ASU No. 2023-07,</div><div style="margin-top:6pt;text-indent:24.75pt">Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures</div><div style="margin-top:6pt;text-indent:24.75pt">ASU No. 2023-07 improves reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The amendments included in this ASU apply to all public entities that are required to report segment information in accordance with Topic 280, including those with a single reportable segment. The amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and should be applied retrospectively to all prior periods presented in the financial statements. Upon transition, the segment expenses categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The Company only has one reportable segment and this ASU impacts disclosures only. The Company has determined that the effects of adopting the amendments in ASU 2023-07 will only impact its disclosures and not have a material impact on its consolidated financial position and the results of its operations when such amendment is adopted.</div><div style="margin-top:6pt;text-indent:24.75pt">On December 14, 2023, the FASB issued ASU No. 2023-09,</div><div style="margin-top:6pt;text-indent:24.75pt">Income

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td style="background-color:#c0c0c0;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"></td><td style="background-color:#c0c0c0;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,957</td><td style="background-color:#c0c0c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued personnel-related expenses</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,162</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,716</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued other expenses</td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">539</td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">743</td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">Total accrued expenses</td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,457</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">7,416</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"></td></tr></div>11756000295700031620003716000539000743000154570007416000Commitments and Contingencies<div style="margin-top:6pt;text-indent:24.75pt">In May 2021, the Company entered into a sublease agreement for office space located in Boston, Massachusetts that expires on January 31, 2026, with no option to renew or terminate early. The base rent increases by approximately 2% annually. The Company issued a letter of credit to the landlord related to the security deposit, secured by restricted cash, which is reflected within other non-current assets on the accompanying condensed consolidated balance sheets as of September 30, 2024 and December 31, 2023. This lease qualifies as an operating lease.</div>0.02Collaboration and License Agreements<div style="margin-top:6pt">UCB Option and License Agreement</div><div style="margin-top:6pt;text-indent:24.75pt">UCB Option and License Agreement</div><div style="margin-top:6pt;text-indent:24.75pt">In December 2022, the Company entered into an Option and License Agreement ("the Collaboration Agreement") with UCB Biopharma SRL ("UCB") for the discovery of small molecule therapeutics as potential treatments of KCNT1-related epilepsies. Under the terms of the Collaboration Agreement, the Company has agreed to perform general biology-related research services as part of a mutually agreed upon research plan in exchange for a \$5.0 million upfront payment. In addition, the Company provided UCB an exclusive option to in-license global development and commercialization rights to any resulting KCNT1 small molecule development candidate identified as part of the research plan. If UCB exercises its option to in-license global development and commercialization rights, the Collaboration Agreement stipulates that UCB will assume research, development, manufacturing and commercialization responsibilities and costs. Under the terms of the Collaboration Agreement, the Company will be eligible to receive an option fee and future success-based development and commercialization milestone payments, totaling up to \$98.5 million, in addition to tiered royalties on net sales of any resulting products from the Collaboration Agreement.</div><div style="margin-top:6pt;text-indent:24.75pt">The Company concluded that UCB is a customer, and as such, the arrangement falls within the scope of Topic 606. At the commencement of the Collaboration Agreement, the Company identified one performance obligation, which was to perform the research services for UCB. The Company determined the transaction price to be \$5.0 million, comprised of the upfront payment it received. The option provided to UCB was determined not to be a material right.</div><div style="margin-top:6pt;text-indent:24.75pt">The Company recognizes revenue for its research services performance obligation over time using an input method over the duration of the research services. During the three and nine months ended September 30, 2024, the Company recognized \$0.3 million and \$1.1 million, respectively, in collaboration revenue related to the Collaboration Agreement in the condensed consolidated statement of operations. As of September 30, 2024, \$1.5 million was included in deferred revenue in the condensed consolidated balance sheet, of which \$1.2 million was classified as current.</div><div style="margin-top:12pt">Tenacia Collaboration and License Agreement</div><div style="margin-top:6pt;text-indent:24.75pt">On January 4, 2024, the Company entered into an exclusive collaboration and license Agreement ("the License Agreement") with Tenacia Biotechnology (Shanghai) Co., Ltd. ("Tenacia"), a China-based portfolio company of Bain Capital, which provides Tenacia an exclusive license to use certain intellectual property for the development and commercialization of ulixacaltamide and products containing ulixacaltamide in China, Hong Kong, Macau and Taiwan. Tenacia is solely responsible for the development and commercialization under the arrangement, with the exception of the associated manufacturing. The Company also entered into a Stock Purchase Agreement ("the Stock Purchase Agreement") with BCPE Tenet Holdings Cayman, Ltd. ("BCPE"), a related party of Tenacia. Pursuant to the terms of the License Agreement, the Company was entitled to an up-front, non-refundable and non-creditable cash payment of \$5.0 million, net of certain tax withholdings. In addition, the Company is eligible to receive \$264.0 million in success-based development and commercialization milestone payments as well as tiered royalties on net sales. Pursuant to the terms of the Stock Purchase Agreement, the Company issued and sold 443,253 shares of its common stock to BCPE at a price per share of \$22.5605 for aggregate gross proceeds of \$10.0 million. The per share price was based on a 20% premium over the 30-day volume-weighted average price.</div><div style="margin-top:6pt;text-indent:24.75pt">Under the terms of the License Agreement, the Company granted to Tenacia an exclusive license to use certain intellectual property for the development and commercialization of ulixacaltamide and products containing ulixacaltamide in China, Hong Kong, Macau and Taiwan. Tenacia is solely responsible for the development and commercialization under the arrangement, with the exception of the associated manufacturing.</div><div style="margin-top:6pt;text-indent:24.75pt">The Company concluded that the License Agreement and the Stock Purchase Agreement is a combined arrangement since they were executed at the same time and in contemplation of each other with the same counterparty or a related party thereof and the combined arrangement falls within the scope of Topic 606.</div><div style="margin-top:6pt;text-indent:24.75pt">The Company's obligations under the arrangement comprise a single promise, or one performance obligation, related to the exclusive development and commercialization license granted to Tenacia. Total proceeds associated with the combined arrangement at inception were \$14.8 million consisting of the following: (i) \$10.0 million gross proceeds from the sale of common stock under the Stock Purchase Agreement and (ii) \$4.8 million, net of tax, related to the up-front payment under the License Agreement, both of which were received in January 2024. During the three and nine months ended September 30, 2024, the Company had not achieved any development or sales milestones or earned any royalties under the License Agreement.</div><div style="margin-top:6pt;text-indent:24.75pt">The Company recorded the common stock sold to BCPE at its issuance date fair value of \$38.95 per share, or \$17.3 million in the aggregate, which exceeded the proceeds received which were calculated based on the 20% premium over the prior 30-day volume-weighted average price. Accordingly, there is no transaction price allocable to the performance obligation. The Company accounted for the excess of the fair value of the equity securities issued over the total proceeds received as consideration paid to a customer for which no distinct good or service was transferred in exchange. As a result, the transaction gives rise to negative revenue on a cumulative basis in the amount of \$2.5 million, which was recorded in research and development expense in the accompanying condensed consolidated statement of operations for the three months ended March 31, 2024. For agreements where the licenses are considered separate performance obligations or represent the only performance obligation, the Company recognizes revenue at the point in time that the Company effectively grants the license, as the licenses or assignments represent functional intellectual property.</div>As of September 30, 2024, the Company did not have any receivables or deferred revenue related to the arrangement with Tenacia. The Company did not recognize any contract assets related to costs to obtain a contract with a customer or costs to fulfill a contract with a customer through September 30, 2024 because no qualifying costs were incurred. During the three and nine months ended September 30, 2024, the Company did not recognize any revenue associated with the combined arrangement.5000000.09850000015000000.03000001100000150000012000005000000.0264000000.044325322.560510000000.00.20P30D11480000010000000480000038.951Stock and Preferred Stock<div style="margin-top:6pt">Reverse Stock Split</div><div style="margin-top:6pt;text-indent:24.75pt">On November 28, 2023, the Company filed a Certificate of Amendment to the Company's Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a 1-for-15 reverse stock split of its common stock. The Reverse Stock Split became effective at 5:00 p.m., Eastern Time, on November 28, 2023.</div><div style="margin-top:6pt;text-indent:24.75pt">As a result of the Reverse Stock Split, every 15 shares of the Company's issued and outstanding common stock were automatically reclassified into one validly issued, fully-paid and non-assessable share of common stock. Any fractional post-split shares as a result of the Reverse Stock Split were rounded down to the nearest whole post-split share. The Reverse Stock Split did not affect the number of authorized shares of common stock or the par value of the common stock. All share amounts and per share amounts for the period prior to the Effective Time disclosed in this Quarterly Report on Form 10-Q have been restated to reflect the Reverse Stock Split on a retroactive basis.</div><div style="margin-top:12pt">Common Stock</div><div style="margin-top:6pt;text-indent:24.75pt">As of September 30, 2024 and December 31, 2023, the authorized capital stock of the Company included 150,000,000 shares of common stock, \$0.0001 par value.</div><div style="margin-top:12pt;text-indent:24.75pt">As of September 30, 2024 and December 31, 2023, the Company did not hold any treasury shares.</div><div style="margin-top:12pt">Follow-On Public Offerings</div><div style="margin-top:12pt">June 2023 Public Offering</div><div style="margin-top:6pt;text-indent:24.75pt">On June 21, 2023, the Company completed a public offering of: (i) an aggregate of 4,296,646 shares of its common stock at a public offering price of \$14.25 per share, including the underwriters' full exercise of their option to purchase 619,979 additional shares of common stock, and (ii) pre-funded warrants to purchase 470,000 shares of common stock at a public offering price of \$14.2485 per share of common stock underlying the warrants. The purchase price per share for each pre-funded warrant represents the per share offering price for the common stock, less the \$0.0015 per share exercise price for each underlying share. Total net proceeds generated from the offering were approximately \$63.4 million, after deducting underwriting discounts, commissions and other offering expenses payable by the Company.</div><div style="margin-top:6pt;text-indent:24.75pt">During the nine months ended September 30, 2024, all pre-funded warrants associated with this offering were exercised via a cashless exercise, resulting in 469,981 shares of common stock issued. No cash proceeds associated with the exercise were received by the Company. As of September 30, 2024, there were no pre-funded warrants associated with this offering outstanding.</div><div style="margin-top:12pt">January 2024 Public Offering</div><div style="margin-top:6pt;text-indent:24.75pt">On January 16, 2024, the Company completed a public offering of: (i) an aggregate of 3,802,025 shares of its common stock at a public offering price of \$35.50 per share, including the underwriters' full exercise of their

option to purchase 633,750 additional shares of common stock, and (ii) pre-funded warrants to purchase 1,056,725 shares of common stock at a public offering price of \$35.4999 per share of common stock underlying the warrants. The purchase price per share of each pre-funded warrant represents the per share offering price for the common stock, less the \$0.0001 per share exercise price of each underlying share. Total net proceeds generated from the offering were approximately \$161.6 million, after deducting underwriting discounts, commissions and other offering expenses payable by the Company.

The pre-funded warrants are exercisable at any time on or after the date of issuance at the option of the holder, subject to a beneficial ownership blocker that may limit exercisability. No holder may exercise any portion of the warrants that would cause the aggregate number of shares of common stock beneficially owned by such holder, together with its affiliates, to exceed 4.99% (or 9.99%) of the issued and outstanding common stock.

A holder of a pre-funded warrant may increase or decrease this percentage up to 19.99% by providing at least 61 days' prior notice to the Company.

The pre-funded warrants do not expire. The pre-funded warrants may be settled through either physical or net share settlement. Following the occurrence of certain fundamental transactions, the holders of the pre-funded warrants have the right to receive upon exercise of the warrants the same amount and kind of securities, cash, or property as they would have been entitled to receive if they had been holders of the common shares issuable under the warrants immediately prior to such transaction.

During the nine months ended September 30, 2024, 152,145 pre-funded warrants were exercised via a cashless exercise, resulting in 152,142 shares of common stock issued. No cash proceeds associated with the exercise were received by the Company. As of September 30, 2024, a total of 904,580 pre-funded warrants associated with this offering remained outstanding.

April 2024 Public Offering

On April 2, 2024 the Company completed a public offering of:

- (i) an aggregate of 3,949,558 shares of its common stock at a public offering price of \$56.50 per share, including the underwriters' full exercise of their option to purchase 530,973 additional shares of common stock; and
- (ii) pre-funded warrants to purchase 221,238 shares of common stock at a public offering price of \$56.4999 per share of common stock underlying the warrants. The purchase price per share for each pre-funded warrant represents the per share offering price for the common stock, less the \$0.0001 per share exercise price of each underlying share. Total net proceeds generated from the offering were approximately \$216.0 million, after deducting underwriting discounts, commissions and other offering expenses payable by the Company.

The pre-funded warrants are exercisable at any time on or after the date of issuance at the option of the holder, subject to a beneficial ownership blocker that may limit exercisability. No holder may exercise any portion of the warrants that would cause the aggregate number of shares of common stock beneficially owned by such holder, together with its affiliates, to exceed 4.99% (or 9.99%) of the issued and outstanding common stock.

A holder of a pre-funded warrant may increase or decrease this percentage up to 19.99% by providing at least 61 days' prior notice to the Company.

The pre-funded warrants do not expire. The pre-funded warrants may be settled through either physical or net share settlement. Following the occurrence of certain fundamental transactions, the holders of the pre-funded warrants have the right to receive upon exercise of the warrants the same amount and kind of securities, cash, or property as they would have been entitled to receive if they had been holders of the common shares issuable under the warrants immediately prior to such transaction.

As of September 30, 2024, none of the pre-funded warrants had been exercised and all remained outstanding.

Shares Reserved for Future Issuance

Contracts in Entity's Own Equity

To determine the appropriate treatment, the Company concluded that the pre-funded warrants are both indexed to its own stock and meet all other conditions for equity classification. Accordingly, the Company has classified the pre-funded warrants as permanent equity.

Shares reserved for exercise of pre-funded warrants related to the June 2023 financing

Shares reserved for exercise of pre-funded warrants related to the June 2023 financing

[illegible]

[illegible]

September 30, 2024

The weighted-average assumptions that the Company used in the Black-Scholes option pricing model to determine the grant-date fair value of stock options granted to employees and non-employees on the date of grant were as follows for the three and nine months ended September 30, 2024:

	Expected volatility	Expected dividend yield	Weighted average grant-date fair value per share	Stock-Based Compensation
Three Months Ended	12.596%	0.1%	\$43.6 million	\$43.6 million
Nine Months Ended	12.596%	0.1%	\$43.6 million	\$43.6 million

As of September 30, 2024, total unrecognized compensation cost related to unvested stock options was \$43.6 million, which is expected to be recognized over a weighted-average period of 2.55 years.

Research and development

General and administrative

[illegible]

[illegible]

Three Months Ended September 30, 2023

Research and development

General and administrative

Total stock-based compensation expense

The following potential common shares presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have been anti-dilutive:

	2023	2022
Unvested restricted stock	42,241	42,241
Potential shares issuable under the 2020 ESPP	7,391	7,391
	49,632	49,632

Outstanding stock options

retroactively adjusted to reflect the 1-for-15 reverse stock split effected on November 28, 2023. See Note 2 for details. Results have been retroactively adjusted to reflect the 1-for-15 reverse stock split effected on November 28, 2023. See Note 2 for details.